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Genetic variations may change the structure and function of individual proteins as well as affect 
their interactions with other proteins and thereby impact metabolic processes dependent on 
protein-protein interactions. For example, cytochrome P450 proteins, which metabolize a vast 
array of drugs, steroids and other xenobiotics, are dependent on interactions with redox and 
allosteric partner proteins for their localization, stability, (catalytic) function and metabolic 
diversity (reactions). Genetic variations may impact such interactions by changing the splicing 
and/or amino acid sequence which in turn may impact protein topology, localization, post 
translational modifications and three dimensional structure. More generally, research on single 
gene defects and their role in disease, as well as recent large scale sequencing studies suggest 
that a large number of genetic variations may contribute to disease not only by affecting gene 
function or expression but also by modulating complex protein interaction networks. 
The aim of this research topic is to bring together researchers working in the area of drug, 
steroid and xenobiotic metabolism who are studying protein-protein interactions, to describe 
their recent advances in the field. We are aiming for a comprehensive analysis of the subject 
from different approaches including genetics, proteomics, transcriptomics, structural biology, 
biochemistry and pharmacology. Of particular interest are papers dealing with translational 
research describing the role of novel genetic variations altering protein-protein interaction. 
Authors may submit original articles, reviews and opinion or hypothesis papers dealing with 
the role of protein-protein interactions in health and disease.
 
Potential topics include, but are not limited to: 
•  Role of protein-protein interactions in xenobiotic metabolism by cytochrome P450s and 
other drug metabolism enzymes.
•  Role of classical and novel interaction partners for cytochrome P450-dependent metab-
olism which may include interactions with redox partners, interactions with other P450 
enzymes to form P450 dimers/multimers, P450-UGT interactions and proteins involved 
in posttranslational modification of P450s.
•  Effect of genetic variations (mutations and polymorphisms) on metabolism affected by 
protein-protein interactions. 
• Structural implications of mutations and polymorphisms on protein-protein interactions. 
• Functional characterization of protein-protein interactions.
• Analysis of protein-protein interaction networks in health and disease.
•  Regulatory mechanisms governing metabolic processes based on protein-protein 
interactions.
•  Experimental approaches for identification of new protein-protein interactions including 
changes caused by mutations and polymorphisms.
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Editorial on the Research Topic
Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function
This editorial describes the articles published under our research topic “Role of protein-protein
interactions in metabolism: Genetics, structure, function.” Our aim was to bring together
researchers working on drug, steroid, and xenobiotic metabolism with interest in protein-protein
interaction for presenting their latest findings and share their opinions on recent advances in the
field. Recent advances in genetics (Meyer, 2004) and structural biology have greatly enhanced
our understanding of molecular details of diversity and differences behind control of metabolic
processes. The topic attracted a wide range of manuscripts using genetics, proteomics, biochemical,
and structural biological approaches in study of protein-protein interactions.
In six original articles, four reviews, and one mini-review, leading experts in the field described
different approaches and use of advanced technologies in the study of protein-protein interactions
related to metabolic processes.
In a review of human UDP-glucuronosyltransfares (UGTs) Fujiwara et al. discussed the current
understanding of the structure and function of UGTs in relation to protein-protein interactions and
oligomerization and summarized their own as well as other related studies on interactions of UGTs
with other proteins (Fujiwara et al., 2010). Nakamura et al. described the modification of UGT2B3
by creation of an N-glycosylation site to alter its sensitivity toward CYP3A1. It has been known
for some time that CYP3A4 can change the activities of UGTs in isoform specific manner (Ishii
et al., 2014). Rouleau et al. used a proteomics approach to study the protein-protein interactions
of human UGT1As with other proteins including UGTs, transporters, and dehydrogenases. Role
of UGTs in gene regulation as well as metabolic regulation by interactions with other proteins has
become an emerging area of interest (Audet-Delage et al., 2017).
Pavek provided a review of pregnane X receptor (PXR) interactions with other nuclear receptors
and its role in gene regulation (Rulcova et al., 2010). Ryu et al. have reviewed the interactions of
cytochrome P450 proteins (Omura, 2010; Zanger and Schwab, 2013) with themembrane associated
progesterone receptors (MAPR). Many MAPRs share similarities to cytochrome b5 and therefore
are evolutionary adapted for interactions with cytochrome P450s (Xie et al., 2011).
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Udhane et al. explored the role of genetic variations in
human NADPH cytochrome P450 oxidoreductase (POR) found
in apparently normal human population, in the metabolism
of drugs and steroid hormones. Human POR (Pandey and
Flück, 2013) is a diflavin reductase containing both the flavin
mononucleotide (FMN) and flavin adenine dinucleotide (FAD)
co-factors in separate domains that are linked by a hinge segment
and interacts with cytochrome P450 proteins (Zanger and
Schwab, 2013) and other redox partners (Pandey and Flück, 2013;
Riddick et al., 2013). Using CYP19A1 (aromatase) (Pandey et al.,
2007) for steroid metabolism and CYP3A4 for drug metabolism
(Flück et al., 2010), Udhane et al. found variable effects of POR
genetic variants in the FMNbinding and hinge regions of POR on
the activities of CYP11A1 and CYP3A4. Režen et al. studied the
polymorphisms ofCYP51A1 (Lewinska et al., 2013) for impact on
interactions with POR. Using computational models Režen et al.
predicted that CYP51A1 variants R277L and D152G have lower
binding affinity for POR.
A thorough review of the biophysical techniques used in
study of Cytochrome P450 proteins as well their interactions
with other proteins involved in xenobiotic metabolism was
provided by Lampe. By examining the X-ray crystal structures
of P450 enzymes, Reed and Backes were able to identify
potential contact points for the formation of P450-P450
complexes when interacting in membranes. This information
allows for the predictions of how P450 system proteins
are organized in the endoplasmic reticulum as well as the
functional consequences of these interactions (Davydov et al.,
2013).
Campelo et al. performed a study on the salt-induced changes
of the dynamics properties of human POR (also described as
CPR, CYPOR) by changing specific amino acids of the hinge
segment which were postulated to play a critical role in electron
transfer to its redox partners. Striking changes in the salt-profile
of cytochrome c reduction by POR were observed with several of
mutations created by Campelo et al. These results demonstrated
that both electrostatics and flexibility of the hinge segment
in POR are critical. Knowledge on the molecular mechanism
of POR’s gated electron transfer is of importance for the
understanding the crucial role POR’s for the activity of its redox-
partners. Such knowledgemay shed light on the impact of specific
human polymorphic variants of POR (Sim et al., 2009) in specific
pathologies but may also find biotechnological applications,
such as P450 mediated metabolite production (Bernhardt and
Urlacher, 2014). Degregorio et al. applied a chimeric approach
for finding the optimal redox conditions to support cytochrome
P450s reactions. A chimeric protein consisting of the reductase
domain of bacterium Bacillus megaterium BM3 and a modified
CYP3A4 was created to achieve a P450 containing its own
reductase domain for a stable and efficient electron transfer
during catalytic reactions. By using different linkers in between
reductase and P450, Degregorio et al. could achieve 2 to 3-fold
maximum velocity and coupling efficiency compared to use of
separate P450 and redox partner proteins (Munro et al., 1996).
In conclusion, this research topic illustrated the up-to-date
status of the field by leading scientists and provided a current
state of the art on the importance of protein-protein interactions
in metabolism and their role in a range of human diseases as
well as biotechnological applications of the findings obtained
from basic studies. We hope that the information gained from
publication of this research topic will stimulate research on the
role of protein-protein interactions in metabolism and facilitate
further advances in the field.
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Mammalian UDP-glucuronosyltransferases (UGTs) catalyze the transfer of glucuronic
acid from UDP-glucuronic acid to various xenobiotics and endobiotics. Since
UGTs comprise rate-limiting enzymes for metabolism of various compounds, co-
administration of UGT-inhibiting drugs and genetic deficiency of UGT genes can cause
an increased blood concentration of these compounds. During the last few decades,
extensive efforts have been made to advance the understanding of gene structure,
function, substrate specificity, and inhibition/induction properties of UGTs. However,
molecular mechanisms and physiological importance of the oligomerization and protein–
protein interactions of UGTs are still largely unknown. While three-dimensional structures
of human UGTs can be useful to reveal the details of oligomerization and protein–
protein interactions of UGTs, little is known about the protein structures of human
UGTs due to the difficulty in solving crystal structures of membrane-bound proteins.
Meanwhile, soluble forms of plant and bacterial UGTs as well as a partial domain of
human UGT2B7 have been crystallized and enabled us to predict three-dimensional
structures of human UGTs using a homology-modeling technique. The homology-
modeled structures of human UGTs do not only provide the detailed information about
substrate binding or substrate specificity in human UGTs, but also contribute with unique
knowledge on oligomerization and protein–protein interactions of UGTs. Furthermore,
various in vitro approaches indicate that UGT-mediated glucuronidation is involved in
cell death, apoptosis, and oxidative stress as well. In the present review article, recent
understandings of UGT protein structures as well as physiological importance of the
oligomerization and protein–protein interactions of human UGTs are discussed.
Keywords: UDP-glucuronosyltransferase (UGT), protein–protein interactions, glucuronidation, glucuronides,
drug-metabolizing enzymes
INTRODUCTION
Humans are exposed on a daily basis to xenobiotics that may potentially be toxic or
pharmacologically active. Xenobiotics are often hydrophobic and therefore may accumulate
in the body. To facilitate the excretion of xenobiotics, detoxifying enzymes metabolize them
mostly in the liver to increase their hydrophilicity. Since such xenobiotic-metabolizing enzymes
play an important role in the metabolism of clinically used drugs, they are also called drug-
metabolizing enzymes. Phase I drug-metabolizing enzymes, such as cytochrome P450s (CYPs) and
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esterases, catalyze oxidation, reduction, and hydrolysis of
xenobiotics (Satoh and Hosokawa, 1998; Nebert and Russell,
2002). The formed metabolites, as well as parental compounds,
are further metabolized by phase II drug-metabolizing enzymes,
such as UDP-glucuronosyltransferases (UGTs), sulfotransferases,
and glutathione S-transferases (Jancova et al., 2010; Miners et al.,
2010). Among these, UGTs have been reported with the highest
contribution to drug metabolism (Williams et al., 2004).
UDP-glucuronosyltransferases-mediated glucuronidation can
be a rate-limiting step in the clearance of endogenous and
exogenous substances. Therefore, inhibition of UGTs by co-
administered drugs or genetic deficiency in the UGT gene
can increase blood concentrations of their substrates in vivo,
whereas induction of UGT genes would result in a decrease of
blood concentrations of their substrates (Lankisch et al., 2009;
Hirashima et al., 2016). Three-dimensional crystal structures
are useful to facilitate the understanding of protein structures
that determine substrate- and/or inhibitor-binding. Due to the
difficulty in obtaining the crystal structure of membrane proteins,
entire three-dimensional structures of human UGTs have not
been determined except for a partial domain of human UGT
(Miley et al., 2007). On the other hand, entire crystal structures
of soluble forms of plant and bacterial UGTs have previously
been reported (Mulichak et al., 2003; Shi et al., 2014). These
solved structures were used as templates of homology modeling
of human UGTs (Fujiwara et al., 2009a). Although amino acid
similarities are not high between mammalian and plant/bacterial
UGTs, the modeled human UGT structures are comparable
to plant and bacterial UGTs, suggesting that the structures of
plant/bacterial UGTs may aid in the structural clarification of
human UGTs.
UDP-glucuronosyltransferases enzymes comprise a
superfamily. One of the most unique and important properties
of UGTs is that they form homo- and hetero-oligomers such
as dimers, trimers, and tetramers (Finel and Kurkela, 2008).
Tukey and Tephly (1981) were the first to report that rat
UGTs functioned in an oligomeric form. Subsequently, various
in vitro techniques such as cross-linking and fluorescence
resonance energy transfer (FRET) imaging demonstrated the
oligomerization of UGT proteins (Ikushiro et al., 1997; Operaña
and Tukey, 2007). Interestingly, accumulating evidence indicates
that UGT–UGT interactions affect their enzymatic activities
(Ishii et al., 2001; Fujiwara et al., 2007a,b). Analyses using
the homology-modeled UGT structures further revealed the
region responsible for the oligomerization of UGTs (Lewis
et al., 2011). Moreover, specific antibodies against UGTs
immunoprecipitated not only UGTs but also CYPs in human
liver microsomes, indicating that UGTs appeared to interact with
other microsomal proteins (Fujiwara and Itoh, 2014). Indeed,
recently developed techniques such as mass spectrometry analysis
of immunoprecipitates revealed that UGTs may interact with
a variety of microsomal proteins including epoxide hydrolase
1, carboxylesterase 1, alcohol dehydrogenases, and glutathione
S-transferases (Fujiwara and Itoh, 2014).
In this review article, recent advances in the knowledge on
the three-dimensional structure, protein interactions of human
UGTs, and physiological roles of UGTs are introduced along with




Human UGT Families and Their Function
UDP-Glucuronosyltransferase (UGT, EC 2.4.1.17), which
belongs to a large glycosyltransferase (GT) 1 family of GTs
(EC 2.4.1.-; GT), is a family of membrane-bound proteins that
catalyze a transfer of glucuronic acid from UDP-glucuronic acid
to various endogenous and exogenous substances (Figure 1)
(Mackenzie et al., 2005). UGTs are specifically expressed in
the ER and most the UGTs are localized in the luminal side of
the ER-membrane, which is rich in UDP-glucuronic acid. In
humans, the UGT gene superfamily contains UGT1 and UGT2.
The single human UGT1 gene, located on chromosome
2q37.1, contains multiple exon 1s and common exons 2–5,
spanning approximately 200 kbp. Individual UGT1 isoforms,
UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7,
UGT1A8, UGT1A9, and UGT1A10, are generated by exon
sharing of the UGT1 gene (Figure 2A). Importantly, Dr. Girard
et al. (2007) discovered that there are two types of exon 5,
exons 5a and 5b, which encodes a shorter amino acid sequence.
Compared to 50–55 kDa proteins encoded by exons 1–4 and 5a
(UGT1A_i1), which is a main variant, the proteins encoded by
exons 1–4 and 5b (UGT1A_i2) are smaller (45 kDa) and generally
exhibit lower enzymatic activities.
Human UGT2 genes, including UGT2A and UGT2B, are
located on chromosome 4q13.2. UGT2A1 and UGT2A2 are
generated by exon sharing of unique exon 1s and common exons
2–6 of the UGT2A gene in the same manner as UGT1A proteins,
whereas a single gene encodes UGT2A3. UGT2B family proteins,
UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17,
and UGT2B28, are encoded by each unique gene in a cluster
(Figure 2B). Transcriptional diversity has been reported in the
UGT2B7 locus. Original six exons as well as extra three exon
1s and two exon 6s of the UGT2B7 gene can produce up to 22
transcript variants which encode 7 types of UGT2B7 proteins
(UGT2B7_i1 to _i7) (Ménard et al., 2011). Similar to UGT1A_i1,
UGT2B7_i1 exhibits the highest enzyme activity compared
to UGT2B7_i2 to _i7 proteins. Recently conducted targeted
RNA next-generation sequencing revealed that transcriptional
diversity, such as new internal exons and exon skipping, could
be observed in other UGT2B genes (Tourancheau et al., 2016).
The expression and enzyme activities of such alternative UGT2Bs
need to be determined in the future.
Tissue Distribution of UGTs
In humans, all of 9 UGT1 and 10 UGT2 isoforms are
expressed in a tissue-specific manner. In the liver, which is the
most important tissue in metabolism of xenobiotics, UGT1A1,
UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7,
UGT2B10, UGT2B15, and UGT2B17 are expressed (Nakamura
et al., 2008; Izukawa et al., 2009). UGT1A8 and UGT1A10 are
mainly expressed in the small intestine, colon, and bladder.
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FIGURE 1 | Conjugation reaction catalyzed by UDP-glucuronosyltransferases (UGTs). UGTs catalyze the transfer of glucuronic acid from UDP-glucuronic
acid to an oxygen, nitrogen, or sulfur atom of their substrates. (R = substrate).
FIGURE 2 | Gene structures of human UGT1 and UGT2. (A) Human UGT1 gene contains multiple exon 1s and common exons 2–5, and each UGT1 isoform are
generated by exon sharing of the gene. Exon 5a produces UGT1A_i1 proteins, while exon 5b produced smaller UGT1A_i2 proteins. (B) UGT2A1 and UGT2A2 are
generated by exon sharing of unique exon 1s and common exons 2–6 of the UGT2A gene in the same manner as UGT1A proteins. UGT2A3 and UGT2B family
proteins are encoded by each unique gene in a cluster.
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UGT1A7 has been characterized as an isoform that is specifically
expressed in the stomach (Strassburg et al., 1997). In the
kidneys, UGT1A9 and UGT2B7 are highly and other UGTs
such as UGT1A4, UGT1A6, and UGT2B11 are moderately
expressed. The expression of UGT2B28 is limited to the bladder,
where various UGT1 and UGT2 members are also expressed.
UGT2A1 and UGT2A2 are expressed in nasal tissue, whereas
UGT2A3 is expressed mainly in liver and small intestine, and
slightly in lung and nasal tissues (Sneitz et al., 2009). Since
UGT2A family isoforms glucuronidate endogenous substances
rather than drugs, it has been believed that they have certain
physiological role in those organs, although more investigation
is required.
Substrate Specificity of UGTs
UDP-glucuronosyltransferases catalyze the transfer of glucuronic
acid from UDP-glucuronic acid to an oxygen, nitrogen, or sulfur
atom in their substrates (Figure 1). UGT1A1 glucuronidates
relatively bulky molecules such as bilirubin, SN-38, and
etoposide, as well as planar or smaller molecules such as estradiol,
1-naphthol, and 4-methylumbelliferone (Bosma et al., 1994;
Watanabe et al., 2003; Mano et al., 2004). While these smaller
compounds can be glucuronidated by several other UGT1 and
UGT2 family proteins, bilirubin is solely glucuronidated by
UGT1A1 (Bosma et al., 1994). UGT1A4 has been recognized as
one of the UGT isoforms that can glucuronidate tertiary amines
(e.g., nicotine, imipramine, trifluoperazine, and lamotrigine)
(Kuehl and Murphy, 2003; Smith et al., 2003; Rowland et al.,
2006). A recent study demonstrated that clearances of nicotine,
amitriptyline, imipramine, and diphenhydramine by UGT2B10-
mediated N-glucuronidation were significantly higher than those
by UGT1A3 and UGT1A4, indicating that UGT2B10 plays
an important role in N-glucuronidation of certain amine-
containing compounds (Kato et al., 2013). As UGT1A6 was
originally characterized as a phenol-glucuronidating enzyme,
it mainly glucuronidates small phenolic substances such as 4-
nitrophenol, 1-naphthol, and 4-methylumbelliferone (Hanioka
et al., 2001). 5-Hydroxytriptamine, also called serotonin, has been
recognized as a specific substrate of UGT1A6 (Krishnaswamy
et al., 2003). UGT1A9 metabolizes a wide variety of substances
such as mycophenolic acid, scopoletin, and entacapone (Kurkela
et al., 2003; Bernard and Guillemette, 2004). Propofol has
been used as a selective substrate of UGT1A9 in the livers,
although it can also be glucuronidated by UGT1A7, UGT1A8,
and UGT1A10 in the gastrointestine (Court, 2005). UGT2B
isoforms are especially important in the glucuronidation of
endogenous compounds such as androsterone, testosterone, and
dihydrotestosterone. Zidovudine and morphine are specifically
metabolized by UGT2B7 (Barbier et al., 2000). It has been shown
that UGT2B15 is the major enzyme responsible for sipoglitazar
glucuronidation in humans, while multiple UGT1A and UGT2B
members slightly glucuronidate sipoglitazar (Nishihara et al.,
2013). UGT2B17, which has more than 95% homology with
UGT2B15, can glucuronidate a wide variety of exogenous and
endogenous compounds, including coumarins, anthraquinones,
flavonoids, and androgens (Turgeon et al., 2003). Therefore, each
UGT isoform exhibits broad but distinct substrate specificities.
Significance of Extrahepatic UGTs
Because bilirubin is solely glucuronidated by UGT1A1, genetic
deficiency in the UGT1A1 gene can result in an onset of
severe hyperbilirubinemia (>20 mg/dL serum bilirubin) in
humans (Beutler et al., 1998). Knockout of Ugt1a1 in mice
causes very severe hyperbilirubinemia (>15 mg/dL serum
bilirubin), which is lethal within 11 days of birth due to the
development of kernicterus (Nguyen et al., 2008). Since UGT1A1
is highly expressed in the liver, it was previously commonly
believed that hepatic UGT1A1 mainly contribute to the bilirubin
glucuronidation. However, a recent study demonstrated that
liver-specific knockout of the Ugt1 gene, including Ugt1a1,
resulted in a mild increase of serum bilirubin (2 mg/dL
serum bilirubin; Chen et al., 2013). Furthermore, increased
expressions of intestinal UGT1A1 lead to decreased serum
bilirubin levels (from 12 to 2 mg/dL) in 14-day-old humanized
UGT1 mice, indicating that intestinal UGT1A1 also plays an
important role in bilirubin metabolism (Fujiwara et al., 2010b,
2012). UGT1A1 expressed in the skin and brain might also
be responsible for bilirubin metabolism in neonates although
to a lesser extent (Sumida et al., 2013; Kutsuno et al., 2015).
In addition to UGT1A1, substantial expression of UGT1A8
and UGT1A10 mRNA are also observed in the small intestine
(Nakamura et al., 2008). Since recombinant UGT1A1, UGT1A8,
and UGT1A10 glucuronidate raloxifene in vitro, these enzymes
might be responsible for the extremely poor oral bioavailability of
raloxifene (Mizuma, 2009). However, it should be noted that the
UGT1A8 protein was barely detected in human small intestine in
a targeted peptide-based quantification study (Sato et al., 2014).
Therefore, the role of UGT1A8 in intestinal glucuronidation
in vivo needs to be carefully investigated in the future. These
data support a concept that in addition to hepatic UGTs,
extrahepatic UGTs also play a dominant role in glucuronidation
of endogenous and exogenous compounds (Fujiwara et al., 2015).
THREE-DIMENSIONAL STRUCTURE OF
HUMAN UGTs
Structure of Glycosyltransferase 1
Family Protein
Due to difficulties in crystallizing membrane-bound protein,
X-ray crystal structures of membrane-bound human UGTs
have not been determined. As mentioned above, human
UGTs belong to a large glycosyltransferase (GT) 1 family.
Because plant and bacterial GT1 family proteins are soluble
forms, several X-ray crystal structures of plant and bacterial
GTs have successfully been determined. In 2003, a 2.8-Å
crystal structure of TDP-epi-vancosaminyltransferase (GtfA),
which is one of the GT1 family proteins that transfer 4-epi-
vancosamine from TDP-epi-vancosamine to its substrate, in
Amycolatopsis orientalis was solved (Mulichak et al., 2003).
The crystal structure (PDB ID: 1PN3) revealed that GtfA
adopts a GT-B fold that consists of two separate Rossmann
domains with a connecting linker and a catalytic cleft. In
addition, other GT1 family proteins such as plant UDP-glucose
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flavanoid 3-O glucosyltransferase (2C1X) and multifunctional
triterpene/flavonoid glycosyltransferase UGT71G1 (2ACV) also
have the GT-B fold (Shao et al., 2005; Offen et al., 2006). These
findings lead us to hypothesize that human UGTs would also be
GT-B fold enzymes.
Predicted Structure of Human UGTs
Human UGT1 and UGT2 family members consist of
approximately 530 amino acids. One of the unique properties of
UGTs is that they sometimes recognize overlapping but specific
substrates, while they commonly recognize a co-substrate UDP-
glucuronic acid (Mackenzie et al., 2005). Because UGT1 family
proteins are generated by exon sharing of the single UGT1 gene
(Figure 2A), their C-terminal amino acid sequences encoded
by the common exons 2–5 are identical. Although UGT2 family
proteins are encoded by their individual genes (Figure 2B), the
C-terminal amino acid sequences exhibit extremely high amino
acid similarity. In contrast, the N-terminal amino acid sequences
of UGT1 and UGT2 family members exhibit relatively lower
amino acid similarity. For example, the sequence homology is
24–49% between N-terminal regions of UGT1 family enzymes
(Mackenzie et al., 1997). Point mutation analyses demonstrated
that mutations in the N- and C-terminal halves dramatically
decreased the affinities toward substrates and UDP-glucuronic
acid, respectively (Xiong et al., 2006; Patana et al., 2007; Fujiwara
et al., 2009b; Kerdpin et al., 2009). These mutagenesis studies
support an assumption that human UGTs have two domains,
the highly conserved C-terminal halves responsible for the
UDP-glucuronic acid binding and the unique N-terminal halves
responsible for the substrate binding. A 1.8-Å resolution apo
crystal structure of the C-terminal half of human UGT2B7
(2O6L), which is a solely available X-ray crystal structure of
human UGTs, confirmed that the C-terminal domain contained
a preserved nucleotide-sugar binding site (Miley et al., 2007).
Homology-Modeled Structure of Human
UGTs
Three-dimensional structures of unsolved proteins can be
modeled by homology-modeling. Locuson and Tracy (2007)
conducted homology modeling of human UGT1A1 using the
crystallized structure of plant UGT71G1 (2ACV) as a template.
The length of the amino acid sequence of human UGT1A1 (533
amino acids) is relatively longer than that of plant UGT71G1
(463 amino acids). The amino acid similarity between UGT1A1
and UGT71G1 is 34%, but it was sufficient to obtain a reliable
homology-model. The overall three-dimensional structure of
UGT1A1 showed two Rossmann fold-like domains (Locuson and
Tracy, 2007). Banerjee et al. (2008) modeled a three-dimensional
structure of human UGT1A10 using UDP-galactose 4-epimerase
(1XEL) from Escherichia coli as a template structure (Banerjee
et al., 2008). The modeled structures of substrate- and UDP
sugar-binding pockets were overlapped well with those of the
template structure. The structural analysis indicated that lysine
residues at 314 and 404 (K314 and K404) would play a critical
role in the UDP-glucuronic acid binding of UGT1A10. They
confirmed, by in vitro mutagenesis analysis, the importance of
K314 and K404 in the UDP-glucuronic acid binding. Therefore,
the homology-modeled structures of human UGTs are relatively
reliable, even though the amino acid similarities are not high
between human and plant/bacteria UGTs. Similar homology-
modeling approaches have been carried out by many research
groups to simulate the three dimensional structures of human
UGTs (Table 1). Structural similarity of C-terminal domains was
very high between the modeled structures and the crystallized
structure of the C-terminal half of human UGT2B7 (2O6L),
supporting the reliability of the homology-modeling technique
(Figure 3).
Among the 19 functional human UGT proteins, UGT1A9
exhibits several unique properties. In 2007, we demonstrated that
UGT1A9 was uniquely stable against heat treatment, while the
other human UGTs lost their enzymatic activities when incubated
at higher temperature (Fujiwara et al., 2007b). Importantly, 13
amino acid residues were found to be specific to UGT1A9 among
9 UGT1A isoforms. To examine the role of these residues in the
thermal stability of UGT1A9, we conducted molecular dynamics
simulation of homology-modeled structures of UGT1A9 as well
as UGT1A8 as a reference at higher and lower temperatures.
The in silico simulation revealed that the UGT1A9-specific
residues were collectively involved in the thermal stability of
UGT1A9 (Fujiwara et al., 2009b). In vitro mutagenesis analysis
confirmed that the UGT1A9-specific residues, Arg42, Lys91,
Ala92, Tyr106, Gly111, Tyr113, Asp115, Asn152, Leu173, Leu219,
His221, Arg222, and Glu241, contributed to protein stability.
Since the results of in silico and in vitro analyses were consistent,
it is considered that the homology-modeled structure of human
UGT1A9 (Figure 3) was relatively reliable.
DIMERIZATION AND OLIGOMERIZATION
OF UGTs
The first evidence to demonstrate the oligomerization of
mammalian UGTs was reported by Tukey and Tephly (1981).
Shortly after the publication, Matern et al. (1982) demonstrated
oligomeric UGTs in . Subsequently, a number of research
groups showed that mammalian UGTs including human UGTs
formed homo- and hetero-oligomers such as dimers, trimers, and
tetramers. In this section, earlier and recent analytical tools used
to show the oligomeric UGTs are summarized.
Gel Permeation Chromatography
Tukey and Tephly (1981) purified two different UGT isoforms,
which mediate estrone and p-nitrophenol glucuronidations,
respectively, from rabbit liver microsomes by DEAE-cellulose
chromatography and affinity chromatography on UDP-
hexanolamine Sepharose-4B. Both enzymes exhibited molecular
weights of 57 kDa in the SDS-PAGE analysis. Interestingly,
a gel filtration study of the purified UGT isoforms by an
Ultragel AcA 34 column revealed that both UGTs had apparent
molecular weights of 230 kDa (Tukey and Tephly, 1981), which
is approximately 4 times larger than the size of monomeric
UGTs. This was the first report demonstrating that mammalian
UGTs could be present as tetramers.
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TABLE 1 | Homology modeled human UDP-glucuronosyltransferases (UGTs) and their template structures.
Modeled UGT Template Template PDB ID Reference
UGT1A1 Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV Locuson and Tracy, 2007
UGT1A1 Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV Li and Wu, 2007
UGT1A1 Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE Laakkonen and Finel, 2010
Amycolatopsis orientalis UDP-glycosyltransferase (GtfB) 1IIR
Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A1 Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE Song et al., 2015
Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA
Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X
UGT1A3 Medicago truncatula multifunctional (iso)flavonoid glycosyltransferase (UGT85H2) 2PQ6 Song et al., 2015
Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X
Medicago truncatula Flavonoid 3-o-glucosyltransferase (UGT78G1) 3HBF
UGT1A3 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Yao et al., 2015; Liu X. et al., 2016
Vitis vinifera UDP-glucose flavonoid 3-o glycosyltransferase (VvGTl) 2C1X
Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE
UGT1A3 Vitis vinifera UDP-glucose flavonoid 3-o glycosyltransferase (VvGTl) 2C1Z Schirris et al., 2015
UGT1A8 and UGT1A9 Amycolatopsis orientalis TDP-epi-vancosaminyltransferase (GtfA) 1PN3 Fujiwara et al., 2009a
UGT1A9 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1Z Wu et al., 2012
UGT1A9 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1Z Li et al., 2016
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A9 and UGT1A10 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Tripathi et al., 2016
Streptomyces fradiae C-glycosyltransferase (UrdGT2) 2P6P
Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A10 Escherichia coli UDP-galactose 4-epimerase 1XEL Banerjee et al., 2008
UGT2B7 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X, 2C1Z, 2C9Z Lewis et al., 2011; Chau et al., 2014
Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV, 2ACW
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT2B7 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Zhang et al., 2016







Homo sapiens UGT2B7 (C-terminal domain) 2O6L Nair et al., 2015
Matern et al. (1982) similarly purified UGTs that catalyze
chenodeoxycholic acid and testosterone glucuronidations
from rat liver microsomes by a series of purification steps
such as polyethylene glycol fractionation, DEAE-Sepharose
CL-6B chromatography, UDP-hexanolamine-Sepharose 4B
chromatography, and Bio-Gel A-1.5 m chromatography. While
the molecular weight of subunit was determined to be 54 kDa
in the SDS-PAGE analysis, the apparent molecular weight of
the enzyme was calculated to be 316 kDa in a polyacrylamide
gradient slab gel electrophoresis (Matern et al., 1982). The data
indicated that rat UGTs were also present as tetrameric or even
larger oligomeric forms.
Radiation Inactivation
Radiation inactivation is an analytical tool to determine
molecular weights of membrane-bound enzymes in situ
(Kempner and Schlegel, 1979). Enzymes are inactivated when
they are irradiated with ionizing radiation. The extent of
radiation-induced inactivation of the enzymes is directly
associated with the radiation dose and the molecular weight
of the concerned enzymes. Peters et al. (1984) determined the
molecular weights of rat UGTs by radiation-inactivation of
SDS-treated lyophilized liver microsomes using a calibrated
60Co source. The radiation-inactivation analysis revealed that
bilirubin mono-glucuronidation was catalyzed by a 41.5 kDa
protein, while bilirubin di-glucuronidation was catalyzed by a
175 kDa protein. It was further demonstrated that proteins with
molecular weight of 142 and 159 kDa catalyzed glucuronidations
of testosterone and phenolphthalein, respectively (Peters
et al., 1984). Similarly, the radiation inactivation analysis
by Gschaidmeier and Bock (1994) revealed that molecular
weights of UGTs catalyzing the glucuronidations of 1-naphthol,
6-hydroxychrysene, 3,6-dihydroxybenzo[a]pyrene, and 3,6-
dihydroxychrysene were 91–218 kDa. The series of radiation
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FIGURE 3 | Homology-modeled structures of human UGT1A9 and UGT1A8. Three-dimensional structures of human UGT1A9 and UGT1A8 were
homology-modeled using Amycolatopsis orientalis GtfA (PDB ID: 1PN3) as template structures. The structures of UGT1A9 and UGT1A8 contain two Rossmann
fold-like domains in the N-terminus and C-terminus. The structures are colored from red at the N-terminal to blue at the C-terminal. Amino acid residues that are
predicted to interact with UDPGA and to be important for the catalysis are shown by red and blue licorice, respectively. The X-ray crystal structure of the C-terminal
domain of UGT2B7 was retrieved from the Protein Data Bank (PDB ID: 2O6L). Adapted from Drug Metabolism and Pharmacokinetics (Fujiwara et al., 2009a).
inactivation analyses clearly demonstrated that mammalian
UGTs were functional as oligomeric proteins that are composed
of two to four subunits.
Cross-Linking
In intact cells, most of proteins are interacting with other
protein(s) (Jeong et al., 2001). Upon the denaturing process in
the SDS-PAGE analysis, such protein interactions via disulfide
binding, hydrogen binding, and hydrophobic or salt-bridge
interactions are disrupted, so that the proteins are separated
according to their molecular weight. Cross-linkers are reagents
that can introduce covalent chemical bonds between specific
amino acids of proteins. Thus, proteins treated with cross-
linkers can be observed as bands with higher molecular
weights rather than their monomeric forms on SDS-PAGE
followed by immunoblotting. Ikushiro et al. (1997) used 1,6-
bis(maleimido)hexane (BMH), which is a homobifunctional
cross-linker that reacts with sulfhydryl-groups of proteins. When
rat liver microsomes that were incubated with BMH and were
applied to the SDS-PAGE followed by the immunoblotting
analysis using anti UGT1 or UGT2B1 antibodies, multiple
bands with molecular masses of 50–60 kDa as well as of
120–130 kDa were observed (Ikushiro et al., 1997). They
concluded that sulfhydryl group(s) of rat UGTs are located
on the outside of the proteins and play a critical role in
the formation of UGT dimers. Ghosh et al. (2001) used the
disulfide cross-linker BMH and an amino group cross-linker
dimethyl 3,3′-dithiobispropionimidate (DTBP) to demonstrate
homo-oligomers of human UGT1A1, finding that both BMH
and DTBT produced bands corresponding to homo-dimers
of UGT1A1 on the SDS-PAGE analysis. The density of
the bands was apparently reduced when UGT1A1-expressed
cells were incubated with DTBP at pH 9.0, indicating that




Immunopurification and immunoprecipitation are classical
methods to identify proteins interacting with a target protein.
When rat liver microsomes were solubilized in buffer containing
1% Emulgen 913 and were applied to a UGT1 antibody-
conjugated Sepharose 4B column, not only UGT1 isozymes
but also unidentified 50-kDa protein(s) were co-eluted by
eluting solution containing UGT1A-peptides (Ikushiro et al.,
1997). Amino acid sequencing of the 50-kDa proteins and
immunoblotting studies further revealed that the protein
interacting with UGT1A was UGT2B1. Although the method
used in a study by Kurkela et al. (2003) was Ni-column which
is not immunopurification, they purified homo-oligomer of
UGT1A9 that consisted of His- and hemagglutinin (HA)-tagged
UGT1A9.
Fremont et al. (2005) conducted immunoprecipitation assays
to examine protein–protein interactions between UGT1A1,
UGT1A6, and UGT2B7 in human liver microsomes. When
solubilized microsomes were incubated with UGT1A1-,
UGT1A6-, and UGT2B7-specific antibodies, not only the
antigenic proteins but also other UGT isozymes were co-
immunoprecipitated. In 2007, we established cell lines that are
individually or simultaneously expressing human UGT1A6
and UGT1A9 (Fujiwara et al., 2007b). A human UGT1A6-
specific antibody co-immunoprecipitated UGT1A9, as well
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as UGT1A6, in the UGT1A6-UGT1A9 double expression
cells, although it did not immunoprecipitate UGT1A9 in the
UGT1A9-expressed cells. When cyan fluorescent protein (CFP)-
and HA-tagged UGT1A1s were simultaneously expressed in
COS cells, anti-HA beads immunoprecipitated both CFP-
and HA-tagged UGT1A1s (Operaña and Tukey, 2007). Taken
together, immunoaffinity purification and immunoprecipitation
assays are typical but still powerful tools to demonstrate homo-
and hetero-oligomerization of UGTs. Immunoprecipitation
assays by Bellemare et al. (2010) further revealed that
inactive UGT1A_i2 proteins form not only homo-oligomers




To examine UGT–UGT interactions in intact cells, Operaña
and Tukey (2007) conducted a FRET analysis using cyan and
yellow fluorescent proteins (CFP and YFP)-tagged recombinant
human UGTs expressed in COS cells. When correction for donor
and acceptor bleed through was performed and FRET signal
was analyzed, it was revealed that the two fusion UGT proteins
resided within ångströms from each other. Their FRET analysis
demonstrated homo-oligomerization of all UGT1A isoforms
as well as hetero-oligomerization of UGT1A1 with the other
UGT1A isoforms. The FRET analysis conducted by a different
research group indicated that not only UGT1As, but also human
UGT2B7 formed homo-oligomers in SF9 cells (Yuan et al., 2015;
Liu Y.Q. et al., 2016).
REGIONS AND AMINO ACID RESIDUES
RESPONSIBLE FOR OLIGOMERIZATION
OF UGTs
Importance of N-terminal Domain
To examine the region responsible for the oligomerization
of UGTs, Meech and Mackenzie (1997) constructed a couple
of chimeric rat UGT2B1 proteins fused with ecdysteroid
glucosyltransferase (EGT), which does not oligomerize.
While intact UGT2B1 formed dimers, the dimerization was
not observed when the C-terminal half of UGT2B1 was
fused with the N-terminal half of EGT. In 2001, two-hybrid
analysis by Ghosh et al. (2001) showed that UGT1A1s that
were mutated or partially deleted in their N-terminal region
(L175E, C233Y, or del152-180) abolished the ability to form
homo-oligomers, while UGT1A1 with partial truncation
of the C-terminal (K530X) still formed homo-oligomers
(Ghosh et al., 2001). These data indicated that the N-terminal
domains are involved in oligomerization of mammalian
UGTs.
Hydrophobic Amino Acids on the
Surface of Modeled UGT2B7
Hydrophobic amino acid residues on the surface of proteins
can mediate protein–protein interactions by introducing proline
brackets and π–π interactions. To identify such hydrophobic
amino acid residues of UGTs, Lewis et al. (2011) obtained a
three-dimensional structure of human UGT2B7 by homology
modeling (Table 1). In the homology-modeled structure of
human UGT2B7, a cluster of highly hydrophobic amino acid
residues on a B′-C loop (amino acid residues 183–200) was
located on the protein surface (Lewis et al., 2011). Thus, not
only in vitro studies, but in silico structural analyses also
supported the involvement of the N-terminal region of UGTs in
oligomerization.
PROTEIN–PROTEIN INTERACTIONS OF
UGTS WITH OTHER PROTEINS
Protein Interactions with CYPs
Cytochrome P450s are phase I drug-metabolizing enzymes that
are expressed in the ER membrane. To investigate the possible
protein-interactions between UGTs and CYPs, Taura et al.
(2000) applied solubilized rat liver microsomes to a CYP1A1-
conjugated Sepharose 4B column. It was found that multiple
UGT isoforms were co-eluted in a fraction where CYP1A1
was eluted. Rat UGTs were detected in immunoprecipitates
when solubilized rat liver microsomes were reacted with specific
antibodies against CYP3A2, CYP2B2, CYP2C11, and CYP1A2
(Ishii et al., 2007). Antibodies against human UGT2B7 and
CYP3A4 immunoprecipitated not only their antigenic proteins
but also CYP3A4 and UGT2B7, respectively, in solubilized
human liver microsomes (Fremont et al., 2005; Takeda et al.,
2005, 2009). These data indicate that mammalian UGTs interact
with CYPs in liver microsomes. It remains to be determined
whether such UGT-CYP interactions can still be observed in a
reconstituted system.
Protein Interactions with Microsomal
Proteins
Immunoprecipitation assay with human UGT2B7 antibody
was conducted using solubilized human liver microsomes.
The obtained immunoprecipitate was digested with trypsin,
and the resulting peptides were analyzed by LC-MS/MS to
identify proteins interacting with UGT2B7 in human liver
microsomes (Fujiwara and Itoh, 2014). The extensive peptide
analysis showed that the peptide sequences of UGT2B7, epoxide
hydrolase 1, carboxylesterase 1, alcohol dehydrogenases, and
glutathione S-transferases, as well as CYPs, were included
in the immunoprecipitates. It was confirmed that such
peptide sequences were not detected in immunoprecipitates
obtained with a control rabbit IgG antibody. Therefore,
UGT2B7 might be able to form a metabolosome, which is
a functional unit of metabolism (Mori et al., 2011) in liver
microsomes.
Protein Interactions with Cytoplasmic
Proteins
In contrast to normal UGT1A proteins (UGT1A_i1) that
are expressed in the luminal side of the ER membrane, a
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portion of UGT1A_i2 is cytoplasmic (Lévesque et al., 2007).
Immunoprecipitates of solubilized human intestine and kidney
homogenates with anti-UGT1A_i2 antibody were applied to
a global peptide analysis (Rouleau et al., 2014). It was
found that cytoplasmic catalase and peroxiredoxin 1 were co-
immunoprecipitated with UGT1A_i2 proteins in both tissues,
indicating that the truncated UGT1A isoform 2 is interacting
with those cytoplasmic proteins. Since such protein–protein
interactions were not observed when anti-UGT1A_i1 antibody
was used, the interactions with cytoplasmic proteins would be





Impact of UGT–UGT Interactions on the
UGT-Mediated Glucuronidations
To investigate the effect of UGT–UGT interactions on the UGT
activities, Ishii et al. (2001, 2004) cloned guinea pig UGT2B21
and UGT2B22 and examined morphine 6-O-glucuronidation
in COS-7 cells expressing these UGTs. While UGT2B21
glucuronidates morphine, UGT2B22 does not have such ability
to glucuronidate morphine. Morphine 6-glucuronide formation
was 4.5-fold higher in COS-7 cells co-transfected with UGT2B21
and UGT2B22 compared to that in the cells transfected with
UGT2B21 alone, indicating that protein–protein interactions
between UGT2B21 and UGT2B22 upregulated the UGT activities
(Ishii et al., 2001, 2004). This observation led us to investigate
the impact of UGT–UGT interactions on the enzyme activities
in humans (Fujiwara et al., 2007b; Nakajima et al., 2007).
When we established stable expression systems of double
human UGT1As in HEK293 cells, the S50 value of UGT1A1-
mediated bilirubin glucuronidation was decreased by twofold
by the co-expressions of UGT1A4 or UGT1A6 (Fujiwara et al.,
2007a). A similar decrease of the S50 value was observed in
the UGT1A1-mediated estradiol 3-O-glucuronidation in a co-
expression system of UGT1A1 and UGT2B7 in HEK293 cells
(Fujiwara et al., 2010a). These data showed that substrate-
binding affinity of UGT1A1 toward bilirubin and estradiol
was increased when UGT1A1 was co-expressed with UGT1A4,
UGT1A6, and UGT2B7. Meanwhile, co-expression of UGT1A9
decreased the Vmax value of UGT1A1-mediated estradiol 3-O-
glucuronidation without affecting the S50 value (Fujiwara et al.,
2007b). Kurkela et al. (2004) demonstrated that the rate of
UGT1A9-catalyzed scopoletin glucuronidation was significantly
decreased by co-expression of UGT1A4. Thus, UGT–UGT-
interactions can modulate the catalytic rate of glucuronidation
as well as the affinity of substrates toward UGTs. Importantly,
the effects are dependent on interacting UGT isoforms and
compounds used as substrates.
Interestingly, even though sorafenib is mainly metabolized
by UGT1A9, it was demonstrated that the AUC of sorafenib
was twice higher in patients with UGT1A1 variants or with
hyperbilirubinemia (Peer et al., 2012). This finding indicates that
UGT1A1 might control the enzyme activity of UGT1A9 in vivo
by interacting with UGT1A9.
Although UGT1A_i2 proteins carry a potential UDP-
glucuronic acid binding-site, they do not show substantial
glucuronidation activity. As described above, the inactive
UGT1A_i2 proteins form hetero-oligomers with functional
UGT1A_i1 proteins. It was shown that glucuronide formation
mediated by UGT1A_i1 proteins was significantly suppressed
when UGT1A_i2 was co-expressed with UGT1A_i1 (Bellemare
et al., 2010). The expression level and the ratio of UGT1A_i1 and
_i2 are different in each tissue (Girard et al., 2007), suggesting
that UGT1A_i2 can be a factor suppressing the glucuronidation
in certain tissues. Interestingly, such suppression of UGT1
activity can also be caused by a truncated mutant of UGT1A1
(Gln331Stop; C to T at nucleotide 991), possibly by forming
oligomers (Koiwai et al., 1996).
Impact of UGT-CYP Interactions on the
UGT Activities
While a Km value of morphine 3-glucuronide formation was
0.38 mM in UGT2B7-expressing COS-1 cells, a much higher
Km value (3.7 mM) was observed in UGT2B7 and CYP3A4 co-
expressing cells (Takeda et al., 2005). In contrast, co-expression
of CYP1A2 or CYP2C9 did not affect the kinetic parameters
of UGT2B7-catalyzed morphine 3-glucuronide formations. In
addition, co-expression of CYP3A4 increased a Km value of
UGT1A6-mediated serotonin glucuronidation by ∼fourfold,
whereas it barely affected Km values of UGT1A1-mediated
4-MU, SN-38-, or estradiol 3-O-glucuronidations as well as
UGT1A7-mediated 4-MU, SN-38-, and 4-hydroxybiphenyl-
glucuronidations (Ishii et al., 2014). Meanwhile, co-expression
of CYP3A4 increased Vmax values of UGT1A1-mediated 4-MU,
SN-38-, and estradiol 3-O-glucuronidations, UGT1A6-mediated
serotonin glucuronidation, and UGT1A7-mediated 4-MU, SN-
38-, and 4-hydroxybiphenyl-glucuronidations, although it did
not affect the UGT2B7-mediated morphine 3-glucuronidation
(Takeda et al., 2005; Ishii et al., 2014). Therefore, CYP
isoforms differently affect UGT-mediated glucuronidations and
the effects are depending on UGT isoforms as well as their
substrates.
Effect UGTs on Other Physiological
Functions
Interestingly, a more than 40-fold interindividual variability
in UGT1A6-catalyzed serotonin glucuronidation was observed
among individual human liver microsomes (Krishnaswamy
et al., 2003, 2005). Such variability could not be explained
even when the activities were normalized with the UGT1A6
content and its genetic polymorphisms, indicating that there
might be some unidentified factor that is capable of modulating
the UGT1A6 activity. Since CYP isoforms can modulate UGT
activities in different ways, interindividual variability in the CYP
expression and function might be one of the causes of these
wide interindividual variabilities in UGT1A6-catalyzed serotonin
glucuronidation.
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Miyauchi et al. (2015) investigated the effect of UGT2B7
on CYP3A4 activities by establishing a co-expression system
of UGT2B7 and CYP3A4. They found that co-expression of
UGT2B7 significantly decreased the Vmax value of CYP3A4
activity without affecting a Km value using luciferin-6′-
pentafluorobenzyl ether as a substrate. Similarly, co-expression
of UGT2B7 decreased the CYP3A4-mediated testosterone 6β-
hydroxylation at a single substrate concentration (Miyauchi et al.,
2015). These observations indicated that UGTs might suppress
the enzyme activities of CYPs.
In a recent study by Liu M. et al. (2016), it was demonstrated
that silencing of UGT1A expressions led to inhibitions of
actinomycin D- and etoposide-induced p53 expressions in
human colon HT29 and LS180 cells. Tissue-specific deletion of
the Ugt1 locus in intestinal crypt stem cells not only reduced
p53 activation, but also compromised apoptosis. It was further
demonstrated that reduced expression of UGT1A in intestine
caused greater size and number of tumors in the colon cancer
models (Liu M. et al., 2016).
When UGT1A_i2 was knocked-down in colorectal
carcinoma-derived HT115 cells, expressions of a number of
genes were up- or down-regulated (Rouleau et al., 2014).
Among those genes, hemoglobin-alpha was significantly
induced by the knockdown of UGT1A_i2. The function
of hemoglobin-alpha proteins has been linked to cellular
antioxidant potential (Widmer et al., 2010). Furthermore, it was
found that knocked-down of UGT1A_i2 reduced a chemical-
induced ROS formation in HT115 cells and significantly induced
superoxide dismutase 1, an antioxidative gene. Although the
underlying mechanism of induction of hemoglobin-alpha by
knockdown of UGT1A_i2 is still unknown, the observation
clearly indicates that UGT1A_i2 proteins are involved in the
regulation of oxidative stress in cells. Taking all these findings
together, it appears that UGTs are multifunctional proteins that
controls metabolism, cell death and development of tumors, and
oxidative stress.
CRITIQUE AND FUTURE RESEARCH
DIRECTIONS
Protein Structure of UGTs
Various three-dimensional structures of human UGTs have
been simulated by homology modeling (Table 1) and they are
relatively acceptable as mentioned above. However, due to the
extremely low amino acid similarity and different length of
the amino acid sequence between human UGTs and template
plant and bacterial UGTs, the reliability of the modeled human
UGT protein structures is still an open question. Indeed, it
is generally believed that the identity of amino acid sequence
with the template needs to be more than 70% to obtain
reliable structure. Furthermore, there is a significant structural
difference between human and plant/bacterial UGTs that human
UGTs are membrane proteins while plant and bacterial UGTs
are not. To obtain a completely reliable modeled structure of
human UGTs, an X-ray crystal structure of human UGTs needs
to be successfully solved. Importantly, as mammalian UGTs
abolish their enzyme activities when they are solubilized, a
solubilized and crystallized structure of human UGTs might
be an enzymatically inactive form. The instability of the
protein structure of human UGTs can also be an obstacle
in crystallizing them. Interestingly, UGT1A9 solely exhibited
its enzymatic activity in the presence of 0.2% Triton X-100,
although activities of other UGT1A and 2B isoforms were
abolished by the detergent treatment (Kurkela et al., 2003).
Human UGT1A9 is uniquely stable against a heat treatment as
well (Fujiwara et al., 2009a), indicating that the protein structure
of UGT1A9 must be more stable than the structures of other UGT
isoforms. Therefore, human UGT1A9 is a promising human
UGT isoform that has a potential to be crystallized as an active
form.
Oligomerization of UGTs In vivo
Gel filtration and radiation inactivation analyses, where
the liver microsomes were mixed with detergents, showed
that monomeric UGTs catalyzed glucuronidation of certain
compounds. It is well known that detergents can disrupt
oligomerization of proteins; therefore, the monomeric UGTs
might have been artificially generated from disruption of UGT
oligomers. While SDS-PAGE shows the molecular weight of
individual subunits of proteins under the reduced and denatured
condition, oligomerization can be preserved in native-PAGE
analysis. Our native-PAGE analysis of recombinant human
UGTs expressed in HEK293 cells showed that most of UGTs
were present as monomers, whereas some of them were
still forming oligomers (Figure 4) (Fujiwara et al., 2007a).
However, again, such monomers could have been a result from
disruption of oligomeric UGTs due to a fact that the native-PAGE
experiment required 1% Triton X-100 and 0.2% SDS to slightly
solubilize the cell homogenates. Therefore, it is unclear whether
UGTs dominantly exist as oligomer or monomer in intact
cells.
Fluorescence resonance energy transfer is an analytical tool
to demonstrate oligomerization of proteins in intact cells.
Interestingly, FRET efficiency, which is a marker for co-
localization and interaction, was 90% in COS cells expressing
CFP- and YFP-tagged UGT1A7s (Operaña and Tukey, 2007),
indicating that most of UGT1A7 was interacting with each
other to form oligomers in intact cells. Meanwhile, the FRET
efficiency was lower in certain UGT1A isoforms such as UGT1A3
and UGT1A9. These observations indicate that UGTs would
exist as both monomeric and oligomeric forms in intact cells
with variable extent depending on UGT isoforms. A limitation
of the FRET analysis is that tagged UGT proteins, not intact
proteins, were used. Therefore, determination of the extent of
monomeric/oligomeric forms of intact UGT in cellulo is a future
issue.
Availability and Application of Ugt1 and
Ugt2 Knockout Mice
Various data indicate that UGTs can be multifunctional
proteins that are involved in cellular metabolism, apoptosis,
carcinogenesis, and oxidative stress as well as glucuronidation.
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FIGURE 4 | Native PAGE analyses of UGT1A isoforms in single or
double expression systems. Single or multiple UGT1A isoforms were stably
expressed in HEK293 cells. Total cell homogenates were solubilized with 1%
Triton X-100 and 0.2% SDS, and then were subjected to a native gel.
Immunoblotting was conducted with rabbit anti-human UGT1A antibody. The
bands with closed and open arrowheads indicate homo- and hetero-dimers,
respectively. Hetero-dimer was detected in the double expression system of
UGT1A1 and UGT1A4, while such oligomer was not observed when single
expression systems of UGT1A1 and UGT1A4 were mixed. Adapted from Drug
Metabolism and Disposition (Fujiwara et al., 2007a).
However, these unique properties of UGTs have not been fully
validated by in vivo data. Ugt1- and Ugt2-knockout animals
are promising in vivo models for investigating the roles of
UGTs in such cellular metabolism, apoptosis, carcinogenesis,
and oxidative stress. With extensive efforts by Drs. Tukey and
Koller and their colleagues, Ugt1- and Ugt2-knockout mice were
previously developed in 2008 and 2015, respectively (Nguyen
et al., 2008; Fay et al., 2015). While Ugt2 knockout mice
can be used for the phenotype analysis, Ugt1 knockout mice
are lethal within 11 days after birth due to development of
a bilirubin-induced irreversible brain damage, kernicterus. To
conduct phenotype analyses in Ugt1 knockout mice, therefore,
we need to first avoid the lethality of the mice. Inhibitors of
bilirubin production and inducers of bilirubin clearance might
have potentials to rescue the lethality of the Ugt1 knockout
mice.
Possible Role of UGTs in Transport of
UGT Substrates and Metabolites
Transporters responsible for the uptake of the co-substrate
UDP-glucuronic acid from cytosol to the luminal side of
ER membrane have been identified (Muraoka et al., 2001).
Although studies suggested that there are proteins that are
involved in the efflux of hydrophilic glucuronide across the
ER membrane (Bánhegyi et al., 1996; Csala et al., 2004), such
transporter(s) has not been identified. As shown in Figure 5, it
was originally hypothesized that oligomerization and/or protein–
protein interactions of UGTs have a role in transporting
glucuronides across the ER membrane (Lin and Wong, 2002; Ishii
et al., 2005); however, such evidence has not yet been obtained.
Even in the immunoprecipitates of liver microsomes with
anti-UGT2B7 antibody, no peptide sequences of transporters
was observed (Fujiwara and Itoh, 2014). Further studies are
required to fully understand the detailed information on the
FIGURE 5 | Proposed model of oligomeric human UGTs. Human UGTs form homo- and hetero-oligomers in ER membrane. As indicated with blue arrows,
oligomerization of UGTs might be involved in the transport of substrates and glucuronides across the ER membrane. Protein–protein interactions of human UGT with
other microsomal and cytoplasmic proteins such as UGT, CYP, and p53 can make a great impact on glucuronidation, oxidation, apoptosis, carcinogenesis, and
oxidative stress.
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transport of UGT substrates and their metabolites across the ER
membrane.
CONCLUSION
In addition to enzyme inhibition and induction, oligomerization
is a predominant factor regulating the function of UGTs.
UGTs are multifunctional proteins that are involved not
only in glucuronidation, but also in cellular metabolism,
apoptosis, carcinogenesis, and oxidative stress in the human
body (Figure 5). Global protein interactions of UGTs with other
microsomal or cytoplasmic proteins might be a contributing
factor to a wide interindividual variability in UGT-catalyzed
glucuronidations.
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Our previous studies have demonstrated functional protein−protein interactions
between cytochrome P450 (CYP) 3A and UDP-glucuronosyltransferase (UGT).
However, the role of carbohydrate chains of UGTs in the interaction with CYP is not
well understood. To address this issue, we examined whether CYP3A1 modulates the
function of UGT2B3 which lacks potential glycosylation sites. We also examined whether
the introduction of N-glycosylation to UGT2B3 affects CYP3A-dependent modulation
of UGT function. To introduce a potential glycosylation site into UGT2B3, Ser 316 of
UGT2B3 was substituted with Asn by site-directed mutagenesis. A baculovirus-Sf-9
cell system for expressing CYP3A1 and UGT2B3/UGT2B3(S316N) was established
using a Bac-to-Bac system. Glycosylation of UGT2B3(S316N) was demonstrated in this
expression system. The microsomal activity of recombinant UGT was determined using
4-methylumbelliferone as a substrate. The effect of CYP3A1 co-expression on UGT
function was examined by comparing the kinetic profiles between single (UGT alone) and
double expression (UGT plus CYP) systems. The kinetics of the two expression systems
fitted a Michaelis−Menten equation. When the 4-MU concentration was varied, co-
expression of CYP3A1 lowered the Vmax of UGT2B3-mediated conjugation. Conversely,
for UGT2B3(S316N), the Vmax in the dual expression system was higher than that in
the single expression system. The data obtained demonstrate that the introduction of
N-glycosylation to UGT2B3 alters its sensitivity to CYP3A1-dependent modulation while
CYP3A1 enhanced UGT2B3(S316N) activity, and wild-type UGT2B3 was suppressed
by CYP3A1. These data suggest that N-glycosylation of UGT is one of the determinants
regulating the interaction between CYP3A and UGT.
Keywords: UDP-glucuronosyltransferase, UGT, cytochrome P450, P450, CYP, protein−protein interaction
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INTRODUCTION
The potential for drug metabolism varies from one individual
to another. Therefore, drug metabolism capacity is a factor
determining whether a drug produces pharmacological or
adverse effects. Drug metabolism is classified into phase 1 and
phase 2 reactions. The major reaction of phase 1 is oxidation
in which cytochrome P450 (CYP) plays a key role (Guengerich
and Rendic, 2010). Of all the enzymes including phase 2, UDP-
glucuronosyltransferase (UGT) is mediating conjugation with
glucuronic acid supplied from a cofactor (UDP-glucuronic acid,
UDPGA) (Rowland et al., 2013). CYP and UGT are bound to the
endoplasmic reticulum membrane, and their catalytic domains
are localized in the cytosolic and luminal sides, respectively
(Shepherd et al., 1989; Yamazaki et al., 1993). These enzymes
have long been considered to work separately. However, we
have shown that several UGTs can be trapped by a CYP1A1-
immobilized affinity column (Taura et al., 2000). Moreover,
our previous studies have shown that interaction between
CYP3A4 and UGT2B7 alters the regio-selectivity of UGT2B7-
catalyzed morphine glucuronidation (Takeda et al., 2005, 2009).
Furthermore, CYP3A4 alters the function of UGT1A subfamily
isoforms in an isoform and allelic variant specific fashion (Ishii
et al., 2014). Rat UGTs are efficiently co-immunoprecipitated
with anti-CYP3A antibody and the CYP3A-UGT complex is
catalytically active for 4-methylumbelliferone glucuronidation
(Ishii et al., 2007). Although the mechanisms of the interaction
between CYP3A and UGT have not been clarified, the J-helix
region of CYP3A4 is a candidate region involved in the
interaction with UGT2B7 (Takeda et al., 2009). The domain(s)
of UGT2B7 involved in the interaction with CYP3A4 has also
been reported (Miyauchi et al., 2015). It is suggested that the
hydrophobic regions at both the carboxyl terminal and luminal
anchoring segment of UGT2B7 are crucial. However, further
details about the interaction remain to be clarified.
Many UGTs have consensus sequences for N-glycosylation
(Mackenzie, 1990a,b; Barbier et al., 2000; Nakajima et al.,
2010; Nagaoka et al., 2012). The sequence can be generalized
as NX(S/T), where X is any amino acid except proline, and
approximately 70-90% of this sequence is glycosylated at its
asparagine (N) residue (Gavel and von Heijne, 1990). Earlier
studies have reported that N-glycosylation affects the enzyme
activity of UGTs (Mackenzie, 1990a,b; Barbier et al., 2000;
Nakajima et al., 2010; Nagaoka et al., 2012). We have reported
that CYP3A4 interacts with UGT1A1, 1A6, 1A7, and 2B7 (Takeda
et al., 2005; Ishii et al., 2014). All of these UGT isoforms
possess potential N-glycosylation sites. However, the role of N-
glycosylation of UGT in the interaction with CYP3A is unknown.
Although the inhibition of N-glycosylation reduces UGT1A9
activity, deglycosylation of the mature form (N-glycosylated
form) did not affect its catalytic properties (Nakajima et al.,
2010). Thus, N-glycosylation has been suggested to be important
for the protein folding of UGT. However, multiple mutations
of the three N-glycosylation sites on UGT2B7 have different
effects on substrate specificities (Nagaoka et al., 2012). Because
of the important roles of N-glycosylation in UGT folding and
function, we hypothesized that the N-glycosylation of UGT
affects the interaction between CYP3A and UGT. To address this
issue, we focused on rat UGT2B3 (Mackenzie, 1987) which does
not possess potential glycosylation sites. We examined whether
CYP3A1 modulates UGT2B3 and whether the introduction
of N-glycosylation to UGT2B3 affects the CYP3A-dependent
modulation of the UGT function.
MATERIALS AND METHODS
Materials
4-Methylumbelliferone (4-MU) and alamethicin were purchased
from Sigma−Aldrich (St. Louis, MO, USA). UDP-Glucuronic
acid (UDPGA) trisodium salt and 4-MU-β-D-glucuronide were
obtained from Nakalai Tesque (Kyoto, Japan). Endoglycosidase
H (EndoH) was purchased from New England Biolabos (Beverly,
MA, USA). All other reagents were of the highest grade
commercially available.
Animals
Animal experiments in this study were conducted following the
approval of the Ethics Committee for Animal Experiments of
Kyushu University. Male Wistar rats (7 weeks-old) were obtained
from Charles River Japan (Tokyo, Japan) and were maintained
for one week with free access to water and a suitable diet under
a 7 a.m. to 7 p.m. light/dark cycle. For isolation of total RNA,
liver tissue was quickly cut into small fragments, immediately
immersed in liquid nitrogen, and stored at−80◦C until required.
Expression System
Baculovirus for expressing CYP3A1 and UGT2B3 in Sf-9 cells
was prepared using a Bac-to-Bac system (Invitrogen). CYP3A1
cDNA was subcloned from P91023(B) (Nagata et al., 1999)
into pFastBac1 vector at an EcoRI site. The sequencing reaction
was carried out using a Big Dye R© Terminator v3.1 Cycle
Sequencing Kit (Life Technologies). Then, cDNA sequences were
confirmed by an ABI 3130xl Genetic Analyzer. CYP3A1 has two
synonymous and one non-synonymous nucleotide substitutions:
C1035G, G1074A, and T1055A, respectively, when compared
with the database (Gonzalez et al., 1985; GenBank accession
M10161). T1055A causes an amino acid substitution, M352K,
and this CYP3A1 is known to be catalytically active (Nagata et al.,
1999). It was used as the CYP3A1 in this study.
UGT2B3 cDNA was amplified from the total RNA of Wistar
rat liver by a reverse transcription-polymerase chain reaction
(RT-PCR), and cloned into pFastBac1. Isolation of total RNA
and the RT-reaction were carried out by a method previously
reported (Mutoh et al., 2006). To amplify the cDNA, nested
PCR with two primer sets was used. The primer set for the
first round PCR was UGT2B3(-20,-1)F1, 5′- TAA GGA TTT
TGA TTT TTA AG-3′ and UGT2B3(1647,1628)R1, 5′-CAT AAA
T TA GAA TGA GGC TG-3′. The primer set for the second
round PCR was PstI-UGT2B3(-5,15)F2, 5′-AAC TGC AGT TAA
GAT GCC TGG GAA GTG G-3′, and PstI-UGT2B3(1615,
1596)R2, 5′-AAC TGC AGT GTA GTG CAT TGT AA ATG AG-
3′ with restriction sites (PstI) underlined. The PCR was carried
out with LA-Taq DNA polymerase (TaKaRa Bio, Kyoto) using
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the manufacturer’s recommended protocol with the following
components: 1xLA-Taq buffer, 2 mM MgCl2, 2.5 mM each dNTP,
the primers F1 and R1 (5 µM each) and the cDNA in 100 µL
(first round PCR). The amplification was carried out using
the PROGRAM TEMP CONTROL SYSTEM PC-800 (ASTEC,
Fukuoka, Japan) with 94◦C, 4 min-(94◦C, 1 min, 50◦C, 1 min,
72◦C, 2 min)×30 cycles-72◦C, 20 min –4◦C, ∞. The second
round PCR was carried out as above but using primers F2 and R2.
The resulting PCR products were restricted with PstI and cloned
into pFastBac1. The sequence was confirmed by DNA sequencing
as described above. UGT2B3 has a non-synonymous nucleotide
substitution, T1498A, which causes a single amino-acid change,
S500T. We used this as a wild-type UGT2B3 in this study.
Escherichia coli DH10Bac was transformed either with
pFastBac1 plasmid carrying UGT2B3 or CYP3A1 cDNA
to prepare recombinant bacmid DNA. Production and
amplification of recombinant baculovirus and expression of
recombinant proteins in Sf-9 cells were carried out according to
the method described previously (Ishii et al., 2014).
The Introduction of a Potential
N-Glycosylation Site into UGT2B3
UGT2B3 exhibits 83% identity to UGT2B2 (Mackenzie, 1986) in
amino acid sequences. The Asn 316 of UGT2B2 is a potential site
for glycosylation. Therefore, the Ser 316 of UGT2B3 was replaced
with Asn by site-directed mutagenesis (SDM), and an expression
system for the UGT2B3(S316N) mutant was constructed in a
similar way as described above. The primers for the SDM were
designed by Quick Change Primer Design (Agilent Technology).
The primers used were UGT2B3(931, 964)(947G→A)SDM-F, 5′-
GGG TCA ATG GTC AGC AAC ATG ACA GAA GAA AAG
G-3′ and UGT2B3(964, 931)(947C→T)SDM-R, 5′-CCT TTT
CTT CTG TCA TGT TGC TGA CCA TTG ACC C-3′. The
procedures were carried out according to the manufacturer’s
recommendations. The introduction of the mutation at the
appropriate position and the absence of other unwanted
mutations were confirmed by DNA sequencing.
Kinetic Analysis
The kinetic analysis was performed using 100 µg microsomal
protein. The amount of microsomal protein used was unified by
adding control baculosomes. The activity of UGT2B3-catalyzed
glucuronidation was determined by high-performance liquid
chromatography (HPLC) with 4-MU as a substrate (Hanioka
et al., 2001). The microsomes and alamethicin were mixed and
preincubated for 30 min on ice. The assay was started by adding
UDPGA and incubation was performed for 60 min at 37◦C.
The reaction was stopped with 100 µL 1 M trichloroacetic acid
(TCA). After chilling on ice for 30 min, the incubation mixture
was centrifuged (15,000 rpm, 4◦C, 10 min). The supernatant
containing the 4-MU glucuronide formed was analyzed by HPLC
with a fluorescence detector (Ex 315 nm, Em 375 nm).
Data Analysis
The kinetics fitted a Michaelis−Menten equation, and the
kinetic parameters were calculated using GraphPad Prism
software (GraphPad Software Inc., San Diego, CA, USA). The
statistical difference in kinetic parameters between UGT2B3
single expression and UGT2B3-CYP3A1 dual expression was
evaluated by repeating the extra sum-of-squares F test.
Immunoblotting
Proteins were determined by the method of Lowry et al.
(1951) with bovine serum albumin as a standard. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed
according to Laemmli (1970). Proteins separated by SDS-PAGE
were electroblotted to a polyviniliden difluoride membrane.
UGT2B3 and UGT2B3(S316N) were detected by a goat
anti-mouse low-pI form UGT antibody (Mackenzie et al.,
1984). CYP3A1 was detected by rabbit anti-CYP3A2 antibody
(Nagata et al., 1990). Immunochemical detection was conducted
either with horseradish peroxidase (HRP)-conjugated secondary
antibodies, HRP-rabbit anti-goat IgG (MP Biomedicals, Santa
Ana, CA, USA), or HRP-donkey anti-rabbit IgG (GE Healthcare,
Piscataway, NJ, USA). These were diluted 10,000- and 40,000-fold
before use, respectively. Clarity Western ECL Substrate (Bio-Rad,
Hercules, CA, USA) was used as the substrate of HRP, and the
chemiluminescence emitted was analyzed by a ChemiDoc MP
System (Bio-Rad).
His-Tag Pull-Down Assay
Introduction of hemagglutinin (HA)-tag at the carboxyl terminus
of UGT2B3 was carried out by a two-step PCR. At the first
step, primer HA(21,1)-UGT2B3(1590,1573)R, 5′-ATC TGG AAC
ATC GTA TGG GTA CTC ATT CTT CAT TTT CTT-3′ and
primer F2 were used. The PCR reaction was basically the same
as that above except that pFastBac1-UGT2B3 was the template.
In the second step, PstI-TCA-HA(27,1)R, 5′-AAC TGC AGT
CAA GGG TAA TCT GGA ACA TCG TAT GGG TA-3′ and
primer F2 were used (Underline, PstI site). In the second step,
the PCR products of the first step were used as a template.
The PCR products were restricted with PstI and cloned into
pFastBac1. To construct HA-tagged UGT2B3(S316N), an SDM
described above was carried out with pFastBac1-UGT2B3-
HA. To construct hexa-histidine (His)6-tagged CYP3A1, PCR
was carried out with the following primers: NotI-CYP3A1
(-4,16)F, 5′-ATA AGA ATG CGG CCG CAG GGA TGG ACC
TGC TTT CAG-3′ and XhoI-CYP3A1-Histag(1510,1494)R, 5′-
CCG CTC GAG TCA GTG ATG GTG ATG GTG ATG
TGA TCC AGT TAT GAT TTC A-3′ (Underlines: NotI and
XhoI sites, respectively). The PCR products were purified and
restricted with NotI and XhoI and then subcloned into pFastBac1
restricted with the same enzymes. Their recombinant baculovirus
was prepared as described above. Sf-9 cells were transfected
with the recombinant virus for either CYP3A1-(His)6 and/or
UGT2B3-HA/UGT2B3(S316N). The resulting microsomes were
solubilized with sodium cholate and the pulled down assays
were carried out as described previously (Miyauchi et al.,
2015).
Modeling of the Structure of the UGTs
The models were constructed using Phyre2 (Protein
Homology/Analogy Recognition Engine V 2.0) web server,
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http://www.sbg.bio.ic.ac.uk/phyre2/html/ (Kelley et al., 2015)
with UGT2B7 (amino acid residue from 285 to 450) as a template
(Miley et al., 2007). Although the program is designed for
prediction using multiple templates, only UGT2B7 was selected
as a template in this case.
RESULTS
Expression of UGT2B3 and the
Glycosylation Mutant, UGT2B3(S316N)
UGT2B3 was expressed in Sf-9 cells, and the protein band in
the 50−60 kDa molecular mass range that was immunoreactive
toward anti-mouse low pI form UGT antibody and was
absent in control microsomes was judged to be UGT2B3
(Figure 1A). To introduce an N-glycosylated sugar chain to
UGT2B3, we referred to UGT2B2 (Mackenzie, 1986) which has
a potential N-glycosylation site and exhibits high similarity to
UGT2B3 in primary sequence. Then, the Ser316 of UGT2B3
was substituted to Asn to establish an expression system
for UGT2B3(S316N). The immune-reactive band with higher
molecular mass and absent in control microsomes was judged
to be UGT2B3(S316N)(Figure 1A). Thus, the molecular mass
was increased by the introduction of a potential glycosylation
site suggesting newly introduced N-glycosylation. This was
also supported by a reduction in size after EndoH-treatment
(Figure 1A).
Effect of Co-Expression of CYP3A1 on
UGT2B3- and UGT2B3(S316N)-Catalyzed
Glucuronidation
CYP3A1 was co-expressed in Sf-9 cells with UGT2B3 or
UGT2B3(S316N). Sf-9 cells, the microsomes of which express
UGT2B3 or UGT2B3(S316N) having a comparable band
intensity to that in the single expression system, were selected
and subjected to further investigation of their enzymatic
properties (Figures 1B–E). The amount of UGT2B3 and
microsomal protein used for the assay was also unified
between the single and dual expression systems. For this,
we rendered the protein level uniform with baculosomes
obtained from Sf-9 cells infected with control baculovirus.
When CYP3A1 was expressed together with UGT2B3, the
Vmax of UGT2B3-catalyzed 4-MU glucuronidation was
significantly decreased (Figure 2; Table 1). The kinetic
profiles for both the single and double expression could be
fitted to a Michaelis−Menten equation. When the 4-MU
concentration was varied, the Vmax was reduced significantly
while the Km was comparable (Table 1). Furthermore, the
same was also true for the kinetics by varying the UDPGA
concentration (Figure 3; Table 1). The Vmax was lowered
by CYP3A1 cotransfection while the Km for UDPGA was
comparable. Therefore, CYP3A1 suppressed the activity of
UGT2B3 which lacks potential glycosylation sites. However,
when CYP3A1 was expressed together with UGT2B3(S316N),
the Vmax of UGT2B3(S316N)-catalyzed 4-MU glucuronidation
was significantly increased (Figure 3; Table 2). The kinetic
FIGURE 1 | Immunoblots of the expression of UGT2B3,
UGT2B3(S316N), and CYP3A1 in Sf-9 cells. To obtain microsomes
simultaneously expressing CYP3A1 and UGT2B3/UGT2B3(S316N), Sf-9 cells
were transfected with recombinant baculovirus for CYP3A1 and
UGT2B3/UGT2B3(S316N). The lanes labeled “UGT2B3” and
“UGT2B3(S316N)” show microsomal samples of single transfected cells. The
lanes labeled “UGT2B3+CYP3A1” and “UGT2B3(S316N)+CYP3A1” show
double transfected cells. Baculosomes (5 µg protein) from UGT2B3
single-expressing Sf-9 cells were electrophoresed (SDS-PAGE). For
baculosomes of CYP3A1-UGT2B3 co-expression systems, protein amounts
equivalent to UGT2B3 for the single-expressing system were used. Similarly,
baculosomes (3 µg protein) from UGT2B3(S316N) single-expressing Sf-9
cells were electrophoresed. For baculosomes of CYP3A1-UGT2B3(S316N)
co-expression systems, protein amounts equivalent to UGT2B3(S316N) for
the single-expressing system were used. Mock represents the baculosomes
(10 µg protein) from Sf-9 cells infected with baculovirus without passenger
DNA which served as controls. The proteins in the gel were electrically
transferred to a polyvinilidene difluoride membrane, and blotted with goat
anti-mouse low pI form UGT (A−C) and rabbit anti-CYP3A2 (D,E), antibodies,
respectively. In right panel of (A), baculosomes (25 µg protein) from
UGT2B3(S316N)-expressing Sf-9 cells were treated with Endoglycosidase H
(EndoH, 500 U) at 37◦C for 17 h. Four microgram protein of the digest was
subjected to immunoblotting with goat anti-mouse low pI form UGT antibody
as a primary antibody. Black and red arrow heads represent original and
deglycosylated UGT2B3(S316N), respectively.
profiles for both single and double expression could be
fitted to a Michaelis−Menten equation. When the 4-MU
concentration was varied, the Vmax was increased significantly
while the Km was comparable (Table 2). Both the Vmax and
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FIGURE 2 | Michaelis−Menten plots of 4-MU glucuronidation
catalyzed by UGT2B3 in the absence and presence of CYP3A1
co-expression. The plots of UGT2B3 single- and UGT2B3-CYP3A1-dual are
shown. The kinetics obtained by varying the 4-MU concentration (A) and
UDPGA concentration (B) are shown. In (A), the 4-MU concentration was
varied over the range 10−1000 µM while the UDPGA concentration was fixed
at 2 mM. In (B), the UDPGA concentration was varied over the range
50 µM–3 mM while the 4-MU concentration was fixed at 1 mM. The total
amount of protein added to the assay mixture was standardized at 100 µg.
For this, when necessary, control baculosomes were added to the reaction
mixture. Kinetic parameters were calculated by fitting the curve to a
Michaelis−Menten equation, and they are listed in Table 1.
Km of UGT2B3(S316N)-catalyzed 4-MU glucuronidation was
significantly increased by varying the UDPGA concentration
(Figure 3; Table 2). In sharp contrast to the wild-type
UGT2B3, co-expression of CYP3A1 increased UGT2B3(S316N)
activity.
Effect of EndoH-Treatment on the
Activity of UGT2B3(S316N)
The glucuronidation activities of microsomes expressing
UGT alone, UGT2B3(S316N), and UGT and CYP,
UGT2B3(S316N)-CYP3A1, were compared with or without
EndoH-treatment (Figure 4). The 4-MU glucuronidation
activity in UGT2B3(S316N)-CYP3A1 was significantly higher
than the UGT2B3(S316N) single expression even after treatment
with EndoH. The deglycosylation did not affect the activity of
UGT2B3(S316N).
TABLE 1 | Kinetic parameters for 4-MU glucuronide formation catalyzed
by Sf-9 microsomes expressing UGT2B3 alone and UGT2B3 + CYP3A1:







By varying 4-MU concentration
UGT2B3 231 ± 31 682 ± 33 2.95
UGT2B3+CYP3A1 278 ± 20 377 ± 11∗ 1.36
By varying UDPGA concentration
UGT2B3 982 ± 70 664 ± 20 0.676
UGT2B3+CYP3A1 1088± 103 356 ± 14∗ 0.327
Data were fitted to a Michaelis−Menten equation (Figure 2). Results are the
estimated value ± SE. ∗Significantly different from UGT2B3 single expression
(p < 0.0001).
Protein−Protein Interaction of CYP3A1
and UGT2B3/UGT2B3(S316N)
(His)6-tagged CYP3A1 was constructed and, the baculovirus
encoding it subsequently co-transfected with either UGT2B3
or UGT2B3(S316N) which were tagged with HA. A band
immunoreactive to an anti-HA antibody was observed in the
precipitates (Figure 5). However, there was no pull down
when they were expressed singly. Therefore, both HA-tagged
UGT2B3 and UGT2B3(S316N) were pulled down by (His)6-
tagged CYP3A1 which suggests that CYP3A1 interacts with not
only UGT2B3 but also UGT2B3(S316N).
Prediction of the Structure of the
Carboxyl Terminal Domain of Wild-Type
UGT2B3 and a Glycosylated Mutant
UGT2B3(S316N)
The structures of part of the carboxyl terminal domain of
UGT2B3 and UGT2B3(S316N) were predicted by Phyre2 with
UGT2B7 as template (Figure 6). For comparison, the structure of
UGT2B3 which has Asn at 316 as a potential N-glycosylation site
was also predicted. For reference, the prediction was also carried
out for the UGT2B7 and UGT2B2 with UGT2B7 as a template.
In UGT2B7, Asn 315 is the corresponding residue. Overall, it
seems that the predicted structures are very similar to each
other. The structure around residue 316 or 315 (for UGT2B7), a
β-strand structure was observed except for UGT2B3. Although
the prediction does not include the effect of the glycosylation
chain, it is assumed that substitution of Ser 316 for Asn altered
the partial structure of UGT2B3.
DISCUSSION
The effect of CYP3A1 on UGT2B3 which lacks a potential
glycosylation site was studied. Since it is evident that CYP3A1
modulates UGT2B3 activity, N-glycosylation is not essential
for CYP3A1 to modulate this UGT. Furthermore, this study
demonstrates that the introduction of N-glycosylation to
UGT2B3 alters UGT sensitivity to a functional protein−protein
interaction with CYP3A: wild-type UGT2B3 which lacks
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FIGURE 3 | Michaelis−Menten plots of 4-MU glucuronidation
catalyzed by UGT2B3(S316N) in the absence and presence of CYP3A1
co-expression. The plots for UGT2B3(S316N) single- and
UGT2B3(S316N)-CYP3A1-dual are shown. The kinetics obtained by varying
the 4-MU concentration (A) and UDPGA concentration (B) are shown. In (A),
the 4-MU concentration was varied over the range 10−1000 µM while the
UDPGA concentration was fixed at 2 mM. In (B), the UDPGA concentration
was varied over the range 50 µM–7.5 mM while the 4-MU concentration was
fixed at 1 mM. The total amount of protein added to the assay mixture was
standardized at 100 µg. For this, when necessary, control baculosomes were
added to the reaction mixture. The kinetic parameters were calculated by
fitting the curve to a Michaelis−Menten equation, and they are listed in
Table 2.
N-glycosylation sites is suppressed by CYP3A1, whereas this
P450 increases UGT2B3(S316N) activity. These results suggest
that although the N-glycosylation of UGT is not essential for
modulation by CYP3A, the N-sugar chain linked to UGT is
one of the factors regulating this interaction between CYP3A
and UGT. In this study, we focused on the effect of CYP3A1
on UGT function. To allow a comparison, we carried out
several transfection experiments to obtain microsomes for UGT
single and CYP3A1-UGT dual microsomes with a comparable
UGT level and the results shown in Tables 1 and 2 allow
an examination of the effect of CYP3A1 on each UGT.
Although the activity of UGT2B3 and UGT2B3(S316N) cannot
be simply compared between Tables 1 and 2, it seems that
the introduction of N-glycosylation to UGT2B3 at this position
reduces the glucuronidation activity. Based on this, it is likely
that CYP3A1 increases the function of the glycosylated mutant
TABLE 2 | Kinetic parameters for 4-MU glucuronide formation catalyzed by
Sf-9 microsomes expressing UGT2B3(S316N) alone and UGT2B3(S316N) +







By varying 4-MU concentration
UGT2B3(S316N) 330 ± 33 143 ± 6 0.433
UGT2B3(S316N)+CYP3A1 444 ± 43 329 ± 43∗ 0.740
By varying UDPGA concentration
UGT2B3(S316N) 513 ± 51 142 ± 4 0.277
UGT2B3(S316N)+CYP3A1 1040 ± 100∗ 256 ± 8∗ 0.245
Data were fitted to a Michaelis−Menten equation (Figure 3). Results are
the estimated value ± SE. ∗Significantly different from UGT2B3(S316N) single
expression (p < 0.0001).
FIGURE 4 | Effect of EndoH-treatment on the glucuronidation
catalyzed by UGT2B3(S316N). Baculosomes (20 µg protein) from
UGT2B3(S316N) single- and UGT2B3(S316N)-CYP3A1 dual-expressing Sf-9
cells were treated with Endoglycosidase H (EndoH, 250 U) at 37◦C for 1 h.
The UGT activity was assayed with 100 or 1000 µM 4-MU and UDPGA fixed
at 3 mM. Significantly different from UGT2B3(S316N) single expression
(∗∗p < 0.001; ∗∗∗p < 0.0001).
UGT2B3(S316N) to approach that of the wild type. In general,
the methods that involve introduction of mutation(s) to the
potential glycosyation site to inhibit glycosylation are a well-
known strategy to investigate the role of glycosylation on enzyme
function. In some enzymes, the activity was increased by reducing
the glycosylation site, while in some other enzymes, the activity
was decreased (Skropeta, 2009). N-Glycosylation is involved in
the protein folding of UGT1A9 and important for catalytic
function (Nakajima et al., 2010). However, deglycosylation
of the mature UGT1A9 did not affect its function. In the
case of UGT2B3(S316N), N-glycosylation resulted in positive
modulation by CYP3A1 (Figure 4). However, the increase
in UGT activity was consistent even after EndoH-treatment
(Figure 4). Therefore, it is suggested that the engineered
glycosylated chain of UGT2B3(S316N) is no longer required after
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FIGURE 5 | Detection of an interaction between CYP3A1 and
UGT2B3/UGT2B3(S316N) by His-tag pull-down assay. UGT2B3-HA and
UGT2B3(S316N)-HA were expressed in the presence and absence of
coexpressed His-CYP3A1. The pull-down assay was performed according to
methods previously published (Miyauchi et al., 2015) with slight modification.
Microsomes (2 mg protein/mL) were solubilized with sodium cholate. Then the
solubilized microsomes were used in each assay. His-CYP3A1 and proteins
trapped by this P450 were eluted with buffer containing imidazole at a high
concentration. Each protein was detected by immunoblotting with a specific
antibody: rabbit anti-HA or rabbit anti-His. Solubilized microsomes and
His-CYP3A1–trapped samples are indicated as Input (30% of the input) and
PD (pull down), respectively. In (A), HA-tagged wild-type UGT2B3 (WT-HA)
was used. In (B), HA-tagged UGT2B3(S316N) (MT-HA) was used.
WT-HA+CYP-His and MT-HA+CYP-His indicate microsomes coexpressing
UGT2B3-HA or UGT2B3(S316N)-HA with His-CYP3A1, respectively.
Duplicate assays were carried out. For each pull-down sample, one half of the
precipitate was subjected to SDS-PAGE for detection with either HA or His
while the lanes shown by “C” represent a negative control sample obtained by
the same procedures but using solubilized control microsomes as an input,
with microsomes prepared from Sf-9 cells transfected with control baculovirus
alone. Details are described in the Section “Materials and Methods”.
maturation and fixing the conformation of UGT2B3(S316N).
This was also true for UGT2B3(S316N) without co-expression
of CYP3A1. Taken together, these findings suggest that the
complex formation with CYP3A1 affects the conformation
of UGT2B3(S316N). Although the kinetics were not studied
when examining the effect of deglycosylation, the activity was
consistent at both low and high substrate concentrations. It
FIGURE 6 | Comparison of the predicted structure of UGT2B3
wild-type, UGT2B3(S316N), UGT2B2, and UGT2B7: the region
spanning from 285 to 450. The models were constructed using the Phyre2
web server (Kelley et al., 2015) with the UGT2B7 (amino acid residue from
285 to 450) as a template. Template: UGT2B7, Miley et al. (2007) (DOI:
10.2210/pdb2o6l/pdb).
is assumed that deglycosylation did not alter the affinity to
the substrate. Since glycosylation of UGT has been shown
to be important during synthesis of the enzyme but not
once the mature enzyme is formed (Nakajima et al., 2010),
it is assumed that the CYP3A1-dependent modulation of
UGT2B3(S316N) that we observed is due to the interaction
of CYP3A4 with the secondary structure of UGT2B3(S316N)
during the process of formation of the mature UGT enzyme.
However, whether glycosylation or merely the presence of the
Asn at that site is sufficient to alter structure and function,
remains to be clarified in a future study. Nevertheless, our
current study suggests that the introduction of a potential
glycosylation site to UGT2B3 alters its CYP3A1-dependent
modulation.
UGT2B7 is known to interact with CYP3A4 (Takeda et al.,
2005, 2009; Miyauchi et al., 2015). Furthermore, the crystal
structure of the cofactor-binding domain of UGT2B7 (from
residues 285 to 450) has been determined (Miley et al., 2007). So
far, that is the sole example of a crystal structure of mammalian
UGTs. Concerning the structural differences between UGT2B3
and UGT2B3(S316N), the structures of the corresponding region
were predicted by Phyre2 with UGT2B7 as a template (Figure 6).
The results were very similar except around the 316th residue.
So, on the basis of the prediction, the substitution of Ser at
the 316th residue of UGT2B3 by Asn converted the random
coil to a β-strand structure (Figure 6). It is reasonable to
suppose that the combination of the structural difference and
the N-glycosylation in UGT2B3(S316N) resulted in a different
susceptibility to modulation by CYP3A1.
Frontiers in Pharmacology | www.frontiersin.org November 2016 | Volume 7 | Article 427 | 30
fphar-07-00427 November 14, 2016 Time: 15:9 # 8
Nakamura et al. CYP3A1-Dependent Alteration of UGT2B3 Activity
This study suggests that N-glycosylation of UGT is one of the
determinants of the functional interaction between CYP3A and
UGT. UGT function is known to be affected by N-glycosylation
(Mackenzie, 1990a,b; Barbier et al., 2000; Nakajima et al., 2010;
Nagaoka et al., 2012). Many UGTs have N-glycosylation at
more than two positions (Barbier et al., 2000; Nagaoka et al.,
2012). Therefore, the role of N-glycosylation of the other UGTs
is very important for functional protein−protein interactions
with CYP3A. Further studies are necessary to determine the
importance of N-glycosylation of UGTs in the UGT-CYP
interactions.
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The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs)
significantly influences the bioavailability and biological responses of endogenous
molecule substrates and xenobiotics including drugs. UGTs participate in the regulation
of cellular homeostasis by limiting stress induced by toxic molecules, and by
controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic,
transcriptional, post-transcriptional and post-translational levels. However, the UGT
protein interaction network, which is likely to influence glucuronidation, has received
little attention. We investigated the endogenous protein interactome of human UGT1A
enzymes in main drug metabolizing non-malignant tissues where UGT expression is
most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis
of affinity-purified UGT1A enzymes and associated protein complexes in liver, kidney
and intestine tissues revealed an intricate interactome linking UGT1A enzymes to
multiple metabolic pathways. Several proteins of pharmacological importance such
as transferases (including UGT2 enzymes), transporters and dehydrogenases were
identified, upholding a potential coordinated cellular response to small lipophilic
molecules and drugs. Furthermore, a significant cluster of functionally related enzymes
involved in fatty acid β-oxidation, as well as in the glycolysis and glycogenolysis
pathways were enriched in UGT1A enzymes complexes. Several partnerships were
confirmed by co-immunoprecipitations and co-localization by confocal microscopy.
An enhanced accumulation of lipid droplets in a kidney cell model overexpressing
the UGT1A9 enzyme supported the presence of a functional interplay. Our work
provides unprecedented evidence for a functional interaction between glucuronidation
and bioenergetic metabolism.
Keywords: UGT, proteomics, protein-protein interaction, affinity purification, mass spectrometry, metabolism,
human tissues
Abbreviations:AP, affinity purification; UGT, UDP-glucuronosyltransferases; IP, immunoprecipitation; PPIs, protein-protein
interactions; UDP-GlcA, Uridine diphospho-glucuronic acid; ER, endoplasmic reticulum; MS, mass spectrometry.
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INTRODUCTION
UDP-glucuronosyltransferases (UGTs) are well known for their
crucial role in the regulation of cellular homeostasis, by limiting
stress induced by toxic drugs, other xenobiotics and endogenous
lipophilic molecules, and by controlling the hormonal signaling
network (Rowland et al., 2013; Guillemette et al., 2014). UGTs
coordinate the transfer of the sugar moiety of their co-substrate
UDP-glucuronic acid (UDP-GlcA) to amino, hydroxyl and thiol
groups on a variety of lipophilic molecules, thereby reducing
their bioactivity and facilitating their excretion. In humans,
nine UGT1A and ten UGT2 enzymes constitute the main
glucuronidating enzymes. UGTs are found in nearly all tissues,
each UGT displaying a distinct profile of tissue expression,
and are most abundant in the liver, kidney and gastrointestinal
tract, where drug metabolism is highly active. These membrane-
bound enzymes localized in the endoplasmic reticulum (ER)
share between 55 and 97% sequence identity, thus displaying
substrate specificity and some overlapping substrate preferences
(Rowland et al., 2013; Guillemette et al., 2014; Tourancheau
et al., 2016). For instance, the alternative first exons of the single
UGT1 gene produce the nine UGT1A enzymes with distinct
N-terminal substrate binding domains but common C-terminal
UDP-GlcA-binding and transmembrane domains. The seven
UGT2B enzymes and UGT2A3 are encoded by eight distinct
genes, whereas UGT2A1 and UGT2A2 originate from a single
gene by a UGT1A-like, alternative exon 1 strategy. However,
similar to UGT1As, substrate binding domains of UGT2 enzymes
are more divergent than their C-terminal domains.
Genetic variations, epigenetic regulation, as well as post-
transcriptional and translational modifications, all contribute to
the modulation of UGT conjugation activity, thereby influencing
an individual’s response to pharmacologic molecules and the
bioactivity of endogenous molecules (Guillemette et al., 2010,
2014; Ramírez et al., 2010; Hu et al., 2014; Dluzen and Lazarus,
2015). For instance, genetic lesions at the UGT1 locus that
impair UGT1A1 expression or activity result in transient or fatal
hyperbilirubinemia, characterizing Gilbert and Crigler-Najjar
syndromes, respectively (Costa, 2006).
Several lines of evidence support protein-protein interactions
(PPIs) among UGTs and with other enzymes of pharmacological
importance (Taura et al., 2000; Fremont et al., 2005; Takeda
et al., 2005a,b, 2009; Ishii et al., 2007, 2014; Operaña and Tukey,
2007). These interactions may also significantly influence UGT
enzymatic activity (Bellemare et al., 2010b; Ménard et al., 2013;
Ishii et al., 2014; Fujiwara et al., 2016). In addition, interactions
of UGT proteins with some anti-oxidant enzymes that have
been recently uncovered have raised the interesting concept of
alternative functions of UGTs in cells (Rouleau et al., 2014).
However, most studies have been conducted in cell-based systems
with overexpression of tagged UGTs and little evidence in
human tissues supports the extent of this mechanism and its
physiological significance.
PPIs are essential to cell functions including responses
to extracellular and intracellular stimuli, protein subcellular
distribution, enzymatic activity, and stability. Understanding
molecular interaction networks in specific biological contexts
is therefore highly informative of protein functions. We aimed
to gain insight on the endogenous protein interaction network
of UGT1A enzymes by applying an unbiased proteomics
approach in main drug metabolizing human tissues. In doing
so, we provide support to a potential coordinated cellular
response to small lipophilic molecules and drugs. Importantly,
a potential functional interplay between UGT1A enzymes and




The anti-UGT1A rabbit polyclonal antibody (#9348) that
specifically recognizes UGT1A enzymes, and not the alternative
UGT1A variant isoforms 2, has been described (Bellemare
et al., 2011). Purification was performed using the biotinylated
immunogenic peptide (K520KGRVKKAHKSKTH533; Genscript,
Piscataway, NJ, USA) and streptavidin magnetic beads
(Genscript) per the manufacturer’s instructions. Antibodies
(3 ml) were incubated O/N at 4◦C with peptide-streptavidin
beads, and then washed with PBS to remove unbound
immunoglobulins. UGT1A-specific antibodies were eluted
using glycine (0.125 M, pH 2.9), and rapidly buffered with Tris
pH 8.0. Purified antibodies were subsequently concentrated
using a centrifugal filter unit (cut off 3 kDa; Millipore (Fisher
Scientific), Ottawa, ON) to a final volume of 1 ml.
Affinity Purification of Endogenous UGT1A
Enzymes and Their Interacting Partners in
Human Tissues and a UGT1A Expressing
Cellular Model
Human liver, kidney and intestine S9 fractions comprised of ER
and associated membranes as well as cytosolic cellular content
(Xenotech LLC, Lenexa, KS, USA) were from 50, 4, and 13
donors, respectively. This study was reviewed by the local ethics
committee and was exempt given that anonymized human tissues
were from a commercial source. Human colon cancer HT-
29 cells (ATCC, Manassas, VA, USA) were grown in DMEM
supplemented with 10% fetal bovine serum (Wisent, St-Bruno,
QC, Canada), 50mg/ml streptomycin, 100 IU/ml penicillin, at
37◦C in a humidified incubator with 5% CO2 as recommended
by ATCC. Immunoprecipitations (IP) were conducted according
to standard procedures (Savas et al., 2011; Ruan et al., 2012),
with at least three independent replicates per sample source.
For each sample, 1mg protein was lysed in 1 ml lysis buffer
A [final concentration: 50mM Tris-HCl pH 7.4, 150mM NaCl,
0.3% deoxycholic acid, 1% Igepal CA-630 (Sigma-Aldrich), 1mM
EDTA, complete protease inhibitor (Roche, Laval, QC, Canada)]
for 45 min on ice. This buffer included deoxycholate to enhance
membrane solubilization and stringency of immunoprecipitation
conditions. Lysates were then homogenized by pipetting up and
down through fine needles (18G followed by 20G) 10–20 times
on ice. Lysates were cleared of debris by centrifugation for 15
min at 13,000 g. UGT1A enzymes were immunoprecipitated
from cleared lysates with 4 µg of purified anti-UGT1A for 1 h
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at 4◦C with end-over-end agitation. After addition of protein
G–coated magnetic beads (200µl Dynabeads, Life Technologies,
Burlington, ON), lysates were incubated O/N at 4◦C. Beads were
washed three times with 1ml lysis buffer A and subsequently
processed for mass spectrometry (MS) analysis, as described
below. Control IPs were conducted in similar conditions using
4 µg normal rabbit IgGs (Sigma-Aldrich) per protein sample.
The inclusion of 150 mM NaCl and 0.3% deoxycholate ensured
stringent wash conditions.
Liquid Chromatography-MS/MS
Identification of UGT1A Interacting
Partners
Protein complexes bound to magnetic beads were washed 5
times with 20 mM ammonium bicarbonate (1 ml). Tryptic
digestion and desalting was performed as described (Rouleau
et al., 2016). Briefly, bead-bound proteins were digested in
10µg/µl trypsin for 5 hrs at 37◦C. The tryptic digest was
recovered, dried, and resuspended in 30µl sample buffer
(3% acetonitrile, 0.1% trifluoroacetic acid, 0.5% acetic acid).
Peptides were desalted on a C18 Empore filter (ThermoFisher
Scientific), dried out, resuspended in 10µl 0.1% formic acid
and analyzed using high-performance liquid chromatography-
coupled MS/MS on a LTQ linear ion trap-mass spectrometer
equipped with a nanoelectrospray ion source (Thermo Electron,
San Jose, CA, USA) or on a triple-quadrupole time-of-flight
mass spectrometer (TripleTOF 5600, AB Sciex, Concord, ON)
as described (Rouleau et al., 2014). Data files were submitted
for simultaneous searches using Protein Pilot version 4 software
(AB Sciex) utilizing the Paragon and Progroup algorithms
(Shilov). The RAW or MGF file created by Protein Pilot
was used to search with Mascot (Matrix Science, London,
UK; version 2.4.1). Mascot was set up to search against the
human protein database (Uniref May 2012; 204083 entries)
supplemented with a complete human UGT protein sequence
database comprised of common UGT coding variations and
protein sequences of newly discovered alternatively spliced UGT
isoforms (assembled in-house November 2013; 882 entries).
Mascot analysis was conducted using the following settings:
tryptic peptides, fragment and parent ion tolerance of 0.100Da,
deamidation of asparagine and glutamine and oxidation of
methionine specified as variable modifications, deisotoping was
not performed, two missed cleavage were allowed. Mass spectra
were also searched in a reversed database (decoy) to evaluate
the false discovery rate (FDR). On-beads digestion and MS
analyses were performed by the proteomics platform of the
CHU de Québec Research Center. The MS proteomics data
have been deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository with the dataset identifier PXD000295.
Identification of proteins in Scaffold (version 4.6.1; Proteome
Software, Portland, OR) was carried out using two sets of criteria:
(1) for UGT proteins, 95% peptide and protein probability, and 1
unique peptide were used, considering the high level of sequence
identity among the proteins in this family. For the same reason
of high sequence identity, each identified peptide was manually
assigned to the proper UGT protein or to the common UGT
sequence (Supplementary Table 1). (2) For UGT1A interacting
proteins, specificity threshold was set to 95% peptide and protein
probability and a minimum of 2 unique peptides. Proteins that
contained similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the principles
of parsimony. Detailed proteomics datasets are provided in
Supplementary Tables 4–7.
Confidence scores of each UGT1A-protein interaction were
determined using the computational tools provided online
at http://crapome.org (Choi et al., 2011). Spectral counts
for each identified protein were normalized to the length of
the protein and total number of spectra in the experiment.
Two empirical scores (FC-A and more stringent FC-B) and
one probability score (SAINT) (Mellacheruvu et al., 2013)
were then calculated based on normalized spectral counts of
identified proteins in UGT1A immunoprecipitation samples
compared to our matching control immunoprecipitation
samples (CRAPome Workflow 3). Confidence score calculations
were conducted separately for each tissue, with the following
analysis options: FC-A: Default parameters; FC-B: User
controls, stringent background estimation, geometric combining
replicates; SAINT: User Controls, Average - best 2 Combining
replicates, 10 Virtual controls and default SAINT options.
Confidence scores for all UGT1A interaction partners are given
in Supplementary Table 2.
Bioinformatics Tools and Data Analysis
The common external contaminants keratins and trypsin were
manually removed from the lists of interacting proteins prior
to pathway enrichment analysis. UGT1A interacting partners
were classified according to KEGG pathways (update November
12, 2016) using ClueGO and CluePedia Apps (v2.3.2) in
Cytoscape 3.4 (Bindea et al., 2009, 2013). Enrichment was
determined based on a two-sided hypergeometric statistical test
and a Bonferroni step down correction method. Only enriched
pathways with P < 0.05 and a Kappa score threshold of 0.4
were considered. The following optional criteria were also used
for the search: minimum # genes = 4, minimum 2% genes.
The UGT1A interactome was generated using Cytoscape basic
tools. Because protein annotations based on tools such as KEGG
and Gene Ontology are partial, the UGT1A interactome was
subsequently manually extended to include significant UGT1A
interactors that were absent in the original output but involved in
enriched pathways, per their Uniprot entries (www.uniprot.org)
and literature mining. Details are included in the legend of
Figure 3.
Validation of Protein-Protein Interactions
by Co-IP and Immunofluorescence (IF)
HEK293 cells stably expressing the human enzyme UGT1A9-
myc/his (a pool of cells) were used (Bellemare et al., 2010a).
Expression and glucuronidation activity of the tagged UGT1A9
in this model have been described and were similar to the
untagged enzyme (Bellemare et al., 2010a). In the current
study, only the myc tag served for UGT1A9 detection and
the his tag was not exploited. Cells were transfected with
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Lipofectamine 2000 (Life Technologies) to transiently express
tagged protein partners. HA-ACOT8 and FLAG-SH3KBP1 were
kindly provided by Dr Ming-Derg Lai (National Cheng Kung
University, Taiwan; Hung et al., 2014) and Dr Mark McNiven
(Mayo Clinic, Rochester, MN; Schroeder et al., 2010) respectively.
The PHKA2-myc-FLAG expression construct was purchased
from OriGene (Rockville, MD, USA).
Co-IP: HEK293 cells (3 × 105 cells plated in 10 cm
dishes) were harvested 40 h post-transfection. Cells were
washed three times with PBS, lysed in 800µl lysis buffer
B (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Igepal,
1mM DTT, complete protease inhibitor) for 1 h at 4◦C and
subsequently homogenized and centrifuged as described above.
Immunoprecipitation with purified anti-UGT1A antibodies
(2 µg) or control rabbit IgG (2µg) and 50µl Protein-
G magnetic beads was as above. Protein complexes were
washed three times in lysis buffer B and eluted in Laemmli
sample buffer by heating at 95◦C for 5 min. Eluates were
subjected to SDS-PAGE, and the presence of interacting partners
was revealed by immunoblotting using anti-tag antibodies
specified in figures and legends: anti-myc (clone 4A6, EMD
Millipore, Etobicoke, ON, Canada; 1:5000), anti-FLAG (clone
M2, Sigma-Aldrich, St-Louis, MO, USA; 1:20 000) and anti-
HA (Y-11, Santa Cruz Biotechnologies, Dallas, TX, USA;
1:500).
IF: HEK293 cells (2 × 105 cells per well of 6-well plates)
grown on coverslips were harvested 36 h post-transfection
and processed for IF, as described (Rouleau et al., 2016).
ACOT8 was detected with anti-HA (1:500), SH3KBP1 with
anti-FLAG (1:1500), UGT1A9-myc/his with anti-myc (1:200)
or purified anti-UGT1A (1:500), and with secondary goat anti-
rabbit, goat anti-mouse or donkey anti-mouse respectively,
conjugated to either AlexaFluor 488 or 594 (1:1000; Invitrogen).
Immunofluorescence images were acquired on a LSM510 META
NLO laser scanning confocal microscope (Zeiss, Toronto, ON,
Canada). Zen 2009 software version 5.5 SP1 (Zeiss) was used for
image acquisitions.
Quantification of Lipid Droplets
HEK293 cells grown on coverslips were fixed in 3.7%
formaldehyde (Sigma) for 30 min at RT. Cells were then gently
washed three times with PBS and incubated for 10min in
0.4µg/mL Nile Red (Sigma). After being rinsed three times,
coverslips were mounted on glass slides using Fluoromount
(Sigma) as a mounting medium. Images were acquired on
a Wave FX-Borealis (Quorum Technologies, Guelph, ON,
Canada) - Leica DMI 6000B (Clemex Technologies inc.,
Longueil, QC, Canada) confocal microscope, with a 491 nm
laser and 536 nm filter. Z-stacks were acquired every 0.15µm.
Stacks were analyzed using ImageJ (v1.51f; U.S. National
Institutes of Health, Bethesda, MD, USA) and the 3-D Object
Counter plugin (Bolte and Cordelieres, 2006). Results are
derived from 3 independent experiments and more than
140 cells per experiment were analyzed for each condition.
Fluorescence images were acquired on an LSM 510 microscope
as above.
FIGURE 1 | UGT1A interaction network investigated by untargeted
proteomics. (A) The nine UGT1A enzymes are distinguished by the amino
acid sequence of their substrate binding domain (unique peptides) whereas
they share identical C-terminal co-substrate and transmembrane domains
(common peptides). The anti-UGT1A antibody used in this study was raised
against a C-terminal peptide common to all nine UGT1A enzymes but does
not recognize the main spliced alternative isoforms 2 or UGT1A_i2s. (B)
Experimental approach to establish endogenous UGT1A protein interactomes
in drug metabolizing tissues and in the colon cancer cell model HT-29.
Immunoprecipitation of UGT1A enzymes was conducted with the anti-UGT1A
antibody. The numbers of common and unique UGT1A protein partners
identified by mass spectrometry and above confidence threshold are
represented in the Venn diagrams. Datasets were established on a minimum of
two biological replicates. A Venn diagram for the 4 matrices is presented in
Supplementary Figure 2. A list of proteins in each group is provided in
Supplementary Table 3.
RESULTS
Endogenous UGT1A Enzymes Associate
with Several Other Metabolic Proteins in
Non-malignant Human Tissues
The endogenous interactome of human UGT1A enzymes was
established in three major metabolic tissues, namely liver, kidney
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FIGURE 2 | Quantitative overview of UGT1A enzymes immunoprecipitated from each tissue. Identification of immunoprecipitated UGT1A enzymes was
based on the detection of peptides unique to specified UGT1A enzymes. (A) The quantitative assessment of each immunoprecipitated UGT1A is given by the total
number of spectral counts for peptides unique to each UGT1A identified by mass spectrometry. Total spectral counts for peptides common to all UGT1A enzymes
(Liver: 465; Kidney: 67; Intestine: 1561) were not considered in the quantitative assessment of specific UGT1As. (B) For each tissue, the number of peptides unique to
each UGT1A identified by MS/MS analysis is represented in ring charts. Detailed quantification and unique/common UGT1A peptides identified are presented in
Supplementary Table 1.
and intestine from pools of 4–50 donors, using S9 tissue fractions
comprised of ER and associated membranes as well as cytosolic
cellular content (Figure 1). IPs were conducted with an antibody
specific to the C-terminal region common to the nine human
UGT1A enzymes, thereby allowing affinity purification of all
UGT1A enzymes expressed in studied tissues (Figure 1A). This
antibody was shown by western blotting to lack affinity for
alternatively spliced UGT1A isoform 2 proteins derived from
the same human UGT1 gene locus (Bellemare et al., 2011).
The experimental approach to establish the endogenous UGT1A
enzymes interactome using the anti-UGT1A enzymes antibody is
presented in Figure 1B.
Multiple UGT1A enzymes were immunopurified from
each tissue in line with their documented expression
profile (Figure 2). The list of specific UGT1A enzymes
immunoprecipitated from each tissue was established based
on their unique N-terminal peptide sequences, whereas
multiple additional peptides corresponding to the common C-
terminal half of the UGT1A proteins and thereby common
to all UGT1A enzymes were also observed (Figure 2B,
Supplementary Figure 1; Supplementary Table 1).
Spectral counts for unique peptides provided a quantitative
appreciation of immunoprecipitated UGT1A (Figure 2A).
UGT1A1 and UGT1A4 were the most abundant UGT1As
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PHKB 36 193 28.55 TOP2B 16 53 5.93 ATP5A1 13 8 4.91
PHKA2 34 180 26.62 PFKL 24 35 4.68 UGT2A3 24 61 4.63
PHKG2 40 68 10.49 TRA2B 24 36 4.21 GBF1 12 60 4.60
PRDX2 47 55 7.62 ATP5A1 33 32 4.10 SLC25A5 35 54 4.37
UGT2B7 19 31 5.53 PRDX2 41 50 3.60 RALGAPB 13 51 4.26
PRDX1 35 25 3.42 PRDX1 44 39 3.08 PRDX2 24 46 4.06
ECH1 28 17 2.61 HSPA8 30 21 2.70 PRDX1 31 45 4.01
SLC25A5 17 9 2.20 SLC34A2 16 17 2.66 RALGAPA2 6 29 3.28
GBF1 4 9 2.15 ACCA2 43 21 2.30 ECH1 30 21 2.84
UGT2B4 11 12 1.98 ASS1 42 21 2.22 PDIA3 5 3 2.82
aExcluding common IP protein contaminants (structural, ribosomal and RNA-binding proteins).
bProteins in bold were identified in the 3 tissues.
cTotal coverage calculated with peptides identified in all replicates (n = 4, 3 and 2 for the liver, kidney and intestine, respectively).
dTotal spectral counts of all replicates.
in hepatic IPs, whereas UGT1A1 and UGT1A10 were
predominantly immunopurified from the intestine and UGT1A9
from the kidney (Figure 2A, Supplementary Table 1). UGT1A9
(n = 51 spectra) was far more abundant than UGT1A6 (n = 2
spectra) in the kidney whereas UGT1A10 (n = 194 spectra)
predominated over most other UGT1A in the intestine,
although all UGT1A enzymes were identified besides UGT1A7
and UGT1A9. These metrics indicated that an exhaustive
immunoprecipitation of UGT1As from each tissue was achieved.
UGT1A Interaction Network and Functional
Annotation
A total of 9 independent AP-MS datasets (4 liver, 3 kidney,
and 2 intestine replicates of control and UGT1A AP-MS)
efficiently immunoprecipitated UGT1A enzymes and associated
proteins. Mass spectra were assigned to specific proteins using
Mascot and Scaffold software. A list of UGT1A-interacting
proteins was created based on the analysis of total spectral
counts assigned to each identified protein in each replicate to
obtain empirical (FC-B) and probability (SAINT) confidence
scores (Supplementary Table 2). Using a FC-B score threshold
of 1.42, we reported a total of 148 proteins forming endogenous
interactions with UGT1A enzymes in the three surveyed
human tissues (31 in the liver, 70 in the kidney and 77 in
the intestine) (Figure 1B, Supplementary Table 2). This FC-
B threshold was selected based on the validated protein
partner having the lowest probability score, corresponding to
PHKA2 in the intestine (see below). This approach was chosen
because of the inherent difficulty to obtain similar replicate
datasets with AP-MS from tissues, especially in intestine, a
variability highly penalized in the SAINT scoring algorithm
(Supplementary Figure 2). To further strengthen the UGT1A
interactome in the gastrointestinal tract, we also conducted
three more replicate AP-MS experiments of endogenous UGT1A
enzymes with the human colon cancer cell line HT-29,
expressing high levels of UGT1As. The intestinal UGT expression
profile is well represented in HT-29 cells, with UGT1A1,
UGT1A6, UGT1A8, and UGT1A10 immunoprecipitated in
similar proportions (Supplementary Table 1). Using the FC-B
threshold used for tissues (1.42), 125 interaction partners were
selected for further analysis. Of those, 44 proteins were common
with those immunoprecipitated in non-malignant tissue samples,
including 26 common with the intestine dataset (Figure 1B,
Supplementary Figure 3). UGT1A protein partners with highest
significance scores are given in Table 1 whereas a complete
list of immunoprecipitated protein partners is provided in
Supplementary Table 2.
To portray the global functions enriched in the UGT1A
interactome, the UGT1A protein partners from the three
surveyed tissues were classified per the KEGG pathway
database. Structural proteins such as tubulins, myosins, actin,
as well as multiple ribosomal protein subunits (RPL/RPS
proteins) and other RNA-binding proteins involved in mRNA
splicing (e.g., heterogeneous ribonucleotide proteins (hnRNPs)
and serine/arginine-rich splicing factors (SRSF) proteins)
were significant classes of proteins immunoprecipitated
with UGT1As. However, because these proteins are
frequently non-specifically enriched in AP-MS experiments
(Mellacheruvu et al., 2013), the specificity of interactions
with UGT1A will require validation and will not be discussed
further.
The interactome of UGT1A enzymes is characterized by
numerous metabolic proteins playing roles in detoxification
and bioenergetic pathways (Figure 3). They include the UGT2
glucuronosyltransferases UGT2A3, UGT2B4, UGT2B7, and
UGT2B17, the glutathione S-transferase GSTA1, glycine N-
acyltransferase GLYAT, the alcohol dehydrogenase ALDH2 and
the antioxidant enzymes PRDX1 and PRDX2 (full protein names
are provided in Table 2). Given their functions in line with
high scoring proteins, ADH1B and PRDX3 were also included
in the final interactome, having confidence interaction scores
just below threshold (FC-B = 1.37; Supplementary Figure 2).
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FIGURE 3 | UGT1A interaction network in drug metabolizing tissues. UGT1A interacting proteins were classified according to KEGG pathways with
ClueGO/CluePedia (Bindea et al., 2009, 2013). Node size is representative of pathway enrichment significance. Interactome was enhanced with significant interaction
partners not part of KEGG pathways that are functionally related based on Uniprot and literature. These proteins are not linked to nodes but are grouped according to
global functions. Structural proteins, ribosomal protein subunits and other RNA-binding proteins involved in mRNA splicing are not shown but were significantly
enriched in UGT1A IPs. Full protein names are provided in Table 2. Complete lists of UGT1A interacting proteins are provided in Supplementary Table 2.
Similarly, the cytochrome P450 CYP3A4 was included because
also observed in liver tissue with a single high confidence peptide
and a previously observed interaction partner (Fremont et al.,
2005; Ishii et al., 2014). Enzymes of the lipid metabolism pathway
were also significantly represented and most particularly
several peroxisomal and mitochondrial proteins involved
in fatty acid β-oxidation, namely ACOT8, ECH1, CPT1A,
and ACAA2. To encompass all potential protein partners
involved in lipid metabolism, a pathway that was functionally
validated at a later stage (see below), relevant but slightly lower
scoring proteins were incorporated in the final interactome,
namely SCP2, ACSL1, EHHADH, ACAT1, and ECHS1
(FC-B = 1.38–1.19; Supplementary Figure 2). Finally, the
glycolysis/pyruvate and glycogenolysis metabolic pathways
were also significantly enriched, given the high number of
immunoprecipitated UGT1A partners in these pathways. Several
other protein partners, including transporters (SLC25A5,
SLC25A13, and SLC34A2) and proteins participating in
vesicular trafficking (RALGAPA1, RALGAPA2, RALGAPB,
and GBF1) were also immunoprecipitated from tissues and
may represent important partners (Table 1, Figure 3). The
interaction network of UGT1A enzymes established in the
HT-29 cell model was consistent with that built from tissues,
with enrichments in xenobiotic and bioenergetics metabolic
pathways. Several transporters, anti-oxidant, lipid metabolism,
glycolytic/glycogen metabolic enzymes and vesicular trafficking
proteins were all significantly identified in AP-MS on cells,
as in tissues (Supplementary Table 2), further supporting
the significance of the endogenous interactome of UGT1A
enzymes.
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FIGURE 4 | Validation of selected protein interactions by immunoprecipitation and immunofluorescence in a UGT negative kidney cell model.
(A) Immunoprecipitation (IP) of UGT1A9, with purified anti-UGT1A antibodies, was conducted in HEK293-UGT1A9_myc/his transiently transfected with the indicated
protein partner. UGT1A9 was immunodetected with anti-myc, whereas protein partners were detected with anti-tag antibodies as specified below immunoblots.
Control IPs were conducted with normal rabbit immunoglobulins (IgG). Lysates (IP input) are shown as references. Protein bands denoted by the asterisk are the
rabbit IgGs used in IPs. (B) Co-localization of UGT1A9 and the protein partners ACOT8 and SH3KBP1/CIN85 assessed by immunofluorescence in
HEK293-UGT1A9_myc/his transiently expressing specified partners. Confocal microscope images are representative of three independent experiments. Partial
co-localization is detected by yellow labeling in merged images. Insets present enlargements of boxed regions in merged images. Bar = 20µm.
Experimental Validation of Selected UGT1A
Partners
Using the non-malignant kidney model cell line HEK293 (a UGT
negative model) stably expressing a myc/his-tagged UGT1A9
enzyme, selected partnerships with enzymes of bioenergetic
cellular pathways were confirmed by a co-IP/immunodetection
approach. The peroxisomal acyl-coenzyme A thioesterase
ACOT8, involved in fatty acid β-oxidation, and the cytosolic
phosphorylase b kinase regulatory subunit A2 (PHKA2),
involved in glycogen degradation, were selected based on their
significant enrichment in more than one tissue (ACOT8 in
kidney, intestine and HT-29; PHKA2 in all 4 matrices). The
cytosolic SH3 domain-containing kinase-binding protein 1, also
known as cbl-interacting protein of 85 kDa (SH3KBP1/CIN85),
an adaptor protein regulating membrane trafficking and receptor
signaling, was also chosen as a representative protein partner
of the vesicular trafficking pathway, given its identification in
the kidney and HT-29 datasets. After transient expression of
selected partners as tagged proteins in the kidney cell model
stably expressing UGT1A9, each of the candidate partners
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FIGURE 5 | Accumulation of cellular lipid droplets in UGT1A9 expressing HEK293 cells. (A) Representative images of lipid droplets (green fluorescence)
stained with Nile Red in HEK293-UGT1A9_myc-his or control HEK cells (stably transfected with the empty pcDNA3.1 vector—UGT negative cells). Bar = 20µm.
(B) Average number of lipid droplets per cell stably expressing UGT1A9 or control HEK cells. Lipid droplets per cell were counted in at least 140 cells per condition
and averaged (n = 3 independent experiments).
was specifically enriched by an IP of UGT1A (Figure 4A).
Likelihood of a physical interaction of ACOT8 and CIN85
with UGT1A enzymes was further supported by their partial
co-localization with UGT1A9 detected by IF and confocal
microscopy (Figure 4B).
Influence of UGT1A on Cellular Lipid
Droplets
Pathway enrichment analysis identified several proteins involved
in lipid metabolism and suggested a possible functional
implication of UGT1A enzymes in this pathway. This was
explored by measuring levels of lipid droplet in HEK293 cells
stably expressing or not the UGT1A9 enzyme. Lipid droplets,
cytoplasmic organelles that constitute a store of neutral lipids
such as triacylglycerides, were labeled with Nile Red and counted.
This analysis revealed that the number of lipid droplets per cell
was significantly higher in UGT1A9-expressing cells relative to
control cells (by 7.5-fold, P < 0.001), whereas average size and
staining intensity of lipid droplets were similar between UGT
negative and UGT1A9-expressing HEK293 cells (Figure 5).
DISCUSSION
Defining protein interaction networks is a key step toward
a better understanding of functional crosstalk among cellular
pathways. In the current work, we established the endogenous
interactome of key metabolic UGT1A enzymes in three
relevant human tissues. Data suggest an interplay between
UGT1A enzymes regulating the glucuronidation pathway and
enzymes involved in multiple cellular energetic pathways,
most notably with lipid and glucose/glycogen metabolism.
This interactome considerably expands what was known
about UGT1A protein interactions in the literature (reviewed
by Ishii et al., 2010; Fujiwara et al., 2016) and public
databases (3 interactions among UGT1A enzymes reported in
STRING database (http://string-db.org/), none in the iRefWEB
database (http://wodaklab.org/iRefWeb/), accessed November 9,
2016).
One of our study’s strength relies on the use of an unbiased
approach targeting endogenous proteins in non-malignant
human tissues, as opposed to most studies that used the
overexpression of an exogenous tagged protein expressed in
a cellular model (Taura et al., 2000; Takeda et al., 2005a,b,
2009; Fujiwara et al., 2007a,b, 2010; Kurkela et al., 2007).
In addition, profiles of immunoprecipitated UGT1A enzymes
replicated well their known tissue distribution, and spectral
peptide counting further reflected the relative abundance of these
UGT1A enzymes previously established by mass spectrometry-
basedmultiple reactionmonitoring and RNA-sequencing (Fallon
et al., 2013a,b; Sato et al., 2014; Margaillan et al., 2015a,b;
Tourancheau et al., 2016). Of note, our data support the notion
that both UGT1A8 and UGT1A10 enzymes are expressed in
the intestine, as peptides unique to each UGT were detected
(Figure 2; Supplementary Table 1) (Strassburg et al., 2000; Sato
et al., 2014; Fujiwara et al., 2016; Troberg et al., 2016). Moreover,
two peptides specific to the UGT1A5 enzyme sequence were
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TABLE 2 | Complete names of most significant UGT1A protein partnersa.
Protein Namesb
Abbreviation Complete names
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial
ACAT1/SOAT1 Sterol O-acyltransferase 1
ACOT8 Acyl-coenzyme A thioesterase 8
ACSL1 Long-chain-fatty-acid–CoA ligase 1
ADH1B Alcohol dehydrogenase 1B
ALDH2 Aldehyde dehydrogenase, mitochondrial
ALDH6A1 Methylmalonate-semialdehyde dehydrogenase [acylating],
mitochondrial
ASS1 Argininosuccinate synthase
ATP5A1 ATP synthase subunit alpha, mitochondrial
CALM1 Calmodulin
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform
CYP3A4 Cytochrome P450 3A4
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial
ECHS1 Enoyl-CoA hydratase, mitochondrial
EHHADH Peroxisomal bifunctional enzyme
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide
exchange factor 1
GLYAT Glycine N-acyltransferase
GSTA1 Glutathione S-transferase A1
HSPA8 Heat shock cognate 71 kDa protein
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial
ITPR2 Inositol 1,4,5-trisphosphate receptor type 2
PC Pyruvate carboxylase, mitochondrial
PCK2 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial
PDIA3 Protein disulfide-isomerase A3
PFKL ATP-dependent 6-phosphofructokinase, liver type
PHKA2 Phosphorylase b kinase regulatory subunit alpha, liver isoform
PHKB Phosphorylase b kinase regulatory subunit beta






RALGAPA1 Ral GTPase-activating protein subunit alpha-1
RALGAPA2 Ral GTPase-activating protein subunit alpha-2
RALGAPB Ral GTPase-activating protein subunit beta
SCP2 Non-specific lipid-transfer protein
SH3KBP1 SH3 domain-containing kinase-binding protein 1
SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2
SLC25A5 ADP/ATP translocase 2
SLC34A2 Sodium-dependent phosphate transport protein 2B
TOP2B DNA topoisomerase 2-beta
TRA2B Transformer-2 protein homolog beta
aComplete list of immunoprecipitated proteins is provided in Supplementary Table 2.
bProtein names are according to Uniprot (www.uniprot.org; accessed December 21,
2016).
detected in the intestine, albeit at low levels (1 spectrum for
each peptide) relative to other expressed UGT1As, providing
evidence for its intestinal expression at the protein level
(Supplementary Figure 4).
We provide unprecedented data on protein-protein
interactions within the UGT family, namely between UGT1A
and UGT2A3 enzymes and/or UGT2B family members.
UGT1A-UGT2 interactions were observed in the liver (UGT2B4
and UGT2B7), in the kidney (UGT2B7) and in the intestine
(UGT2B7, UGT2B17, and UGT2A3), and reflect the expression
profiles of these UGT2 enzymes (Harbourt et al., 2012;
Fallon et al., 2013a,b; Sato et al., 2014; Margaillan et al.,
2015a,b; Tourancheau et al., 2016). Our current study offers
a representative view of the endogenous UGT1A enzyme
interactome in relevant drug metabolizing tissues. Findings
are consistent with the interactions between several UGT1A
enzymes and UGT2B7 detected in microsomes from liver
tissues (Fremont et al., 2005; Fujiwara and Itoh, 2014) and
when overexpressed in heterologous cell model systems as
tagged proteins (Kurkela et al., 2007; Operaña and Tukey, 2007;
Fujiwara et al., 2010; Ishii et al., 2010, 2014; Liu et al., 2016). In
addition, other transferases and anti-oxidant PRDX1, PRDX2
and PRDX3 enzymes were also found associated with UGT1A
enzymes. The interaction network is also in line with a model
favoring detoxifying enzymes acting in a “metabolosome,” i.e.
a complex of xenobiotic-metabolizing enzymes and associated
transport proteins regulating drug and xenobiotics inactivation
and elimination (Taura et al., 2000; Takeda et al., 2005a,b, 2009;
Akizawa et al., 2008; Mori et al., 2011; Fujiwara and Itoh, 2014;
Ishii et al., 2014; Rouleau et al., 2014; Fujiwara et al., 2016).
The significant number of peroxisomal and mitochondrial
enzymes regulating fatty acid β-oxidation identified in protein
complexes with UGT1A enzymes hinted toward a potential
involvement of UGT1A in regulating lipid metabolism. The
higher number of lipid droplets, a reservoir of neutral lipids
(such as fatty acids, sterol esters and phospholipids) (Thiam
et al., 2013), in the UGT negative kidney cell model HEK293
overexpressing UGT1A9 lends support to this hypothesis. This
observation is reminiscent of higher levels of lipid bodies induced
by the overexpression of the peroxisomal ACOT8 protein, a
confirmed UGT1A protein partner (Ishizuka et al., 2004). A
modulation of lipid storage levels by overexpression of the
UGT2B7 enzyme was also recently uncovered in breast and
pancreatic cancer cell line models (Dates et al., 2015). This
potential functional link between UGTs and lipid metabolism is
intriguing and may be independent of the glucuronidation of
some bioactive lipids previously reported (Turgeon et al., 2003).
The underlying mechanism(s) of increased lipid droplets and
the potential involvement of protein complexes comprised of
UGT1A enzymes thus remain to be addressed and are aspects
that fall beyond the scope of this study.
While UGT1A are ER-resident enzymes, their presence
in other subcellular compartments such as the mitochondria
is suggested by their co-localization with markers of several
organelles (Rouleau et al., 2016). An intimate connection
between ER, mitochondria, peroxisomes, and lipid droplets
is also well recognized (Currie et al., 2013; Schrader et al.,
2015). This is consistent with the significant number of
peroxisomal and mitochondrial proteins interacting with
UGT1A enzymes. Indeed, peroxisomes and lipid droplets are
ER-derived substructures, whereas interactions between the ER
and mitochondria at the so-called mitochondria-associated ER
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membranes are gaining recognition as important sites of ER-
mitochondria crosstalk where regulation of calcium signaling,
lipid transport and tricarboxylic acid cycle take place (Hayashi
et al., 2009; Tabak et al., 2013; Lodhi and Semenkovich, 2014; Pol
et al., 2014).
The UGT1A interaction network exposes multiple links
with enzymes of bioenergetic pathways. Besides lipids, glycogen
catabolism as well as glycolytic and tricarboxylic acid cycle
pathways may be influenced by the interactions of UGT1A with
several subunits of the phosphorylase b and glycolytic/TCA cycle
enzymes. It could be envisioned that UGT1A enzymes participate
in the regulation of metabolite levels to prevent the toxic impact
of excess concentrations of basic constituents, a hypothesis that
remains to be addressed. Interestingly, mice with a disrupted
UGT1 gene locus (UGT1−/− mice) are short-lived, dying within 1
week of birth. Whereas hyperbilirubinemia induced by UGT1A1
deficiency appears largely responsible for early death, highly
perturbed hepatic expression of genes involved in general cellular
metabolic function, and notably those of starch, sugar and fatty
acid metabolism was also observed in UGT1−/− mice, also
supporting a contribution of UGT1A enzymes in those metabolic
pathways (Nguyen et al., 2008). Rodent cell models fromUGT1A-
deficient mice or Gunn rats may constitute valuable models to
investigate the interplay between UGT1A enzymes and global
metabolic pathways.
One of the limitations of this study is that it examines
complexes in which UGT1A enzymes reside and it does not
provide information on direct interactions of UGT1A with
proteins. Approaches such as proximity ligation and fluorescence
resonance energy transfer are necessary to move forward with
a better understanding of direct protein interactions and the
domains involved. It is well documented that UGTs, like
numerous metabolic enzymes, homo- and hetero-oligomerize
with other UGTs (Fujiwara et al., 2007a; Kurkela et al., 2007;
Operaña and Tukey, 2007; Bellemare et al., 2010b). It is therefore
conceivable that UGT1A enzymes influence the activity of other
metabolic enzymes by direct interactions that could alter the
stoichiometry or composition of metabolic protein complexes.
In turn, interactions of UGT1A enzymes with other metabolic
enzymes may influence the glucuronidation pathway and thus
contribute to the variable conjugation rates of individuals. This
notion is supported by the altered activity of several UGT1A
enzymes by CYP3A4 demonstrated in a cell-based system (Ishii
et al., 2014). As well, the antagonistic or stimulatory functions
of interactions among UGT1A and UGT2 enzymes, or with
alternatively spliced isoforms, are consistent with a potential
mode of regulation of UGTs by PPI (Fujiwara et al., 2007a;
Bellemare et al., 2010b; Bushey and Lazarus, 2012; Rouleau et al.,
2014, 2016; Audet-Delage et al., 2017).
In summary, we established an effective affinity purification
method coupled to mass spectrometry for the enrichment and
identification of protein complexes interacting with endogenous
UGT1A enzymes. We successfully applied this approach to
UGT1A enzymes expressed in drug metabolizing tissues and
a UGT positive cell model to uncover an interaction map
linking glucuronidation enzymes to other metabolic proteins
involved in detoxification, as well as in the regulation of
bioenergetic molecules (lipids and carbohydrates). Our data
also support physical and functional interactions between ER
and other subcellular compartments. The crosstalk among
cellular metabolic functions exposed in this work warrants
future investigations to address the impact of UGT1A-protein
interactions on detoxification functions of UGT1A enzymes and
of UGT1A enzymes on global metabolic cellular functions.
AUTHOR CONTRIBUTIONS
Conceptualization: CG; Methodology, MiR, MéR, YAD, CG;
Investigation, MéR, YAD, CGB, SD; Formal Analysis, MiR, MéR,
YAD, CGB, SD, CG. Writing—Review and Editing, All authors;
Visualization, MiR, YAD, CG; Supervision, MiR, CG; Funding
Acquisition, CG.
ACKNOWLEDGMENTS
The authors would like to thank Dr. MD Lai (National Cheng
Kung University, Taiwan) and Dr. MA McNiven (Mayo Clinic,
Rochester, USA) for the gift of reagents, Mario Harvey, Lyne
Villeneuve and Joannie Roberge for technical assistance, Sylvie
Bourassa at the Proteomics Platform of CHUdeQuébec Research
Center for mass spectrometry analysis, and France Couture
for artwork. This work was supported by the Natural Sciences
and Engineering Research Council of Canada (342176-2012).
YAD received a Ph.D. studentship award from the Fonds de
Recherche Québec-Santé, MéR received a Canadian Institutes for
Health Research Frederick Banting and Charles Best Graduate
Scholarship award, CGB received a studentship from the Fonds
de l’Enseignement et de la Recherche of the Faculty of Pharmacy
of Laval University. CG holds a Tier I Canada Research Chair in
Pharmacogenomics.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2017.00023/full#supplementary-material
Supplementary Figure S1 | MS identification of human UGT1A in drug
metabolizing tissues.
Supplementary Figure S2 | Confidence interaction scores SAINT vs. FC_B
for interaction partners of UGT1A enzymes.
Supplementary Figure S3 | Overlap of UGT1A enzymes interacting
proteins identified in each non-malignant human tissue and in the
gastrointestinal cancer model cell line HT-29.
Supplementary Figure S4 | Identification of UGT1A5 enzyme expression in
the intestine.
Supplementary Table S1 | UGT1A enzymes affinity purified from human
tissue S9 fractions.
Supplementary Table S2 | LC-MS/MS identification of interacting proteins
in human tissue S9 fractions.
Supplementary Table S3 | List of proteins in each group of the Venn
diagrams (Figure 1B and Supplementary Figure 2).
Supplementary Table S4 | Liver proteomics data.
Supplementary Table S5 | Kidney proteomics data.
Supplementary Table S6 | Intestine proteomics data.
Supplementary Table S7 | HT-29 proteomics data.
Frontiers in Pharmacology | www.frontiersin.org February 2017 | Volume 8 | Article 23 | 43
Rouleau et al. Human UGT1A Interaction Network
REFERENCES
Akizawa, E., Koiwai, K., Hayano, T., Maezawa, S., Matsushita, T.,
and Koiwai, O. (2008). Direct binding of ligandin to uridine 5’-
diphosphate glucuronosyltransferase 1A1. Hepatol. Res. 38, 402–409.
doi: 10.1111/j.1872-034X.2007.00285.x
Audet-Delage, Y., Rouleau, M., Rouleau, M., Roberge, J., Miard, S., Picard, F., et al.
(2017). Cross-talk between alternatively spliced UGT1A isoforms and colon
cancer cell metabolism.Mol. Pharmacol. 91, 1–10. doi: 10.1124/mol.116.106161
Bellemare, J., Rouleau, M., Girard, H., Harvey, M., and Guillemette, C.
(2010a). Alternatively spliced products of the UGT1A gene interact with the
enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.
Drug Metab. Dispos. 38, 1785–1789. doi: 10.1124/dmd.110.034835
Bellemare, J., Rouleau, M., Harvey, M., and Guillemette, C. (2010b). Modulation
of the human glucuronosyltransferase UGT1A pathway by splice isoform
polypeptides is mediated through protein-protein interactions. J. Biol. Chem.
285, 3600–3607. doi: 10.1074/jbc.M109.083139
Bellemare, J., Rouleau, M., Harvey, M., Popa, I., Pelletier, G., Tetu, B., et al. (2011).
Immunohistochemical expression of conjugating UGT1A-derived isoforms in
normal and tumoral drug-metabolizing tissues in humans. J. Pathol. 223,
425–435. doi: 10.1002/path.2805
Bindea, G., Galon, J., andMlecnik, B. (2013). CluePedia Cytoscape plugin: pathway
insights using integrated experimental and in silico data. Bioinformatics 29,
661–663. doi: 10.1093/bioinformatics/btt019
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky,
A., et al. (2009). ClueGO: a Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks. Bioinformatics 25,
1091–1093. doi: 10.1093/bioinformatics/btp101
Bolte, S., and Cordelieres, F. P. (2006). A guided tour into subcellular
colocalization analysis in light microscopy. J. Microsc. 224, 213–232.
doi: 10.1111/j.1365-2818.2006.01706.x
Bushey, R. T., and Lazarus, P. (2012). Identification and functional characterization
of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential
importance in tobacco-related cancer susceptibility. J. Pharmacol. Exp. Ther.
343, 712–724. doi: 10.1124/jpet.112.198770
Choi, H., Larsen, B., Lin, Z. Y., Breitkreutz, A., Mellacheruvu, D., Fermin, D., et al.
(2011). SAINT: probabilistic scoring of affinity purification-mass spectrometry
data. Nat. Methods 8, 70–73. doi: 10.1038/nmeth.1541
Costa, E. (2006). Hematologically important mutations: bilirubin UDP-
glucuronosyltransferase gene mutations in Gilbert and Crigler-Najjar
syndromes. Blood Cells Mol. Dis. 36, 77–80. doi: 10.1016/j.bcmd.2005.10.006
Currie, E., Schulze, A., Zechner, R., Walther, T. C., and Farese, R. V. Jr.
(2013). Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161.
doi: 10.1016/j.cmet.2013.05.017
Dates, C. R., Fahmi, T., Pyrek, S. J., Yao-Borengasser, A., Borowa-Mazgaj, B.,
Bratton, S. M., et al. (2015). Human UDP-Glucuronosyltransferases: effects of
altered expression in breast and pancreatic cancer cell lines. Cancer Biol. Ther.
16, 714–723. doi: 10.1080/15384047.2015.1026480
Dluzen, D. F., and Lazarus, P. (2015). MicroRNA regulation of the major drug-
metabolizing enzymes and related transcription factors. Drug Metab. Rev. 47,
320–334. doi: 10.3109/03602532.2015.1076438
Fallon, J. K., Neubert, H., Goosen, T. C., and Smith, P. C. (2013a). Targeted precise
quantification of 12 human recombinant uridine-diphosphate glucuronosyl
transferase 1A and 2B isoforms using nano-ultra-high-performance
liquid chromatography/tandem mass spectrometry with selected reaction
monitoring. Drug Metab. Dispos. 41, 2076–2080. doi: 10.1124/dmd.113.
053801
Fallon, J. K., Neubert, H., Hyland, R., Goosen, T. C., and Smith, P. C. (2013b).
Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in
human liver using NanoUPLC-MS/MS with selected reaction monitoring. J.
Proteome Res. 12, 4402–4413. doi: 10.1021/pr4004213
Fremont, J. J., Wang, R. W., and King, C. D. (2005). Coimmunoprecipitation
of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. Mol.
Pharmacol. 67, 260–262. doi: 10.1124/mol.104.006361
Fujiwara, R., and Itoh, T. (2014). Extensive protein-protein interactions involving
UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. Drug
Metab. Pharmacokinet. 29, 259–265. doi: 10.2133/dmpk.DMPK-13-RG-096
Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T., et al.
(2010). Interactions between human UDP-glucuronosyltransferase (UGT) 2B7
and UGT1A enzymes. J. Pharm. Sci. 99, 442–454. doi: 10.1002/jps.21830
Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., and Yokoi, T.
(2007a). Interactions between human UGT1A1, UGT1A4, and UGT1A6
affect their enzymatic activities. Drug Metab. Dispos. 35, 1781–1787.
doi: 10.1124/dmd.107.016402
Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro,
S., et al. (2007b). Effects of coexpression of UGT1A9 on enzymatic
activities of human UGT1A isoforms. Drug Metab. Dispos. 35, 747–757.
doi: 10.1124/dmd.106.014191
Fujiwara, R., Yokoi, T., and Nakajima, M. (2016). Structure and protein-protein
interactions of human UDP-glucuronosyltransferases. Front. Pharmacol. 7:388.
doi: 10.3389/fphar.2016.00388
Guillemette, C., Levesque, E., Harvey, M., Bellemare, J., and Menard, V. (2010).
UGT genomic diversity: beyond gene duplication. Drug Metab. Rev. 42, 24–44.
doi: 10.3109/03602530903210682
Guillemette, C., Levesque, E., and Rouleau, M. (2014). Pharmacogenomics of
human uridine diphospho-glucuronosyltransferases and clinical implications.
Clin. Pharmacol. Ther. 96, 324–339. doi: 10.1038/clpt.2014.126
Harbourt, D. E., Fallon, J. K., Ito, S., Baba, T., Ritter, J. K., Glish, G. L., et al. (2012).
Quantification of human uridine-diphosphate glucuronosyl transferase 1A
isoforms in liver, intestine, and kidney using nanobore liquid chromatography-
tandem mass spectrometry. Anal. Chem. 84, 98–105. doi: 10.1021/ac201704a
Hayashi, T., Rizzuto, R., Hajnoczky, G., and Su, T. P. (2009). MAM: more than just
a housekeeper. Trends Cell Biol. 19, 81–88. doi: 10.1016/j.tcb.2008.12.002
Hu, D. G., Meech, R., McKinnon, R. A., and Mackenzie, P. I. (2014).
Transcriptional regulation of humanUDP-glucuronosyltransferase genes.Drug
Metab. Rev. 46, 421–458. doi: 10.3109/03602532.2014.973037
Hung, Y. H., Chan, Y. S., Chang, Y. S., Lee, K. T., Hsu, H. P., Yen, M. C.,
et al. (2014). Fatty acid metabolic enzyme acyl-CoA thioesterase 8 promotes
the development of hepatocellular carcinoma. Oncol. Rep. 31, 2797–2803.
doi: 10.3892/or.2014.3155
Ishii, Y., Iwanaga, M., Nishimura, Y., Takeda, S., Ikushiro, S., Nagata, K.,
et al. (2007). Protein-protein interactions between rat hepatic cytochromes
P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the
functionally active UGT in P450-UGT complex. Drug Metab. Pharmacokinet.
22, 367–376. doi: 10.2133/dmpk.22.367
Ishii, Y., Koba, H., Kinoshita, K., Oizaki, T., Iwamoto, Y., Takeda, S., et al.
(2014). Alteration of the function of the UDP-glucuronosyltransferase
1A subfamily by cytochrome P450 3A4: different susceptibility for UGT
isoforms and UGT1A1/7 variants. Drug Metab. Dispos. 42, 229–238.
doi: 10.1124/dmd.113.054833
Ishii, Y., Takeda, S., and Yamada, H. (2010). Modulation of UDP-
glucuronosyltransferase activity by protein-protein association. Drug Metab.
Rev. 42, 145–158. doi: 10.3109/03602530903208579
Ishizuka, M., Toyama, Y., Watanabe, H., Fujiki, Y., Takeuchi, A., Yamasaki,
S., et al. (2004). Overexpression of human acyl-CoA thioesterase
upregulates peroxisome biogenesis. Exp. Cell Res. 297, 127–141.
doi: 10.1016/j.yexcr.2004.02.029
Kurkela, M., Patana, A. S., Mackenzie, P. I., Court, M. H., Tate, C. G., Hirvonen,
J., et al. (2007). Interactions with other human UDP-glucuronosyltransferases
attenuate the consequences of the Y485D mutation on the activity and
substrate affinity of UGT1A6. Pharmacogenet. Genomics 17, 115–126.
doi: 10.1097/FPC.0b013e328011b598
Liu, Y. Q., Yuan, L. M., Gao, Z. Z., Xiao, Y. S., Sun, H. Y., Yu, L. S., et al. (2016).
Dimerization of human uridine diphosphate glucuronosyltransferase allozymes
1A1 and 1A9 alters their quercetin glucuronidation activities. Sci. Rep. 6:23763.
doi: 10.1038/srep23763
Lodhi, I. J., and Semenkovich, C. F. (2014). Peroxisomes: a nexus for
lipid metabolism and cellular signaling. Cell Metab. 19, 380–392.
doi: 10.1016/j.cmet.2014.01.002
Margaillan, G., Rouleau, M., Fallon, J. K., Caron, P., Villeneuve, L.,
Turcotte, V., et al. (2015a). Quantitative profiling of human renal UDP-
glucuronosyltransferases and glucuronidation activity: a comparison of
normal and tumoral kidney tissues. Drug Metab. Dispos. 43, 611–619.
doi: 10.1124/dmd.114.062877
Frontiers in Pharmacology | www.frontiersin.org February 2017 | Volume 8 | Article 23 | 44
Rouleau et al. Human UGT1A Interaction Network
Margaillan, G., Rouleau, M., Klein, K., Fallon, J. K., Caron, P., Villeneuve,
L., et al. (2015b). Multiplexed targeted quantitative proteomics predicts
hepatic glucuronidation potential. Drug Metab. Dispos. 43, 1331–1335.
doi: 10.1124/dmd.115.065391
Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J. P., St-Denis, N. A., Li, T.,
et al. (2013). The CRAPome: a contaminant repository for affinity purification-
mass spectrometry data. Nat. Methods 10, 730–736. doi: 10.1038/nmeth.2557
Ménard, V., Collin, P., Margaillan, G., and Guillemette, C. (2013). Modulation
of the UGT2B7 enzyme activity by C-terminally truncated proteins
derived from alternative splicing. Drug Metab. Dispos. 41, 2197–2205.
doi: 10.1124/dmd.113.053876
Mori, Y., Kiyonaka, S., and Kanai, Y. (2011). Transportsomes and channelsomes:
are they functional units for physiological responses? Channels 5, 387–390.
doi: 10.4161/chan.5.5.16466
Nguyen, N., Bonzo, J. A., Chen, S., Chouinard, S., Kelner, M. J., Hardiman, G., et al.
(2008). Disruption of the ugt1 locus in mice resembles human Crigler-Najjar
type I disease. J. Biol. Chem. 283, 7901–7911. doi: 10.1074/jbc.M709244200
Operaña, T. N., and Tukey, R. H. (2007). Oligomerization of the UDP-
glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis
by fluorescence resonance energy transfer and co-immunoprecipitation. J. Biol.
Chem. 282, 4821–4829. doi: 10.1074/jbc.M609417200
Pol, A., Gross, S. P., and Parton, R. G. (2014). Review: biogenesis of the
multifunctional lipid droplet: lipids, proteins, and sites. J. Cell Biol. 204,
635–646. doi: 10.1083/jcb.201311051
Ramírez, J., Ratain, M. J., and Innocenti, F. (2010). Uridine 5′-diphospho-
glucuronosyltransferase genetic polymorphisms and response to cancer
chemotherapy. Future Oncol. 6, 563–585. doi: 10.2217/fon.10.17
Rouleau, M., Roberge, J., Bellemare, J., and Guillemette, C. (2014). Dual roles
for splice variants of the glucuronidation pathway as regulators of cellular
metabolism.Mol. Pharmacol. 85, 29–36. doi: 10.1124/mol.113.089227
Rouleau, M., Tourancheau, A., Girard-Bock, C., Villeneuve, L., Vaucher, J.,
Duperre, A. M., et al. (2016). Divergent expression and metabolic functions
of human glucuronosyltransferases through alternative splicing. Cell Rep. 17,
114–124. doi: 10.1016/j.celrep.2016.08.077
Rowland, A., Miners, J. O., and Mackenzie, P. I. (2013). The UDP-
glucuronosyltransferases: their role in drug metabolism and detoxification. Int.
J. Biochem. Cell Biol. 45, 1121–1132. doi: 10.1016/j.biocel.2013.02.019
Ruan, H. B., Han, X., Li, M. D., Singh, J. P., Qian, K., Azarhoush, S.,
et al. (2012). O-GlcNAc transferase/host cell factor C1 complex regulates
gluconeogenesis by modulating PGC-1alpha stability. Cell Metab. 16, 226–237.
doi: 10.1016/j.cmet.2012.07.006
Sato, Y., Nagata, M., Tetsuka, K., Tamura, K., Miyashita, A., Kawamura, A., et al.
(2014). Optimizedmethods for targeted peptide-based quantification of human
uridine 5’-diphosphate-glucuronosyltransferases in biological specimens using
liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 42,
885–889. doi: 10.1124/dmd.113.056291
Savas, J. N., Stein, B. D., Wu, C. C., and Yates, J. R. III. (2011). Mass spectrometry
accelerates membrane protein analysis. Trends Biochem. Sci. 36, 388–396.
doi: 10.1016/j.tibs.2011.04.005
Schrader, M., Godinho, L. F., Costello, J. L., and Islinger, M. (2015). The different
facets of organelle interplay-an overview of organelle interactions. Front Cell
Dev Biol 3:56. doi: 10.3389/fcell.2015.00056
Schroeder, B., Weller, S. G., Chen, J., Billadeau, D., and McNiven, M. A. (2010). A
Dyn2-CIN85 complexmediates degradative traffic of the EGFR by regulation of
late endosomal budding. EMBO J. 29, 3039–3053. doi: 10.1038/emboj.2010.190
Strassburg, C. P., Kneip, S., Topp, J., Obermayer-Straub, P., Barut, A., Tukey, R.
H., et al. (2000). Polymorphic gene regulation and interindividual variation of
UDP-glucuronosyltransferase activity in human small intestine. J. Biol. Chem.
275, 36164–36171. doi: 10.1074/jbc.M002180200
Tabak, H. F., Braakman, I., and van der Zand, A. (2013). Peroxisome formation
and maintenance are dependent on the endoplasmic reticulum. Annu. Rev.
Biochem. 82, 723–744. doi: 10.1146/annurev-biochem-081111-125123
Takeda, S., Ishii, Y., Iwanaga, M., Mackenzie, P. I., Nagata, K., Yamazoe,
Y., et al. (2005a). Modulation of UDP-glucuronosyltransferase function
by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed
glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 67, 665–672.
doi: 10.1124/mol.104.007641
Takeda, S., Ishii, Y., Iwanaga, M., Nurrochmad, A., Ito, Y., Mackenzie, P. I., et al.
(2009). Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase
2B7: evidence for protein-protein association and possible involvement
of CYP3A4 J-helix in the interaction. Mol. Pharmacol. 75, 956–964.
doi: 10.1124/mol.108.052001
Takeda, S., Ishii, Y., Mackenzie, P. I., Nagata, K., Yamazoe, Y., Oguri, K.,
et al. (2005b). Modulation of UDP-glucuronosyltransferase 2B7 function
by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9
and CYP3A4. Biol. Pharm. Bull. 28, 2026–2027. doi: 10.1248/bpb.
28.2026
Taura, K. I., Yamada, H., Hagino, Y., Ishii, Y., Mori, M. A., and Oguri, K.
(2000). Interaction between cytochrome P450 and other drug-metabolizing
enzymes: evidence for an association of CYP1A1 with microsomal epoxide
hydrolase and UDP-glucuronosyltransferase. Biochem. Biophys. Res. Commun.
273, 1048–1052. doi: 10.1006/bbrc.2000.3076
Thiam, A. R., Farese, R. V. Jr., and Walther, T. C. (2013). The biophysics
and cell biology of lipid droplets. Nat. Rev. Mol. Cell Biol. 14, 775–786.
doi: 10.1038/nrm3699
Tourancheau, A., Margaillan, G., Rouleau, M., Gilbert, I., Villeneuve, L., Levesque,
E., et al. (2016). Unravelling the transcriptomic landscape of the major
phase II UDP-glucuronosyltransferase drug metabolizing pathway using
targeted RNA sequencing. Pharmacogenomics J. 16, 60–70. doi: 10.1038/tpj.
2015.20
Troberg, J., Jarvinen, E., Ge, G. B., Yang, L., and Finel, M. (2016). UGT1A10
is a high activity and important extrahepatic enzyme: why has its role
in intestinal glucuronidation been frequently underestimated? Mol. Pharm.
doi: 10.1021/acs.molpharmaceut.6b00852. [Epub ahead of print].
Turgeon, D., Chouinard, S., Belanger, P., Picard, S., Labbe, J. F., Borgeat, P.,
et al. (2003). Glucuronidation of arachidonic and linoleic acid metabolites
by human UDP-glucuronosyltransferases. J. Lipid Res. 44, 1182–1191.
doi: 10.1194/jlr.M300010-JLR200
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Rouleau, Audet-Delage, Desjardins, Rouleau, Girard-Bock and
Guillemette. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org February 2017 | Volume 8 | Article 23 | 45
fphar-07-00456 November 23, 2016 Time: 17:3 # 1
REVIEW





of Clinical Pharmacology, Germany
Reviewed by:
Ramiro Jover,







This article was submitted to
Pharmacogenetics
and Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology
Received: 29 August 2016
Accepted: 14 November 2016
Published: 25 November 2016
Citation:
Pavek P (2016) Pregnane X Receptor
(PXR)-Mediated Gene Repression
and Cross-Talk of PXR with Other
Nuclear Receptors via Coactivator




and Cross-Talk of PXR with Other
Nuclear Receptors via Coactivator
Interactions
Petr Pavek*
Department of Pharmacology and Toxicology and Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove,
Charles University in Prague, Hradec Kralove, Czechia
Pregnane X receptor is a ligand-activated nuclear receptor (NR) that mainly controls
inducible expression of xenobiotics handling genes including biotransformation enzymes
and drug transporters. Nowadays it is clear that PXR is also involved in regulation
of intermediate metabolism through trans-activation and trans-repression of genes
controlling glucose, lipid, cholesterol, bile acid, and bilirubin homeostasis. In these
processes PXR cross-talks with other NRs. Accumulating evidence suggests that the
cross-talk is often mediated by competing for common coactivators or by disruption
of coactivation and activity of other transcription factors by the ligand-activated PXR.
In this respect mainly PXR-CAR and PXR-HNF4α interference have been reported
and several cytochrome P450 enzymes (such as CYP7A1 and CYP8B1), phase II
enzymes (SULT1E1, Gsta2, Ugt1a1), drug and endobiotic transporters (OCT1, Mrp2,
Mrp3, Oatp1a, and Oatp4) as well as intermediate metabolism enzymes (PEPCK1 and
G6Pase) have been shown as down-regulated genes after PXR activation. In this review,
I summarize our current knowledge of PXR-mediated repression and coactivation
interference in PXR-controlled gene expression regulation.
Keywords: PXR, nuclear receptor, gene regulation, metabolism, cross-talk
INTRODUCTION
Pregnane X receptor (PXR) is now accepted as a master transcription factor of xenobiotic- and
drug-inducible expression of key genes that encode members of the phase I and phase II metabolic
enzymes and drug transporters. Moreover, accumulating evidence suggests that PXR plays an
integral role also in endobiotic metabolism by regulating important genes implicated in glucose,
Abbreviations: CAR, constitutive androstane receptor; ChiP, Chromatin immunoprecipitation assay; CREB, cAMP-
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lipid, and bile acid metabolism. In addition, it was documented
that PXR both induces as well as suppresses expression of
numerous hepatic transcripts. The latest report shows that PXR
up-regulates 164 genes, but down-regulates expression of 334
genes in primary human hepatocytes (Kandel et al., 2016). In
this review I summarize well-documented examples of PXR-
mediated trans-repression and coactivation interference in the
PXR-mediated transactivation.
Pregnane X Receptor
Nuclear receptors (NRs) form a super-family of transcription
factors implicated in various physiological functions, from
development, detoxification to homeostasis. Many NRs are
ligand-activated transcription factors sharing a common
evolutionary history and similar sequence features at the protein
level, mainly in their DNA-binding domain (DBD), and to a
lesser extent in ligand binding domains (LBD). PXR (or NR
subfamily 1, group I, member 2, NR1I2), together with CAR
(NR1I3), and vitamin D receptors (VDR, NR1I1), form a group I
of the subfamily 1 of NRs (Moore et al., 2006; di Masi et al., 2009;
Smutny et al., 2013).
Mouse PXR (mPXR) was first identified in 1998 by using
an expressed sequence tag to screen a mouse liver library. It
was found to be activated by derivatives of dexamethasone
and pregnenolone (Kliewer et al., 1998). At the same time, the
human steroid X receptor was cloned (Blumberg et al., 1998)
and established to be the human homologue of mPXR involved
in CYP450 3A4 regulation (CYP3A4) (Bertilsson et al., 1998;
Lehmann et al., 1998).
Human PXR (hPXR) is the product of the NR1I2 gene, which
is located on chromosome 3, locus 3q11–q13.3. The NR1I2 gene
comprises 10 exons separated by nine intronic regions (Hustert
et al., 2001; Zhang et al., 2001). PXR, like any other member in the
NR super-family, is composed of the DBD, the H region, and the
C-terminal LBD. PXR-DBD is involved in receptor dimerization
and in the binding of specific DNA sequences. H region (or Hinge
region) is a flexible domain that connects the DBD with the
LBD. PXR heterodimerizes with RXRα to form a transcriptionally
active complex (Blumberg et al., 1998; Lehmann et al., 1998).
The flexible ligand-binding pocket of PXR-LBD enables
binding of a wide range of structurally unrelated endogenous
and exogenous ligands. Watkins et al. (2001) first showed the
crystal structure of the ligand-binding domain both alone and in
complex with the PXR ligand SR12813. The PXR-LBD structure
consists of a three-layered α-helical sandwich (α1–α3/α4–α5–
α8–α9/α7–α10) and five-stranded antiparallel β-sheets (β1, β10,
β2, β3, and β4). Interestingly, PXR-LBD contains an insert of
approximately 60 residues which is unique within members of the
NR super-family. This is the main reason for the larger cavity as
well as the wider substrate diversity of PXR ligands. The apo-PXR
binding cavity volume is approximately 1150 Å3; in the presence
of ligands it can extend to 1290–1540 Å3 (Chrencik et al., 2005).
Thus, the binding cavity volume is substantially larger than that
of many other NRs. The ligand pockets of PXR, CAR as well as
VDR are lined by mostly hydrophobic residues. The cavity of
PXR is lined by 28 amino acids, of which eight have polar or
charged side chains (Watkins et al., 2001; di Masi et al., 2009).
The PXR-LBD ends with a short helix (αAF) which is critical for
the structural organization of the AF-2 (the activation function
2) region to recruit transcriptional coregulators. In NR LBDs, the
AF-2 region binds the Leu-Xxx-Xxx-Leu-Leu (LXXLL) motifs of
transcriptional coactivators, and the Ile/Leu-Xxx-Xxx-Ile/Val-Ile
motifs of corepressors (Lazar, 2003; Rosenfeld et al., 2006). The
coactivator recruitment appears to play a central role in fixing
ligands in the correct arrangement in the large PXR cavity after
a coreppresor release.
Pregnane X receptor is primarily expressed in the liver,
intestine, and to a lesser extend in the kidney. Expression
of PXR/Pxr mRNA in other tissues including lung, stomach,
peripheral blood monocytes, uterus, ovary, breast, adrenal gland,
bone marrow, and some regions of the brain is minor (see
the comprehensive review by Pavek and Dvorak, 2008). Mouse
liver immunostaining suggests that mPXR is mainly located
in the cytosol of untreated liver cells. Similar to CAR/mCar,
mPxr forms a protein complex with cytoplasmic CAR retention
protein (CCRP) and the heat shock protein 90 (hsp90), which
retains the cytosolic localization of PXR. Upon ligand binding
to mPxr, the Pxr dissociates from the multi-protein complex
and translocates to the nucleus in primary mouse hepatocytes to
activate gene transcription (Kawana et al., 2003; Squires et al.,
2004). In contrast, nuclear localization of human PXR has been
reported in mammalian tumor derived cell lines (Saradhi et al.,
2005).
Pregnane X receptor was originally characterized as the key
transcription factor that activates hepatic genes encoding drug-
metabolizing enzymes and drug efflux transporters (Kliewer
et al., 2002). PXR protects the body from harmful foreign
toxicants or endogenous toxic substances by an autoregulation
mechanism. PXR ligands activate a number of genes involved
in their metabolism that in feedback manner contribute to their
clearance. PXR has a wide spectrum of ligands belonging to
drugs (such as antibiotic rifampicin, anticancer drugs tamoxifen
and taxol, antihypertensive drug nifedipine, antifungal drug
clotrimazole, or herbal antidepressant hyperforin), endogenous
ligands (including steroids such as lithocholic acid) or products of
gut microflora (di Masi et al., 2009; Smutny et al., 2013; Venkatesh
et al., 2014).
Nowadays, it is clear that the xenobiotic-sensing PXR
pathway regulates also energy metabolism, and reciprocally, the
energy homeostasis affects drug metabolism. In the review, I
focus on the PXR-mediated regulation of phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase),
two rate-limiting enzymes of hepatic gluconeogenesis; Hmgcs2,
the key enzyme involved in ketogenesis; the active form of
SREBP-1, which regulates genes required for sterol biosynthesis,
fatty acid and lipid production and glucose metabolism; and
lastly CYP7A1 and CYP8B1 enzymes critically involved in
bile acid synthesis. PXR or its rodent orthologues have also
been shown to be involved in heme, bilirubin and thyroxin
clearance, in bone homeostasis and vitamin D metabolism.
In addition, PXR activation is known to suppress the activity
of NF-κB, which is the key regulator of inflammation and
In all NRs, m and h denote mouse and human, respectively.
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immune response (Xie et al., 2003; Zhou et al., 2009;
Gao and Xie, 2012; Wang et al., 2012). These effects of PXR
activation are, however, beyond the scope of the present
review.
PXR Coactivation
Coactivators and corepressors have been found critical for
the function of DNA-binding transcription factors (TFs).
Coactivator and corepressor proteins are components of
multisubunit coregulator complexes involved in transcriptional
gene regulation machinery (for a comprehensive review on
coactivator/corepressors see Rosenfeld et al., 2006; Oladimeji
et al., 2016).
PXR-LBD AF-2 region binds the LXXLL motifs of
transcriptional coactivators as was shown with a 25 amino
acid residue fragment of the human SRC-1. The motif forms
hydrophobic contacts with the surface of hPXR in a groove
composed of α3, α4, and AF-2 region. From the LBD side, PXR
ligands are in direct contacts with αAF of AF-2 region (Xue
et al., 2007). Both the SR12813 ligand and SRC-1 coactivator
peptide in the crystal model stabilize the LBD of PXR. A charge
clamp involving PXR residues Lys259 and Glu427 stabilizes the
weak helix dipole at the C- and N-terminus of the LXXLL motif
(Watkins et al., 2003; Xue et al., 2007).
SRC-1 was the first coactivator identified for hPXR (Kliewer
et al., 1998; Lehmann et al., 1998). The members of the
SRC family contain several conserved structural domains: a
N-terminal basic helix-loop-helix-Per/ARNT/Sim (bHLH-PAS)
domain, a central NR interaction domain (RID) with three
LXXLL motifs, and two activation domains (AD1 and AD2) at
the C-terminus. Once recruited to the target gene promoters by
ligand-activated NRs, SRCs trigger the/an assembly of a multi-
protein coactivator complex by further recruiting secondary
coactivators and histone modifying enzymes to activation
domains 1 and 2 (AD-1 and AD-2) such as CBP/p300,
coactivator associated arginine methyltransferase 1 (CARM1)
and protein arginine methyltransferase 1 (PRMT1). The formed
transcriptional complex remodels transcriptionally inactive
chromatin within the target gene and attracts components
of the RNA polymerase II transcriptional complex. The AD-
1 domain binds p300 and CBP, both of which are potent
histone acetyltransferases (HATs) that remodel chromatin to
allow accessibility for the transcription preinitiation complex.
The AD-2 domain recruit protein arginine N-methyltransferase
(PRMT) family members, such as CARM1 and PRMT1,
which methylate residues of histone proteins and other
chromatin-associated proteins (Szwarc et al., 2014; Wang et al.,
2016).
The paradigm of NR action is that ligand binding enhances
the receptor’s affinity for coactivator proteins, while decreasing its
affinity for corepressors such as the silencing mediator of retinoid
and thyroid receptors (SMRT, NR corepressor 2, NCoR2) and of
the NR corepressor (NCoR, NCOR1), allowing further binding
of the coactivators. Coactivators often have an intrinsic HAT
activity, which weakens the association of histones to DNA, and
therefore promotes gene transcription. On contrary, corepressors
recruit histone deacetylases (HDACs), which strengthen the
association of histones to DNA, and therefore repress gene
transcription.
The mechanism of ligand-dependent activation of PXR
significantly differs from that seen in many other NRs.
Coactivation by SRC-1 stimulated after PXR activation has
not been confirmed in some rigorous biophysical studies
(Navaratnarajah et al., 2012). It was also demonstrated that
PXR and SRC-1 interact in the absence of a PXR ligand,
and further, that the interaction is strengthened by rifampicin
(Saini et al., 2005; Li and Chiang, 2006; Rulcova et al., 2010;
Krausova et al., 2011; Hyrsova et al., 2016). Moreover, no ligand
activated release, or even stronger interaction with SMRTα has
been reported for PXR (Takeshita et al., 2002; Mani et al.,
2005; Li et al., 2009; Navaratnarajah et al., 2012; Hirooka-Masui
et al., 2013). Nevertheless, also contradictory results have been
published regarding SMRT and NCoR interaction with PXR
(Ding and Staudinger, 2005b; Johnson et al., 2006). SMRT (or
its overexpression) has been documented as the repressor of
PXR-mediated transactivation (Takeshita et al., 2002; Mani et al.,
2005; Johnson et al., 2006; Hirooka-Masui et al., 2013). In
addition, repressed PXR by SMRT has been reported to inhibit
the activation of CYP24A1 gene by vitamin D receptor (Konno
et al., 2009).
Recently, Masuyama et al. (2000) also found that PXR interacts
with SRC-1 and NR interacting protein 1 (NRIP1, RIP140) in
a ligand dependent manner. These data indicate that different
ligands may specifically change the conformation of PXR-LBD
resulting in different interaction with coactivators.
The interactions of co-factors with TFs are governed by post-
translational modifications. Phosphorylation plays an important
role in the regulation of NRs functions, enabling integration
of different cellular and extracellular stimuli in their functions.
PXR is phosphorylated by protein kinase A (PKA), resulting in
strengthened interaction with SRC-1 and PBP coactivators (Ding
and Staudinger, 2005a). In contrast, the activity of PXR can be
repressed by the activation of protein kinase C (PKC) isoforms
which alters the phosphorylation status of PXR and represses
PXR-SRC-1 interaction, but strengthens PXR-NCoR interaction
(Ding and Staudinger, 2005b). Therefore, the phosphorylation
status of PXR can modulate coactivator/corepressor recruitment
which could reflect the ligand-independent activation of
PXR.
NR CROSSTALK BASED ON
COACTIVATORS PROTEIN−PROTEIN
INTERACTIONS
As other NRs, PXR needs coactivators and corepressors for its
transcriptional activity and for tuning of the tissue-, ligand-, and
promoter (gene)-specific transactivation (Smutny et al., 2013).
Coactivators and corepressors are common for the most of
NRs and TFs. In addition, some NRs share the same response
elements in transactivation of their target genes. This is the most
strikingly evident in case of the CYP3A4 gene, when PXR, CAR,
and VDR share four different response elements in proximal
promoter and two enhancer elements in gene- and tissue-specific
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manner (Pavek et al., 2010). This is the mechanistic molecular
base for so called cross-talk of NRs in positive and negative
transcriptional regulation, in forming negative feedback loops
and in hierarchy of NRs in regulatory networks (Pascussi et al.,
2008).
Recently, the competition for common coactivators emerged
as an important process in the NR-mediated gene regulation.
Competition for the common coactivators PGC-1α or GRIP-
1 has been recently reported as a putative mechanism of
crosstalk between CAR and the estrogen receptor (Min
et al., 2002), HNF4α and PXR (Bhalla et al., 2004; Li and
Chiang, 2005), and HNF4α and CAR (Miao et al., 2006).
Competition for the common Src-1 coactivator has been
reported for Pxr-Car crosstalk (Saini et al., 2005), as well as
for Lxr and the retinoid-related orphan receptor α (Rorα)
interaction (Wada et al., 2008); and considered as the underlying
mechanisms in cases of Car-Lxrα/LXRα interaction (Zhai et al.,
2010).
Competition For Coactivators and
Cross-Talk in PXR-Mediated Regulation
of Intermediary Metabolism
Pregnane X Receptor has been shown to regulate glucose
and lipid homeostasis during fasting and modifies the
risk of hyperglycemia, diabetes, obesity, dyslipidemia, and
hepatosteatosis. Key transcription factors and their cofactors in
glucose and lipid homeostasis have been described to crosstalk
with PXR regulation.
CREB
In response to fasting and/or starvation, the liver increases
the production of glucose by stimulating both gluconeogenesis
and glycogenolysis. In the process glucagon up-regulates the
transcription of the hepatic genes that encode rate-limiting
enzymes of glucose homeostasis, such as the glucose-
6-phosphatase catalytic subunit (G6Pase), or PEPCK1
(phosphoenolpyruvate carboxykinase 1, PCK1). Glucagon
stimulates PKA (cAMP-dependent protein kinase) that
phosphorylates the CREB [CRE (cAMP response element)-
binding protein]. The phosphorylation of CREB leads to the
recruitment of HATs CBP/p300, binding of CREB to CREB
response elements (CREs), and the activation of the CRE-
bearing genes, such as those for G6Pase and PEPCK1, as well
as PGC-1α. The coactivators linked to CREB transactivation
(as well as FOXO1) include CBP/p300, CREB regulated
transcription coactivator 2 (CRTC2), PGC-1α, and protein
arginine methyltransferases (PRMTs) (Oh et al., 2013).
It has been reported that rifampicin-activated PXR represses
the transcription of the G6Pase gene by inhibiting the DNA-
binding ability of CREB to its response element CRE and that
direct interaction of PXR with CREB is involved (see Figure 1)
(Kodama et al., 2007).
In opposite to suppressive effects of PXR/mPxr activation
on gluconeogenic genes via CREB signaling, human-specific
induction of PEPCK and G6Pase genes have been described
recently in rifampicin-treated HepG2 cells stably expressing
human PXR. In these observations, serum- and glucocorticoid-
regulated kinase 2 (SGK2) has been found as an essential
factor for the PXR-induced G6Pase gene up-regulation. Non-
phosphorylated SGK2 has been found to co-activate PXR-
mediated trans-activation of gluconeogenic genes in human
liver cells, thereby enhancing gluconeogenesis and glucose
production (Gotoh and Negishi, 2014, 2015). In the mechanism
the activated PXR scaffolds both the protein phosphatase 2C
(PP2C) and SGK2 in order to stimulate PP2C to dephosphorylate
SGK2. Dephosphorylated SGK2 co-activates PXR in the trans-
activation of these genes (see Figure 2). At the same time,
the ligand-activated PXR stimulates expression of the SGK2
gene (Gotoh and Negishi, 2014). This finding of PXR-induced
gluconeogenesis is consistent with the clinical observation that
rifampicin can increase blood glucose level in humans (Hakkola
et al., 2016; Rysa et al., 2013) even though the effect was
attributed to the hepatic glucose transporter 2 (Glut2) mRNA
down-regulation in subsequent experiments in rats (Rysa et al.,
2013).
FOXO1
The forkhead box O transcription factor FOXO1 is regarded
as a master regulator of energy metabolism in numerous
organs including the liver, pancreas, adipose tissue and skeletal
muscle. FOXO1 regulates the transcriptional cascades controlling
glucose and lipid metabolism. FOXO1 is an activator of
gluconeogenic genes, such as PEPCK1, G6P, and insulin-like
growth factor-binding protein 1 (Igfbp1) via promoting the
function of PGC-1α during fasting. Insulin inhibits FOXO1
activity leading to the repression of these genes. These
gluconeogenic genes contain an insulin response sequence (IRS),
which FOXO1 directly binds to, and activates them in the absence
of insulin. Insulin triggers the phosphorylation of FOXO1
through the phosphatidylinositol 3-kinase (PI3K)-Akt pathway.
Phosphorylation inactivates FOXO1 by decreasing its binding
affinity to IRS of its target genes, which results in translocation
of FOXO1 from the nucleus (see reviews by Kousteni, 2012; Oh
et al., 2013).
It has been shown that Foxo1 coactivates mouse Pxr (mPxr)
in an insulin-PI3K-Akt-signaling dependent manner in the same
way as CAR (Kodama et al., 2004). Foxo1 stimulates the Pxr-
mediated transactivation of the CYP3A4 gene reporter construct.
Insulin as well as the constitutively active Akt abolished the
coactivation of mPxr by mouse Foxo1 in CYP3A4 luciferase
reporter construct activation in HepG2 cells (Figure 3A). At
the same time PCN-activated Pxr inhibited the mouse Foxo1
binding to the IRS of human IGFBP1 gene in EMSA assays.
Based on the given data, Foxo1 and PXR were proposed to
reciprocally coregulate their target genes (Figure 3B) (Kodama
et al., 2004).
FoxA2
FoxA2, a winged-helix/forkhead transcription factor, is the key
regulatory factor for the normal development of endoderm-
derived organs, such as the liver, pancreas, lungs, and prostate.
FoxA2 is also important factor in the glucose and lipid
metabolism control. FoxA2 activates gluconeogenic genes such
Frontiers in Pharmacology | www.frontiersin.org November 2016 | Volume 7 | Article 456 | 49
fphar-07-00456 November 23, 2016 Time: 17:3 # 5
Pavek PXR-Mediated Repression and Crosstalk
FIGURE 1 | Pregnane X Receptor represses the transcription of the G6Pase. PXR represses the transcription of the G6Pase gene by inhibiting the
DNA-binding ability of CREB to its response element CRE. PXR directly interacts with CREB. The figure has been drawn based on data by Kodama et al. (2007).
Black bold arrows indicate effects of activated PXR on the G6Pase gene expression. Blue arrows indicate stimulation or activation. Dashed arrow indicates
squelching (competition for a common coactivator). CRE -CREB response element.
FIGURE 2 | Human-specific induction of PEPCK and G6Pase genes by PXR. In the model, serum- and glucocorticoid-regulated kinase 2 (SGK2) has been
found as an essential factor for PXR-induced glucose 6-phosphatase (G6Pase) up-regulation. Non-phosphorylated SGK2 co-activates PXR-mediated
trans-activation of gluconeogenic genes in human liver cells, thereby enhancing gluconeogenesis and glucose production (Gotoh and Negishi, 2014, 2015). In the
mechanism, activated PXR scaffolds the protein phosphatase 2C (PP2C) and SGK2 to stimulate PP2C to dephosphorylate SGK2. Dephosphorylated SGK2
co-activates PXR in the trans-activation of these PEPCK1 and G6Pase genes. At the same time, ligand-activated PXR transactivates the expression of SGK2 (Gotoh
and Negishi, 2014). Blue arrows indicate the effect of the activated PXR on tested genes expression. PSRE, PXR-SGK2 response elements; IRS, insulin response
sequence (IRS).
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FIGURE 3 | Reciprocal crosstalk of Pxr and Foxo1. (A) Foxo1 coactivates PXR in an insulin-PI3K-Akt-signaling dependent manner (Kodama et al., 2004). Foxo1
stimulates Pxr-mediated transactivation of CYP3A4 gene reporter construct. Insulin as well as the constitutively active Akt abolishes the coactivation of mPxr by
mouse Foxo1 in CYP3A4 gene luciferase reporter construct activation in HepG2 cells. (B) PCN-activated mPxr inhibits mFoxo1 binding to IRS of human IGFBP1
gene in EMSA assay (Kodama et al., 2004). Black bold arrows indicate effects of activated Pxr on gene expression. PCN, pregnenolone 16α-carbonitrile, a rodent
specific ligand of Pxr
as Pepck and G6p genes, as well as Cpt1a and Hmgcs2. These
enzymes are activated to increase the supply of glucose or ketone-
bodies in fasting mouse liver (Wolfrum et al., 2004; Friedman and
Kaestner, 2006).
Pregnane X Receptor cross-talks with the FoxA2 to repress
the transcription of the Cpt1a and Hmgcs2 genes. mPXR
was found to directly bind to the DBD of FoxA2 to
inhibit its binding to the FoxA2 response elements in Cpt1a
and Hmgcs2 genes promoters (Nakamura et al., 2007) (see
Figure 4).
SREBP-1
Sterol regulatory element binding protein 1 is a lipogenic
transcription factor of the basic helix-loop-helix family.
Srebps are a group of transcription factors which activate
an array of genes involved in the synthesis of cholesterol
and triglycerides. Whereas Srebp-2 is mainly involved
in cholesterol biosynthesis, Srebp-1a and Srebp1c, two
isoforms encoded from different promoters, mainly activate
genes involved in fatty acid and triglyceride synthesis.
SREBP-1 binds to sterol regulatory elements (SREs) in
promoters of lipogenic genes and induces fatty acid and
triglyceride synthesis (Bakan and Laplante, 2012; Guo et al.,
2014).
It was observed that SREBP-1 attenuates drug-mediated
induction of hepatic CYPs. The activation of SREBP-1 by
insulin or low cholesterol levels in mouse liver and primary
human hepatocytes inhibits the transcriptional effects of PXR
(as well as of CAR) by SREBP-1 binding to and competing with
coactivators such as SRC-1 (Roth et al., 2008b). Conversely, PXR
transcriptionally activates Insig-1 by binding to an enhancer
sequence of the Insig-1 gene. Insig-1 in turn reduces the
nuclear protein level of the active Srebp-1 (Roth et al., 2008a)
(Figure 5).
COMPETITION FOR COACTIVATORS
AND CROSS-TALK IN PXR-MEDIATED
REGULATION OF CYP450 ENZYMES
INVOLVED IN CHOLESTEROL/BILE ACID
METABOLISM AND IN DETOXIFICATION
MECHANISMS
Pregnane X Receptor is an important factor in controlling both
cholesterol and bile acid synthesis, as well as in xenobiotic
and endobiotic metabolism, respectively. CYP7A1, CYP8A1, and
CYP3A4 genes and their animal orthologs are major target genes
of the activated PXR/Pxr in these processes.
PGC-1α
PPARgamma coactivator 1α is a key metabolic regulator
of liver energy metabolism in fasting adaption and it was
originally identified as a peroxisome proliferator-activated
receptor-γ-interacting coactivator in brown adipose tissue.
Numerous studies showed that PGC-1α is a versatile coactivator
for numerous NRs implicated together in diverse biological
functions including lipid and glucose metabolisms. In the liver
PGC-1α has been shown to increase the HNF-4α-mediated
transactivation of CYP7A1 and together with FOXO1 and
Frontiers in Pharmacology | www.frontiersin.org November 2016 | Volume 7 | Article 456 | 51
fphar-07-00456 November 23, 2016 Time: 17:3 # 7
Pavek PXR-Mediated Repression and Crosstalk
FIGURE 4 | Pregnane X Receptor cross-talks with the FoxA2 to repress the transcription of the Cpt1a and Hmgcs2 genes. Mouse Pxr directly bounds to
with the DBD of FoxA2 to inhibit its binding to the FoxA2 response elements and to repress Cpt1a and Hmgcs2 genes transactivation (Nakamura et al., 2007). Black
bold arrows indicate effects of activated Pxr on gene expression.
FIGURE 5 | SREBP-1 inhibits PXR-mediated transactivation of hepatic CYPs. Activation of SREBP-1 by insulin in mouse liver and primary human
hepatocytes inhibits the transcriptional effect of PXR due to SREBP-1 competing with coactivators such as SRC-1 (Roth et al., 2008b). PXR transcriptionally
activates Insig-1 by binding to an enhancer sequence of the Insig-1 gene reducing nuclear protein levels of the active form of Srebp-1. SREBP1a strongly interacts
with PXR. Black bold arrows indicate the effect of activated PXR on genes expression.
HNF4α controls the fasting-induced hepatic gluconeogenesis via
PEPCK1 and G6Pase genes. In addition, PGC-1α is involved
in fatty-acid β-oxidation, ketogenesis and heme biosynthesis.
In extrahepatic tissues, it controls adaptive thermogenesis,
homocysteine metabolism, mitochondrial biogenesis, peripheral
circadian clock, fiber-type switching in skeletal muscle and in
heart development. The basal hepatic expression of PGC-1α
is relatively low in fed conditions, but its expression is
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FIGURE 6 | Crosstalk of PXR with HNF4α in CYP7A1 and CYP8A1 regulation. (A) Rifampicin did not inhibit HNF4α binding to the native promoters of CYP7A1
and CYP8B1 (and PEPCK1) genes but stimulates dissociation of PGC-1α from HNF4α by competing for binding PGC-1α to HNF4α. This leads to attenuation of
HNF4α-mediated transactivation and down-regulation of the genes (Bhalla et al., 2004). (B) In another model, activated PXR triggers interaction of PXR with HNF4α
in the context of promoter resulting in chromatin remodeling and release of PGC-1α. This again results in HNF4α-controlled expression attenuation (Li and Chiang,
2005). Black bold arrows indicate the inhibitory effects of activated PXR on genes expression. Dashed arrow indicates squelching (competition for a common
coactivator).
readily upregulated by fasting, glucagon and diabetes, mainly
through an altered insulin–glucagon balance. PGC-1α cannot
bind to DNA itself but functions as a coactivator via its
LXXLL motif by interacting with a number of NRs and
TFs, such as peroxisome proliferator-activated receptor alpha
(PPARα), FOXO1, hepatocyte nuclear factor 4 alpha (HNF4α),
mineralocorticoid (MR), glucocorticoid (GR), liver X receptors
(LXR), the CAR, vitamin D receptor (VDR), or PXR. In addition,
PGC-1α has a strong transcriptional activation domain at the N
terminus, which interacts with several HAT complexes including
CBP/p300 (Handschin, 2009; Liu and Lin, 2011).
Rifampicin, a prototype ligand for human PXR, is known
to reduce hepatic bile acid levels in patients with cholestasis.
Therefore, a functional cross-talk between PXR and HNF-4α,
a key hepatic regulator of genes involved in bile acid synthesis
including the cholesterol 7-alpha hydroxylase (CYP7A1)
and sterol 12-alpha hydroxylase (CYP8B1) genes, has been
studied. It was shown that PXR interacts with the coactivator
PGC-1α through its C-terminal ligand binding domain in a
rifampicin-dependent manner and that PGC-1α coactivates
PXR transactivation (Bhalla et al., 2004; Li and Chiang, 2005,
2006; Hyrsova et al., 2016). Consistently, endogenous Pgc-1α
from mouse liver extracts was found to bind to PXR, and
recombinant PGC-1α directly interacts with PXR. In addition,
rifampicin-dependent interaction of PXR with PGC-1α was
shown in cells by co-immunoprecipitation and by intranuclear
localization studies using confocal microscopy (Bhalla et al.,
2004). Nevertheless, also conflicting results have been reported
as regards significant rifampicin-mediated stimulation of PXR
interaction with PGC-1α. No evidence of interaction was
observed in GST pull-down assay and only a weak effect was
seen in the mammalian two hybrid (M2H) assay (Li and Chiang,
2006).
PGC-1α at the same time coactivates and enhances the
transcriptional activity of HNF-4α in the regulation of several
liver-specific genes, including CYP7A1, CYP8A1, SHP, OCT1
(SLC22A1), and PEPCK1 (Bhalla et al., 2004; Li and Chiang,
2005, 2006; Hyrsova et al., 2016). This PGC-1α coactivation
of HNF4α was reported to be suppressed by PXR ligands
in an SHP-independent manner. In the case of CYP7A1
and CYP8A1 genes, rifampicin treatment did not inhibit
HNF-4α binding to native promoters of these genes but
resulted in dissociation of PGC-1α from HNF4α-formed
transcription complex and subsequent gene repression (Bhalla
et al., 2004). Most interestingly, the same effect was also
observed in the PEPCK1 regulation. The authors therefore
proposed that PXR could be inhibitory in the process by
competing for PGC-1α binding to HNF4α that dominantly
controls the high hepatic expression of CYP7A1, CYP8A1, and
PEPCK genes (Bhalla et al., 2004) (see also chapter HNF4α,
Figure 6A).
A slightly different model of PXR-HNF4α crosstalk inCYP7A1
gene repression has been proposed by Li and Chiang (Li and
Chiang, 2005). In their experiments employing M2H assay and
ChiP, rifampicin enhanced PXR interaction with HNF4α in
the context of CYP7A1 gene promoter, but reduced PGC-1α
interaction with HNF4α resulting in overall CYP7A1 repression
(see also chapter HNF4α, Figure 6B).
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FIGURE 7 | Crosstalk of PXR and HN4α in OCT1 gene repression. Activated PXR competes and deplete (“squelches”) the SRC-1 coactivator from
HNF4-mediated transactivation of OCT1 (SLC22A1) gene. OCT1 is dominantly regulated by HNF4α in the liver (Hyrsova et al., 2016). Dashed arrow indicates the
squelching (competition for common coactivator). Black bold arrows indicate the effects of activated PXR on genes expression
In a recent study, we examined the suppressive effect of
activated PXR on OCT1 (SLC22A1) expression. OCT1 is one of
the most tightly controlled genes with HNF4α transactivation.
We rather observed competition for SRC-1 than PGC-1α
coactivator in PXR-HNF4α interaction, thereby suggesting a
gene(promoter)-specific crosstalk of PXR-HNF4α in the case of
OCT1 gene regulation (Hyrsova et al., 2016) (Figure 7).
HNF4α
Hepatocyte nuclear factor 4α is a master transcriptional activator
for a large number of genes in hepatocytes and pancreatic
cells. HNF4α belongs to the “orphan” NRs (it is classified as
NR2A1), although fatty-acid CoA thioesters have been proposed
as its ligands. Mutations in this gene have been associated
with the monogenic autosomal dominant non-insulin-dependent
diabetes mellitus type I (MODY 1, maturity onset diabetes of the
young). HNF4α also belongs among the so called liver-enriched
transcription factors controlling liver physiology, differentiation
and drug-metabolism enzymes expression (Jover et al., 2009).
By using a combination of ChiPs and promoter microarrays,
910 genes in hepatocytes and 758 genes in pancreatic islets were
regulated by HNF4α in regulatory circuits together with HNF1α
and HNF6 transcription factors (Odom et al., 2004). HNF4α is
essential for cholesterol and glucose/energy metabolism because
it is a key factor for the basal hepatic expression of CYP7A1,
CYP8B1, G6Pase, and PEPCK genes, respectively.
These genes all contain functional HNF4α-binding sites in
their promoter, and mutation of these sites substantially disrupt
promoter activation. HNF4α binds as a homodimer mainly to
DR1 response elements. Such DR1 motifs have been found in the
bile acid responsive element (BARE) II region at−148 to−129 in
the human CYP7A1 gene promoter and at +198 to +227 of the
human CYP8B1 gene promoter. The promoter of human PEPCK
gene also contains a functional HNF4α-binding site at −431 to
−418 (Watt et al., 2003; Crestani et al., 2004).
Hepatocyte nuclear factor 4α augments the PXR/Pxr-
mediated transactivation of the human CYP3A4 and mouse
Cyp3a11 genes (Tirona et al., 2003; Li and Chiang, 2006). This
enhancement was proposed through cis-acting HNF4α-binding
sites in the proximal promoter and at the far upstream
enhancer region for the CYP3A4 gene (Tirona et al., 2003;
Matsumura et al., 2004; Pavek et al., 2010) even though an
HNF4α-RE independent mechanism has also been proposed
(Li and Chiang, 2006). Rifampicin strongly stimulates PXR
and HNF4α interaction in CYP3A4 gene transactivation, which
is further augmented by PGC-1α and SRC-1 coactivators,
but inhibited by Small heterodimer partner (SHP, NR0B2)
(Tirona et al., 2003; Li and Chiang, 2006). ChiPs revealed
that the rifampicin-activated PXR recruits HNF4α and SRC-
1 (but not PGC-1α) to the CYP3A4 gene chromatin. In
CYP3A4 transactivation, SHP, PXR, and HNF4α have been
proposed to interact and compete for binding to each other
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FIGURE 8 | Model of PXR-mediated transactivation of CYP3A4 gene. In the model, PXR ligands stimulate PXR/Pxr binding to DNA and interaction of PXR with
HNF4α. PXR-HNF4α-SRC-1 complex transactivates CYP3A4 gene promoter (A). PXR at the same time trans-represses SHP gene expression. SHP interferes with
PXR-HNF4α-SRC-1 coactivation and with PXR-DNA interaction (B) (Ourlin et al., 2003; Li and Chiang, 2006).
(Li and Chiang, 2006). Concomitantly, PXR has been proposed
to inhibit SHP promoter activity and to repress SHP gene
transcription by disrupting PGC-1α coactivation of HNF4α (Li
and Chiang, 2006) (Figure 8).
In the case of CYP7A1 gene promoter, HNF4α directly
binds with PXR and both NRs are strongly co-activated by
PGC-1α (Li and Chiang, 2005, 2006). With respect to PXR-
mediated CYP7A1 gene repression, two theories regarding
the mechanism have been postulated based on the PXR-
HNF4α-PGC-1α crosstalk. Bhalla et al. (2004; Dr. Jongsook
Kim Kemper’s group) proposed that PXR competes for the
binding of PGC-1α with HNF4α in CYP7A1 gene regulation
and squelches PGC-1α from HNF4α/DNA complex (Figure 6A).
The group of Dr. Chiang proposed that the activation of
PXR by rifampicin promotes PXR interaction with HNF4α in
the CYP7A1 gene promoter, but blocks PGC-1α interaction
mainly with HNF4α and to a lesser extend with PXR. This
results in the inhibition of CYP7A1 gene expression dominantly
transactivated by HNF4α-PGC-1α (Li and Chiang, 2005)
(Figure 6B). The latter authors also argue that “squelching”
of the common coactivator PGC-1α is an unlikely mechanism
since PGC-1α mostly interacts with PXR in a ligand-independent
manner.
Pregnane X Receptor activation by rifampicin was also found
to repress the estrogen sulfotransferase 1E1 (SULT1E1)
gene. Mechanistic studies showed that activated PXR
displaces HNF4α bound to the PXR-responsive enhancer of
SULT1E1 gene resulting in promoter remodeling, histone
3 deacetylation and repressed expression (Kodama et al.,
2011).
SRC-1
Steroid receptor coactivator 1 is a well-known coactivator
with the conserved N-terminal basic helix−loop−helix-
Per/ARNT/Sim (bHLH-PAS) domain, a central NR interaction
domain (RID) with three LXXLL motifs, and two activation
domains (AD1 and AD2) at the C-terminus. SRC-1 interacts
with many NRs including PXR, LXRα, CAR, FXR, HNF4α, GR
etc. It was shown that PXR and SRC-1 interact in the absence of
a PXR ligand and the interaction is strengthened by rifampicin
(Saini et al., 2005; Li and Chiang, 2006; Rulcova et al., 2010;
Krausova et al., 2011; Hyrsova et al., 2016), although SRC-1 was
proposed to bind to PXR much weaker that PGC-1α (Li and
Chiang, 2005).
Interesting results have been obtained with Pxr-null, Car-
null and double-KO mice. In Pxr-null mice, Car target genes
Mrp2, Mrp3, Ugt1a1, Oatp4, and Gsta2 were up-regulated.
A detailed investigation has shown that unliganded Pxr may
attract coactivators such as Src-1 from Car to dominate over Car
and to control the constitutive activity of Car in detoxification
enzymes regulation (Saini et al., 2005). Based on this, the ligand-
free Pxr can suppress both the constitutive and ligand-induced
activity of Car by competing for common coactivator Src-1 in
a target gene specific manner. This finding also highlights a
regulatory hierarchy of Pxr/Car (PXR/CAR) cross-talk in the
regulation of common target detoxifying enzymes (Saini et al.,
2005).
The antidiabetic drug metformin was reported to suppress
PXR-regulated transactivation of CYP3A4 gene (Krausova et al.,
2011). Metformin did not affect PXR expression, instead it
disturbed PXR interaction with SRC-1 (Krausova et al., 2011).
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Since there is some analogy with the regulation of PXR
and PGC-1α interaction by metformin-induced SIRT1, we can
speculate that SIRT1 can play a role in the process (Hakkola et al.,
2016).
SHP
The small (or short) heterodimer partner (SHP) is a NR (NR
subfamily 0, group B, member 2) encoded by the NR0B2 gene in
humans. SHP is unusual as a NR in that it lacks a DNA binding
domain. No endogenous ligand has been found, therefore SHP
belongs to the “orphan” subfamily. SHP executes its regulatory
function through protein–protein interactions as a coreppresor
of numerous NRs (including PXR, CAR, LXRs, PPARs, HNF4α,
LRH-1, GR, TRβ, RARα, FXR, ERs, ERRs etc.), TFs (such as
FOXO1, C/EBPα, NF-κB etc.) or kinases (such as C-jun or
Smad3) (Zhang et al., 2011). SHP represses the transcriptional
activities of its target proteins by utilizing two functional LXXLL-
related motifs in the LBD domain. The binding of SHP to
TFs/NRs either competes or dissociates coactivators on the AF-
1/2 domains from the receptors. SHP is thus involved in bile
acid, cholesterol, triglyceride, glucose, and drug metabolism.
SHP mainly plays important role in the negative regulation of
the conversion of cholesterol to bile acids via FXR, as well in
regulating the expression of genes playing roles in bile acid
transport (BSEP, NTCP), lipid metabolism (SREBP1C), and
gluconeogenesis (PEPCK, G6Pase) (Zhang et al., 2011; Zou et al.,
2015).
It was shown that SHP inhibits PXR-mediated transactivation
of the CYP3A4 gene by interfering with PXR binding to promoter
response elements (Ourlin et al., 2003; Pavek et al., 2012; Smutny
et al., 2014). However, this finding has been questioned by
Li and Chiang (Li and Chiang, 2006). Instead, they proposed
that HNF4α and SHP compete for binding to PXR in CYP3A4
gene transactivation after rifampicin treatment. In addition, SHP
partially blocks PXR-SRC-1 (but not PXR-PGC-1α) interaction
in CYP3A4 gene regulation (Li and Chiang, 2006). Interestingly,
rifampicin strongly enhanced PXR−SHP interaction in M2H
and GST pull-down assays (Li and Chiang, 2006). In addition,
it was shown that the activated PXR trans-represses SHP
expression, which is dominantly controlled by HNF4α-PGC-
1α regulation, by blocking PGC-1α recruitment to SHP gene
promotor chromatin (Li and Chiang, 2006). By this mechanism,
PXR may concomitantly inhibit SHP gene transcription and
maximizes the PXR-mediated induction of the CYP3A4 gene in
human livers (Li and Chiang, 2006) (see Figure 8).
SIRT1
SIRT1 (silent mating type information regulation 2 homolog
1) also named as NAD+-dependent deacetylase sirtuin-1, is a
protein that is encoded by the SIRT1 gene in humans. SIRT1
is a deacetylase protein which is both catalytically activated
by increased NAD+ level and also transcriptionally induced
during fasting. SIRT1, a mammalian ortholog of the yeast Sir2
protein, belongs into the class III of HDAC that has been
reported to deacetylate many target proteins including some NRs,
either activating or repressing their functions. Sirtuin 1 is a key
metabolic/energy sensor and mediates homeostatic responses to
caloric restriction. Accumulating evidence indicates that Sirtuin
1 is a master regulator that controls hepatic lipid metabolism.
During fasting conditions, SIRT1 deacetylates and alters the
expression and the activities of key transcriptional regulators
involved in hepatic lipogenesis, β-oxidation, and cholesterol/bile
acid metabolism (Moore et al., 2012; Kemper et al., 2013).
In addition, SIRT1 deacetylates PGC-1α and thus enhances its
ability to coactivate gluconeogenic genes (Rodgers et al., 2005).
SIRT1 is one of two major regulators of hepatic energy
homeostasis (together with PGC-1α) involved in PXR signaling.
SIRT1 binds and deacetylates PXR after the ligand-dependent
activation of PXR (Biswas et al., 2011; Buler et al., 2011).
Interestingly, Buler et al. (2011) found PGC-1α-mediated
regulation of PXR expression. SIRT1 was also shown to
interfere with PCN-induced Pxr coactivation by Pgc-1α in
Cyp3a11 gene transactivation (Figure 9). Thus SIRT1 and
PGC-1α fasting-activated pathways differentially affect PXR/Pxr-
mediated function.
RXRα
Pregnane X Receptor heterodimerizes with the NR retinoid
X receptor α (RXRα, NR2B1), encoded by the RXRA gene
(Blumberg et al., 1998; Kliewer et al., 1998). Similarly, other
NRs such as CAR, FXR, LXR, and PPARs form heterodimers
with hetero-oligomeric partner RXRα. Therefore, it is logical
to suppose crosstalk due to the competition for the common
heteropartner. However, no NR−NR interactions have been
reported at the level of RXR crosstalk between these receptors
in the literature. It was shown that ligand-activated LXRα
transactivates CYP3A4 gene expression but suppresses the PXR-
dependent transcription of CYP3A4 through known PXR-
responsive elements dNR1 and eNR3A4. However, the amount
of RXRα was not found as the limiting factor in CYP3A4
transcription after simultaneous activation of PXR and LXRα
(Watanabe et al., 2013). We can thus speculate that there is
sufficiently high amount of RXRα in hepatocytes to sustain
parallel heterodimerization with several activated NRs. We
should also take into account that PXR forms functional
homodimer, which again suggests that RXRα amount may not
be a limiting factor for PXR activity (Noble et al., 2006).
Some retinoids and rexinoids, ligands of RXRα, significantly
induce the PXR/RXR-mediated transactivation (Wang et al.,
2006; Pettersson et al., 2008). Interestingly, rexinoids can
antagonize PXR activation by rifampicin due to the reduced
binding of PXR/RXR to PXR response elements. In addition,
rexinoids, bexarotene (LGD1069), and LG100268 can stimulate
protein degradation of both PXR and RXR (Pettersson et al.,
2008). Therefore, ligand-dependent PXR-RXR interactions may
have an effect on PXR target genes expression.
NF-κB
Proinflammatory stimuli down-regulate CYP expression and
drug-metabolizing activities in the liver.
NF-κB is the key regulator of inflammation and immune
responses. The NF-κB family comprises five members, namely
p65 or Rel A, Rel B, c-Rel, p50, and p52. NF-κB normally resides
in the cytoplasm bound to the protein inhibitor of NF-κB (IκB).
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FIGURE 9 | SIRT1 represses Pxr-PGC-1α coactivation in Cyp3a11 gene regulation. SIRT1 binds to PXR and deacetylate PXR after its ligand-dependent
activation. Sirt1 interferes with Pxr-Pgc-1α coactivation in Cyp3a11 gene regulation (Biswas et al., 2011; Buler et al., 2011).
FIGURE 10 | Crosstalk of NF-κB p65 and PXR-RXRα in PXR-mediated CYPs regulation. Proinflammatory cytokine interleukin 6 (IL-6) down-regulates PXR
mRNA in primary human hepatocytes. In addition, activation of NF-κB by either LPS or TNF-α leads to PXR suppression through interaction of NF-κB p65 and the
PXR-RXRα heterodimer. NF-κB p65 directly binds to RXRα DBD and thus disrupts the association of the PXR/RXRα complex with the PXR responsive sequence
ER6 of the CYP3A4 gene (Pascussi et al., 2000; Gu et al., 2006).
Activating signals, such as pro-inflammatory cytokines lead to
phosphorylation and degradation of IκB, thus allowing NF-κB
to translocate to the nucleus. In the nucleus, NF-κB directly
regulates the transactivation and expression of its target genes.
Signaling mediated by lipopolysaccharide (LPS) and
cytokines, such as IL-1 and TNFα, leads to the activation of
NF-κB. Activated NF-κB was shown to repress PXR activation
and the PXR-mediated induction of several CYPs. Pascussi et al.
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first have shown that the proinflammatory cytokine interleukin
6 (IL-6) down-regulates PXR mRNA in primary human
hepatocytes and inhibits the rifampicin-mediated induction of
the PXR target CYPs genes such as CYP2B6, CYP2C8/9, and
CYP3A4. However, PXR activity itself was not affected by the IL-6
in reporter assays (Pascussi et al., 2000).
Gu et al. (2006) reported that the activation of NF-κB by
either LPS or TNF-α leads to PXR suppression through the
interaction of NF-κB p65 and PXR-RXRα heterodimer. NF-κB
p65 disrupted the association of the PXR/RXRα complex with
the PXR responsive sequences ER6 in electrophoretic mobility
shift and ChiPs. This interference has been explained by the direct
binding of NF-κB p65 to the RXRα DBD in the GST pull-down
assay (Figure 10).
Zhou et al. (2006) further corroborated the NF-κB-PXR
crosstalk and reported that NF-κB activation inhibits hPXR
activation, and that inhibition of NF-κB potentiates PXR
activation. In addition, they showed that NF-κB target genes
are up-regulated and small bowel inflammation is significantly
increased in Pxr−/− mice.
In addition to NF-κB signaling, both protein kinase C
and A (PKC and PKA) signaling is involved in repressing
CYP3A gene expression by affecting the PXR activity during
inflammation. Mechanistically, posttranslational modifications
of PXR by the kinase signaling are involved. I refer to other
reviews for more details (Smutny et al., 2013; Oladimeji et al.,
2016).
Thus, the reciprocal crosstalk between PXR and NF-κB is the
proposed mechanism for the anti-inflammatory function of PXR
and down-regulation of PXR target CYPs during inflammation.
DISCUSSION AND CONCLUSION
In the review, I comprehensively summarize our current
knowledge about the molecular mechanisms of: (i) competition
for coactivator binding to PXR, (ii) coactivation of PXR by
other transcription factors or NRs leading to NRs cross-talk, (iii)
signaling and posttranslational modification of PXR that impairs
its coactivation and (iv) trans-repression of TFs and NRs by
PXR. All these processes form the NR-signaling network that
enables at the same time sensing to caloric restriction or to
toxic injury. Some of the mechanisms confirm our view on the
hierarchy of xenobiotic and endobiotic metabolism regulation
and propose novel targets for drug development. However,
considering the number of NRs, coactivators, corepressors and
signaling pathways that orchestrate transcriptome and proteome
regulation, it is clear that we have discovered only a minor part of
the network.
Pregnane X Receptor plays both positive and negative roles
in regulating numerous genes involved in homeostasis and
detoxification. Indeed, the latest report shows that PXR down-
regulates expression of twice as many genes than it induces in
primary human hepatocytes (Kandel et al., 2016). According to
current knowledge, SULT1E1, SHP, HNF4α, OCT1, and FOXO1
genes are the only candidates that have been reported as repressed
genes of activated PXR in detailed mechanistic studies (Li and
Chiang, 2006; Zhou et al., 2006; Kodama et al., 2011; Kodama
et al., 2015). In the case of these genes, however, protein−protein
interactions of coactivators with NRs or TFs take place and no
direct trans-repression via a cis-acting PXR repression element
has been reported so far.
Therefore, a better understanding of the coactivator/coreppresor
relationships in PXR-mediated gene regulation may help us do
delineate the regulation of other genes repressed by activated
PXR in PXR expressing tissues.
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Membrane-associated progesterone receptors (MAPR) are a group of four rather
small, partially homologous proteins, which share a similar non-covalent heme-binding
domain that is related to cytochrome b5, a well-known functional interaction partner
of microsomal cytochrome P450 (CYP) monooxygenase systems. Apart from their
structural similarities the four proteins progesterone membrane component 1 (PGRMC1,
also referred to as IZA, sigma-2 receptor, Dap1), PGRMC2, neudesin (NENF) and
neuferricin (CYB5D2) display surprisingly divergent and multifunctional physiological
properties related to cholesterol/steroid biosynthesis, drug metabolism and response,
iron homeostasis, heme trafficking, energy metabolism, autophagy, apoptosis, cell cycle
regulation, cell migration, neural functions, and tumorigenesis and cancer progression.
The purpose of this mini-review is to briefly summarize the structural and functional
properties of MAPRs with particular focus on their interactions with the CYP system.
For PGRMC1, originally identified as a non-canonical progesterone-binding protein that
mediates some immediate non-genomic actions of progesterone, available evidence
indicates mainly activating interactions with steroidogenic CYPs including CYP11A1,
CYP21A2, CYP17, CYP19, CYP51A1, and CYP61A1, while interactions with drug
metabolizing CYPs including CYP2C2, CYP2C8, CYP2C9, CYP2E1, and CYP3A4 were
either ineffective or slightly inhibitory. For the other MAPRs the evidence is so far less
conclusive. We also point out that experimental limitations question some of the previous
conclusions. Use of appropriate model systems should help to further clarify the true
impact of these proteins on CYP-mediated metabolic pathways.
Keywords: cytochrome P450, membrane-associated progesterone receptor, neudesin, neuferricin, PGRMC1,
PGRMC2, protein-protein interaction
INTRODUCTION
Inter- and intraindividual variability in the expression and activity of drug metabolizing enzymes,
transporters and their regulators is a major determinant of drug response, both in terms of
drug efficacy and adverse events. The cytochrome P450 enzymes, a superfamily of microsomal
and mitochondrial hemoproteins (CYP), are particularly variable between and within subjects
(Zanger and Schwab, 2013). Despite half a century of pharmacogenetic research, much of the
Frontiers in Pharmacology | www.frontiersin.org March 2017 | Volume 8 | Article 159 | 62
fphar-08-00159 March 23, 2017 Time: 15:31 # 2
Ryu et al. MAPR Proteins and Cytochrome P450 Function
interindividual variation remains unexplained (Meyer, 2004;
Lauschke and Ingelman-Sundberg, 2015). This “dark variation”
may be explained by so far unidentified or unexplored genes
that influence drug metabolism at the level of protein-protein
interactions (PPI). The multiple monooxygenase functions
of microsomal CYP enzymes strictly depend on PPI with
the single microsomal flavoprotein NADPH:cytochrome P450
oxidoreductase (POR) to allow electron transfer from NADPH
to the heme iron (Pandey and Fluck, 2013; Kandel and Lampe,
2014). Since POR is present in the endoplasmic reticulum (ER)
at sub-stoichiometric amounts compared to CYP, it has been
proposed that their interactions involve transient oligomeric
complexes (Backes and Kelley, 2003). In contrast to POR, the
small hemoprotein cytochrome b5 (CYB5), which is located
together with CYB5-reductase and the other components on
the cytoplasmic side of the ER, is not an obligatory electron
donor for CYPs but acts as modulator of enzyme activity
in CYP- and sometimes substrate-dependent way (Henderson
et al., 2015). For a long time, POR and CYB5 were the only
proteins known to functionally interact with CYPs during the
microsomal monooxygenase reaction. Only in recent years new
PPI candidates for cytochromes P450 have been considered (see
other articles in this Research Topic).
A particularly intriguing group of proteins are the so-
called “membrane-associated progesterone receptor” (MAPR)
proteins. The term emphasizes their common ability to bind
progesterone and to elicit rapid steroidal effects independent of
the classical steroid hormone receptors (Wehling, 1997; Mifsud
and Bateman, 2002). Following the initial purification of a high-
affinity progesterone-binding protein (later termed progesterone
receptor membrane component 1, PGRMC1) from porcine liver
membranes and cDNA cloning (Meyer et al., 1996; Gerdes
et al., 1998), MAPRs were recognized as evolutionarily conserved,
distant homologs of CYB5, that can principally interact with
CYPs and modulate their functions (Min et al., 2004; Hughes
et al., 2007).
The purpose of this review is to provide an overview
and critical assessment of the studies elucidating potential
interactions of MAPRs with CYPs. Apart from this, MAPRs
interact with an increasing number of different proteins and
are involved in a wide variety of cellular functions including
cholesterol and steroid homeostasis, cell cycle regulation, cell
migration, neurogenesis, autophagy, heme homeostasis and more
that are only briefly mentioned but not the focus of this review.
Readers interested in these aspects are referred to excellent
reviews by others (Losel et al., 2008; Ahmed et al., 2012; Kimura
et al., 2012; Neubauer et al., 2013; Cahill et al., 2016; Hasegawa
et al., 2016).
MOLECULAR, BIOCHEMICAL AND
CELLULAR PROPERTIES OF MAPRs
The four MAPR proteins PGRMC1, PGRMC2, neuferricin
and neudesin share a homologous CYB5-like heme/steroid-
binding domain but lack homology with the classical nuclear or
membrane-bound steroid receptors (Mifsud and Bateman, 2002;
Min et al., 2005; Kimura et al., 2012). Recent crystallographic
analyses confirmed the hemoprotein nature of PGRMC1 with
a special five-coordinated heme iron involving Tyr113, as
opposed to the six-coordinated heme with two axial histidines
in CYB5 (Min et al., 2005; Kaluka et al., 2015; Kabe et al.,
2016). Interestingly, this difference allows human PGRMC1
to form stable homodimers through hydrophobic heme-heme
stacking interactions, explaining earlier observations of dimeric
complexes (Min et al., 2004; Kabe et al., 2016). Since the heme-
binding residues are conserved among MAPRs, these proteins
may all share the ability of heme-dependent homo- and/or
heterodimerization (Peluso et al., 2014). Although PGRMC1 had
originally been defined as a component of a progesterone-binding
protein complex with affinities in the nM range (Meyer et al.,
1996), it remained questionable whether progesterone actually
binds directly to PGRMC1 itself. A recent study provided first
qualitative spectroscopic evidence that this is indeed the case,
while it is still not proven for other MAPRs (Kaluka et al., 2015).
PRGMC1
PRGMC1 is predominantly expressed in mammalian liver
and kidney but also found in steroidogenic and reproductive
tissues, brain, breast, heart, lung, skeletal muscle, pancreas,
and other organs (Gerdes et al., 1998; Kimura et al., 2012).
Typically it is colocalized with CYPs in the smooth ER, but
it has also been localized in the nucleus, cytoplasm, plasma
membrane, and mitochondria (Kimura et al., 2012; Piel et al.,
2016). Expression is inducible by carcinogens, including dioxin
(Selmin et al., 1996), and increased in breast and other tumors,
where it contributes to cancer progression (Neubauer et al.,
2008; Ruan et al., 2017). Reported physiological functions
affected by PGRMC1 include cholesterol/steroid biosynthesis and
metabolism (see below), iron homeostasis and heme trafficking
by regulating hepcidin expression and ferrochelatase activity
(Craven et al., 2007; Li et al., 2016; Piel et al., 2016), promotion
of autophagy through interaction with MAP1LC3B (Mir et al.,
2013), regulation of cell cycle, proliferation, and cell death (Peluso
et al., 2014), maintenance of female reproductive functions in
PGRMC1 conditional knock-out mice (McCallum et al., 2016),
cell migration and invasion (Sueldo et al., 2015), amyloid beta
binding and synaptotoxicity in a mouse model of Alzheimer’s
disease (Izzo et al., 2014), and others (Losel et al., 2008; Ahmed
et al., 2012; Neubauer et al., 2013; Cahill et al., 2016; Hasegawa
et al., 2016). A growing number of studies supports furthermore
a role of PGRMC1 in drug response and as potential drug target,
e.g., by increasing susceptibility to tyrosine kinase inhibitors
(Ahmed et al., 2010), decreasing doxorubicin cytotoxicity (Lin
et al., 2015), or mediating atypical antipsychotic drug-induced
lipid disturbances (Cai et al., 2015). Importantly, in 2011
PGRMC1 was identified as the elusive sigma 2 receptor (S2R), an
intracellular orphan receptor that binds to many drugs and that is
abundant in liver and kidney (Xu et al., 2011; Ahmed et al., 2012).
PGRMC2
PGRMC2 harbors a structurally similar CYB5 domain as
PGRMC1, while there are differences in the N-terminal
transmembrane domain (Cahill, 2007). Human PGRMC2
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protein is 247 amino acids in length. Despite its structural
similarities to PGRMC1, PGRMC2 has been less well studied
(Wendler and Wehling, 2013; Hasegawa et al., 2016). Expression
appears to be ubiquitous with similar intracellular localization
(Chen et al., 2010; Intlekofer and Petersen, 2011). In SKOV-3
ovarian cancer cells no differences between PGRMC1 and 2 in
regard to cell viability or response to cisplatin and progesterone
were found, but only PGRMC2 inhibited cell migration (Albrecht
et al., 2012). PGRMC2 was also implicated in cell cycle regulation
(Peluso et al., 2014).
Neudesin
Neudesin was originally identified as a mouse secreted protein
with neurotrophic activity and termed neuron-derived
neurotrophic factor (NENF) (Kimura et al., 2005). In adult
mice, neudesin was expressed preferentially in the CNS spinal
cord but also in several peripheral tissues (Kimura et al., 2005,
2012). NMR studies suggested a similar structure with a potential
heme-binding pocket (Han et al., 2012). The physiological roles
of neudesin as a secreted protein appear to be significantly
different from PGRMC1/2, including particularly neurotrophic
activity that required heme binding and was mediated through
mitogen-activated protein (MAP) and phosphatidylinositol
3-kinase (PI-3K) pathways (Kimura et al., 2005). Several
neurological functions have been studied in knockout mice as
summarized elsewhere (Ohta et al., 2015). Extracellular/secreted
neudesin may be involved in carcinogen resistance and tumor cell
immortalization, although specific receptors remain unknown
(Ohta et al., 2015).
Neuferricin
Neuferricin (CYP5D2) was discovered via a homology-
based search of the CYB5-like heme/steroid-binding domain
of neudesin, alternatively termed cytochrome B5 Domain
Containing 2 (CYB5D2) (Kimura et al., 2010). Neuferricin is
also widely expressed in several tissues including the CNS,
heart, adrenal glands, and kidneys. Human neuferricin is 264
amino acids in length and includes a cleavable signal sequence
at its N terminus followed by a heme-binding domain that
may involve aspartic acid (D86) instead of tyrosine in heme
binding (Bruce and Rybak, 2014). CYB5D2 can be detected as
secreted hemoprotein in some cell lines but also colocalized
with POR in the ER (Xie et al., 2011; Bruce and Rybak, 2014).
Ectopic CYB5D2 expression inhibited cell proliferation and
anchorage-independent colony growth of HeLa cells (Bruce and
Rybak, 2014).
SPECIFIC INVOLVEMENT OF MAPRS IN
CYP FUNCTIONS
The available evidence suggesting that MAPR proteins can
interact with the microsomal CYP-monooxygenase system to
modulate its function is based on different species from
yeast to human, various experimental systems, and relates to
CYP enzymes catalyzing steroidogenic or xenobiotic reactions
(Table 1). The levels of interactions may include not only physical
PPIs but also indirect influences via heme transfer, heme and iron
homeostasis, and transcriptional regulation (Figure 1).
PGRMC1
First indications for a link between PGRMC1 and CYP function
came from two independent studies. Identification of the
adrenal “inner zone antigen” (IZA) as a MAPR member (Raza
et al., 2001), its localization in both steroidogenic and steroid
metabolizing tissues and the fact that an anti-IZA monoclonal
antibody decreased certain adrenal steroidhydroxylase activities
led the authors to suggest a function in steroid hormone
biosynthesis and/or metabolism (Min et al., 2004). By
coexpressing IZA/PGRMC1 with CYP21A2, CYP11B1 or
CYP17 in COS-7 cells they found differential effects, namely
enhancement of progesterone 21-hydroxylation, no effect on
progesterone 11β- or 17α-hydroxylation, and activation of
the CYP17-catalyzed 17–20 lyase reaction (Min et al., 2004,
2005). About at the same time a search for novel yeast genes
involved in DNA damage response led to the identification of
Dap1 (Hand et al., 2003). Steroid analyses of Saccharomyces
cerevisiae yeast cells lacking Dap1 revealed decreased levels of
ergosterol but increased levels of its intermediates, suggesting a
partial defect in sterol synthesis by lanosterol-14-demethylase,
the highly conserved yeast-essential Erg11/CYP51 (Hand et al.,
2003). Genetic follow-up studies supported a model in which
heme binding by Dap1 is required to activate Erg11/CYP51,
although a Dap1-Erg11 complex could not be directly detected
by immunoprecipitation experiments (Mallory et al., 2005).
Further evidence for a role of Dap1/PGRMC1 in CYP
function was provided by Hughes et al. (2007) working with
Schizosaccharomyces pombe. After confirming that fission yeast
Dap1 is also a hemoprotein and directly binds to and activates
enzymatic activities of CYP51A1 (Erg11) and CYP61A1 (Erg5),
they investigated whether PGRMC1 is required for cholesterol
synthesis in mammals (Hughes et al., 2007). RNA interference-
mediated knock-down of hPGRMC1 in HEK293 cells resulted in
lanosterol accumulation, indicating that PGRMC1 was required
for the demethylation of lanosterol by the Erg11 homolog,
CYP51A1. Using a coexpression/coimmunoprecipitation
approach PGRMC1 was shown to form a stable complex
with CYP51A1 (Hughes et al., 2007). The authors applied the
latter experiment also to CYP7A1, CYP21A2, and CYP3A4,
demonstrating physically stable PGRMC1-CYP complexes in
all cases. PGRMC1 was later shown to also activate CYP19
aromatase (Ahmed et al., 2012). Collectively these studies
strongly suggest the ability of PGRMC1 to form functional
PPIs with steroidogenic and possibly other CYPs. Interestingly,
the documented functional influence of PGRMC1 on various
steroidogenic CYPs appeared to be generally positive.
The above mentioned ability of PGRMC1 to complex with
CYP3A4 first indicated the possibility that PGRMC1 may also
interact with drug metabolizing P450s (Hughes et al., 2007).
Although the authors emphasized the apparent existence of
stoichiometric and physically stable complexes, it should be
kept in mind that the experimental conditions of overexpressing
tagged and manipulated proteins were quite artificial and that it
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TABLE 1 | Functional interactions between membrane-associated progesterone receptors (MAPR) proteins and cytochrome P450 system.
MAPR CYP System Enzymatic activity Direction of influence Reference
IZA/PGRMC1 (rat) CYP21A2 (rat) Inhibition by anti-IZA
monoclonal antibody
Progesterone 21-hydroxylase Activation Laird et al., 1988
IZA/PGRMC1 (rat) CYP21A2 (rat) COS-7 cell coexpression Progesterone 21-hydroxylase Activation Min et al., 2004
IZA/PGRMC1 (rat) CYP17 (guinea pig) COS-7 cell coexpression Progesterone 17α-hydroxylase Little or no influence Min et al., 2005
IZA/PGRMC1 (rat) CYP17 (guinea pig) COS-7 cell coexpression 17α-Hydroxyprogesterone
17–20 lyase
Activation Min et al., 2005
IZA/PGRMC1 (rat) CYP11B1 (rat) COS-7 cell coexpression Progesterone 11β-hydroxylase Little or no influence Min et al., 2004
PGRMC1 (human) CYP19A1 (human) CYP19-engineered MCF-7




Activation Ahmed et al., 2012
Dap1/PGRMC1
(S. cerevisiae)
CYP51A1 (S. cerevisiae) S. cerevisiae genetics Lanosterol-14-demethylase Activation Hand et al., 2003
Mallory et al., 2005
Dap1/PGRMC1
(S. pombe)
CYP51A1 (S. pombe) S. pombe strain lacking
DAP1
Lanosterol-14-demethylase Activation Hughes et al., 2007
Dap1/PGRMC1
(S. pombe)
CYP61A1 (S. pombe) S. pombe strain lacking
DAP1
Lanosterol-22-desaturase Activation Hughes et al., 2007
PGRMC1 (rabbit) CYP2C2 (rabbit) HEK293, HepG2 cell
coexpression




PGRMC1 (human) CYP2C8 (human) HEK293, HepG2 cell
coexpression















Inhibition Oda et al., 2011





Inhibition Oda et al., 2011






No influence Oda et al., 2011
PGRMC2 (human) CYP3A4 (human) Human liver genetic
association
Atorvastatin 2-hydroxylase Inhibition Klein et al., 2012




Activation Bruce and Rybak,
2014
is unknown, whether PGRMC1 abundance in the ER is sufficient
for the formation of 1:1 complexes at higher concentrations.
Two studies have investigated the question whether PGRMC1
affects drug metabolizing CYPs functionally. Szczesna-Skorupa
and Kemper, using cotransfection and coimmunoprecipitation
of FLAG-tagged PGRMC1 with variously tagged rabbit CYP2C2
and human CYP2C8 and CYP3A4 in HEK293 cells could show
efficient binding of PGRMC1 to all three CYPs, for CYP2C2
mainly mediated by the cytoplasmic domain (Szczesna-Skorupa
and Kemper, 2011). The effect of PGRMC1 on enzymatic activity
was tested by siRNA-mediated downregulation of endogenous
PGRMC1, and by coexpression with functional CYP plasmids
in HEK293 and HepG2 hepatoma cells (Table 1). Surprisingly,
the results were quite opposite to those of steroidogenic
CYPs, as CYP activities were either unchanged or slightly
increased in PGRMC1-deficient cells, but decreased in presence
of exogenously expressed PGRMC1. Interestingly, the inhibitory
effect could be partially and CYP isoform-dependently reversed
by increased expression of POR, also shown to directly
interact with PGRMC1. The authors concluded that in contrast
to steroidogenic CYPs, PGRMC1 is not required by drug
metabolizing CYPs for enzymatic activity and that the CYP
differential effects may be explained by the intricate PPI affinities
in triple CYP-POR-PGRMC1 systems (Szczesna-Skorupa and
Kemper, 2011).
Oda et al. (2011) found differential effects of PGRMC1
cotransfection with CYP2C9, CYP2E1, and CYP3A4 in HepG2
cells. While CYP3A4 had increased Km and decreased Vmax with
two different substrates (testosterone and midazolam), CYP2C9
Km was unchanged but Vmax also decreased, and CYP2E1 activity
(chlorzoxazone, 7-ethoxycoumarin) remained unchanged. The
authors also confirmed direct interactions of PGRMC1 with all
three CYPs (Oda et al., 2011).
More recently, Kabe et al. (2016) in their structural study
investigated the relevance of heme-mediated dimerization on
functional interactions with human CYPs. By incubation of
FLAG-tagged PGRMC1 with microsomes from insect-cells
expressing POR, CYB5, and either CYP1A2 or CYP3A4, they
showed by immunoprecipitation that only wild-type PGRMC1
but not the Y113F mutant interacted with the present CYP.
The interaction with CYP1A2 was furthermore blocked by
incubation with a CO-generating reagent, indicating that
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FIGURE 1 | Confirmed and hypothetical interactions of membrane-associated progesterone receptors (MAPRs) with microsomal cytochrome P450
(CYP) system. MAPR proteins located in the endoplasmic reticulum (ER) membrane can directly interact with each other to form homo- and heterodimers; MAPR
monomers and dimers may participate in PPIs with P450 oxidoreductase (POR), cytochrome b5 (CYB5) and/or CYPs. Transfer of heme to CYB5 and possibly CYPs
as well as involvement in iron/heme homeostasis may influence heme integration and thus CYP function. Furthermore, MAPRs participate in diverse signaling
pathways that may affect transcriptional regulation of CYP gene expression (double arrows, confirmed protein-protein interactions; solid arrows, confirmed influence;
dashed arrows, hypothetical influence).
PGRMC1 dimerization is necessary for the interaction. To test
whether CYP-mediated enzymatic functions are affected they
used HCT116 human colon cancer cells stably expressing control
or PGRMC1 shRNA to reduce endogenous PGRMC1 expression
and incubated them with doxorubicin. PGRMC1 knock-down
suppressed the conversion of doxorubicin to doxorubicinol,
and increased cell sensitivity to doxorubicinol. This effect was
partially reversed by coexpression of the wild-type PGRMC1
but not of the Y113F mutant. Assuming that CYP2D6 and
CYP3A4 are the relevant enzymes for doxorubicinol-formation
in HCT116 cells, the authors concluded that interaction of
CYPs with the PGRMC1 dimer was a crucial component of
CYP activity (Kabe et al., 2016). However, this conclusion is
severely flawed because the metabolic step from doxorubicin to
doxorubicinol is not a hydroxylation but in fact a 2-electron
reduction of a ketogroup to an aliphatic alcohol. This reduction is
not catalyzed by CYPs 2D6 and 3A4 as indicated in the paper, but
mainly by cytosolic carbonyl reductase 1 (Kassner et al., 2008).
Furthermore the use of HCT116 cells with very low CYP3A4
expression seems inappropriate for CYP metabolism studies
(Habano et al., 2011). We therefore believe that this and other
previously reported functional and cellular effects of PGRMC1
on doxorubicin-metabolism or cytotoxicity (e.g., Friel et al., 2015;
Lin et al., 2015) are not due to interactions with CYPs but must
have other reasons.
Finally the recent study by Piel et al. (2016) should be
mentioned here again as it demonstrated a role of PGRMC1 in
heme homeostasis and its ability to directly transfer heme to
CYB5 in vitro. The authors suggest that PGRMC1 may be a heme
chaperone or sensor, and this could of course have additional
direct or indirect implications for CYP function (Figure 1).
PGRMC2
Despite its high similarity to PGRMC1 much less is known
about PGRMC2 (Wendler and Wehling, 2013). The first
observation indicating a role in CYP function was made in
a pharmacogenetic screen in human livers, where an intronic
PGRMC2 polymorphism (rs3733260) was significantly associated
with lower levels of mRNA expression, protein and enzyme
activity (Klein et al., 2012). Although the directionality of this
influence was the same as that observed for PGRMC1 and
CYP3A4, it should be noted that the data are correlative in nature
and would also be compatible with gene regulatory mechanisms
(Figure 1). Stable physical interactions of PGRMC2 were
demonstrated in human embryonic kidney cells for CYP1A2 and
CYP3A4, suggesting similar interaction potential as for PGRMC1
(Albrecht et al., 2012). It should thus be interesting to investigate
the potential of PGRMC2 to modulate CYP function and/or
expression in a valid system.
Neudesin and Neuferricin
To our knowledge, only one study (Bruce and Rybak, 2014)
directly addressed the potential interaction of these proteins
with CYPs. The authors showed that neuferricin is colocalized
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with POR in HeLa cells. Neuferricin knockdown reduced
endogenous CYP51A1 (lanosterol demethylase) protein levels,
which lead to increased sensitivity toward mevalonate, an
intermediate of the cholesterol synthesis pathway. This suggested
a stabilizing role of neuferricin for CYP51A1, as previously
described for PGRMC1 and Dap1 (Hughes et al., 2007). Data
further indicated that neuferricin knockdown also decreased
the fraction of endogenous CYP3A4 activity that was enhanced
by overexpressed POR, indicating activation of CYP3A4 by
neuferricin, in contrast to the inhibitory effects of PGRMC1 (see
above). However, it should be pointed out that the neuferricin
data consists of a single point measurement carried out in a cell
model that is not usually applied for drug metabolism studies,
leaving it unclear whether the conclusion can be generalized.
The same argument applies to the studies on HeLa cell exposure
to chemotherapeutic agents such as paclitaxel, cisplatin, and
doxorubicin, which resulted in increased sensitivities in CYB5D2
deficient cells (Bruce and Rybak, 2014). Since the expression
levels of drug metabolizing CYPs are very low in HeLa cells,
the construction of a link between CYB5D2 and function of




Direct physical interactions of MAPRs, especially of mammalian
PGRMC1 or yeast Dap1, with various cytochromes P450 are
strongly supported by experimental data. However, data are still
limited and in our view use of inappropriate model systems
questions some conclusions on functional interactions with
CYPs. Open questions that remain to be studied are, for example:
which direct MAPR-CYP interactions are possible in binary,
ternary, and higher order complexes and how do they affect
function; how could MAPRs indirectly influence CYP function,
e.g., by regulating heme supply and protein stability; are there
MAPR signaling pathways that affect transcriptional regulation
of CYPs and possibly other drug metabolizing enzymes, etc. It
is of eminent importance that valid experimental systems, which
express the CYP system at physiological levels, e.g., primary
hepatocytes or genetically modified mice, are used in future
studies.
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All cytochromes P450s in the endoplasmic reticulum rely on P450 oxidoreductase (POR)
for their catalytic activities. Mutations in POR cause metabolic disorders of steroid
hormone biosynthesis and affect certain drug metabolizing P450 activities. We studied
mutations A115V, T142A, Q153R identified in the flavin mononucleotide (FMN) binding
domain of POR that interacts with partner proteins and P284L located in the hinge
region that is required for flexibility and domain movements in POR. Human wild-type
(WT) and mutant POR as well as CYP3A4 and CYP19A1 proteins in recombinant
form were expressed in bacteria, and purified proteins were reconstituted in liposomes
for enzyme kinetic assays. Quality of POR protein was checked by cytochrome c
reduction assay as well as flavin content measurements. We found that proteins carrying
mutations A115V, T142A located close to the FMN binding site had reduced flavin
content compared to WT POR and lost almost all activity to metabolize androstenedione
via CYP19A1 and showed reduced CYP3A4 activity. The variant P284L identified
from apparently normal subjects also had severe loss of both CYP19A1 and CYP3A4
activities, indicating this to be a potentially disease causing mutation. The mutation
Q153R initially identified in a patient with disordered steroidogenesis showed remarkably
increased activities of both CYP19A1 and CYP3A4 without any significant change in
flavin content, indicating improved protein–protein interactions between POR Q153R
and some P450 proteins. These results indicate that effects of mutations on activities of
individual cytochromes P450 can be variable and a detailed analysis of each variant with
different partner proteins is necessary to accurately determine the genotype-phenotype
correlations of POR variants.
Keywords: POR, P450 oxidoreductase, CYP19A1, CYP3A4, polymorphisms, protein–protein interaction,
cytochrome P450
INTRODUCTION
Cytochrome P450 proteins metabolize a wide range of drugs, steroids and xenobiotics
(Schuster and Bernhardt, 2007; Omura, 2010; Zanger and Schwab, 2013). There are two
distinct types of cytochrome P450 proteins in humans (Omura, 2010). Type 1 P450s, that are
located in the mitochondria, are primarily involved in the metabolism of steroids and use
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adrenodoxin/adrenodoxin reductase proteins as redox partners
(Omura, 2006; Zalewski et al., 2016). The type 2 P450s, located
in the endoplasmic reticulum, rely on a single redox partner,
the cytochrome P450 oxidoreductase (POR, NCBI# NP_000932,
UniProt# P16435), for supply of electrons (Lu et al., 1969). POR
is a flavoprotein that contains both the flavin mononucleotide
(FMN) and the flavin adenine dinucleotide (FAD) and supplies
electrons to cytochromes P450 and other proteins (Matsubara
et al., 1976; Nagao et al., 1983; Guengerich, 2005). The structure
of the FMN binding domain of human POR has been determined
by x-ray crystallography (Zhao et al., 1999) and a more recent
open conformation structure of POR shows potential interaction
possibilities for redox partners (Aigrain et al., 2009).
P450 oxidoreductase deficiency (PORD, OMIM: 613537 and
201750) is a form of congenital adrenal hyperplasia, initially
described in patients with altered steroidogenesis (Flück et al.,
2004) followed by several reports with a broad spectrum of
disorders (Adachi et al., 2004; Arlt et al., 2004; Pandey and Flück,
2013; Flück and Pandey, 2014; Pandey and Sproll, 2014; Burkhard
et al., 2017). Sequencing of the POR gene revealed mutations
in patients with disorders of steroid biosynthesis (Flück et al.,
2004; Miller et al., 2004; Pandey et al., 2004). Afterward, many
other laboratories reported mutations in POR in patients with
steroidogenic disorders and/or bone malformation syndromes
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005;
Pandey and Flück, 2013; Riddick et al., 2013). While initial
studies on POR mutations focused on steroid metabolism,
effects on other partner proteins like heme oxygenase and drug
metabolizing P450s have also been studied (Agrawal et al.,
2008, 2010; Flück et al., 2010; Nicolo et al., 2010; Pandey
et al., 2010). Large scale sequencing projects have identified
many variations in the POR gene, in several different human
sub-populations, and multiple variants have been implicated in
altered drug metabolism (Gomes et al., 2008, 2009; Huang et al.,
2008; Agrawal et al., 2010; Nicolo et al., 2010; Pandey et al.,
2010). Since POR is involved in multiple steroid biosynthesis
reactions catalyzed by cytochrome P450 proteins, a complex
disorder of steroidogenesis is expected from mutations in POR
(Figure 1). Many POR variants found in patients as well as
normal population have been tested for enzymatic activities
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005,
2006; Homma et al., 2006; Pandey, 2006; Huang et al., 2008;
Sim et al., 2009). While mutations in POR can be found in
all regions of the protein, based on analysis of previously
identified mutations, some general observations can be made.
Mutations found in the co-factor binding sites (FMN, FAD and
NADPH) generally result in a severe form of the disease with
the mutations causing loss of FMN or FAD showing most severe
effects on activities of all supported redox partners. We have
previously shown that aromatase (CYP19A1) activity responsible
for conversion of androgens to estrogens (Figure 1) is more
susceptible to changes in NADPH binding site mutations in
POR (Pandey et al., 2007; Flück et al., 2011; Flück and Pandey,
2017). The studies described in this report were conducted by
embedding POR and P450 proteins in liposomes followed by
removal of detergents. In the current study, we have investigated
effects of some mutations in the FMN binding domain and
the hinge region of POR that facilitate interactions with redox
partner proteins, including P450s, to transfer electrons from
NADPH.
MATERIALS AND METHODS
Recombinant Expression of POR and
Membrane Purification
The WT and variant POR (NCBI# NP_000932, Uniprot#
P16435) proteins were expressed in bacteria using the expression
constructs described previously (Huang et al., 2005, 2008; Pandey
et al., 2007; Nicolo et al., 2010). The protocol for expression
of N-27 form of POR variants and subsequent membrane
purification is described and adopted from our previous
publications (Huang et al., 2005; Pandey et al., 2007, 2010;
Parween et al., 2016; Flück and Pandey, 2017). The cDNAs for
WT or mutant POR in pET22b were transformed into Escherichia
coli BL21(DE3), single colonies were selected for growth on
ampicillin and grown in terrific broth pH 7.4 supplemented with
40 mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4,
2 mM CaCl2, 2 mM CuCl2, 2 mM H3BO3, 0.5 mg/ml riboflavin,
100 µg/ml carbenicillin at 37◦C to an optical density (OD)
600 nm of 0.6 and temperature was reduced to 25◦C for 16 h.
The bacterial cells were collected by centrifugation, washed with
PBS and suspended in 100 mM Tris–acetate (pH 7.6), 0.5 M
sucrose, and 1 mM EDTA and treated with lysozyme (0.5 mg/ml)
and EDTA (0.1 mM [pH 8.0]) at 4◦C for 1 h with slow stirring
to generate spheroplasts. The spheroplasts were pelleted by
centrifugation at 5000× g for 15 min; and suspended in 100 mM
potassium phosphate (pH 7.6), 6 mM MgOAc, 0.1 mM DTT,
20% (v/v) glycerol, 0.2 mM PMSF, and 0.1 mM DNase I; and
disrupted by sonication. A clear lysate devoid of cellular debris
was obtained by centrifugation at 12,000× g for 10 min, and then
the membranes were collected by centrifugation at 100,000 × g
for 60 min at 4◦C. Membranes were suspended in 50 mM
Potassium phosphate buffer (pH 7.8) and 20% (v/v) glycerol and
stored at−70◦C. Protein concentration was measured by RC-DC
protein assay (Protein Assay Dye Reagent, Bio-Rad, Hercules,
CA, United States) and POR content in membrane proteins was
quantitated by western blot analysis.
Quantification of POR Content in the
Bacterial Membranes by Western Blot
Analysis
For Western blots, 1 µg of WT and POR bacterial membrane
proteins were separated on SDS–PAGE gel and blotted on to
polyvinyldifluoride (PVDF) membranes. Blots were probed with
a rabbit polyclonal antibody against wild-type human POR
from Genscript (Genscript, Piscataway, NJ, United States) at a
dilution of 1:1000. We used a secondary goat anti-rabbit antibody
that was labeled with a phthalocyanine infrared dye (IRDye
700DX, LI-COR Bioscience Inc., Lincoln, NE, United States)
at a dilution of 1:10000. Signals were detected with the green
fluorescent channel (700 nm) on an Odyssey Infrared Imaging
System (LI-COR Bioscience Inc., Lincoln, NE, United States), and
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FIGURE 1 | Role of POR in the steroid hormone biosynthesis. In the first steps of steroid biosynthesis, cholesterol is transported to mitochondrion by steroidogenic
acute regulatory protein (StAR). Then, inside the mitochondria, the cholesterol is metabolized by CYP11A1 to pregnenolone, and adrenodoxin and adrenodoxin
reductase act as the redox mediators in this reaction. The pregnenolone produced in the mitochondria is further metabolized in the endoplasmic reticulum to
downstream products 17OHPreg, DHEA, androstenedione or androstenediol; and then this process continues toward the production of testosterone in the Leydig
cells of the testes. Testosterone is further metabolized to dihydrotestosterone (DHT) in the genital skin. In the placenta, DHEA is converted to androstenedione and
then to testosterone, which is further metabolized to estrogens. In fetal liver, inactive precursor DHEAS is converted to 16αDHEAS, which gets converted to
16αDHEA in placenta to produce estrogens. The estrogen biosynthesis process requires CYP19A1 activity that is dependent on POR. The deficiency in POR can
alter the enzymatic reactions of many cytochrome P450 enzymes and these changes can be variable based on structural properties of the mutation and nature of
the redox partner. CYP11A1, P450scc, cholesterol side-chain cleavage enzyme; StAR, steroidogenic acute regulatory protein; FDX1, Adrenodoxin; FDXR, NADPH
adrenodoxin oxidoreductase; CYP17A1, P450c17, 17α-hydroxylase/17,20-lyase; HSD3B2, 3βHSD2, 3β-hydroxysteroid dehydrogenase, type 2; CYB5, cytochrome
b5; POR, P450 oxidoreductase; HSD17B3, 17βHSD3, 17β-hydroxysteroid dehydrogenase, type 3. Full steroid names: 17OHPreg, 17-hydroxypregnenolone;
17OHProg, 17-hydroxyprogesterone; 17OH-DHP, 17-hydroxydihydroprogesterone (5α-pregnan-3α,17α-ol-20-one); DHEA, dehydroepiandrosterone. Copyright ©
2017 Udhane, Parween, Kagawa and Pandey.
bands were quantitated using Odyssey software. POR content of
each membrane preparation was measured, and all samples were
normalized against purified wild-type POR used as standard. In
all experiments the normalized amount of POR content was used
in each experiment for all mutants as well as WT protein.
Cytochrome c Reduction Assay by WT
and Mutant POR
The cytochrome c reduction by bacterially expressed WT or
mutant POR was assayed as described previously by measuring
the change in absorbance at 550 nm (ε = 21.1 cm−1 mM−1)
(Guengerich et al., 2009). Briefly, the reaction was performed
in 96-well plates, in triplicate, with 5 µg of POR membrane
preparation in each well, using a microplate reader (Spectramax
M2e, Molecular Devices, Sunnyvale, CA, United States). The
NADPH concentration was fixed at 100 µM and different
concentrations of cytochrome c (0.6–80 µM) were used. The
change in absorbance at 550 nm was monitored against time.
Data were fitted based on Michaelis–Menten kinetics (Michaelis
and Menten, 1913) using GraphPad Prism (GraphPad Software,
La Jolla, CA, United States) to determine the Vmax and Km.
Flavin Content Analysis of WT and
Mutant POR
To differentiate the conformational changes and effects of co-
factor binding, we evaluated the relative flavin content in POR
variants as the activity of POR is affected by the binding of
cofactors FMN and FAD. Protein bound flavin molecules were
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released by thermal denaturation of POR proteins (Faeder and
Siegel, 1973). Flavin content of WT and mutant POR proteins
(100 µg/ml) was determined by heating protein samples at 95◦C
for 10 min in the dark, followed by centrifugation at 14000 × g
for 10 min to remove the coagulated protein. The FMN and
FAD ratio was determined by measurement of fluorescence of the
supernatant at pH 7.7 and pH 2.6 (excitation at 450 nm, emission
at 535 nm) (Faeder and Siegel, 1973) using commercially
available FMN and FAD as standards (Sigma–Aldrich, Basel,
Switzerland).
CYP19A1 Expression and Purification
The CYP19A1 vector for bacterial expression was transformed
in E. coli BL21(DE3) cells and the recombinant protein
was expressed and purified following previously published
protocols (Kagawa et al., 2003; Kagawa, 2011), with slight
modifications. Briefly, a single transformed colony was selected
for protein expression at 25◦C. After 4 h of incubation, 1 mM
δ-aminolevulinic acid (a heme precursor) and 4 mg/ml arabinose
(for induction of molecular chaperones GroEL/GroES) were
added to the culture and further incubated for 20 h. Cells
were harvested and spheroplasts were prepared with 0.2 mg/ml
lysozyme in 50 mM Tris–Acetate (pH 7.6), 250 mM sucrose and
0.5 mM EDTA and stored at −80◦C. For protein purification,
spheroplasts were lysed using 10XCellLytic B (Sigma–Aldrich)
in buffer containing 100 mM potassium phosphate (pH 7.4),
500 mM sodium acetate, 0.1 mM EDTA, 0.1 mM DTT, 20%
glycerol, and 1 mM PMSF. The cell lysate was centrifuged
and the supernatants were pooled for purification by Ni2+
affinity chromatography. Purification was performed at 4◦C and
protein concentration after the dialysis was determined by DC
protein assay (Protein Assay Dye Reagent, Bio-Rad, Hercules,
CA, United States) using BSA as standard.
Aromatase Activity Measurement in
Reconstituted Liposome System
Purified recombinant CYP19A1 using the bacterial expression
system was used to test the effect of POR variants to support the
aromatase activity of CYP19A1. Standard tritiated water release
assay for the CYP19A1 activity was performed in a reconstituted
liposome system using androstenedione as substrate. Bacterial
membranes containing POR and purified CYP19A1 were
reconstituted into DLPC-DLPG liposomes. The liposomes were
prepared as described in Figure 2. Aromatase activity was
measured by the tritiated water release assay originally described
by Lephart and Simpson (1991) with modifications as described
by us previously (Pandey et al., 2007; Flück and Pandey,
2017) using a reconstituted lipid-CYP19A1-POR system and
androstenedione as the substrate. Reaction mixture consisted of
100 pmol of CYP19A1, 400 pmol of POR, 100 mM NaCl and 3H
labeled androstenedione ([1β-3H(N)]-andros-tene-3,17-dione;
∼20,000 cpm) in 100 mM potassium-phosphate buffer (pH 7.4).
Different concentrations (10–1000 nM) of androstenedione were
used for kinetic analysis. The catalytic reaction was initiated
by the addition of 1 mM NADPH and the reaction tube was
incubated for 1 h under shaking. Data were fitted based on
Michaelis–Menten kinetics using GraphPad Prism (GraphPad
Software, La Jolla, CA, United States).
CYP3A4 Activity Measurement in
Reconstituted Liposome System
To compare the activities of CYP19A1 with another steroid
binding cytochrome P450, we tested the effect of POR mutations
to support the enzyme activity of CYP3A4. The activity
of the major drug metabolizing enzyme CYP3A4 supported
by WT or mutant POR was tested using the fluorogenic
substrates [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)
and DBOMF dibenzylmethylfluorescein] (Invitrogen Corp,
Carlsbad, CA, United States) as described earlier (Flück et al.,
2010). The purified CYP3A4 (CYPEX, Dundee, Scotland,
United Kingdom) was used to test the activities of the
POR variants using 20 µM BOMCC or 5 µM DBOMF as
substrate (the apparent Km value of CYP3A4 for BOMCC,
10 µM, DBOMF 2.5 µM were derived from pilot experiments
using WT POR and CYP3A4). In vitro CYP3A4 assays were
performed using a reconstituted liposome system consisting
of WT/mutant POR, CYP3A4 and cytochrome b5 at a ratio
of 4:1:1 (POR:CYP3A4:b5). Reconstitution of liposomes was
carried out similarly as described before. The final assay
mixture consisted of liposomes and proteins (80 pmol POR:
20 pmol CYP3A4: 20 pmol b5), 2.5 mM MgCl2, 2.5 µM
GSH and 20 µM BOMCC or 5 µM DBOMF in 50 mM
HEPES buffer and the reaction volume was 200 µl. The
catalytic reaction was initiated by addition of NADPH to
1 mM final concentration and fluorescence was monitored on
a Spectramax M2e plate reader (Molecular Devices, Sunnyvale,
CA, United States) at an excitation wavelength of 415 nm and
emission wavelength of 460 nm for BOMCC and at an excitation
wavelength of 490 nm and emission wavelength of 520 nm for
DBOMF.
Statistical Analysis
Data are presented as mean standard errors of mean (SEM)
in each group or replicates. Differences within the subsets of
experiments were analyzed using Student’s t-test with GraphPad
Prism (GraphPad Software Inc., CA, United States). P-values less
than 0.05 were considered statistically significant.
3D Protein Models
Three dimensional structural models of POR (NCBI#
NP_000932) proteins were obtained from protein structure
database1. We used the structures of the FMN binding domain
of human POR (PDB # 1B1C) as well as an open structure of
POR protein (PDB# 3FJO) to analyze the location of amino acids
described in this report (Zhao et al., 1999; Aigrain et al., 2009).
Structure models were drawn using the software Pymol2 and
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FIGURE 2 | Reconstitution of POR and CYP19A1 proteins into liposomes. Lipids (DLPC: DLPG) were dissolved in chloroform and kept overnight for drying in a fume
hood. Next day, dried lipids were solubilized in detergent to prepare liposomes. The CYP19A1 and POR membranes were added to the liposomes and the
protein-liposome mixture was incubated for 1 h with shaking to incorporate the proteins into the liposomes. After 1 h, biobeads were added to remove the
detergent, and samples were incubated for another 1 h. After incubation, the mixture was cleared by centrifugation and the supernatant was used for assay of
CYP19A1 activity. Copyright © 2017 Udhane, Parween, Kagawa and Pandey.
FIGURE 3 | Cytochrome c reduction assay with WT and mutant POR.
Cytochrome c reduction assays was performed with the WT and variant forms
of POR. Kinetic assay relied on the changes in absorbance at 550 nm when
oxidized cytochrome c is converted into reduced cytochrome c. Data were
fitted as Michaelis–Menten kinetics model using GraphPad Prism. The
calculated Km and Vmax values are summarized in Table 1.
RESULTS
Cytochrome c Reduction Assay
Cytochrome c reduction assay with WT and POR variants
was performed to assess the basic quality and general catalytic
efficiency of POR as well as internal electron transfer in POR.
As compared to WT POR, 40–70% loss of activity in reducing
cytochrome c was observed with POR variants A115V, T142A
and P284L (Figure 3 and Table 1). This loss of activity indicates
that these mutations affect electron transport in POR through
flavins to cytochrome c since reduction of cytochrome c requires
the participation of both FAD and FMN as do the cytochromes
P450. Interestingly, Q153R showed 25% higher cytochrome c
reduction activity than WT POR (Table 1).
Flavin Content
As compared to WT POR, a 40–50% decrease in flavin content
of A115V mutant was observed (0.52 mol FMN/mol of POR
and 0.59 mol FAD/mol of POR). Both the FMN as well as the
FAD binding was severely affected due to T142A mutation with
approximately 80% loss of relative flavin content as compared
to WT (0.19 mol FMN/mol of POR and 0.22 mol FAD/mol
of POR) (Figure 4). The total flavin content of the gain of
function mutation Q153R (1 mol FMN/mol of POR and 0.99 mol
FAD/mol of POR) was comparable to WT and for the loss
of function mutation P284L the FMN content was similar to
WT (0.91 mol FMN/mol of POR) while the FAD content was
reduced by 25% (0.75 mol FAD/mol of POR) suggesting that
these mutations do not severely affect either the FMN or the FAD
binding to POR (Figure 4).
CYP19A1-Aromatase Activity
The POR variants A115V, T142A and P284L showed almost
complete loss of CYP19A1 activity (Figure 5 and Table 1).
For the T142A variant, the apparent Km for androstenedione
was increased fourfold as compared to WT POR suggesting
that T142A mutation affects either substrate interaction of
CYP19A1 or the CYP19A1-POR interaction. The apparent Km
with P284L variant was comparable to that of WT POR but the
apparent Vmax was reduced by 85%. Interestingly, POR variant
Q153R showed 47% higher value of Vmax/Km compared to
WT POR.
CYP3A4 Enzyme Activity
The A115 V and T142A variants of POR showed 2–10%
activity compared to WT (Figure 6). In human POR residues
A115V and T142A are directly involved in FMN binding.
The POR variant P284L resulted in 12–15% of CYP3A4
activity (Figure 6). The CYP3A4 activity of POR variant
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TABLE 1 | Kinetic parameters for activities of cytochrome c reduction and CYP19A1 activity supported by WT and mutant POR.
Km, cytochrome c (µM) Vmax nmol/min/mg Vmax/Km % WT
Cytochrome c reduction assay
67.4 ± 11.2 1279 ± 123.7 19 100
A115V 20.9 ± 11.1∗ 133.4 ± 2.8∗ 6.4 34
T142A 27.0 ± 13.4∗ 298.1 ± 15.4∗ 11 58
Q153R 81.5 ± 18.2∗ 1968 ± 270.2∗ 24.2 127
P284L 53.7 ± 10.5∗ 610 ± 63.5∗ 11.4 60
Km androstenedione (nM) Vmax pmol/min/nmol Vmax/Km % WT
CYP19A1; aromatase (androstenedione to estrone)
WT 80 ± 14.5 0.72 ± 0.03 0.0090 100
A115V nd nd nd –
T142A 308.4 ± 121.5∗ 0.11 ± 0.01∗ 0.0004 5
Q153R 65.62 ± 11.38∗ 0.86 ± 0.03∗ 0.0132 147
P284L 82.4 ± 62.5∗ 0.039 ± 0.008∗ 0.0005 5
For the cytochrome c reduction assay, the NADPH concentration was fixed at 100 µM and different concentrations of cytochrome c (0.6–80 µM) were used. For the
conversion of androstenedione to estrone, variable concentrations (10–1000 nM) of androstenedione were used for kinetic analysis in presence of 1 mM NADPH. Data
are presented as mean ± SEM of independent replicates. ∗ Indicates p-values < 0.05. nd: not detectable.
FIGURE 4 | Flavin content of WT and mutant POR proteins. Flavin content was measured by boiling protein samples under different buffer conditions. Relative
fluorescence unit (RFU) of the flavins released from POR variants obtained at pH 7.7 (F7.7) and pH 2.6 (F2.6) were plotted. RFU of WT was set as hundred percent.
(A) Shows FMN measurements and (B) shows FAD measurements. p-values for significance analysis compared to wild-type sample are indicated above the bars.
Data are presented as mean ± SEM of three replicates.
Q153R was nearly three times more than wild-type (WT) POR
(Figure 6).
DISCUSSION
P450 oxidoreductase is a membrane associated protein that binds
NADPH, causing a conformation change that brings NADPH
and FAD close together to transfer electrons. Afterward, further
conformation changes cause a closing of the POR structure and
brings FAD and FMN closer for electron transfer from FAD to
FMN. The FMN binding domain of POR interacts with P450s
and other partner proteins through charge pair interactions
involving arginine and lysine residues on P450s and aspartate
and glutamate residues on POR. Considering the importance of
FMN binding domain of POR in protein–protein interactions we
investigated the effects of mutations in this region of POR for
enzymatic activities on partner proteins. The mutations studied
in this report are either located close to the FMN binding site
of POR (A115V, T142A and Q153R) or in the putative hinge
region (P284L) required for flexibility of POR to interact with
redox partners. Using WT and variant POR and P450 proteins
expressed in bacteria, we determined the enzymatic activities
for metabolism of androstenedione by CYP19A1 and compared
them with CYP3A4 activities which can bind and metabolize
testosterone. Some very interesting and surprising findings were
made from this study, including the severe effect of POR variant
A115V which was previously suspected as a polymorphism (rs
199634961, POR∗11) and shows variable activities (Huang et al.,
2005; Agrawal et al., 2008, 2010; Pandey et al., 2010; Pandey and
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FIGURE 5 | Aromatase activity supported by WT and mutant POR proteins.
Bacterially expressed purified recombinant CYP19A1 and POR membranes
were incorporated into liposomes and their activity to convert [3H] labeled
androstenedione to estrone was tested by the tritiated water release assay.
Data were fitted with Michaelis–Menten kinetics model using GraphPad Prism.
The calculated Km and Vmax values are summarized in Table 1.
Flück, 2013; Burkhard et al., 2017). The POR variants P284L was
found to result in severe loss of activities while mutation Q153R
showed an activating effect. These results provide further insights
into the interactions of POR with its redox partner proteins
and help in establishing the genotype-phenotype correlations of
POR variants and their metabolic effects. Loss of flavins could
explain differences in activities for some mutations. Since the
A115 and T142 residues are near the FMN binding site, a loss of
FMN binding could be expected. However, both these mutants
also showed loss of FAD binding indicating that binding of
FMN may influence FAD binding. A similar relationship of
FAD binding to FMN binding has been observed by Shen et al.
(1989) in experiments with rat POR. Several different proposals
could be made to explain this observation. It is likely that
binding of FMN is required for recognition of FAD by POR. An
FMN dependent change if affinity of POR for FAD is possible
(Shen et al., 1989). The observation of Kurzban and Strobel
(1986) that FAD comes of more readily from POR compared
to FMN seems to support the hypothesis that affinity of POR
for FMN is higher. Mutations in the FAD binding domain of
POR result in complete loss of activities (Flück et al., 2004;
Pandey et al., 2004; Huang et al., 2005; Pandey and Flück, 2013).
For some POR mutations a rescue of activities may be possible
by flavin supplementation (Marohnic et al., 2010; Nicolo et al.,
2010).
Aromatase catalyzes the conversion of androstenedione
to estrone (E1), testosterone to estradiol (E2) and
16-hydroxytestosterone to estriol (E3) (Simpson et al., 1994)
(Figure 1). The CYP19A1 reaction requires multiple interactions
with POR, and therefore, changes in redox partner binding
sites on either CYP19A1 or POR may alter enzymatic activities.
To test this hypothesis, we selected several mutations located
in the FMN binding domain and the hinge region of POR,
which facilitate interactions with partner proteins. One of
the variants studied here, the A115V was first identified in
a patient (Huang et al., 2005). The patient harboring A115V
FIGURE 6 | CYP3A4 activity supported by WT and mutant POR proteins.
CYP3A4 enzyme activity assays were performed to compare WT and mutant
POR using either (A) 20 µM BOMCC or (B) 5 µM DBOMF as substrate.
Activity with the WT POR was set as hundred percent and results are shown
as percentage of WT activity. Data are presented as mean ± SEM of three
independent replicates.
mutation was from Caucasian background and had Beare–
Stevenson syndrome, which results in skeletal as well as
genital abnormalities (Przylepa et al., 1996; Huang et al.,
2005). A rugated labia majora and anteriorly placed anus had
been reported but no steroid or biochemical analysis were
available (Huang et al., 2005). Structure analysis of A115V
mutation revealed hydrogen bonding interaction between A115
and V85 and Y87 residues located on the neighboring beta
sheet, implicating its role in structural stability (Figure 7A).
Previously Agrawal et al. (2008) have shown that A115V
mutation caused complete loss of CYP1A2 and CYP2C19
activities, while only a 20–30% loss of 17-hydroxylase and
17,20 lyase activities was observed in CYP17A1 assays (Huang
et al., 2005). Our results indicate the severe loss of CYP19A1
aromatization activity could lead to abnormal steroid metabolism
in patients with A115V mutation in POR gene. A detailed steroid
analysis of such patients would be necessary to confirm this
linkage.
The patient with T142A mutation was from Iraqi/Yemeni
parents and did not have bone malformation but showed
abnormal genitalia (Augarten et al., 1992). The ACTH
stimulation test for the adrenal function indicated combined
CYP17A1 and CYP21A2 deficiencies, but no genetic defects in
these genes were found. Augarten et al. (1992) had hypothesized
that a deficiency in another enzyme, likely a flavoprotein may
be the cause but this was not pursued further, and only in 2005
the T142A mutation in the POR from this patient was identified
(Huang et al., 2005). In previous reports a 97% loss of CYP1A2
activity and complete loss of CYP2C19 activity has been reported
by Agrawal et al. (2008) for the T142A mutation, while a 40–50%
loss of CYP17A1 activity was observed by Huang et al. (2005).
The patient with T142A mutation of POR had low serum levels of
testosterone; and androstenedione and dehydroepiandrosterone
sulfate were low (but present) and did not improve upon ACTH
stimulation, consistent with loss of CYP17A1 activities (Augarten
et al., 1992). This is consistent with crucial physiological role
of androgen regulating enzyme CYP17A1, where complete loss
of activities is lethal. The mutation T142A (POR∗12) is located
next to the Y143 residue which is crucial for the FMN binding
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FIGURE 7 | Location of amino acid changes in POR described in current study. The x-ray crystal structures of the human POR (NCBI# NP_000932) protein; the
FMN binding domain (PDB# 1B1C) and the flexible hinge region (PDB# 3FJO) showing the location of mutations studied in this report. (A) Location of residue A115.
Structure analysis revealed hydrogen bonding interaction between A115 and V85 and Y87 residues located on a neighboring beta sheet in the FMN binding domain
of POR, implicating its role in structural stability. The models are colored in rainbow colors with violet at the N-terminus and red at the C-terminus. The co-factors
FMN and FAD are shown as sticks. (B) Location of residues T142 and Q153. The mutation T142A is located next to Y143 residue crucial for FMN binding to POR
and its mutation affected FMN binding. The Q153 residue is located at the surface of POR and predicted to have a role in the interactions with the redox partners.
(C) A surface representation of the POR FMN binding domain showing mutated residues in red. The Q153 residue is exposed to surface, while residues A115 and
T142 are also partially exposed. (D) Location of P284 residue in the hinge region of the POR. Hinge region is required for conformational flexibility and mutations in
this region are predicted to cause conformational changes that would alter both the electron transport and the interaction with redox partners.
to POR, and its mutation may affect FMN binding (Figure 7B).
Consistent with this we found a severe loss of flavins in the
T142A variant of POR (Figure 4). Loss of flavins could also make
subtle conformation changes in POR and as these changes would
be in the FMN binding domain of POR which interacts with
redox partners via shape as well as charge-based protein–protein
interactions, a change in activities of redox partners is expected.
Severe loss of both CYP19A1 as well as CYP3A4 activities due to
T142A mutation indicates a major impact on both steroid and
drug metabolism in the patients carrying this mutation.
The mutation Q153R was first described from an
Algerian family and was the product of an abortion carried
out at 22 weeks of gestation due to information from an
ultrasonographic examination which showed craniosynostosis
with bilateral radiohumeral synostosis, bowing of long bones,
and arachnodactyly (Huang et al., 2005). The karyotype
of the fetus was 46,XY, and no abnormalities in external
genitalia were detected. Steroids were not measured, but,
since ABS was suspected, a GC-MS analysis of liver tissue
was performed which indicated “substantially increased”
lanosterol and dihydrolanosterol. In previous studies, the
Q153R (POR∗13) variant of POR was found to retain only
25–30% of WT activity in assays with CYP17A1 (Huang
et al., 2005) but has shown higher activities in other
assays (Agrawal et al., 2008). A higher level of activity
with CYP19A1 observed with this mutation would not
indicate any damaging effect on a 46,XY fetus, but GC-
MS analysis indicates this mutation may affect CYP51A1
activity. The Q153 residue is located at the surface of POR
and may have a direct role in the interactions with the redox
partners (Figure 7C). However, higher levels of activities
observed in both the CYP19A1, as well as the CYP3A4
assays indicate that the impact of Q153R variant may be
selective for individual P450 enzymes with some being
adversely affected while others would be activated due to
potentially better protein–protein interactions. The activating
effect of Q153R variant of POR can be useful for potential
biotechnological applications where commercial production of
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expensive chemicals through P450 mediated biotransformation is
the preferred method of manufacturing.
The last mutation studied in this report, the P284L (rs
72557938), is located in the hinge region of POR, that is
important for domain movements and efficient interactions
between FMN and FAD binding regions and for the transfer
of electrons from FAD to FMN (Figure 7D). In the sequencing
study by Huang et al. (2008) the P284L mutation was present
at an allele frequency of 0.003 in Chinese American population
and in the currently available ExAc dataset containing 121000
samples it is present at an allele frequency of 0.00004132. A 54%
loss of 17-hydroxylase activity was reported by Huang et al but
the 17,20 lyase activity of CYP17A1 was 82% of the WT POR
(Huang et al., 2008). No loss of flavin content was observed
in the P284L variant which indicates altered inter as well as
intra molecular protein–protein interactions may be responsible
for the loss of activities in both the CYP19A1 as well as the
CYP3A4 assays. Since the hinge region of POR is important
for the domain motions to bring the FMN closer to the FAD
for the transfer of electrons, a change in this region may
affect the efficiency of electron transport process in POR, and
therefore, affect the activities of partner proteins. It is possible
that some redox partners of POR may experience greater impact
on their catalytic activities while others may retain close to
WT activities depending on their mode of interaction with
POR.
In these studies, we have used POR and P450 proteins
embedded in liposomes and removed the detergents used for
solubilization of POR and P450s by treatment with biobeads
(Bio-Rad Corp., Hercules, CA, United States) which provided
a robust assay system. These results also emphasize the need
for assay of POR variants with different partner proteins and
substrates to accurately determine the impact of individual
variations. The major polymorphism observed in POR is A503V
(rs 1057868, POR∗28), which is present in about 27% of all
alleles and shows wide variability across different populations
(Caucasian and Hispanic populations: 31%; Pacific Islanders:
48%; Asian populations 35%; Japanese, 40%; African Americans
16%) (Burkhard et al., 2017). There is some evidence of
POR∗28 allele influencing the activities of drug metabolizing
enzymes but more direct evidence is needed before any firm
conclusions can be drawn (Pandey and Flück, 2013; Pandey
and Sproll, 2014). As seen with the P284L mutation, there
may be variations of POR in apparently normal populations
with potentially disease causing effects. Since POR variations
have now been linked to the metabolism of several drugs
and steroids, it may be prudent to include the sequencing of
POR gene while looking for genetic causes of altered drug or
steroid metabolism. A detailed examination of the polymorphic
variants of POR would be required to estimate their damaging
effects.
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Cholesterol is essential for development, growth, and maintenance of organisms.
Mutations in cholesterol biosynthetic genes are embryonic lethal and few polymorphisms
have been so far associated with pathologies in humans. Previous analyses show that
lanosterol 14α-demethylase (CYP51A1) from the late part of cholesterol biosynthesis has
only a few missense mutations with low minor allele frequencies and low association
with pathologies in humans. The aim of this study is to evaluate the role of amino acid
changes in the natural missense mutations of the hCYP51A1 protein. We searched
SNP databases for existing polymorphisms of CYP51A1 and evaluated their effect on
protein function. We found rare variants causing detrimental missense mutations of
CYP51A1. Some missense variants were also associated with a phenotype in humans.
Two missense variants have been prepared for testing enzymatic activity in vitro but
failed to produce a P450 spectrum. We performed molecular modeling of three selected
missense variants to evaluate the effect of the amino acid substitution on potential
interaction with its substrate and the obligatory redox partner POR. We show that two of
the variants, R277L and especially D152G, have possibly lower binding potential toward
obligatory redox partner POR. D152G and R431H have also potentially lower affinity
toward the substrate lanosterol. We evaluated the potential effect of damaging variants
also using data from other in vitro CYP51A1 mutants. In conclusion, we propose to
include damaging CYP51A1 variants into personalized diagnostics to improve genetic
counseling for certain rare disease phenotypes.
Keywords: CYP51A1, SNP, polymorphism, molecular dynamics simulations, POR
INTRODUCTION
CYP51A1, lanosterol 14α-demethylase, is a cytochrome P450 involved in cholesterol biosynthesis
and is present in all biological kingdoms. It was proposed to be one of the oldest cytochromes
P450 and is evolutionary highly conserved. Amino acid sequence identity is 95% among mammals
and about 23–34% among biological kingdoms (Lepesheva and Waterman, 2007). CYP51A1 is
catalytically strict and all forms catalyze oxidative removal of the 14α-group from the sterol
intermediates. The reaction occurs in three steps and requires a NADPH type reducing agent and
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the presence of POR (cytochrome P450 oxidoreductase).
Lanosterol and 24,25-dihydrolanosterol are CYP51A1 substrates
in mammals. Since the reaction catalyzed by CYP51A1 is
substrate specific, there are certain amino acids conserved
through biological kingdoms (Lepesheva and Waterman, 2007).
These are clustered in six substrate recognition sites (SRS1-6),
which are CYP51A1 specific. There are also conserved signature
structures of the CYP450 superfamily, such as surroundings of
heme-Cys pocket and helices B, F, G, and I (Lepesheva et al.,
2003).
Cholesterol biosynthesis is an essential housekeeping
pathway and knockouts of genes involved in this pathway
are embryonic lethal except for a few enzymes toward
the end of the synthesis pathway (Horvat et al., 2011).
Mouse Cyp51a1 knockout is lethal at day 15 post coitum
(Keber et al., 2011). This suggests that also in humans two
mutated CYP51A1 alleles rendering no active protein would
be embryonic lethal. Heterozygous knockout Cyp51a1+/−
mice are developmentally and morphologically normal and
fertile; however, when challenged with high lipid diet, the
response revealed a hidden susceptibility to detrimental
effects of the diet (Lewinska et al., 2014). Studies in mice also
revealed gender biased consequences of mutations in Cyp51a1
(Lorbek et al., 2013; Lewinska et al., 2014; Urlep et al., 2017).
Consequences of CYP51A1 heterozygosity in humans need yet
to be studied.
TABLE 1 | CYP51A1 polymorphisms associated with phenotypes in humans and population frequency from 1,000 genomes.
cDNA NM_000786.3 Protein NP_000777.1 Phenotype References SNP ID (population
frequency)
c.1263G>A p.W421Ter Infantile onset central and lamellar cataract,
developmental delay, brain white-matter
abnormality, cryptogenic neonatal liver
cirrhosis, spastic diplegia, increased lanosterol
Gillespie et al., 2014, 2016 rs141654764 (0.00001647)
/
c.935T>C p.I312T
c.829C>T p.R277C Congenital cataract, neurologically and
systemically normal
Aldahmesh et al., 2012;
Khan et al., 2015
rs944015648 (NA)
c.695T>C p.L232P (SRS2) Congenital cataract, neonatal fulminant
hepatic, failure, and global developmental delay
Patel et al., 2016 /
c.56T>C p.V19A Significant association with HDL-C level Charlesworth et al., 2009 rs2229188 (0.00000825)
c.56T>C p.V19A Significant association with hypertension Han et al., 2013 rs2229188 (0.00000825)
c.56T>C p.V19A Negative association with lifespan Yashin et al., 2015 rs2229188 (0.00000825)
c.56T>C p.V19A Association with hypertension Wang and Lin, 2014 rs2229188 (0.00000825)





c.*377T>C / Association with lower LDL-C and TC in
second trimester
Lewinska et al., 2013 rs6465348 (0.3576)
c.251G>C 3′UTR Associated with glycemic HbA1c Ren et al., 2016 rs7793861 (0.3644)
Association with expression of genes in
pancreas
NA, non-available.
We have searched all available GWAS and other databases
connecting SNPs with phenotype in humans. Only few
phenotypes were so far associated with CYP51A1 polymorphisms
(Table 1). Several are associated with a rare variant rs2229188
causing a change of Val19 to Ala. This SNP was found associated
with HDL-C level, hypertension, and lifespan (Charlesworth
et al., 2009; Han et al., 2013; Yashin et al., 2015). This missense
mutation lies at the N-terminal part of the protein and is
responsible for interaction with themembrane; therefore, it is not
directly involved in enzymatic activity (Pikuleva and Waterman,
2013). Also, Polyphen-2 or SIFT do not predict a detrimental
effect of this variant. It is thus unclear how this missense
variant affects the observed phenotypes. CYP51A1 mutations
were also associated with the incidence of pediatric cataracts.
A mutation of Arg277 to Cys resulted in neurologically and
systemically normal children with pediatric cataract (Aldahmesh
et al., 2012; Khan et al., 2015). However, three other rare variants
were clearly pathogenic in causing not only cataract but global
developmental delay and hepatic failure (Gillespie et al., 2014,
2016; Patel et al., 2016). These are termination of protein at
Trp421, change of Ile312 to Thr and Leu232 to Pro. All these
mutations were labeled as damaging by Polyphen-2 or SIFT.
Additionally, common CYP51A1 SNPs in noncoding regions
were associated with spontaneous premature labor, and lower
LDL-C and TC in second trimester of pregnancy (Lewinska et al.,
2013). Another common variant in 3′UTR region was reported
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to be associated with HbA1c and expression of genes in pancreas
(Ren et al., 2016).
The aim of this study was to analyse natural CYP51A1
missense SNPs in vitro and by molecular dynamics modeling in
relation to the substrate lanosterol and obligatory redox partner
POR (cytochrome P450 oxidoreductase). We selected three
missense SNPs for in silico prediction and two for in vitro testing
of the effect of the polymorphism on enzymatic activity. All these
amino acids are highly conserved and were identified by SIFT
and Polyphen-2 as damaging. We also searched the conserved
regions of the protein for missense SNPs and evaluated their
effect on the enzymatic activity. We show that up to date, there
are only few potentially damaging SNPs of CYP51A1 present
in the human population. Although, we could not produce
an active protein with the two SNPs, we in silico showed a
potential effect of D152G and R431H mutation on enzymatic
activity by increased distance between the heme and lanosterol
and a less favorable binding of lanosterol in comparison to
the wild type. Calculations also predicted D152G and R277L
variants to have less favorable binding to the redox partner
POR.
MATERIALS AND METHODS
Search of Human CYP51A1 Polymorphisms
and Associated Phenotypes
We have searched different GWAS databases for CYP51A1 SNPs
associated with any kind of phenotype in humans. We used
NHGRI-EBI GWAS Catalog (Welter et al., 2014), GRASP, and
FSNP etc. We also searched all available literature by PubMed.
Results of this search are shown in Table 1. We also searched
and evaluated CYP51A1 SNPs using databases: dbSNP (https://
www.ncbi.nlm.nih.gov/SNP/); COSMIC (Catalog of somatic
mutations in cancer) (Forbes et al., 2016); and Exome Variant
Server (http://evs.gs.washington.edu/EVS/, NHLBI GO Exome
Sequencing Project). We used PolyPhen-2 and SIFT for
prediction of variant effect (Ng and Henikoff, 2003; Adzhubei
et al., 2010). We used NP_000777.1 as a reference for designating
amino acid position.
Preparation of Mutant Proteins
Two mutant CYP51A1 proteins were prepared by site-directed
mutagenesis of wild type human CYP51A1 cloned in pCWori+
plasmid. The mutants were Arg431His and Arg277Leu. Site-
directed mutagenesis was performed using QuikChangeTM Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) and
primers R277L (forward primer: 5′-GCAATCCAGAAACTC
AGACAGTCTCAAG-3′ and reverse primer: 5′-CTTGAGACT
GTCTGAGTTTCTGGATTGC-3′), R431H (forward primer: 5′-
GGACTTTAATCCTGATCACTACTTACAGGATAACC-3′ and
reverse primer: 5′-GGTTATCCTGTAAGTAGTGATCAGGAT
TAAAGTCC-3′) (Sigma-Aldrich, Munich, Germany) according
to manufacturer recommendations with some changes in PCR
run (longer elongation time and higher concentration of
primers). Plasmids were transformed in the E. coli strain
HMS174 (DE3) (Novagen, Darmstadt, Germany) and isolated
using GenElute HP Plasmid Miniprep Kit (Sigma Aldrich,
Munich, Germany). Plasmids were linearized using HindIII
(Roche, Basel, Switzerland) and size was checked using 0.7%
agarose gel. Successful change in code and the CYP51A1 insert
in the plasmid was confirmed by sequencing. Expression was
carried out at 26◦C after induction with IPTG (Isopropyl β-D-
1-thiogalactopyranoside) and addition of δ-aminolevulinic acid
for 45 h. The cells were pelleted and resuspended in 50 mM
potassium phosphate, pH 7.4 (containing 10% glycerol, 0.1%
Triton X-100, 200 mM NaCl, 0.5 mM phenylmethylsulfonyl
fluoride, and protease inhibitor cocktail). After sonification on ice
for 4× 15 s, Triton X-100 was added to final 0.4% concentration
followed with ultracentrifugation at 100,000× g for 1 h. Proteins
were purified with Ni-nitriloacetic-acid agarose column (Qiagen,
Valencia, CA, USA) as described before (Lepesheva et al.,
2003). Concentration and reduced CO difference spectra was
determined as described before (Zelenko et al., 2014). We used
200µl of 3µMprotein extract for measurement of CO spectrum.
Western blot analysis was done as described before (Lorbek et al.,
2015).
Molecular Dynamics Simulations (MD) of
CYP51A1 Mutants
In addition to the wild type structure of CYP51A1 protein,
we modeled its three mutants: Asp152Gly, Arg431His, and
Arg277Leu, in two different environments, aqueous solution
and in complex with cytochrome P450 reductase (POR). For
CYP51A1 we have chosen 3LD6 structure and for POR 3ES9
structure from RCSB Protein Data Bank (Berman et al.,
2000). The point mutations were prepared using “residue
mutagenesis” procedure in Pymol [2]. Appropriate rotamers were
chosen, taking into account neighboring amino acids, as not
to significantly perturb the structure of the protein. Following
our previous work (Lewinska et al., 2013) we have generated
appropriate structural models of CYP51A1-heme-lanosterol
complexes and performed all-atom molecular dynamics (MD)
simulations of all systems using the software package CHARMM
(Brooks et al., 1983) and the available force field (MacKerell
et al., 1998). The force-field parameterization for lanosterol was
taken from work of Cournia et al. (2005). In addition, the
proper connection between the heme (Fe) and Cys449 (S) atom
was achieved by the correct protonation state of Cys449 and
an additional harmonic restraint. Each protein was embedded
in a tetragonal simulation cell with dimensions of 75 × 80
× 80 Å in explicit water environment modeled by the TIP3P
water model (Jorgensen et al., 1983). Initially we performed 100
steps of steepest descent minimization followed by 500 steps
of adopted-basis Newton-Raphson minimization. Subsequent
MD simulations were run at constant pressure of 1 bar and
temperature 300K with a time-step of 1 fs for 10 ns to enable
thermodynamic equilibration of the each system.
Protein structures obtained at the end of each all-atom
simulation was taken further as the starting structures for
docking of proteins. Docking was achieved using the server-
side docking software Zdock (Pierce et al., 2014). According
to the work (Sündermann and Oostenbrink, 2013) the POR
should occupy an elongated conformation when forming contact
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with CYP51A1. Therefore, we used weak harmonic constraints
on extended-parts of the POR through CHARMM module
MMFP GEO to smoothly stretch the protein to a structure
resembling the one shown in the reference (Sündermann and
Oostenbrink, 2013) during short term MD simulations. While
for the CYP51A1 it is not known explicitly which residues
take part in the interaction with POR, such information is
available for other members in the CYP family, namely for
CYP2D6 and CYPB24. In addition the similarity of electrostatic
surfaces between proteins of the CYP family can be used as an
indication of the interaction surface. We performed a sequence
alignment followed by a structural superposition with refinement
of different CYP proteins in Pymol. This method is known to
be reliable if sequence homology is around 30%. Our proteins
have 26–28% sequence identity based on the output of the BLAST
algorithm, thus satisfying this criterion (Altschul et al., 1990). In
addition we also found favorable electrostatic complementarity
of protein contact surfaces.
Based on clustering of residues in the wild type and mutants
around key interacting residues of CYP2D6 and CYPB24, we
choose the following residues as key interacting residues in
CYP51A1: K127, A172, K175, K364, K442, R452, N459, and
corresponding residues of POR: E92, 93, 142. The isolated
protein structures were subsequently docked using an online
protein-protein docking software Zdock (Pierce et al., 2014)
producing between 2 and 10 different poses of the complex.
The three poses with the best result regarding the scoring
function were taken for further evaluation. Based on the position
of key homologous interacting residues with known favorable
interactions for between CYP and POR the best-scored pose was
chosen. For the final production run of the docked complexes,
we used the implicit solvent method FACTS (Haberthür and
Caflisch, 2008) to perform a more efficient sampling of the
conformational space. The reliability of the FACTS method for
the present system, was demonstrated by high level agreement
between averages over FACTS and explicit solvent trajectories.
FACTS parameters were set as follows: Tfps 3, dielectric constant
1.0, and gamma constant 0.015. The MD simulations were run
at a temperature of 300K with a time step of 1 fs. The non-
bonded interactions were treated using a set of cut-offs. The
distance cut off in generating the list of pairs was set to 20
Å. At 16 Å the switching function eliminated all contributions
to the overall energy from pairwise interactions. At 14 Å the
smoothing function began to reduce a pair’s contribution. Last
20 ns of overall 40 ns of performed FACTS MD simulations
were used for analysis. Simulated systems were visualized using
Pymol. Analysis of results was done by in-house developed tools
in addition to those available in CHARMM.
RESULTS
CYP51A1 Variants in Human Population
We searched the databases for SNPs in the human population
causing missense mutations in any of the known regions
important for substrate recognition, enzymatic activity, POR
interaction and azole binding (Nitahara et al., 2001; Lepesheva
et al., 2003; Strushkevich et al., 2010). We also compared existing
SNPs to previously published in vitro mutations of human and
rat CYP51A1 and proposed a potential effect of such mutation
in humans (Table 2). For some variants we can conclude that
they probably affect enzymatic activity of CYP51A1, for example
Y137C, D152G, Y233∗, and H320P, while for other variants in
vitromutants do not confirm any effect on enzymatic activity.
Search of the dbSNP database revealed less than 200 SNPs
causing a missense mutation in CYP51A1. Majority are labeled
benign or tolerated by Polyphen-2 or SIFT. Looking at the
regions not previously connected to any aspects of the protein
activity we found 12 rare variants predicted deleterious and
damaging by both softwares (Table 3). Next, we searched
only for SNPs existing in SRS regions or any other region
predicted to be involved in any aspect of enzymatic activity
(Table 4). In total, we found 33 missense mutations. In SRS1
there are 8 missense mutations and majority of them were
predicted damaging by SIFT and Polyphen-2. Both variants
in SRS2 region are pathogenic. One was found only once in
carcinoma tissue (Y233∗), and second (L232P) in only one family
causing congenital cataract, neonatal hepatic failure and global
developmental delay. In SRS3 three variants of the same amino
acid exists with different predicted effect. In SRS4 there are only
two variants with predicted damaging effect on the protein. SRS5
TABLE 2 | Human SNP and rat/human in vitro mutant pairs.
Human SNP Rat/human
mutant
Mutant effect Predicted human SNP
effect
Y137C ratY131F/S, No protein, no activity No activity
humanY137F 55% expr, no activity,
spectr. ok
humanY137A Decrease in binding of
substrate
R139H ratR133G Normal activity Unknown
D152G/N ratD146A Normal express, 106%
activity
Decreased activity




Y233* ratY227F 55% activity Lower activity
H242R humanH242A Destabilization of the
protein
Unknown effect
H320P ratH314F/A/K/D Lower activity (42.6,
34.9, 20.2, 14)





T325A ratT319A Normal activity Normal activity
R383V/L humanR383A Decrease in binding of
substrate
Unknown
R388Ter ratR382A No protein No protein
T492A ratT486A Normal activity Normal activity
T496I ratT490A Normal activity Normal activity
E375* ratE369A No protein No protein
Rat and humans in vitro mutants were published previously (Nitahara et al., 2001;
Lepesheva et al., 2003; Bellamine et al., 2004; Mukha et al., 2011).
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TABLE 3 | CYP51A1 SNPs predicted as deleterious or damaging by SIFT and PolyPhen-2 in regions not connected to enzymatic activity.
dbSNP SIFT (score) PolyPhen-2 (score) SNP position Amino-acid location
rs372875744 Damaging (0.03) Probably damaging (0.993) N125H Helix B
rs535433995 Damaging (0.01) Probably damaging (0.975) H177R Helix D
rs151249652 Damaging (0.01) Probably damaging (0.984) E194C Beta sheet 3-1
rs536125410 Damaging (0) Probably damaging (0.982) L253S Loop between helix F′′/G, surface
rs141009880 Damaging (0.01) Possibly damaging (0.892) I274T Helix G
rs140702410 Damaging (0) Probably damaging (0.969) R277L Helix G
rs140118347 Damaging (0.02) Possibly damaging (0.799) A334S Helix I
rs554366054 Damaging (0.02) Probably damaging (1) L417R Loop between helix K′ and meander, surface
rs138109473 Damaging (0) Probably damaging (0.974) R431H Meander ηk
rs542915180 Damaging (0) Probably damaging (0.999) R454H Cys pocket
rs563098505 Damaging (0) Probably damaging (0.98) Y462D Helix L, next to cys pocket
rs553164028 damaging (0) Probably damaging (0.997) R507K C-terminal of the protein
Bold are SNP used for molecular dynamical modeling and in vitro protein expression. Amino acid location according to Lepesheva et al. (2003).
TABLE 4 | Reported missense SNPs in CYP51A1 conserved regions (source: exome variant server, cosmic, dbSNP).
SNP ID Protein PolyPhen-2/SIFT Location
rs368261783 Y137C Possibly damaging (0.497)/damaging (0) SRS1
rs750743669 S138N Benign (0.262)/ damaging (0.04) SRS1
rs758553106 R139C Probably damaging (0.946)/damaging (0.03) SRS1
rs140356336 R139H Benign (0.029)/tolerated (0.65) SRS1
COSM5500428 V144A Probably damaging (0.994)/tolerated (0.29) SRS1
rs312262912 Y151D Probably damaging (0.962)/damaging (0) SRS1
rs371492794 D152G Probably damaging (0.988)/damaging (0.01) SRS1
COSM1202901 rs755026542 D152N Probably damaging (0.985)/damaging (0.01) SRS1
rs776271983 A172V Benign (0.101) /tolerated (0.22) POR interaction
/ L232P Probably damaging (0.995)/damaging (0) SRS2
COSM353554 Y233* Unknown SRS2
COSM2863985 W245S Probably damaging (0.981)/damaging (0.01) Azole interaction
rs753673809 W245Ter No protein Azole interaction
COSM1579448 W250S Probably damaging (0.999)/damaging (0.02) Azole interaction
rs200921006 COSM3663398 R258C Probably damaging (0.999)/ damaging (0) SRS3
rs765961879 COSM1202902 R258H Benign (0.93)/ damaging (0) SRS3
rs765961879 R258L Benign (0.168)/ damaging (0.01) SRS3
rs745413412 H320P Possibly damaging (0.899)/ damaging (0) SRS4
rs377725460 T325A Benign (0.359)/ damaging (0.01) SRS4
rs760669078 P381T Probably damaging (0.990)/tolerated (0.08) SRS5
rs150090274 I383V Benign (0.024)/damaging (0.05) SRS5
rs150090274 I383L Benign (0.143)/tolerated (0.14) SRS5
COSM3698597 M384I Probably damaging (0.930)/tolerated (0.34) SRS5
rs759341868 I385F Benign (0.075)/damaging (0.01) SRS5
rs773893086 M386V Benign (0.376)/tolerated (0.12) SRS5
rs532896478 M386I Benign (0.044)/tolerated (1) SRS5
rs765119371 M387I Possibly damaging (0.758)/damaging (0.05) SRS5
COSM5986705 M387delM Unknown SRS5
rs748782320 R388Ter No protein SRS5
rs528934873 R452H Benign (0.082)/ damaging (0.04) POR interaction
rs779786966 R452C Benign (0.166)/ damaging (0)
rs768113032 T492A Benign (0.117)/tolerated (0.15) SRS6
rs749633381 M493V Possibly damaging (0.545)/damaging (0.02) SRS6
Bold is SNP used for molecular dynamical modeling. SRS, substrate recognition site.
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has many variants, but majority are predicted as tolerated or
benign as nonpolar amino acids are replaced by other nonpolar
amino acids. SRS6 has also only two SNPs. Based on clustering
of residues in the wild type and mutants around key interacting
residues of CYP2D6 and CYPB24, the following residues were
chosen as POR key interacting residues in CYP51A1: K127,
A172, K175, K364, K442, R452, and N459. Among these only
three SNPs at two positions exist in human population and
are labeled deleterious by SIFT and benign by Polyphen-2.
Additional conserved regions were also searched; however, only
few have missense mutations with potentially deleterious effect
existing in human population. Very interesting are also variants
at positions predicted to interact with azoles (Strushkevich et al.,
2010). There are two variants where large aromatic tryptophan
is changed to a small polar serine. This change could potentially
affect binding affinity toward azoles.
Next, we selected three variants for further analyses. All
three were predicted as deleterious or damaging by Polyphen-
2 and SIFT (Tables 3, 4, bold). First variant, D512G lies
in SRS1 region, important for enzymatic activity, where
a change of small negative aspartate to small non-polar
glycine is potentially pathogenic. Second variant, R431H is
in meander region with unknown function. A change from
positively charged aliphatic arginine to positively charged
aromatic histidine has an unknown effect on enzymatic activity.
Third variant, R277L lies in SRS3 region and changes large
positive arginine to small non-polar leucine. As a SNP at
this position was associated with pediatric cataracts, we can
postulate that the mutation affects the enzymatic activity of the
protein.
Molecular Dynamics Simulations of Natural
SNPs
Molecular simulations were done simulating wild type and three
natural variants present in human population (Table 3, bold).
Lanosterol has apart from a single hydroxyl group mainly a
nonpolar surface and therefore, interacts through hydrophobic
interactions with nonpolar residues of the CYP51A1. In order
to quantify the position of lanosterol in each of the simulated
proteins (mutants and wild type) we have determined all
CYP51A1 residues taking part in hydrogen bonding with
lanosterol hydroxyl group during a production run. Hydrogen
bonds (HB) were determined according to the distance criterion
for donor-acceptor atoms that fit the cut-off of 2.4 Å. The
relative occupation times for hydrogen bonds (HB) formed
mainly with the backbone amide groups of individual residues
are shown in Table 5. While the lanosterol HB distribution of
the mutant R277L resembles that found for the native protein,
distributions of R431H and D152G indicate clear deviation
from the relative position the lanosterol has in the native
protein.
Another measure for the lanosterol position is the distance
between the heme iron atom and the methyl carbon C30 of
lanosterol. This distance is important because lanosterol is axially
coordinated to the heme iron with the methyl carbon C30,
which is the lanosterol’s center of oxidation. Distances between
TABLE 5 | Relative occupation times of lanosterol’s hydroxyl group and its
hydrogen bond formed with a given residue (amide group of the protein
backbone) during production run (20 ns).












Comparison between native CYP51A1 and its three mutants.
the aforementioned atoms were calculated as a function of
simulation time across entire trajectories. It was found that the
characteristic distance between the heme’s iron and lanosterol’s
C30 atoms of the R277L mutant most closely resembles the
wild type, while the R431H and D152G mutants distance are on
average around 4 Å further away. The distances were also found
to be quite stable during the production run of the simulations.
The iron-C30 distances are plotted in Figure 1A for isolated
CYP51A1 and its mutants in aqueous solution, while Figure 1B
shows the situation for the CYP51A1 proteins in also contact with
POR.
Next, we calculated binding energies of individual complex by
subtracting the thermodynamic averages of internal energies of
individual components from the complex:
Eb = 〈Ucmplx〉 − 〈Um1〉 − 〈Um2〉, (1)
where 〈 〉 stands for the average over the entire trajectory
of individual component. Each term in the above formula
is calculated in a separate simulation. Here, 〈Um1〉 was the
average internal energy of isolated lanosterol molecule in aqueous
environment, 〈Um2〉 average internal energy of CYP protein
without lanosterol and 〈Ucmplx〉 average internal energy of CYP-
lanosterol complex. Calculations of total energy of the complex’s
between the CYP’s and POR showed that the wild type protein
in complex with POR had the most favorable total energy
while the others had significantly less favorable calculated total
energies (Figure 2A). Especially, mutant D152G has almost zero
binding enthalpy between CYP51A1 and POR. Calculations of
binding energy between lanosterol in the various CYP proteins
had shown that on average lanosterol is most favorably bound
in the wild type, followed by the R277L mutant, while in the
R431H and D152G mutants lanosterol is bound significantly
less to the interacting molecules (Figures 2B,C). This was shown
for calculations in aqueous solution and in complex with POR.
Figure 3 show interactions between CYP51A1 (wild type and
three mutants) and POR amino acid residues including FMN and
heme.
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FIGURE 1 | The heme iron-C30 distances as a function of simulation time (sim. time) for isolated CYP51A1 and its mutants in (A) aqueous solution and (B) complex
with POR. Green line is wild type hCYP51A1, dark blue is variant R431H, red is R277L, and light blue is D152G.
FIGURE 2 | Comparison between the binding enthalpies of various mutants
and the wild type CYP51A1 and (A) POR; (B) lanosterol; (C) lanosterol in
complex with POR.
CO-Difference Spectra of Mutants
We prepared two mutant CYP51A1 proteins R277L and R431H
(Table 3). We used site directed mutagenesis and mutated
a CYP51A1 insert in expression vector. Expression level
determined from absolute spectra (420 nm) was 2 times reduced
for mutant R277L and 3 times for mutant R431H. Western
blot analyses using CYP51A1 specific antibody confirmed the
presence of CYP51A1 protein in the extracts (Supplementary
Figure 1). Wild type hCYP51A1 spectrum shows a typical
CO-difference spectrum, with a peak at 417 nm representing
catalytically inactive form of hCYP51 and a peak at 447 nm
representing the active form of wild type hCYP51A1 as a result of
coordinated CO in the active site (Figure 4). Mutants with amino
acid changes R431H and R277L were unable to produce a peak
at 447 nm and were therefore inactive. The preparation of the
hCYP51A1 mutant protein was performed several times and in
two different laboratories always yielding a protein with no P450
spectrum.
DISCUSSION
CYP51A1 is an essential housekeeping enzyme with only few
known associations with diseases in humans. We searched
human natural CYP51A1 SNPs to find the damaging variants,
performed molecular dynamic modeling for wild type, three
selected variants, and measured CO-difference spectra of
proteins. Reported damaging variants are rare variants often
reported only once, which is in agreement with the requirement
of this protein for normal embryonal development and adult
life. In addition, only few variants have been connected to any
phenotype in humans. This indicates that damaging missense
variants are highly unfavorable and have not been preserved
in the human populations. Clinically, CYP51A1 variants have
been proposed to be included in genetic testing in certain
clinical conditions, such as pediatric cataract, to enable a more
accurate genetic counseling (Gillespie et al., 2014). On the other
hand, Cyp51a1+/− heterozygous mice indicate that this genotype
renders subjects potentially more susceptible to detrimental
effects of unhealthy life style. Therefore, we propose to include
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FIGURE 3 | Cartoon representing predicted CYP51A1 residues interacting with POR (depicted in cyan color) in (A) wild type, (B) R277L variant, (C) R431H variant,
and (D) D152G variant. (A–D are depicted in pink color).
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FIGURE 4 | CO-difference spectra for wild type hCYP51-wt (black line),
hCYP51-R277L (red line), and hCYP51-R431H (blue line) protein.
selected CYP51A1 variants into personalized diagnostics panel
for evaluating risks for pediatric cataract, neonatal hepatic
failure, global developmental delay, azole susceptibility, and
cardiovascular and metabolic diseases.
We selected three mutants with predicted deleterious effects
on protein activity, prepared mutant proteins in vitro, and
compared them with wild type protein using molecular dynamic
simulations. Aspartate at position 152 lies within SRS1 region
and is part of a highly conserved CYP51A1 signature present
among all kingdoms (Lepesheva et al., 2003). Exception are T.
brucei and L. major where alanine is at this position. In vitro
mutants of aspartate to alanine had no effect in rat Cyp51a1,
but significantly decreased activity of humanCYP51A1 (Nitahara
et al., 2001; Lepesheva et al., 2003). In human SNP database,
two substitutions of aspartic acid are reported, to glycine and
to asparagine. Both are predicted to be pathogenic and we
selected D152G mutant to test the effect of this mutation
using molecular modeling. Results indicate that this amino acid
change dramatically affected different CYP51A1 interactions
with its substrate lanosterol and obligatory redox partner POR.
Therefore, we can propose that this variant is highly pathogenic
and results in a less active or even in inactive protein.
Interestingly, among SNPs associated with any phenotype in
humans almost all are outside parts of the CYP51A1 known to
be critical for enzymatic activity. Exception is leucine change
to proline at position 232 lying within SRS2. Missense variants
associated with any phenotype in humans are all rare variants
and are predicted to be damaging by Polyphen-2 and SIFT. One
of these variants is termination of protein at 421, which very
likely results in no active protein. Another rare variant associated
with a mild phenotype is R277C (Aldahmesh et al., 2012), which
is at the end of helix G and changes a large positively charged
arginine to smaller uncharged but polar cysteine. We selected a
similar variant where large positively charged arginine is changed
to small non-polar leucine (R277L). We were not successful in
in vitro preparation of this mutant, but molecular modeling
gave us some hints about the potential effect of this variant.
Calculations of binding enthalpies indicated that this variant has
lower binding properties toward redox partner POR compared
to the wild type; however, binding of lanosterol is not affected.
Therefore, we could predict that poorer interactions with POR
would indicate that R277L variant would have a potentially lower
enzymatic activity. Since the change to cysteine has been shown
to be associated with pediatric cataracts, we can confirm that
protein activity is affected also in vivo in humans.
Another mutant we selected to test was arginine change to
histidine at position 431. This variant lies in a region with
unknown function; however, it is highly conserved among
CYP51A1 members from all kingdoms. Again, we were not
successful in preparing in vitro the mutant protein; however,
molecular dynamic modeling gave us some hints about the
nature if this variant. R431H variant has unfavorable interactions
with lanosterol but the variant does not affect interactions with
POR. We could speculate that this variant could have potentially
lower enzymatic activity but additional evidence to support this
conclusion would be required.
It is not known how human CYP51A1 actually interacts with
POR, therefore, we predicted amino acid residues (K127, A172,
K175, K364, K442, R452, N459) to be involved in interaction
with POR using CYP2D6 and CYP2B4 as a model. Only three
rare variants exist at these positions. One is at position 172 where
an alanine is changed to valine, both are nonpolar but valine is
larger the alanine. However, both Polyphen-2 and SIFT predicted
this variant as benign/tolerated. Two variants are at position 452
where arginine is changed to cysteine or histidine. These two
variants are predicted by Polphen-2 as benign but deleterious
by SIFT. Additional data would be needed to fully evaluate the
consequences of these variants on interaction with POR.
Other interesting variants are at the positions predicted to be
involved in azole interactions with CYP51A1 (Strushkevich et al.,
2010). As large tryptophan at position 245 and 250 is changed
to smaller serine this could affect the interaction with azoles,
affecting individual susceptibility to azole treatments. Another
amino acid potentially involved in azole interaction is Y151,
where hydroxyl group of tyrosine is sterically interfering with
fluconazole. A mutation of human Y151 to histidine increased
affinity for fluconazole (Bellamine et al., 2004). Therefore, variant
Y151D could also have a different affinity for azoles, affecting
individual susceptibility to azoles. Y151 is part of the CYP51A1
signature at SRS1 and a change from tyrosine to aspartic acid was
predicted to be damaging (Lewinska et al., 2013). This tyrosine
was shown before to form an H-bond with heme and molecular
modeling predicted that the change to smaller aspartic acid would
make the distance to heme too large to form an H-bond. This
position was also predicted to interact with POR and a change
of polar uncharged amino acid to negatively charged amino acid
could affect interactions with POR.
Y137 is proposed to interact with heme and is important
for enzymatic activity. Interestingly, although tyrosine can be
substituted by phenylalanine, this change at position 137 resulted
in no protein and activity (Lepesheva et al., 2003). This indicates
that OH-group is essential for catalytic activity. A mutation
of rat CYP51A1 tyrosine to serine, which has an OH-group
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but no aromatic group, also resulted in no expressed protein
(Nitahara et al., 2001). Mutation of tyrosine to cysteine, present
in human population, brings in a nonaromatic amino acid with
SH group. However, according to in vitro mutants it seems that
any amino acid change at this position is highly unfavorable and
we can postulate that this mutation results in a defective protein
in humans. The RRR (257–259) motif in SRS3 is proposed to
interact with the membrane phosphates through salt-bridges
(Strushkevich et al., 2010). Three missense mutations exist at
position 258 in the middle of RRR motif. Mutation of arginine
is to cysteine, leucine, or histidine. The change to leucine and
histidine was predicted to be benign, and change to cysteine was
predicted pathogenic. As these amino acids do not form readily
salt bridges, we could predict a weakening of the interaction
with the membrane. Another CYP51A1 signature is HTS region
in SRS4 where only one SNP exists (Lepesheva and Waterman,
2007). This is histidine 320 replaced by proline. Mutating the
histidine to phenylalanine, alanine, lysine or aspartate lowered
activity of rat Cyp5a11 and replacement of histidine to aspartate
or asparagine also dramatically affected activity ofM. tuberculosis
CYP51A1 (Nitahara et al., 2001). H320 is necessary for proton
transfer for the formation of activated oxygen. These results
indicate that at this position an aromatic amino acid is necessary,
for substitution with an aliphatic side chain proline, we could
expect a lower activity of such protein.
In conclusion, CYP51A1 is an essential enzyme and only
rare variants affecting enzymatic activity exist in the human
population. Using molecular dynamic modeling we showed
that two missense variants, D152G and R277L, probably
affect enzymatic activity also through lowered interaction with
obligatory redox partner POR. We propose to include damaging
CYP51A1 variants in genetic testing to increase the discovery of
underlying causes for diseases such as pediatric cataract neonatal
hepatic failure, global developmental delay, azole susceptibility,
and cardiovascular and metabolic diseases.
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In recent years, a growing appreciation has developed for the importance
of protein-protein interactions to modulate the function of drug metabolizing
enzymes. Accompanied with this appreciation, new methods and technologies
have been designed for analyzing protein-protein interactions both in vitro and
in vivo. These technologies have been applied to several classes of drug
metabolizing enzymes, including: cytochrome P450’s (CYPs), monoamine oxidases
(MAOs), UDP-glucuronosyltransferases (UGTs), glutathione S-transferases (GSTs), and
sulfotransferases (SULTs). In this review, we offer a brief description and assessment of
the impact of many of these technologies to the study of protein-protein interactions in
drug disposition. The still expanding list of these techniques and assays has the potential
to revolutionize our understanding of how these enzymes carry out their important
functions in vivo.
Keywords: cytochrome P450, protein-protein interaction, cytochrome P450 reductase, cytochrome b5,
homodimer, heterodimer, allosterism, PGRMC
INTRODUCTION
Drug metabolism and disposition continues to be an important part of the drug discovery and
development process in the pharmaceutical industry (Wienkers andHeath, 2005; Evers et al., 2013).
While our knowledge of the structure-function relationships of the various drug metabolizing
enzymes involved with metabolism and disposition has improved dramatically in the past 50 years
(Ortiz de Montellano, 2005; Guengerich, 2006), there is still much that is unknown regarding
their functioning in vivo. One particular aspect of this is how their structure and function may
be modulated by protein-protein interactions.
Abbreviations: CYP, cytochrome P450; CPR, cytochrome P450 reductase; b5, cytochrome b5; SULT, sulfotransferase;
GST, glutathione-S-transferase; HLM, human liver microsomes; HO, heme oxygenase; UGT, uridine 5′-diphospho-
glucuronosyltransferase; UDPGA, uridine 5′-diphospho-glucuronic acid; MAO, monoamine oxidase; sEH, soluble epoxide
hydrolase; 2D NMR, two dimensional nuclear magnetic resonance; Pdx, putidaredoxin; SLF, separated local field; 2D
PELF, two dimensional proton evolved local field; INEPT, insensitive nuclei enhanced by polarization transfer; DREPT,
dipolar enhanced polarization transfer; FRET, fluorescence resonance energy transfer; NHS, N-Hydroxysuccinimide; ER,
endoplasmic reticulum; SER, smooth endoplasmic reticulum; PGRMC1, progesterone receptor membrane component 1;
PAPS, 3′-phosphoadenosine-5′-phosphosulfate.
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Protein-protein interactions are a hallmark of biological
systems. They mediate a vast number of critical cellular
processes, including: cell division, hormone-receptor binding,
signal transduction, enzyme allostery, molecular transport, and
electron transfer (Murakami et al., 2017). Additionally, protein-
protein interactions are essential to the function of many, if not
all, of the enzymes involved in drug metabolism and disposition
(Kandel and Lampe, 2014). These types of interactions may
take the form of interactions with electron transfer partners,
such as the case with cytochrome P450 (CYP) enzymes, or
homo and hetero dimerization as observed with sulfotransferase
(SULT; Yoshinari et al., 2001) and glutathione-S-transferase
(GST; Balogh et al., 2009) enzymes. Protein-protein interactions
between enzymes and proteins that are not directly required
for enzymatic function may also be important for modulating
specific activity of drug metabolizing enzymes in different
contexts, such as the interaction of progesterone receptor
membrane component 1 (PGRMC1) with CYP enzymes in the
endoplasmic reticulum (ER) membrane (Rohe et al., 2009; also
see the excellent recent review by Ryu et al., 2017). Unfortunately
for the experimentalist, most protein-protein interactions are
of a transient nature; i.e., short lifetime, low affinity, and low
stability; which makes them difficult to analyze, since typically
a large amount of stable complex is required for traditional
biophysical techniques (Henzler-Wildman and Kern, 2007). This
has hindered our basic understanding of the functional impact
of many protein-protein interactions in drug metabolizing
enzymes. Despite this, there have been numerous efforts made
to apply biophysical methodologies and techniques to examine
protein-protein interactions in proteins involved in metabolism
and disposition. These range from traditional types of analysis,
such as X-ray crystallography, NMR, and fluorescence, to
more exotic techniques, such as luminescence resonance energy
transfer (LRET) and conductometric monitoring. Each of these
have their strengths and limitations in regards to the amount
of sample needed, tolerance for lipid, cost, time commitment,
and the type of observable information retrieved (Table 1).
The reward for the experimentalist bold enough to apply these
biophysical techniques is a richer understanding of protein-
protein interactions in these important enzymes.
In this review, we offer an overview of many of the biophysical
techniques that have been applied over the years to understand
protein-protein interactions in drug metabolizing enzymes, with
a focus on the techniques themselves and the salient information
that has been obtained from each. Additionally, we will provide
a perspective on the future of the field and some newly emerging
techniques of interest to the active researcher.
X-RAY CRYSTALLOGRAPHY
Over the course of the previous two decades, X-ray
crystallography has provided us with an enormous amount
of information regarding protein structure in drug metabolizing
enzymes (Cupp-Vickery et al., 2000; Podust et al., 2001;
Yoshinari et al., 2001; Williams et al., 2003; Yano et al., 2004;
Nagano and Poulos, 2005; Nagano et al., 2005; Grahn et al., 2006;
He et al., 2006; Wilderman et al., 2012; Basudhar et al., 2015),
for a recent review in this area, see (Reed and Backes, 2017).
Despite this, structures of multi-protein complexes involved in
drug metabolism and disposition are exceedingly rare. While
direct examples of crystal structures of protein complexes are
uncommon, there have been many clues provided as to how
proteins might interact with one another in their native state.
One such case is the interaction of CYPs with their endogenous
electron transfer partners, cytochrome P450 reductase (CPR)
and cytochrome b5 (b5). In order to oxidize the various drugs
that serve as their substrates, CYPs must receive electron
reducing equivalents from CPR and/or b5 (Ortiz de Montellano,
2005; Henderson et al., 2013). This involves formation of a
protein complex that allows electrons to be directly shuttled
from CPR/b5 to the CYP. Despite more than 50 years of
study, the exact molecular process by which this occurs still
remains somewhat of a mystery. X-ray crystal structures utilizing
traditional techniques have demonstrated that the interaction is
predominantly mediated by electrostatics (Hiruma et al., 2013;
Tripathi et al., 2013). However, the question has remained as
to the role of conformational dynamics in the electron transfer
process, as the CPR enzyme has previously been crystalized in a
“closed” conformation (Vincent et al., 2012) that limits access to
the flavin mononucleotide (FMN) domain. In order to determine
the distinct conformational state of CPR that interacts with
the CYP enzyme, a co-crystal structure of the two proteins in
complex was needed. A breakthrough came in this regard when
Sevriukova and colleagues were able to determine the crystal
structure between the heme and FMN-containing domains of the
model cytochrome P450BM-3 (Sevrioukova et al., 1999). This
was facilitated by a novel strategy of individual expression and
purification of the heme, FMN, and FAD containing domains
of the enzyme (Sevrioukova et al., 1997) and then carefully
reconstituting both the heme containing domain with the FMN
domain (Sevrioukova et al., 1997, 1999). The structure itself
indicated that the proximal side of the heme was the primary site
of interaction with the FMN domain and, furthermore, identified
a pathway for electron transfer from the FMN domain to the
heme iron (Sevrioukova et al., 1999). This led to the hypothesis,
developed somewhat later, that a “hinging” motion opens the
protein and allows the FMN domain to directly interact with the
CYP heme (Hall et al., 2001; Hamdane et al., 2009; Sugishima
et al., 2014).
A clever strategy involving crystallization of a four amino
acid deletion mutant demonstrated that the CPR protein can
pivot along the C terminus of the hinge region and thereby
undergo a conformational rearrangement that allows sufficient
opening of the protein to expose the FMN domain to the CYP
interface (Hamdane et al., 2009). Interestingly, this hypothesis
of a conformational rearrangement being necessary for an
effective route of electron transfer to be formed between the
CPR and CYP proteins was later confirmed when CPR was co-
crystalized with heme oxygenase (HO; Sugishima et al., 2014).
In this complex, it became clear that shortening the CPR hinge
region leads to a protein that favors the open conformation
and promotes association with HO (Sugishima et al., 2014).
These studies demonstrate the utility of combining the power of
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X-ray crystallography with traditional site-directed mutagenesis
techniques to obtain answers to structural questions that might
not be readily available by either technique alone.
X-ray crystallography has also been useful for dissecting the
protein-protein interactions of another CYP electron transfer
partner, b5. Using a combination of chemical crosslinking and
protein crystal structures, Peng et al. were able to propose a
model for the b5 mediated stimulation of the 17,20-lyase activity
of cytochrome P450c17 (Peng et al., 2014), suggesting that
electrostatic interactions predominate in the CYP-b5 interaction,
as they do with the CYP-CPR complex. In another example,
X-ray crystal structures of b5 have informed our understanding
of electron transfer from b5 to individual CYPs, such as CYP2B4,
where ligand-induced structural changes were found to be
coupled to b5 effector binding (Scott et al., 2004).
It has also been useful in defining novel interactions with
CYP proteins, as well as those currently known. In an X-ray
crystallography study comparing the b5-like protein, Ncb5or,
with b5, Deng et al. determined that the positioning of the
second histidine heme ligand (His 112) in b5 is critical for
efficient electron transfer, both from b5 reductase and to the
(CYP) electron transfer partner (Figure 1; Deng et al., 2010).
These are just a few of the many examples available where X-ray
crystallography has been used to interrogate CYP and electron
transfer partner interactions.
However, CYPs are also known to form both hetero and homo
oligomers which can influence their functional activity (Davydov,
2011, 2016; Reed and Backes, 2016, 2017). In this aspect, X-ray
crystallography has contributed to our structural understanding
of the factors involved in dimer formation. For example, the
M. tuberculosis CYP126A1 protein was recently demonstrated
to form homodimers under crystallization conditions (Chenge
et al., 2017). The dimer interface is composed of interactions
along the hydrophobic B/C and F/G loop regions of the protein,
which are known substrate recognition regions. Interestingly,
the CYP126A1 protein forms a dimer both in the ligand-free
state and also with substrate bound. However, the dimer is
disrupted when the inhibitor ketoconazole is bound to the
protein, leading to conversion to the monomer (Chenge et al.,
2017). Similarly, CYP2C8 has been shown to crystalize as a
dimer (Schoch et al., 2008). As observed with CYP126A1,
the CYP2C8 homodimer was formed around interactions at
the hydrophobic F/G loop interface. The presence of the
dimer was also confirmed in solution as well as under the
original crystallization conditions used (Schoch et al., 2008).
Remarkably, two molecules of the substrate palmitic acid
were found to be bound in the dimer interface, illustrating
the potential physiological relevance of dimer formation.
In contrast to CYP126A1, the presence of ligand did not
prevent dimer formation, suggesting that homodimeric protein-
protein interaction modes may vary between different CYPs.
Despite this, the peripheral ligand binding site identified in
CYP2C8 has been proposed to be important in modulating the
cooperative effects observed with multiple ligand binding in
certain CYPs (Davydov et al., 2013a, 2015; Reed and Backes,
2017), and may also serve as a “hot spot” for protein-protein
interaction.
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FIGURE 1 | The crystal structure of the b5-like protein, Ncb5or (PDB: 3LF5),
showing the heme (in red), with the Fe atom coordinated between the two
active site histidine residues.
X-ray crystallography has also been useful in informing
our understanding of the function of protein dimers of other
drug metabolizing enzymes as well. Both cytosolic GST (Balogh
et al., 2009) and SULT (Yoshinari et al., 2001) enzymes have
been crystalized as dimers. Moreover, dimerization seems to be
important to function in both classes of enzymes (Kakuta et al.,
1997; Petrotchenko et al., 2001; Abdalla et al., 2002). In the
case of GST enzymes, the dimer is composed of a two-fold axis
between each monomer with multiple hydrophobic, so called
“ball-and-socket”, interactions between the different domains
of each monomer (Figure 2) (Balogh et al., 2009). The crystal
structure ofmaleylacetoacetate isomerase/glutathione transferase
zeta revealed that residues M51 and F52 from a loop between
helix α2 and strand β3, where the residues are wedged into
a hydrophobic pocket formed between the α4 and α5 helices,
thereby vividly illustrating the ball-and-socket type structure
(Polekhina et al., 2001).
In SULT enzymes, the dimerization domain (Figure 3)
consists of ten residues near the C-terminus of the protein,
represented by the consensus sequence KXXXTVXXXE, also
known as the KTVEmotif (Petrotchenko et al., 2001). In contrast
to the interaction interface observed with GST enzymes, this
region forms a hydrophilic loop that creates multiple contacts
between the two individual monomers. This is reinforced by
multiple hydrophobic contacts internal to the KTVE motif,
resulting in a “dumbbell”-like structure (Petrotchenko et al.,
2001; Yoshinari et al., 2001). While the exact role dimerization
plays in catalysis is not totally understood in these enzyme
families, it is likely that future X-ray crystal structures will help
elucidate it.
Unfortunately, our structural understanding of UGT enzymes
is much more limited. While there is ample biophysical evidence
to support the existence of UGT dimers (Meech and Mackenzie,
1997; Lewis et al., 2011; Suzuki et al., 2014), the lack of structural
data has hampered protein-protein interaction research with this
FIGURE 2 | The crystal structure of GST A1-1 (PDB: 3I6A), showing the
“ball-and-socket” dimer interface and the GSH binding site.
enzyme class. Interestingly, the structural data that does exist
for human UGT enzymes, that of a partial UGT2B7 structure,
does provide an indication for the presence of homo dimers
(Miley et al., 2007; Fujiwara et al., 2016; Audet-Delage et al.,
2017). In the asymmetric unit, the C terminus of one monomer
packs into the predicted UDPGA binding site of the other
monomer (Miley et al., 2007). At first glance, this may seem
somewhat counter intuitive, as the UDPGA co-factor is needed
for enzymatic activity. However, the UDPGA binding site of the
other UGT2B7 monomer in the asymmetric unit is not occluded,
indicating that this monomer may be active while the other sub-
unit is blocked. As Miley and co-workers demonstrated, removal
of the C-terminal residues, in an effort to eliminate blockage of
the UDPGA binding site, produced protein samples that were
highly unstable and could not be crystallized (Miley et al., 2007).
This may suggest that the blockage of the UDPGA co-factor
binding site serves as a form of regulatory control of enzymatic
activity, although this has not yet been established.
The situation with the MAO enzymes is a bit more complex,
with MAO-A being represented as a monomer, while MAO-B is
a functional homodimer (Binda et al., 2001, 2011). Comparison
studies between the human and rat MAO-A enzymes, with
the latter also being a dimer, have suggested that dimerization
increases structural stability and may directly influence the
kinetic properties of the individual enzymes (Wang and
Edmondson, 2007). Others have hypothesized that dimerization
may be essential to orient the protein dipole-dipole moment
toward the anionic membrane surface in order to promote
catalysis (Binda et al., 2011). While human MAO-A crystalized
as a monomer, it is not entirely clear if this is an artifact of the
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FIGURE 3 | The crystal structure of SULT2A3 (PDB: 1EFH), demonstrating the dimer interaction motif (center).
crystallization conditions, or has direct functional relevance, as
MAO-A is thought to be a dimer in the membrane bound form
of the enzyme (Binda et al., 2011). This illustrates a critical point
in examining protein-protein interactions withmembrane bound
proteins: protein-protein interactions are highly dependent on
local conditions, particularly the presence/absence of lipid.
Soluble EH (sEH) has also been observed to form dimers
upon crystallization (Argiriadi et al., 1999). The sEH dimer
structure itself is stabilized by “domain-swapped” or “handshake”
architecture, whereby the vestigial and catalytic domains adopt
unrelated α/β folds and are connected by a 16-residue,
proline-rich linker (Thr-219–Asp-234). A “domain-swapped”
architecture occurs when the domain of one monomer is
displaced by the same domain of the other monomer in
the asymmetric unit thereby forming a stable dimer interface
(Gill, 1983). While the vestigial active site does not participate
in epoxide hydrolysis, the vestigial domain plays a critical
structural role by stabilizing the dimer. More recent studies
have confirmed the importance of dimerization for enzymatic
activity (Nelson et al., 2013). Moreover, it has been suggested
that the dimer interface may make an attractive target for small
molecule therapeutics designed against sEH (Nelson et al., 2013;
Matsumoto et al., 2014).
NUCLEAR MAGNETIC RESONANCE (NMR)
A powerful and complementary technique to X-ray
crystallography is protein NMR (Lampe et al., 2008, 2010;
Vallurupalli et al., 2008; Raman et al., 2010; Ahuja et al., 2013;
Hiruma et al., 2013; Basudhar et al., 2015). In particular, solution
NMR can report not only on protein tertiary structure, but
also on conformational dynamics which are important to the
interaction with protein partners (Lampe et al., 2008, 2010). An
additional advantage is that protein NMR can be performed in
the presence of lipid bilayer mimetics, such as bicells (Ahuja
et al., 2013) or nanodiscs (Kijac et al., 2007; Gluck et al.,
2009), allowing the investigator to examine the effect of lipid
on protein-protein interactions. Protein NMR has been most
widely used to examine interactions between CYP enzymes
and their electron transfer partners (Ahuja et al., 2013; Estrada
et al., 2013, 2014, 2016). The Scott lab has been a leader in this
area, examining the interactions of CYP17A1 with b5 (Estrada
et al., 2013, 2014) and the FMN domain of reductase (Estrada
et al., 2016). This system has a particular advantage in that
multiple types of interaction can be monitored through titrations
involving substrate, CYP, b5, reductase FMN domain, or any
combination thereof. One important result to come out of these
studies is that the strength of the CYP17A1- b5 interaction is
dependent on the identity of the substrate, with the CYP17A1-
b5 interaction being stronger when the hydroxylase substrate
pregnenolone is present in the CYP17A1 active site than when
the lyase substrate 17α-hydroxypregnenolone is bound (Estrada
et al., 2013). In these titration experiments, only the b5 protein
was isotopically labeled with 15N. When the “reverse” titration
experiment was conducted (i.e., where the CYP17A1 molecule
is 15N labeled and the b5 protein was isotopically “silent”), the
results were similar (Estrada et al., 2014). Additionally, titration
of b5 into the
15N-labeled CYP17A1-pregnenolone complex
induced a set of conformational substates closely resembling
those of CYP17A1-17α-hydroxypregnenolone complex without
b5, suggesting that b5 may also be able to allosterically induce
enzymatically productive conformations in CYP17A1, even in
the absence of the lyase substrate (Estrada et al., 2013, 2014).
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While these data have yet to be replicated with any other drug
metabolizing CYP enzymes, it is intriguing to postulate that the
results may be extrapolated to b5 interactions with other CYPs.
As noted above, a particular advantage of using NMR to
examine protein-protein interactions is that it can tolerate the
presence of lipid. This fact was exploited by Ramamoorthy et al.
to determine the structure of full-length, membrane bound b5
in the presence of CYP2B4 (Ahuja et al., 2013). This was the
very first time that a structure of b5 had been determined in the
presence of a phospholipid bilayer. The structure confirmed the
electrostatic nature of the CYP-b5 interaction, revealing a large
number of charge-charge interactions between surface residues
on CYP2B4 and b5 enabling complex formation between the two
proteins (Ahuja et al., 2013). Interestingly, it also hinted at the
importance of hydrophobic interactions between the complex
and the phospholipid bilayer. Confirming the result observed
by Estrada et al. when examining the CYP17A1- b5 interaction,
Ramamoorthy et al. also observed increased affinity between the
CYP and b5 in the presence of a small molecule substrate or
inhibitor. Finally, their data suggested a pathway for electron
transfer between b5 and CYP2B4, mediated through a salt bridge
from the heme propionates of b5 with Arg125 of CYP2B4.
More recently, Ramamoorthy et al. have extended their original
studies to examine the interactions of the CYP-b5 complex
using phospholipid bilayer nanodiscs (Zhang et al., 2016). The
advantage of this versatile phospholipid bilayer memetic is that it
permits exquisite control over the composition of lipid, allowing
researchers to examine the effects of various lipid components
on structure and catalysis. The examples above illustrate the
advantages of 2D protein NMR to obtain detailed structural data
for protein-protein interactions in the CYP enzyme family.
Almost 20 years ago, Lian pioneered a novel approach
combining both X-ray crystallography and NMR to study homo-
and hetero-dimeric interactions in the GST A1-1 isoform (Lian,
1998). In the crystal structure of GST A1-1, the hydrophobic
C-terminal region of the protein is highly disordered and absent
from the structure, as is often the case with dynamic regions
of proteins. Lian’s group was able to resolve this region of
the protein in the 2D HSQC spectrum and identify residues
that might be involved in ligand binding and/or protein-
protein interactions. Since that time, a number of studies relying
on protein NMR have been conducted using GST enzymes
(McCallum et al., 1999; Mahajan et al., 2006).
While fewer structural NMR studies have been carried out
with the SULT family of enzymes, a recent novel example of
NMR, combined with the use of a nitrox spin label positioned
in dynamic regions of the enzyme, gave information regarding
dimer interaction and the structure of the catechin ligand binding
site on the protein (Cook et al., 2016). This was accomplished
by replacing each cysteine residue in the protein with an
unreactive residue, then selectively reincorporating a cysteine
at each position of interest and reacting the protein with a
nitroxyl-oxygen spin label (3-maleimido-PROXYL). The label
was attached to the protein at six individual cysteine positions in
the protein in order to saturate the dimer in a paramagnetic field
of sufficient strength to detect its effects on the solution NMR
spectrum, without compromising the catalytic integrity of the
enzyme. The design allowed the entire surface of the enzyme to be
covered in a detectible paramagnetic field and allowed ligands to
be positioned within the active site by triangulating their protons
from multiple spin labels attached at various positions within
the active site (Cook et al., 2016). After obtaining the NMR
spectrum for each mutant, the spectrum was overlaid on the
previously determined crystal structure and the final structure
was obtained using distance-constrained molecular dynamics
docking. This approach was advantageous, and preferred over
others, in that: (1) it is applicable over a wide range of ligand
affinities, (2) does not require much protein, (3) does not require
an isotopic label, and (4) has essentially no molecular weight
limitations. Moreover, the same strategy may apply to other
drug metabolizing enzyme protein-protein complexes that have
limiting cysteine residues.
Progress in applying NMR to the study of UGT enzymes has
been slower due to the integral attachment to cellular membranes
but, as in the case of the CYP enzymes, it is likely that newly
emerging technologies, such as nanodiscs and membrane bicells
will be useful in defining their interaction with protein partners.
FLUORESCENCE TECHNOLOGIES
The use of both endogenous and exogenous fluorescence
labels for conducting protein-protein interaction studies has a
long history (Lakowicz, 1999). Indeed, they have been used
very effectively in defining the structural determinants and
dynamics required for interaction among drug metabolizing
enzymes (Nisimoto et al., 1983; Schwarze et al., 1983; Wu
and Yang, 1984; Centeno and Gutierrez-Merino, 1992; Davydov
et al., 1996, 2001). Most studies to date have preferred to
use exogenous fluorophores due to the fact that they typically
exhibit much higher quantum yields than the endogenous
fluorophores; tryptophan, tyrosine, phenylalanine, and the
fluorescent prosthetic groups.
Unarguablely, the greatest use of fluorescence to monitor
protein-protein interactions has been with the CYP enzymes. A
key early study, suggesting the presence of CYP homodimers
in the ER membrane, involved monitoring the fluorescence
anisotropy of the substrate diphenylhexatriene as a proxy for
membrane rigidity (Gut et al., 1985). Fluorescence anisotropy
is the phenomena by which fluorophore containing molecules
emit polarized light when the exciting light source is also
polarized. The degree of the polarization of the emitted light is
proportional to the anisotropy (r), or rotational motion, of the
molecule (Lakowicz, 1999). This can be a powerful technique
to determine the relative size of molecules or macromolecular
complexes, and has been exploited as such in antibody-based
assays, among others (Gorovits and Horowitz, 1995; Lim et al.,
1995). In a similar fashion, fluorescence depolarization has also
been extensively used to monitor CYP-CYP interactions as well
(Greinert et al., 1979, 1982; Schwarz et al., 1993).
Other aspects of fluorescence have also been exploited in
studying CYP protein-protein interactions. The technique of
fluorescence resonance energy transfer (FRET), whereby an
excited donor molecule is able to quantitatively transfer energy
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to an acceptor molecule that then emits in another region of
the spectrum, has been used successfully in several studies of
protein-protein interactions among drug metabolizing enzymes
(Nisimoto et al., 1983; Schwarze et al., 1983; Davydov et al., 1996,
2000, 2010, 2013a, 2015; Szczesna-Skorupa et al., 2003; Praporski
et al., 2009). A singular advantage of this fluorescence technique
is that it allows for an indirect measurement of distance between
the two fluorophores due to the phenomena of Förster energy
transfer (Lakowicz, 1999). In an elegant FRET study conducted
in 2003, Kemper et al. were able to observe a direct physical
interaction between individual CYPs in a live cell membrane
utilizing CYP2E1 and CYP2C2 which were labeled with donor
and acceptor fluorophores in cells transfected with murine CYP
cDNA (Szczesna-Skorupa et al., 2003). They discovered that,
while FRET occurred between individual CYP2C2 molecules in a
membrane, it could not be detected between CYP2E1monomers,
representing a homomeric self-association with CYP2C2, but not
CYP2E1. Later work confirmed the existence of the CYP2C2
dimers inmurine hepatocyte endoplasmic reticulummembranes,
demonstrating the potential in vivo relevance of these types of
protein-protein interactions (Li et al., 2011).
Sligar’s group at the University of Illinois was an early
adopter of fluorescence technologies tomonitor CYP interactions
with effector proteins, such as b5 (Stayton et al., 1988). By
selectively replacing threonine residues with cysteine in b5, they
were able to site-specifically introduce the sulfhydryl selective
fluorescent reagent, acrylodan, at different positions in the
protein. Acrylodan generally reacts with accessible thiol groups
more slowly than maleimides or iodoacetamides, but tends to
form highly stable thioether bonds (Weber and Farris, 1979).
Additionally, in the excited state there is a substantial charge
separation between the amino and carbonyl groups, which
produces large spectral shifts in a hydrophobic environment,
making it an ideal spectral probe for monitoring protein-
protein interactions. When the labeled b5 protein was allowed
to interact with CYP P-450cam, a model bacterial isoform,
a significant fluorescence enhancement and blue shift was
observed, indicating the fluorophore’s transition to a more
hydrophobic binding site and an increased binding free energy
for the two proteins.
More recently, Usanov et al. expanded on the Sligar lab’s
early work by using a chimeric b5-GFP to examine protein-
protein interactions between b5 and CYP3A4 (Yantsevich et al.,
2009). Utilizing this chimeric construct, the authors were able
to determine binding affinities between various b5 and CYP3A4
complexes. An interesting result from this report was that the
hydrophobic domain of b5 was observed to participate both in
hemeprotein interaction and electron transfer directly from b5
to the CYP enzyme. Simonov et al. used a CYP17A1 with eCFP
fused to the C-terminus and eYFP fused to the N-terminus of
b5 to examine CYP17A1- b5 protein-protein interactions using
FRET (Simonov et al., 2015). They combined this technique with
structural modeling andmolecular dynamics simulations to show
that b5 interacts directly with CYP17A1 in the ER membrane to
stimulate the lyase reaction.
Fluorescence tools have also proven useful to examine CYP-
CPR interactions. A unique approach by Davydov et al. to
study the effect of substrate binding on CYP protein-protein
interactions involved substituting the ferric-protoprophyrin
IX heme with an aluminum-protoporphyrin IX (Nisimoto
et al., 1983). While previous studies had used zinc substituted
protoporphyrins, the replacement of the iron atom with
aluminum resulted in an isosteric displacement, since both
transition metals have approximately the same interatomic
radius. Therefore, the aluminum substitution was unlikely to
have a major effect on the overall structure of the active site.
Additionally, while the aluminum atom is not able to donate
or accept electrons, it imparts a high degree of fluorescence
to the protoprophyrin, thereby introducing an internal probe
which allowed the authors to monitor the interactions between
CYP P450 BM-3 and its substrates and protein partners
using fluorescence energy transfer (Davydov et al., 2013b).
The CYP P450 BM-3 retained its ability to interact with the
reductase domain despite the substitution in the protoprophyrin
and the newly imparted fluorescence from the aluminum-
protoporphyrin IX allowed the authors to determine affinity
between the CYP domain and the reductase domain.
Fluorescence studies have also been useful in the study of the
human UGT enzymes (Operana and Tukey, 2007; Fujiwara et al.,
2016; Yuan et al., 2016). Turkey et al. used FRET to examine
UGT1A oligomerization in vivo (Operana and Tukey, 2007).
Using this technique, they were able to show that UGT1A1, 1A3,
1A4, 1A6, 1A7, 1A8, 1A9, and UGT1A10 all form homodimers
in live cells. Additionally, the authors confirmed heterodimer
interactions between UGT1A1 and the UGT1A3, 1A4, 1A6, 1A7,
1A8, 1A9, and UGT1A10 isoforms. More recently, Yuan et al.
used FRET to demonstrate that UGT2B7 was able to form homo
oligomers with both wild-type and mutant forms of the enzyme,
which had the possibility of affecting zidovudine glucuronidation
(Yuan et al., 2015). Yuan further went on to demonstrate that
the UGT isoforms UGT1A1, 1A9, and 2B7 were all able to form
heterodimeric complexes, expanding on their previous work that
examined homodimerization in this enzyme class (Yuan et al.,
2016).
Beckman et al took a unique approach to studying
intersubunit communication in dimeric complexes of SULT
enzymes, by examining fluorescence quenching of the enzyme’s
intrinsic fluorophores upon binding of the inhibitors, 2,6-
dichloro-4-nitrophenol (DCNP) and pentachlorophenol (PCP;
Beckmann et al., 1998). Using this technique, the authors
were able to determine that binding of the co-factor 3′-
phosphoadenosine-5′-phosphosulfate (PAPS) facilitated positive
cooperative binding between the individual subunits. This
illustrates the use of a powerful fluorescence technique that
does not rely on introduction of an extrinsic fluorophore to
obtain information on protein-protein interactions, allowing for
an examination of protein-protein interactions in the native state
of the enzyme.
Another seminal FRET study, this time involving GST P1-1,
demonstrated that the C-terminus of c-Jun N-terminal kinase
could interact directly with this GST enzyme (Wang et al., 2001).
This was an early study that identified a role for GST P1-1 in
regulating certain kinase pathways. The Atkins group has used
both intrinsic fluorescence of proteins (Wang et al., 1993; Dietze
Frontiers in Pharmacology | www.frontiersin.org August 2017 | Volume 8 | Article 521 | 99
Lampe Biophysical Techniques to Monitor Protein Interactions
et al., 1996) and of ligands (Lu and Atkins, 2004) to examine the
interaction of GST dimers and their substrates.
PHOTO-AFFINITY LABELS AND
CROSSLINKING STUDIES
Photoaffinity labels and chemical crosslinking agents have long
been recognized as useful tools to understand protein-protein
interactions. Photoaffinity labels are particularly useful if they
are also enzyme substrates, as they are typically localized at
the CYP active site until activated with irradiation (Wen et al.,
2005, 2006). Wen and Lampe utilized the photoaffinity label
lapachenole in combination with cysteine-scanning mutagenesis
to identify specific residues of CYP3A4 that interact with CPR,
including cysteine 98, using LC-MS (Wen et al., 2006). Similarly,
Sulc et al. employed the photoaffinity ligand 3-azidiamantane
to label CYP2B1 (Hodek and Smrcek, 1999) and CYP2B4 (Sulc
et al., 2008). While, in this case, the diamantoid probe did not
function specifically as a probe of protein-protein interactions, it
has the potential to report on specific conformational changes in
the CYP enzyme that may accompany interaction with protein
partners.
In general, crosslinking agents are more versatile and
have been used more extensively in assessing protein-protein
interactions. In particular, LC-MS combined with crosslinking,
can be powerful in detecting specific interactions between
two proteins that are known to interact. However, the non-
specificity of most chemical crosslinking agents make the
large datasets generated from such experiments difficult to
analyze. Gao et al. developed a software tool called Pro-
CrossLink to address this specific issue (Gao et al., 2006a).
Using this tool, combined with a site-directed mutagenesis
approach and the standard crosslinking agent, 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), they
were able to identify relevant protein-protein interactions that
occurred between CYP2E1 and b5 (Gao et al., 2006b). Their
strategy relied on an 18O-labeling method that incorporated
twice as many 18O atoms in cross-linked peptides as non-
cross-linked peptides when proteolysis was conducted in 18O-
labeled water. Subsequent tandem mass spectrometric (MS/MS)
analysis of the selected cross-linked peptide candidates led to
the identification of two intermolecular cross-links, one at K428-
CYP2E1 to D53-b5 and K434-CYP2E1 to the E56 residue of
b5. These results provided some of the first direct biophysical
evidence for the interacting orientations of a microsomal CYP
and b5.
More recently, investigators have used chemical crosslinkers
to identify CYP interaction with other, non-canonical proteins.
Using the amine-reactive EGS crosslinker, Losel et al. was
able to demonstrate that PGRMC1, a known CYP modulator,
interacts with a yet-to-be-identified 52 kDa protein, presumably
a CYP enzyme, in pig liver microsomes (Losel et al., 2008).
Additionally, substantial progress has been made examining
the homodimeric interactions of other CYPs, such as CYP3A4
(Davydov et al., 2015) and others (Reed et al., 2010) using
crosslinking technology.
SPR AND SURFACE IMMOBILIZATION
Surface Plasmon Resonance (SPR) and related surface biolayer
technologies have been mainstay technologies for examining
protein-protein interactions in a variety of systems for many
years (Cooper, 2002). These technologies rely on immobilization
of the target, or “receptor,” protein onto the solid surface of a
chip (usually Au), then a (potential) protein partner, the “ligand,”
is allowed to flow over the surface of the chip and, if binding
occurs, this results in a cascading plasmon wave in the gold
layer that causes a detectable change in the refractive index of an
incident light source (usually a laser) that is directly proportional
to the binding interaction (Cooper, 2002). Early studies with
CYP enzymes demonstrated the sensitivity of this technology in
monitoring ligand binding directly to CYP enzymes, paving the
way for more sophisticated protein-protein interaction studies
(Pearson et al., 2006). More recently, this technology has been
applied to examining CYP interactions with electron transfer
partners (Ivanov et al., 1997, 1999, 2001; Kuznetsov et al., 2004;
Archakov and Ivanov, 2011; Yablokov et al., 2017).
Yablokov et al. used a modified construct of b5 covalently
attached through an NHS linkage to a gold SPR chip to directly
monitor the interactions between b5 and various human CYP
isoforms, including both CYP’s whose activity was allosterically
regulated by b5 and those whose activity was unchanged in
the presence of b5 (Yablokov et al., 2017). Interestingly, they
determined that the CYP-b5 interactions fell into two classes:
those that were enthalpy driven and those that were entropy
driven. The CYP-b5 interactions that were enthalpy driven
tended to belong to CYPs that were allosterically regulated by
b5 (i.e., whose activity could be modulated by b5), whereas the
CYP-b5 interactions that were entropy driven tended to represent
the CYP’s whose activity was unaffected by b5. The authors
attributed the differences in these effects to positive 1H values
corresponding to displacement of the solvation shells of proteins
upon clustering (Yablokov et al., 2017).
Gannett and his team applied SPR to examine CYP-CYP
interactions between CYP2C9, CYP3A4, CYP2D6, and other
isoforms (Bostick et al., 2016). Somewhat surprisingly, they
found that the highest affinity complex was formed between
CYP2C9 and CYP2D6, a heterodimeric complex, with the affinity
between CYP2C9 and CPR being lower than that of heterodimers
and CYP2C9 homodimers. Additionally, they observed that the
affinities of specific complexes were highly dependent on the
order of addition of the individual proteins involved.
Previously, in a clever application combining two
technologies, Shimada and Guengerich used immobilized
CYP proteins, coupled with an enzyme-linked affinity approach,
to measure relative affinities between the CYP-CPR complexes
and CYP-b5 complexes (Shimada et al., 2005). Individual
CYP proteins were purified and bound to separate wells
of a polystyrene plate, after which the biotinylated partner
enzymes were added. Finally, a streptavidin-peroxidase complex
was added to each well and protein-protein interaction was
monitored by measuring peroxidase activity of the bound
biotinylated proteins. This allowed for an indirect calculation of
Kd’s for the individual CYPs to CPR and b5.
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The ever-expanding and versatile nature of the SPR
platform(s) indicate that this technology will continue to
be useful for monitoring protein-protein interactions in the





Today is an exciting time to study protein-protein interactions
in drug metabolizing enzymes. A number of new technologies
are beginning to emerge that have the power to revolutionize our
understanding of how protein-protein interactions modulate the
activity of these important proteins. Quartz crystal microbalance
studies have helped define the protein-protein interactions
between CYP17A1 and b5, in part explaining enzymatic product
distribution ratios (Simonov et al., 2015). Additionally, these
types of studies have also been useful in identifying sites
of protein-protein interaction in CYP19 (aromatase; Martin
et al., 2015). Along with quartz crystal microbalance studies,
conductometric monitoring is another emerging technology that
has the potential to provide information on protein-protein
interaction in drug metabolizing enzymes (Spera et al., 2013).
In conclusion, the future use of traditional and emerging
biophysical technologies to monitor protein-protein interactions
is likely to provide us with further insight to the function
and regulation of these enzymes critically important for drug
metabolism and disposition.
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Cytochrome P450 enzymes, which catalyze oxygenation reactions of both exogenous
and endogenous chemicals, are membrane bound proteins that require interaction
with their redox partners in order to function. Those responsible for drug and foreign
compound metabolism are localized primarily in the endoplasmic reticulum of liver, lung,
intestine, and other tissues. More recently, the potential for P450 enzymes to exist as
supramolecular complexes has been shown by the demonstration of both homomeric
and heteromeric complexes. The P450 units in these complexes are heterogeneous
with respect to their distribution and function, and the interaction of different P450s can
influence P450-specific metabolism. The goal of this review is to examine the evidence
supporting the existence of physical complexes among P450 enzymes. Additionally,
the review examines the crystal lattices of different P450 enzymes derived from
X-ray diffraction data to make assumptions regarding possible quaternary structures
in membranes and in turn, to predict how the quaternary structures could influence
metabolism and explain the functional effects of specific P450–P450 interactions.
Keywords: P450 cytochrome, protein–protein interaction (PPI), crystal structure, drug metabolism, microsomes,
liver
INTRODUCTION
The mammalian cytochromes P450 (P450 or CYP) that are primarily housed in the endoplasmic
reticulum are versatile catalysts that metabolize 75–90% of marketed drugs (Guengerich, 2006;
Lynch and Price, 2007). These enzymes use a heme group, coordinated in one of the axial positions
with a critical thiolate residue, to catalyze a diverse set of reactions through the mixed-function
oxygenation of substrate carbons and heteroatoms (Guengerich, 2001). In addition to catalyzing a
variety of reactions, the mammalian P450s also recognize a wide range of exogenous substrates
due to a variety of closely related enzymes, representing three to four gene families, that have
differing but overlapping substrate specificities (Nelson, 2006). Humans contain 57 P450 genes
expressed in a tissue-specific fashion (Zanger and Schwab, 2013), with approximately 13 P450s
being responsible for the majority of in vivo drug metabolism.
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The P450 catalytic cycle relies on molecular oxygen and
electrons supplied by the redox partners, cytochrome P450
reductase (CPR) and/or cytochrome b5. In this process, two
distinct electron-transfer steps occur (White and Coon, 1980),
each one following a protein-protein interaction with one of
the potential redox partners (Miwa et al., 1979). Thus, protein-
protein interactions are essential for optimal catalytic activities
of the P450s. In addition to the interactions with redox partners,
P450s also interact with each other. There is now considerable
evidence that these P450–P450 interactions influence P450-
mediated catalytic activities in form- and substrate-specific
manners. In fact, studies now demonstrate that the function
of a given P450 also can be altered by its own homomeric
interaction (Davydov et al., 2010; Reed et al., 2012). Our recent
review on this topic (Reed and Backes, 2016), in addition
to several other excellent reviews (Davydov, 2011; Reed and
Backes, 2012; Kandel and Lampe, 2014), have summarized the
studies that demonstrated the effects of specific P450–P450
interactions on enzyme function and have categorized the effects
mechanistically.
Although significant progress has been made to demonstrate
that the interaction of specific P450s can influence enzyme
function in membrane systems, very little is known about
the specific quaternary structures of the P450 complexes in
membranes and more importantly, into the ways in which
different types of physical interactions between P450s influence
function. Although many biophysical techniques have been
employed to detect multimeric P450 in membranes, these studies,
for the most part, are not conclusive with regards to specific
protein-protein interactions within the P450 complexes or to the
exact sizes of the multimeric complexes.
In contrast to the limits associated with the biophysical
techniques used to analyze membrane systems, X-ray crystal
structures provide clear images of protein conformation and
intermolecular arrangement. In addition, these structures clearly
elucidate the ways in which protein conformations change upon
the binding of different substrates. The crystallographic analysis
of human P450 forms has exploded this century. Numerous
structures of mammalian P450s with a variety of substrates have
been reported [reviewed in (Johnson and Stout, 2013)]. Because
of limitations related to determining both the specific sizes of
P450 complexes and the relative orientations of the P450 units
contained in these heteromeric complexes, detailed information
about the ways in which P450s may interact in vivo might
be inferred from X-ray crystal structures and crystallographic
lattices of the individual, purified forms. This approach was
used previously (Hazai et al., 2005); however, when the study
was published, there were only a limited number of available
structures of the mammalian P450s to analyze. Thus, in the
current review, the X-ray structures and the corresponding lattice
arrangements of human CYP1A2 (PDB: 2HI4); rabbit CYP2B4
(PDB: 1SUO and 1PO5); human CYP2C8 (PDB: 1PQ2); human
CYP2C9 (PDB: 1OG5); human CYP2C19 (PDB: 4GQS); human
CYP2D6 (PDB: 2F9Q);; human CYP3A4 (PDB: 2V0M, 2J0D,
1TQN, and 1W0F) have been interpreted with respect to the
reported effects of specific P450-P450 interactions on enzymatic
function.
Unlike our previous reviews that emphasized the functional
effects of P450–P450 interactions, this review will focus on the
physical studies that have been used to elucidate the nature of
P450 multimers and summarize the current state of knowledge
derived from these studies regarding the physical characteristics
of these oligomers. The crystal structures and crystallographic
arrays of different P450s will then be analyzed for their possible
relationships to protein–protein interactions in membranes and
to the possible ways that these interactions may explain some of
the functional effects associated with these interactions. Initially,
we will discuss instances of homomeric P450–P450 interactions
in membrane systems that appear to correspond very nicely
with available crystal structures of these P450s. Various types
of homomeric interactions identified in the crystal structures
will then be used to propose explanations for the functional
effects that are associated with specific heteromeric P450–P450
interactions. The possible role of protein conformational changes
in the functional effects of P450–P450 interactions will also be
addressed. Hopefully, the comparison of crystal structures will
provide a framework for future studies to determine whether
these functional effects can indeed be attributable to the 450–
P450 interactions deduced from the crystallographic analyses.
PHYSICAL STUDIES OF MEMBRANE
SYSTEMS CONTAINING P450s
Determination of P450–P450 Binding
Affinities
Purified P450s have a remarkable tendency to aggregate in
aqueous solutions (Guengerich and Holladay, 1979; French et al.,
1980; Dean and Gray, 1982; Myasoedova and Berndt, 1990;
Myasoedova and Tsuprun, 1993). The arrangement of purified,
detergent-free homomeric CYP1A2 (as well as CYP2B4) in
solution was defined by electron microscopy as being hexameric
with two layers of P450 trimers that are comprised of two
types of distinct P450–P450 interactions (Tsuprun et al., 1986;
Myasoedova and Tsuprun, 1993). Because of this characteristic
of P450s, it is expected that the enzymes would have a very
low KD for homomeric interactions in membranes. Using a
new approach to study P450–P450 interactions both physically
and functionally, CYP2C9 was covalently immobilized to a self-
assembled monolayer on gold film and its homomeric and
heteromeric interactions with CYP2D6, CYP3A4, and CPR
were monitored by surface plasmon resonance (Bostick et al.,
2016). This technique allowed interactions between immobilized
CYP2C9 and its binding partners in real time. From the data,
the KD constants for the various dimeric interactions were
calculated and ranged from 1 to 18 nM. Similarly, in a global
analysis of data derived from a thorough kinetic study involving
CYP2E1-mediated metabolism of para-nitrophenol over a range
of CYP2E1 and CPR concentrations, a KD of 38 nM was
approximated for the homomeric association of the CYP2E1
within a lipid milieu (Jamakhandi et al., 2007).
It should be pointed out that measurements of KD which
are based on volumetric concentrations, while providing a
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relative number that is more easily appreciated, are actually
not relevant to P450–P450 binding affinities that occur in
the two-dimensional lipid membrane (the interactions detected
by surface plasmon resonance actually did occur with the
enzymes in solution). Davydov et al. (2015) measured the two-
dimensional binding affinities for both the homomeric and
heteromeric interactions of CYP2E1, CYP3A4, and CYP3A5 by
luminescence resonance energy transfer (LRET) after each of
the pair of enzymes were variably labeled at cysteine residues
with LRET molecular partners. The binding constants [defined
as the P450 concentrations at which the fluorescence resonance
energy transfer (FRET) level reached 50% of the maximum]
for the various homomeric and heteromeric interactions ranged
from 0.07 to 0.56 pmol/cm2, and the corresponding two-
dimensional binding constant for homomeric CYP2E1 binding
was 0.16 pmol/cm2 [as compared to a KD of 38 nM (Jamakhandi
et al., 2007)]. In many cases, the heteromeric P450 associations
detected in these studies had higher binding affinities than the
homomeric interactions. Because the surface density of P450 in
the endoplasmic reticulum of mouse hepatocytes is estimated to
be in the range of 0.6–2.8 pmol/cm2 (Watanabe et al., 1993),
P450s are likely highly oligomerized in vivo.
Studies Measuring Rotational Mobility of
P450s
As summarized in our previous reviews (Reed and Backes,
2012; Brignac-Huber et al., 2016; Reed and Backes, 2016), the
literature provides many different lines of evidence that P450s
physically interact in lipid membranes by the application of
a variety of techniques that studied the rotational mobility of
P450s such as the following: (1) optical rotary diffusion (ORD)
following photolysis of the ferrous P450-CO complex with plane
polarized light (McIntosh et al., 1980; Gut et al., 1982, 1983;
Kawato et al., 1982; Iwase et al., 1991); (2) electron paramagnetic
resonance (EPR) of P450s containing cysteine groups that were
labeled with a maleimide containing a spin probe (Schwarz
et al., 1982); and (3) time-resolved polarized fluorescence of
cysteine residues in P450 that were labeled with diiodofluorescein
iodoacetamide (Greinert et al., 1982). Specifically, in these
studies, the mobility and rotation of P450s incorporated in
lipid bilayers of a given viscosity were compared with the
theoretical mobility and rotation for a monomeric sphere with
the approximate dimensions of the P450. These studies provided
useful information regarding certain characteristics of the P450
complexes in the lipid environment. These parameters were also
measured under conditions that would favor dissociation of P450
aggregates such as high lipid:P450 ratios (Kawato et al., 1982) or
high salt (Iwase et al., 1991).
When microsomes were studied or when P450s were
incorporated in artificial membranes at lipid:P450 ratios that
are comparable to those in the endoplasmic reticulum at
37◦C, there was a high proportion (approximately 50% or
higher) of aggregated P450 in the membrane as indicated by
immobilized protein over the time course of the experiments
(Gut et al., 1982; Iwase et al., 1991). Lower temperatures
favored higher proportions of immobilized P450s (Kawato
et al., 1982). Although these data did not provide specific
determinations of the sizes of the P450 aggregates, rotational
relaxation/correlation times suggest that the mobile fraction of
P450 in these microsomes and lipid bilayers is at least dimeric in
size (and probably larger) (Kawato et al., 1982), which in turn,
indicates that the immobilized fraction is represented by higher
degrees of aggregation, and the fluorescent study generated data
consistent with a rotating hexameric aggregate (Schwarz et al.,
1982). Interestingly, the fluorescent study indicated that changes
in the angle between orientation of the fluorescent label on
CYP2B4 and the plane normal to the membrane occurred upon
substrate binding and reduction by CPR. This was indicative
of functional changes in protein conformation (and not protein
aggregation) that could correspond to the change from the open
to the closed conformation of CYP2B4 [as determined in X-ray
crystal structures (Scott et al., 2003; Scott et al., 2004)].
The interaction of rabbit CYP1A2 and CYP2B4 is the
most studied P450–P450 interaction. For many substrates, the
functional effects of this interaction are stimulation of CYP1A2-
mediated activity and inhibition of that by CYP2B4 (Backes et al.,
1998; Reed et al., 2010). There is also evidence that CYP1A2 (and
other P450s) can form homomeric complexes (Reed et al., 2012).
Although rotational studies show that an excess concentration
of either lipid or CPR can disperse homomeric aggregates of
CYP1A (Iwase et al., 1991) and CYP2B4 (Gut et al., 1982) within
membranes, this does not diminish the significance of the high-
affinity heteromeric CYP1A2-CYP2B4 interaction in vivo (Backes
et al., 1998; Cawley et al., 2001).
Many P450–P450 hetero-interactions have been shown to be
resistant to disruption by CPR. The interaction of CYP2C9 with
both CYP2D6 and CYP3A4 (which both result in inhibition
of CYP2C9-mediated activity) was evidenced in the presence
of equimolar or excess CPR (if the P450s were mixed before
CPR was added) (Subramanian et al., 2009, 2010). The effect
of CYP2E1 on the apparent Km of CYP2B4 for metabolism
of benzphetamine also was observed when CPR concentrations
were in excess (Kenaan et al., 2013). Thus, some mixed P450
complexes are clearly refractory to dissociation upon the binding
of CPR. Taking into account these findings and the fact that
many heteromeric P450 interactions tend to display higher
binding affinities (discussed above), these interactions may occur
preferentially in biological membranes.
Cross-Linking Studies with P450s
Another method that has been used to demonstrate P450
complex formation in membranes and to estimate the size(s) of
P450 multimers is chemical cross-linking. There is some evidence
to suggest that the hexameric level of aggregation for P450s in
solution (Tsuprun et al., 1986; Myasoedova and Tsuprun, 1993)
(discussed above) may also exist when the P450s are incorporated
in membranes. Covalent crosslinking of CYP2B4, either in
detergent-free solution or when incorporated into lipid vesicles
of varying composition, generated virtually identical cross-linked
protein bands in terms of mass distribution and densities
(Myasoedova and Berndt, 1990). This suggests that the levels
of aggregation were similar for CYP2B4 under either condition.
This conclusion also was drawn from gel filtration studies with
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CYP2B1 showing that the aggregation state of the enzyme was
unaffected by its association with dilauroylphosphatidylcholine
(DLPC) (Rietjens et al., 1989).
Chemical cross-linking studies have shown that amine-
reactive cross-linkers generate high levels of cross-linked P450s
in incubations with purified, reconstituted systems (Reed et al.,
2010) (Myasoedova and Berndt, 1990). The cross-linked proteins
are characterized by a range of bands (dimeric to at least
tetrameric) with tight grouping of three or more closely migrating
bands for each size of oligomer when the samples are separated
by PAGE indicating that multiple amine groups are in close
proximity at the interface of the interacting P450s.
In contrast, studies of P450–P450 interactions using cysteine-
reactive cross linkers have generated only a limited sized range
of P450 multimers showing primarily dimeric (and in some
cases trimeric) associations without significant evidence of higher
levels of associations (McIntosh and Freedman, 1980; McIntosh
et al., 1980; Davydov et al., 2015). Thus, cysteine–cysteine
interactions between P450s may be more representative of
specific, evolutionarily conserved interactions between the P450s.
Certainly, this would seem to be the case for the homomeric
interaction of CYP2C8 as disulfide bonds between the cysteines
of adjacent protein units in CYP2C8 dimers helped stabilize the
interaction when the enzyme was expressed in cells (discussed
below).
Tsalkova et al. (2007) and Davydov et al. (2015) have designed
a number of studies regarding protein interactions involving
CYP3A4 that used site-directed mutagenesis to generate CYP3A4
mutants in which various cysteine residues in the enzyme were
substituted for serine or alanine. In one study examining cysteine
cross-linking with these mutants, the interaction of CYP3A4 was
suggested to be dominantly trimeric both in solution and in
membranes. Furthermore, the interaction apparently involved
two different types of contact between the trimer units as
indicated by the disappearance of the trimeric cross-linked band
in gel electrophoresis (leaving the cross-linked dimer as the
prevalent band) when one of the conserved cysteines was mutated
to a serine (Davydov et al., 2015). The cross-linking experiment
in this study also provided support for predictions of the
arrangement of units in CYP3A4 oligomers that were based on
examination of the X-ray crystal structure of the P450. Cysteine-
reactive cross-linking was also used effectively with site-directed
mutagenesis to demonstrate the dimerization of CYP2C8 and
to elucidate details regarding the quaternary structure of the
dimer (Hu et al., 2010). The details regarding the cross-linking
studies involving CYP3A4 and CYP2C8 are discussed below in
the section regarding the crystal structures of the P450s and
their relationship to the homomeric P450–P450 interactions in
membranes.
Fluorescent Studies with P450s
Studies with fluorescently labeled [or P450s labeled with probes
capable of fluorescence or luminescence resonance energy
transfer (LRET)] P450s have also revealed aspects of P450–P450
interactions. Originally, Davydov et al. (2001) used different
thiol-reactive fluorescent compounds to label the cysteine
residues in P450s and CPR. FRET involving the variably labeled
enzymes provided physical evidence for the interactions of
CYP1A2 and CYP2B4 in addition to their interactions with
CPR. This study provided physical evidence that the binding of
CYP1A2 and CPR was enhanced when the P450 was in a mixed
complex with CYP2B4, a finding that was predicted previously by
kinetic analyses of CYP1A2- and CYP2B4-mediated metabolism
as a function of the CPR concentration (Backes et al., 1998).
Luminescence resonance energy transfer and FRET
experiments have been useful in demonstrating the homomeric
interactions of CYP3A4 (Fernando et al., 2007; Davydov et al.,
2013, 2015). FRET caused by the binding of 1-pyrenebutanol to
the active site and its resulting interaction with the heme group
of a CYP3A4 mutant (that did not display cooperative binding
of the compound like the wild type enzyme) indicated a simple
binding equilibrium (Fernando et al., 2007). However, spectral
experiments using constant variation of substrate and enzyme
concentrations (Job’s titration) indicated enzyme oligomerization
influenced substrate binding. It was then shown that the binding
of apo form of the mutant CYP3A4 to the holo-enzyme resulted
in a loss of cooperative binding typically associated with the wild
type enzyme, and removal of the apo form restored cooperativity.
Luminescence resonance energy transfer of appropriately
labeled CYP3A4 CYS-depleted mutants (discussed above) was
also used to demonstrate that homomeric interaction of the
P450 possibly explained the heterotropic activation of CYP3A4-
mediated metabolism by α-naphthoflavone (ANF) (Davydov
et al., 2013). Interestingly, the effects of ANF and the
oligomerization of the P450s were coincident with high surface
density of the P450 in the proteoliposomes. The homomeric
oligomerization of the enzyme was cooperative as shown by the
LRET. Furthermore, using FRET to measure the interaction of
a fluorescent substrate with pyrene-labeled CYP3A4 at different
positions (in addition to the LRET technique), it was shown
that ANF (and other substrates) could affect the degree of
oligomerization of the enzyme at low protein concentrations
by binding to a peripheral, allosteric site on the enzyme that
was far removed from the active site (Tsalkova et al., 2007;
Davydov et al., 2012, 2013; Sineva et al., 2013). The effects of
ANF on enzyme oligomerization occurred over the same enzyme
concentration range that resulted in cooperative metabolism of
7-benzyloxy-4-trifluoromethylcoumarin by CYP3A4. Thus, the
heterotropic effects of ANF on CYP3A4-mediated metabolism
may relate to its ability to influence the oligomerization of the
P450 and may not be caused solely by altering substrate binding
through interactions within the active site as proposed previously
(Korzekwa et al., 1998; Shou et al., 2001; Houston and Galetin,
2005).
Luminescence resonance energy transfer was also used to
characterize the nature of P450–P450 interactions involving
CYP3A4, CYP3A5, and CYP2E1, and, as mentioned above, the
two-dimensional binding dissociation constants for each binary
combination were generated from these data (Davydov et al.,
2015). These data also demonstrated that the CYP3A protein–
protein interactions (but not those involving CYP2E1) were
cooperative with Hill coefficients ranging from 2 to 3.7. As
in the study with ANF, the cooperative homomeric interaction
of the LRET-labeled CYP3A was associated with cooperative
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metabolism of 7-benzyloxyquinoline by CYP3A. The study also
showed that the interaction of CYP2E1 with CYP3A resulted
in both stimulation of the kcat of CYP2E1-mediated metabolism
of 7-methoxy-trifluoromethylcoumarin and a decrease in the 7-
methoxy-trifluoromethylcoumarin binding affinity of CYP2E1.
This LRET study also implicated the likely quaternary structure
of the CYP3A4 multimer which is discussed in the section below
regarding P450 crystal structures.
Fluorescence resonance energy transfer and bimolecular
fluorescence complementation (BiFC) studies have been
invaluable in demonstrating specific homo- and hetero-
interactions of the enzymes of the P450 monooxygenase system
in natural membranes and in discerning the relative tendencies of
these labeled proteins to interact after co-expression in COS1 cells
and HEK293 T cells (Szczesna-Skorupa et al., 2003; Ozalp et al.,
2005). Briefly, FRET or BiFC pairs were co-expressed as fusion
proteins by linking the cDNAs of complimentary fluorescent
probes to the cDNA of the P450 system proteins. These studies
showed the homomeric interaction of CYP2C2 as well as its
interaction with the CPR. Although the interaction with CPR
could also be detected for CYP2E1, the homomeric interaction of
CYP2E1 was not detected in the cellular membranes. However,
the heteromeric interaction of CYP2E1 and CYP2C2 was
detected. The studies also were significant in showing the roles
of specific protein domains in mediating the protein-protein
interactions. The N-terminal, membrane-spanning domain was
critical for CYP2C2 self-oligomerization, whereas the cytosolic
domain (N-truncated form of the enzyme) was implicated in
the interactions of CYP2C2 with both the CPR and CYP2E1.
These findings again support the assumption that heteromeric
P450–P450 interactions occur more readily than homomeric
interactions.
Positional Heterogeneity of P450–P450
Complexes
One of the most striking attributes of P450–P450 complexes
is their stability over time. This trait is ultimately responsible
for the functional effects of P450–P450 interactions and has
been demonstrated by many studies. A koff for the dissociation
of CYP2B4 oligomers was calculated in the FRET study by
Davydov et al. (2001) (discussed above) by measuring the rate
of change in FRET after mixing two populations of CYP2B4
in which the sulfhydryl groups were labeled with different
fluorescent probes. The very low value for koff calculated in this
experiment was 0.44 h−1. Interestingly, the quasi-irreversible
nature of the heteromeric interactions of CYP2D6 and CYP2C9
also were demonstrated functionally by showing that the changes
in metabolism caused by the interaction of the enzymes could
be influenced by the order that P450s and CPR were added to
the reconstituted system (Subramanian et al., 2009). Excess CPR
could only attenuate inhibition of CYP2C9-mediated activity,
caused by its interaction with CYP2D6, when CPR was added
concurrently or before addition of the second P450 and not when
the two P450s were added before the CPR.
“Positional heterogeneity” (or “persistent conformational
heterogeneity”) of P450–P450 complexes are synonymous terms
that have been used to describe the quasi-irreversible nature
of P450–P450 complexes (Davydov, 2011; Davydov et al.,
2015). Davydov, working with various researchers, has clearly
demonstrated the significance of this trait using a variety of
approaches. Initially, heterogeneity in the CYP2B4 homomeric
complex was demonstrated by hyperbaric studies of the ferrous
CYP2B4-CO complex (Davydov et al., 1995). This study
indicated that a specific population of the CYP2B4 subunits in
P450 multimers was susceptible to a pressure-induced conversion
to P420. The different populations of CYP2B4 also could be
distinguished by the equilibrium between low and high spin
forms of the enzymes, a transition that occurs very rapidly unless
the spin state of the enzyme is “frozen” through the quasi-
irreversible interaction with other P450s. Evidence that these
traits were associated with multimeric enzyme complexes was
demonstrated by loss of enzyme heterogeneity when the P450 was
treated with detergent. Given that P450 half-lives range from 4 to
37 h (Zhukov and Ingelman-Sundberg, 1999), quasi-irreversible
P450–P450 interactions could have a profound influence on drug
metabolism.
The interaction of CYP1A2 and CYP2B4 was initially inferred
by its functional effects by Backes in the mid to late 1990s (Cawley
et al., 1995; Backes et al., 1998). These studies showed that upon
interaction of the two P450s, CYP2B4-mediated activity was
inhibited, whereas that of CYP1A2 was dramatically activated.
Davydov provided physical evidence for the formation of this
complex using the hyperbaric technique (Davydov et al., 2000b).
In this study, P450 stability as a function of pressure was
compared for CYP1A2 and CYP2B4. Unlike CYP2B4, the ferrous
CYP1A2-CO complex did not demonstrate a susceptibility to
convert to P420 under increasing pressure. More importantly,
when CYP1A2 and CYP2B4 were pre-incubated for 9 h (but
not when measurements were made immediately after mixing
the P450s), the barotropic instability of CYP2B4 disappeared
and the peak absorption of the Soret band of the CYP2B4-
CO complex shifted from 450 to 448 nm, similar to that of
CYP1A2. Furthermore, there was a “steeper” dependence of
spin state change to the change in pressure when the CYP2B4
was in a complex with CYP1A2 indicating greater hydration
of the CYP2B4 active site as a result of its interaction with
CYP1A2.
More recently, Davydov et al. (2016) conducted a hyperbaric
study to demonstrate a pressure-induced conformation
change in CYP3A4 that was either dual-labeled with a LRET
donor/acceptor pair or an electron spin probe. It was determined
that only approximately 15% of the CYP3A4 population
adopted the “high pressure” conformation at ambient pressure.
Furthermore, the allosteric activator, testosterone, caused a shift
to this “high pressure” conformation when bound to the enzyme.
By selective modification of the protein with fluorescent and
nitroxide side-chain spin probes, the region of the CYP3A most
affected by the conformation changes was defined as the regions
involving the α-helices, A/A′, and the meander loop and was
shown to correspond to open and closed states of the enzymes.
The pressure-induced conformation change was consistent
with the putative change in the oligomeric state of the enzyme
associated with ANF and other allosteric activators (discussed
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above) indicating that the conformational state of the protein is
intimately related to its state of aggregation.
Conformational heterogeneity of many P450s has also been
explored by using CO-flash photolysis of the ferrous CO-P450
complex (Koley et al., 1994, 1995, 1996, 1997). Because the CO-
complex that absorbs maximally at 450 nm is photo-sensitive, the
kinetics of CO-rebinding to a P450 can be monitored on a rapid
time scale by stopped flow spectrophotometry after subjecting
the complex to a flash of white light. In the study with CYP3A4
(Koley et al., 1995), the experiments clearly demonstrated three
populations of enzymes corresponding to three conformations
of the enzyme. Furthermore, the equilibrium between the
conformers was influenced by the substrate bound to the enzyme.
These results are quite consistent with the findings regarding
CYP3A4 oligomerization and heterogeneity by Davydov and co-
workers (discussed above). Specifically, a trimer of the P450 was
implicated in which there was a conformational equilibrium that
was influenced by substrate/effector binding.
Positional heterogeneity of P450 multimers has also been
demonstrated by the multiphasic, time-dependent chemical
reduction of populations of CYP2B4 (Davydov et al., 1985) and
of CYP3A4 (Davydov et al., 2005) by dithionite. Subsequent to
measuring the chemical reduction of CYP3A4, heterogeneity in
the CYP3A4 multimer was demonstrated by its time-dependent,
enzymatic reduction using the soluble reductase domain of
the bacterial P450, BM3 (Fernando et al., 2008). These studies
showed the rate of reduction was related to the spin state of
the enzyme. The low spin form was chemically reduced most
rapidly; whereas, high spin form was more rapidly reduced
enzymatically indicating this form preferentially interacted with
the redox partner. These studies showed that the differences
in reduction due to spin state were related to heterogeneity
within the enzyme oligomer by using detergents to disperse
the P450 multimers whereupon the reduction of P450 became
monophasic with respect to time. The solubilized P450 was
refractory to a substrate-induced spin state change. However, the
study examining chemical reduction of CYP3A4 by dithionite
also utilized nanodiscs to disperse the CYP3A4. Nanodiscs utilize
phospholipid and a membrane scaffolding protein that allows
for the stabilization of small, discoidal lipid-bilayer particles
that are reported to contain monomeric enzyme when mixed at
appropriate relative concentrations (Baas et al., 2004). This was
significant because nanodisc-incorporated CYP3A4 was capable
of a substrate-induced spin state change (Baas et al., 2004). More
recent studies have indicated that CYP3A4 incorporated into
nanodiscs with CPR also was catalytically active (Grinkova et al.,
2010; Denisov et al., 2015). Thus, the monomeric state of the
P450 was not necessarily inactive as might be concluded from the
studies using detergents to disperse the P450.
THE RELEVANCE OF P450 CRYSTAL
STRUCTURES TO P450–P450
INTERACTIONS IN MEMBRANES
Because of the lack of detail concerning the arrangement of P450s
in their multimeric form, the crystal structures and lattices have
been interpreted for their potential relevance to the functional
effects of P450–P450 interactions. This approach also has been
used in a previous study (Hazai et al., 2005). Of the four types of
P450–P450 interactions that were evaluated in the prior study,
it was concluded that none of the regions involved in binding
for a given P450 dimer overlapped with the regions involved in
other types of dimers. Thus, there was the potential for large
aggregates to be built from the different types of dimers, and any
given aggregate could be characterized by a variety of P450–P450
contacts.
The assumption in drawing inferences from P450 crystal
structures is that each type of P450 has a tendency to arrange
itself in characteristic associations that also may be observed in
solution and in lipid membranes. As the crystal structures are
generated from soluble P450 mutants that lack the N-terminal,
membrane-spanning sequence and thus, are favorable to the
formation of crystals, there is some uncertainty about the
relevance of these structures to P450–P450 interactions within a
lipid milieu. Speculation about the quaternary structure of mixed
P450 complexes is even more problematic given that crystal
structures for mixed P450 complexes do not exist. Despite the
limitations of the approach, P450 crystal structures reveal some
intriguing interactions that could explain some of the functional
effects related to the physical interactions of different P450s.
In order to discuss the potential significance of arrangements
in P450 crystal lattices, it is necessary to provide a basic
description of the prominent structural features of the P450
protein. The enzymes are comprised of approximately 460
amino acids making up a series of α-helices, β-sheets, and
interconnecting regions that are organized around a central heme
prosthetic group. The drug-metabolizing P450s are tethered to
the membrane by the insertion of a hydrophobic, N-terminal
tail. The N-terminal region is connected to the structural core of
the protein, known as the catalytic domain, via the polar linking
region that contains several cationic amino acids and protrudes
out the cytosolic side of the membrane.
It has been postulated that the polar linking region would
be positioned to interact with the anionic charges of the
phosphate groups in membrane lipids as a means to modulate
membrane positioning of the P450s (Ozalp et al., 2006) and
presumably, the interaction with redox partners and other
P450s. Both the membrane penetration and α-helical content of
CYP1A2 were increased in the presence of anionic phospholipids
(Ahn et al., 1998), and these changes may be attributable to
stronger electrostatic interactions between the negatively charged
phospholipids and the positively charged, polar linking regions
of this P450. Furthermore, these protein-lipid interactions may
allow for tighter packing of the polar linking regions between
adjacent P450s as they might minimize the repulsion between the
like-charged, cationic amino acids in the polar linker regions of
adjacent enzymes. The cross-linking results with amine-reactive
cross-linkers (discussed above) would be consistent with covalent
bonds involving this region in adjacent protein units of P450
multimers. Interactions involving this region also have been
implicated in a membrane-bound, dimeric CYP2C8 complex
(discussed below). Interestingly, electrostatic interactions have
been implicated in the homomeric interaction of CYP1A2 that
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causes inhibition of the enzyme (Reed et al., 2012) and have
been shown to be involved in both the heteromeric CYP1A2-
CYP2B4 (Kelley et al., 2005) and CYP1A2-CYP2E1 (Kelley et al.,
2006) interactions. Future work is needed to show whether the
electrostatic interactions between lipids and the polar linking
regions are those responsible for these P450–P450 interactions.
P450s are wedge-shaped with two prominent sides that have
important functional roles and are identified by their relative
orientation with respect to the heme group. The distal side
(relative to the heme group) protrudes out from the heme
and contains the F and G helices that form the outer wall
of the substrate binding cavity. For many P450s, the B-C
loop and F-G loop/minor helices region between the F and G
helices has been shown to play a role in substrate recognition
(Ibeanu et al., 1996; Williams et al., 2004; Pochapsky et al.,
2010). Studies examining P450s in nanodiscs indicate that the
monomeric enzyme is tilted at an angle with respect to the
membrane surface with the distal region partially buried in
the membrane along with the hydrophobic, N-terminal tail of
the P450 (Baylon et al., 2013). Indeed, truncated P450s lacking
the N-terminal tails interact with membranes by virtue of the
F-G region (Pernecky et al., 1993; Pernecky and Coon, 1996;
Williams et al., 2000a; Scott et al., 2001). P450s demonstrate
conformational flexibility, and dramatically different open and
closed structures involving primarily changes in the positions of
the B-C loop and the F-G helices have been identified for some
P450s (Scott et al., 2003; Ekroos and Sjogren, 2006; Roberts et al.,
2010).
The other prominent face of the P450 is the proximal side
of the enzyme. This surface constitutes a broad, flat area with
multiple, positively charged residues that facilitate interaction
with and electron transfer from the redox partners, CPR and
cytochrome b5 (Tamburini et al., 1986; Bridges et al., 1998;
Sevrioukova et al., 1999; Davydov et al., 2000a). The results with
amine-reactive cross-linkers may also implicate this region as
the interface of P450 multimers. In the section below regarding
P450 crystal structures, proximal-to-proximal interactions are
observable in the crystal lattices of some P450s and may
explain some of the functional effects attributable to P450–P450
interactions.
When considering the potential functional consequences of a
protein–protein interaction using the crystal structure as a model,
it is important to only consider crystal structure interactions
in which the N-terminal ends of the interacting P450s can be
contained in a single plane (representative of the surface of
the membrane lipid bilayer) that does not intersect the center
of the interface of the interacting units or have the two (or
more) proteins projecting outward from opposite sides of the
imaginary plane. Structures not meeting these criteria would not
likely be plausible in vivo (unless P450s could interact on the
opposing folds of the endoplasmic reticulum membrane) given
the physical constraint that the P450s are known to be tethered to
the membrane by the N-terminal tails.
Quaternary structures that have been elucidated from the
crystal structures in this study have also been evaluated
using the program, PDBePISA (Proteins, Interfaces, Structures,
and Assemblies) (European Bioinformatics Institute, Hinxton,
England). This algorithm evaluates the interfaces of protein–
protein contacts within the crystal to assess their potential
stability within the membrane and also predicts the sizes of
complexes that would be formed from these intermolecular
interactions. The strength of the interaction is evaluated based
on the number of potential hydrogen bonds, salt bridges, and
disulfide bonds that can be detected within the interaction and
is quantified by a Complex Significance Score (CSS) that ranges
from 0 to 1 (with 1 being a strong interaction). The analysis
can also determine the interface area of the contact and the
number of interacting residues between protein units for any
given arrangement in the crystal.
Interestingly, evaluations of P450–P450 interactions using this
program generally predict that the proteins exist as monomers
(CSS scores close to 0) despite the preponderance of evidence
for multimeric P450s in membranes (as described above). In
conjunction with this trend, none of the P450–P450 complexes
we evaluated in this study were predicted to be stable in the
membrane (shown in Table 1) even though the direct evidence
suggests that quaternary structures very similar to those identified
from the CYP2C8 (Figure 1) and CYP3A4 (Figure 2) crystal
structures have been demonstrated in membranes (as discussed
below). The uncertainties regarding the in silico interpretation
of intermolecular interactions may reflect the importance of the
N-terminal, hydrophobic tails (which are absent in x-ray crystal
structures of P450s) in stabilizing P450–P450 complexes in the
membrane.
Examination of the available crystal lattices of P450s shows
many different types of plausible interactions that could exist in
the membrane including distal-to-distal, proximal-to-proximal,
and those involving the sides between the proximal and distal
faces of the enzymes. Interactions involving the sides between
distal and proximal faces of a P450 will be referred to as side-on
or side-to-side interactions. These side-on interactions also can
involve contacts between the proximal and distal regions of the
interacting partner. Direct interactions between the proximal and
distal sides are not commonly observed in the crystal structures
for mammalian P450s. However, this arrangement has been
identified in the crystal structure of the bacterial reductase-P450
fusion protein, BM3 (Ravichandran et al., 1993). Our analysis
will start with examples of crystal structures that have been
demonstrated to be likely representations of the homomeric
interactions of certain P450s in membranes.
Homomeric Crystal Structures That have
been Supported by Data in Cellular
Systems
Homomeric CYP2C8
Computer modeling and hydropathy analyses indicate that
lipophilic P450 substrates presumably enter the active site via
the B-C loop and F-G helices region in the membrane, and the
P450-generated products exit through a solvent access channel
often found between the F and I helices (Petrek et al., 2006, 2007;
Cojocaru et al., 2011). Thus, the distal region plays an important
role in substrate binding to most mammalian P450s. A distal-to-
distal arrangement in P450 crystal structures has been observed
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TABLE 1 | Binding characteristics of the different homomeric complexes of P450 shown in the figures as determined from PISA analysis.
Complex Figure # Nature of complex Nresa Interface area (Å2) 1iGb kcal/mol NHBc NSBd NDSe CSSf
CYP2C8 Figure 1 Distal-to-distal 11 265.6 −2.2 4 2 0 0.000
CYP3A4 Figure 2 Distal-to-distal 17 444.9 −6.4 0 0 0 0.000
CYP1A2 Figure 3 Proximal-to-proximal 17 523.6 1.3 0 0 0 0.000
CYP2B4 (closed form) Figure 4 Interface 1g Side-to-side 26 644 0.4 4 2 0 0.000
CYP2B4 (closed form) Figure 4 Interface 2g Side-to-side 25 789 −4.5 1 0 0 0.000
CYP2B4 (open form) Figure 5 18 290 2.6 4 2 0 0.000
CYP3A4 (open form) Figure 6 Proximal-to-proximal 20 469 −1.1 4 0 0 0.000
CYP2C9 Figure 7 Proximal-to-side 21 553.1 3.8 5 6 0 0.000
CYP2C19 Figure 8 Side-to-side 11 359.7 −4.4 3 0 0 0.047
CYP2C9 Figure 9h Hexameric 17 398.3 −1.2 4 1 0 0.000
The binding characteristics of P450 homomeric complexes shown in Figures 1–9 were determined by using the program PDBePISA (EMBL-EBI, Hinxton, England).
aNres – The number of interacting residues in the complex. b1iG – the solvation free energy gain upon formation of the interface of the P450–P450 complex. cNHB – The
number of hydrogen bonds detected. dNSB – The number of salt bridges detected. eNDS – The number of disulfide bonds detected. fCSS – Complexation significance
score. gFigure 4 depicts a trimer of CYP2B4. Interface 1 corresponds to the interaction of the center unit with the left-most unit of CYP2B4, whereas interaction 2
corresponds to the right-most interaction. hThe figure represents a hexamer of CYP2C9. The interactions comprising the “arms” of the hexamer are those depicted in
Figure 7. Thus, the values shown for Figure 9 represent those for the central interacting units of the hexamer.
FIGURE 1 | Crystal structure of dimeric form of CYP2C8 bound to
palmitate (PDB: 1PQ2). The units of the dimer are oriented with the
N-terminal region (shown in blue) at the base of the dimers in a “membrane
plane” running perpendicular to the plane of the image. The heme groups are
shown as red spheres with α-helices drawn as cylindrical features. The dimers
are joined at F-G loop region. The F-G helices on the surface of the distal
faces of the dimer are shown in yellow. Two molecules of palmitate bound on
the periphery of the active site at the junction of the dimer are shown in pink.
All molecular structures in this study were generated in PyMOL v. 1.8.4.1
(Schr dinger, Cambridge, MA, USA).
with many different drug-metabolizing P450s including CYP3A4
(1W0F), CYP1A2 (PDB: 2HI4), CYP2D6 (PDB: 2F9Q), CYP2A6
(PDB: 2FDV), and the open form of CYP2B4 (PDB: 1PO5).
Recent studies involving CYP2C8 (PDB:1PQ2) (Hu et al., 2010)
and CYP3A4 (Davydov et al., 2013, 2015) have provided evidence
that this type of dimer is also formed from the homomeric
interactions of these P450s when they are membrane-bound.
Studies with purified CYP2C8 in which Trp residues were
introduced by mutagenesis in order to examine the interaction
(by Trp fluorescence quenching) of the mutated P450 with
spin-labeled lipids in artificial membranes (Ozalp et al., 2006)
FIGURE 2 | Crystal structure of distal-to-distal dimeric form of CYP3A4
bound to progesterone (PDB: 1W0F). The units of the dimer are oriented
with the N-terminal region (shown in blue) at the base of the dimers in a
“membrane plane” running perpendicular to the plane of the image. The heme
groups are shown as red spheres with α-helices drawn as cylindrical features.
The F-G helices region indicating the distal surface is shown in yellow. The
peripheral effector site for binding of two molecules of progesterone are
shown in pink.
suggested that the F-G loop did not interact with the membrane
as predicted from similar studies with human CYP2J2 (McDougle
et al., 2015) and hydropathy analysis of a similar CYP2C
enzyme (Williams et al., 2000b). Interestingly, this region also
was the major point of interaction in the dimeric X-ray crystal
structure of CYP2C8 (PDB:1PQ2; Figure 1; Table 1). It was
predicted from the crystal structure that the dimerization
would be facilitated by adjacent sulfhydryl groups in cysteine
residues of the interacting CYP2C8 units. Dimerization was
then demonstrated on electrophoretic gels after either oxidation
or cross-linking of the cysteine residues on CYP2C8 that was
transiently expressed in bacterial membranes and in AD-293 cells
(Hu et al., 2010). Subsequent mutagenesis experiments indicated
that dimerization through the sulfhydryls was dependent on
Frontiers in Pharmacology | www.frontiersin.org January 2017 | Volume 8 | Article 28 | 112
fphar-08-00028 January 25, 2017 Time: 15:36 # 9
Reed and Backes Predicting P450–P450 Complex Formation
having cysteine residues within either the polar linker sequence
(between the N-terminal, membrane-spanning region and the
catalytic domain) or the F-G loop. Thus, these regions were
implicated as the points of contact in the membrane-bound
CYP2C8 dimer.
Dimerization through the sulfhydryls was not observed in the
cell membranes when the hydrophobic N-terminal membrane
anchor was deleted or substituted with a hydrophilic N-terminal
sequence. This is consistent with BiFC (Ozalp et al., 2005)
and FRET (Szczesna-Skorupa et al., 2003) studies of the closely
related CYP2C2 in COS1 cells (discussed above) showing that
homomeric P450–P450 interactions required the N-terminal
membrane domain. Similarly, N-terminal truncation prevented
the interaction of CYP3A4 and CYP2C9 (Subramanian et al.,
2010). Thus, the N-terminal region is very important in
stabilizing some P450–P450 interactions in the membrane.
Interestingly, the arrangement of subunits in the crystal
structure of CYP2C8 were such that the cysteines in the polar
linker regions of adjacent units did not align in close enough
proximity to allow for disulfides and/or cross linking to occur
between the units. In fact, for the polar-linking regions of the
dimer units to be in close proximity, the F-G loop would have
to be pulled out of the membrane. Thus, dimers with similar
features were apparently formed with both full-length CYP2C8
in membranes and with truncated CYP2C8 in solution. However,
the membrane interaction that is stabilized by the N-terminal
sequence of the full-length form imparts a slight change in
alignment within the dimer that allows for cross-linking through
adjacent sulfhydryls in the polar linker region. It was speculated
that the high enzyme concentrations needed to form CYP2C8
crystals facilitated dimerization even without the N-terminal
sequences. However, the N-terminal segment was needed for
stabilization of the dimer after transient expression of the enzyme
in cellular membranes. Unfortunately, the functional effects of
the CYP2C8 homomeric interaction were not assessed. However,
as discussed above, movement of the F-G loops, which form part
of the substrate access channel from out of the membrane bilayer
upon the formation of the dimer, would undoubtedly influence
the binding of substrate by the enzyme.
Homomeric CYP3A4 and Its Functional Effects
CYP3A4 is quantitatively the most important P450 in drug
metabolism (Anzenbacher and Anzenbacherová, 2001;
Guengerich, 2003). As a result, considerable effort has been
devoted to resolving crystal structures for this enzyme, and a
number of conformations have been identified for the P450
when bound to different compounds (Williams et al., 2004; Yano
et al., 2004; Ekroos and Sjogren, 2006). Several lines of evidence
have suggested that a dimeric arrangement of CYP3A4 in the
crystal lattice has functional relevance to the multimeric state
of the membrane-bound enzyme. The quaternary structure is
unusual because it has two molecules of progesterone bound to a
peripheral “cleft” formed in the interface of a homomeric dimer
[PDB: 1W0F; Figure 2)]. Interestingly, the CYP2C8 crystal dimer
(PDB: 1PQ2) also displayed a peripheral binding site for two
palmitate molecules in a similar location to that of the CYP3A4
dimer, but its functional significance was not explored.
Davydov et al. (2016) have now provided evidence from
studies using LRET/FRET and chemical cross-linking that the
CYP3A4 crystal dimer is a reasonable analog to a quaternary
structure adopted in the membrane. First, it was described above
how FRET/LRET studies indicated that the binding of ANF
to CYP3A4 could change the oligomeric state of the enzyme.
FRET was also measured after mixing different combinations
of specific cysteine-depleted mutants that were variably labeled
with donor/acceptor FRET pairs (Tsalkova et al., 2007; Sineva
et al., 2013). From dramatic FRET changes upon the binding
of the effector, ANF, it was possible to prove a change in
conformation that was not elicited when a prototypical substrate
bound to the heme active site. These findings are consistent with
the hyperbaric study (described above) monitoring a pressure-
dependent conformation change in CYP3A4 that was facilitated
by the allosteric effector, testosterone (Davydov et al., 2016).
Using another approach, the FRET/LRET efficiencies and the
F rster radius of the donor/acceptor pair, it was possible to
approximate the separation distance between adjacent cysteines
on an interacting pair of variably labeled CYP3A4 cysteine
mutants (Davydov et al., 2015). For each pair of mutants, the
calculated distances between the cysteine locations were within
the range of error of the distances that would be expected in the
progesterone-bound crystal. Similarly, by using cysteine-reactive
cross-linkers of different lengths with the CYS-depleted CYP3A4
mutants in order to explore the distance between adjacent
cysteines in CYP3A4 multimers, it was possible to demonstrate
that the results were also consistent with the progesterone-bound
CYP3A4 structure. From these studies, it was proposed that ANF
and other effectors bound to the same peripheral site bound
by progesterone in the implicated crystal structure, and that its
binding changed the oligomerization state of the enzyme and
in turn, its catalytic activity. From the crystal structure, it was
proposed that the progesterone-binding site could play a role in
initial substrate recognition because it lines up with a suitable
route (through the F-G helices region) from the membrane to
the active site (Williams et al., 2004). Thus, in light of the other
biophysical data, the conformation change required to open up
this putative channel may be facilitated by interactions with the
peripheral ligand. Interestingly, the less catalytically active form
of CYP3A4 in the absence of effector binding may also be a
distal-to-distal dimer (from crystal structure PDB:1W0G). Thus,
the change in oligomerization caused by effector binding to the
peripheral binding may only be a subtle repositioning of the
dimer that opens up a putative substrate access channel through
the F-G helices region and not necessarily a change from the
monomeric state to a multimeric enzyme complex.
Metabolism by CYP3A4 is often characterized by sigmoidal,
homo-, and heterotropic cooperativity (Korzekwa et al., 1998;
Shou et al., 2001; Houston and Galetin, 2005). One of the best
examples of heterotropic cooperativity involves the effects of
ANF on CYP3A4-mediated metabolism. This compound often
activates metabolism by eliminating sigmoidal enzyme kinetics.
Until recently, cooperativity was attributed to a large active
site that is capable of binding multiple substrates. Effector
compounds could thus influence positioning of a substrate (and
in turn its metabolism) by simultaneous binding to the active
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site. It has also been postulated that effector binding may elicit
a change in CYP3A4 conformation that is more catalytically
active. In support of these ideas are crystal structures of CYP3A4
(Ekroos and Sjogren, 2006) showing multiple compounds
within the active site (PDB: 2V0M) as well as variations in
conformation upon binding to different substrates (PDB: 2J0D).
Various biophysical techniques also indicate a ligand-influenced
equilibrium between multiple conformations of the enzyme
(Koley et al., 1995; Sineva et al., 2013; Davydov et al., 2016). In
addition, studies with CYP3A4, reconstituted in nanodiscs with
excess CPR, observed both homotropically cooperative substrate
binding (Baas et al., 2004) and heterotropically cooperative
substrate metabolism (Denisov et al., 2015).
In contrast, the LRET/FRET studies with CYP3A4 described
above suggest that effector-induced changes in protein
conformation lead to changes in protein oligomerization, and it
may in fact be the latter changes that directly relate to cooperative
metabolism by CYP3A4. The relative roles that effector-mediated
substrate re-positioning in the active site and effector-mediated
changes in protein conformation/oligomerization play in causing
cooperative CYP3A4-mediated metabolism have not yet been
determined. However, one of the objectives of this review is
to entertain the possibility that many functional changes of
P450–P450 interactions could simply be explained by positional
changes of enzyme units in P450 multimers and not solely by
changes in enzyme conformation and substrate-positioning
within the active site.
Using Positional Re-arrangement within
P450 Multimers to Explain the Functional
Effects of P450–P450 Interactions
The reported functional effects involving a given P450 that are
caused by its interaction with another P450 will be considered
with respect to any distinctive features observed in the crystal
lattice arrangement of the P450 that may impart functional
properties to the homomeric complex. The validity of this
approach lies in the fact that any discussion about the functional
effects of P450–P450 interactions is relative to the frame of
reference. As discussed in detail above, the P450 units in
homomeric multimers are not identically distributed within the
aggregate but are characterized by different spin states and
different abilities to be reduced/bind substrates. Furthermore,
the transition between subunit positions within the aggregate
is extremely limited or hindered as indicated by removal of
a segment of the P450 population from the rapid spin state
equilibrium. Thus, any aggregate of P450 is inhibitory by nature
of the fact that some of the units in the aggregate may not
be fully functional. With this in mind, any heteromeric P450–
P450 interaction that causes activation of a P450 could be due to
the homomeric interactions of the affected P450 being relatively
inhibitory. Conversely, inhibitory P450–P450 interactions would
be related to subunit arrangements in the hetero-complex
that contrast with those associated with higher functionality
in the homomeric complex. Studies that have elucidated the
kinetic mechanisms by which P450–P450 interactions influence
metabolism will be used to explain how specific homomeric
interactions may be more or less functional.
P450–P450 Interactions That Influence
CPR Binding
CYP1A2 Interactions
Several studies have demonstrated that the ability of a P450 to
bind CPR is altered when it forms a mixed complex with another
P450. For the P450–P450 interactions of CYP1A2-CYP2B4
(Backes et al., 1998), CYP1A2-CYP2E1 (Kelley et al., 2006),
CYP2C9-CYP2C19 (Hazai and Kupfer, 2005), and CYP2E1-
CYP2B4 (Kenaan et al., 2013), CYP1A2 and CYP2C9 (and
CYP2E1 in its interaction with CYP2B4) were able to bind CPR
more readily (and thus be more catalytically active) when bound
to the indicated P450s; whereas the ability of the interacting
P450 to bind CPR was either inhibited or unaffected. If one only
considers the relative positions of the protein “units” in a P450
multimer (and not necessarily the conformation of the enzyme as
a determinant in its activity), CPR binding could most logically
be affected by interactions involving the proximal side of the P450
enzyme sterically disturbing formation of the CPR·P450 complex
and consequently electron transfer.
Thus, taking the CYP1A2-CYP2B4 interaction as the most
well-studied example of this effect and the line of reasoning
used in the introductory paragraph to this section, the activation
of CYP1A2 via enhanced CPR binding in mixed P450–P450
complexes would imply that its homomeric complex is limited
in its ability to bind CPR. In support of this conclusion, research
from our lab has clearly demonstrated that the homomeric
interaction of CYP1A2 inhibits its activity by a mechanism that
involves a lower CPR-binding affinity (Reed et al., 2012). In
these studies, CYP1A2 activities showed a sigmoidal response
as a function of CPR concentration, which is consistent with a
CYP1A2·CYP1A2 dimer that is inactive (Reed et al., 2012).
Interestingly, a proximal-to-proximal interaction is very
prevalent in the crystal lattice for CYP1A2 (PDB: 2HI4, Figure 3).
With this proximal-to-proximal arrangement, the units in the
CYP1A2 dimer directly overlay the proximal face of the identical
binding partner in a manner that would completely prevent
access for CPR binding. Thus, the stimulation of CYP1A2
caused by heteromeric P450 interactions (with either CYP2B4
or CYP2E1) may stem from the CYP1A2 having a different
arrangement with its proximal face exposed in the presence of
these other P450s. This in turn, would cause a higher proportion
of the CYP1A2 to be available to functionally interact with CPR.
Proximal-to-Proximal Interactions with
Open Conformations of P450s
The proximal-to-proximal interaction is very unusual in closed
forms of P450s. For instance, the closed conformation of CYP2B4
(PDB: 1SUO) is predominated by side-to-side interactions
(Figure 4). However, a proximal-to-proximal interaction is
observed in the crystal lattice of an open form of CYP2B4
(PDB:1PO5; Figure 5A). The open form of this P450 was
crystallized as a distal-to-distal dimer (Figure 5B). This
conformation of CYP2B4 adopts many different arrangements
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FIGURE 3 | Crystal structure showing lattice arrangement of
proximal-to-proximal dimer of CYP1A2 bound to the inhibitor, ANF
(PDB:2HI4). The units of the dimer are oriented with the N-terminal region
(shown in blue) at the base of the dimers in a “membrane plane” running
perpendicular to the plane of the image. The heme groups are shown as red
spheres with α-helices drawn as cylindrical features. The bound ligand, ANF is
shown in the active site in a pink color. The F-G helices region on the distal
face of the enzyme is shown in yellow.
FIGURE 4 | Crystal structure showing side-to-side lattice arrangement
of a CYP2B4 trimer of closed form CYP2B4 with
4-(4-chlorophenyl)imidazole (shown in pink) bound to the active site
(PDB:1SUO). The units of the trimer are arranged with the N-terminal ends
(shown in blue) at the base of the units in a “membrane plane” running
perpendicular to the plane of the page. Regions involved in the interactions
include the G-, H-, J-, C-, and D-helices. The heme groups are shown as red
spheres with α-helices drawn as cylindrical features. The F-G helices region
on the distal face of the enzyme are shown in yellow.
in its crystal structure including two types of side-to-side
interactions in addition to the distal-to-distal and proximal-to-
proximal orientations. The open-form, intercalated, distal-to-
distal dimer represents an inactive complex having a His in
the F-helix of one open unit coordinating with the active site
heme of the other open CYP2B4 unit. An evaluation of the
open conformation of the CYP2B4 crystal structure led to the
conclusion that this form of CYP2B4 also would be deficient in
functionally interacting with CPR because of repositioning of
the C helix (Scott et al., 2003). Thus, whether or not the open
CYP2B4 is in a proximal-to-proximal interaction, it is probably
FIGURE 5 | The crystal structure of open-formed, ligand-free CYP2B4
(PDB:1PO5) showing lattice arrangements of a proximal-to-proximal
dimer (A) and an intercalated, distal-to-distal dimer (B). The units of the
dimers are oriented with the N-terminal region (shown in blue) at the base of
the dimers in a “membrane plane” running perpendicular to the plane of the
image. The heme groups are shown as red spheres with α-helices drawn as
cylindrical features. The F-G helices regions on the surface of the distal faces
of the enzyme units are shown in yellow.
not reducible by CPR. In the inhibition of CYP2B4 caused by
its interaction with CYP1A2, it seems conceivable that the effect
could be due in part, to a proximal-to-proximal association of
open form CYP2B4 with CYP1A2 in which the CYP2B4-binding
site for CPR is blocked. The hyperbaric studies of the CYP1A2-
CYP2B4 complex (Davydov et al., 2000b) showed that there was
increased hydration of the active site of CYP2B4 as a result of its
interaction with CYP1A2 which is consistent with the interaction
involving the open form of CYP2B4.
A proximal-to-proximal interaction can also be observed
in the crystal lattice of an open form of CYP3A4 bound to
ketoconazole (PDB: 2V0M; Figure 6) (Ekroos and Sjogren,
2006). Furthermore, the crystal structure of the open CYP3A4
dimer associated with the binding of erythromycin is arranged
in an offset proximal-to-proximal orientation (PDB: 2J0D). As
is the case with CYP2B4, proximal-to-proximal interactions
of the open CYP3A4 are not observed in crystal lattices of
closed CYP3A4 forms (discussed above). CYP3A4 metabolizes
very large substrates, and the open form apparently is adopted
when large substrates are metabolized by the P450. Thus, unlike
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FIGURE 6 | Crystal structure showing lattice arrangement of
proximal-to-proximal dimer of open-formed CYP3A4 with two
molecules of ketoconazole bound to each active site (shown in pink)
(PDB:2V0M). The units of the dimer are oriented with the N-terminal region at
the base of the dimers in a “membrane plane” running perpendicular to the
plane of the image. The heme groups are shown as red spheres with
α-helices drawn as cylindrical features. The two ketoconazole molecules
bound to each active site are shown in pink.
CYP2B4, the open CYP3A4 form is likely to be catalytically active.
Similar to the crystal lattice of open CYP2B4, the open form of
CYP3A4 also displays a variety of arrangements including distal-
to-distal (not intercalated) and side-to-side. Thus, these open
forms may be versatile in the types of associations they can adopt.
The open conformation has also been implicated for a
R108H mutant of CYP2C9 through the use of size exclusion
chromatography, UV-visible spectrophotometry, pulsed electron
paramagnetic resonance, and molecular dynamics simulations
(Roberts et al., 2010). The mutant was isolated in a conformation
in which the substituted His in the B-C loop coordinated
intramolecularly with the heme group. Thus, this form is a
monomer, but the mobility of the B-C loop in coordinating
with the heme is similar to the conformational mobility needed
to form the open conformation of CYP2B4. Because this
conformation was ascertained by physical techniques other than
X-ray crystallography, the tendency of this form to associate in a
proximal-to-proximal orientation cannot be determined.
Any open form in which inter- or intramolecular
rearrangement blocks substrate access to the active site would be
inhibitory. Thus, it seems open conformations of P450s may in
general, be a means to limit the activities of the P450s by favoring
the formation of proximal-to-proximal arrangements that are
deficient in binding to CPR. Unfortunately, very few P450
crystal structures have been isolated in the open conformation to
confirm that this form consistently adopts these arrangements.
Thus, this hypothesis needs further testing. However, it should
be pointed out that the arrangement is observed in all of the
available open-form crystal structures.
It is clear that the crystal structure of CYP1A2 is unusual
in adopting a proximal-to-proximal arrangement in the closed
conformation. Furthermore, it can also be argued that CYP1A2
would be incapable of adopting the open conformation given its
narrow active site that is conducive for metabolism of planar,
aromatic substrates (Sansen et al., 2007). If the conformation
of CYP1A2 did open up, the P450 would be expected to
metabolize a wider range of substrates. Thus, the proximal-
to-proximal interaction may have an important regulatory role
in P450-mediated catalysis, and CYP1A2 may utilize its ability
to adopt this arrangement in the closed form to influence the
conformation and quaternary structure of interacting P450s.
CYP2C9 Interactions
Stimulation of CYP2C9-mediated activity through a mechanism
involving higher CPR binding affinity was also reported for
the interaction of the P450 with CYP2C19 (Hazai and Kupfer,
2005). An explanation for this effect was proposed through an
examination of CYP2C9 crystal structure in a subsequent study
(Hazai et al., 2005). At the time of this study, the number of
available crystal structures for mammalian P450s was limited, and
the functional effects of P450–P450 interactions were interpreted
solely by the potential effects on CPR binding as this was the only
identified mechanism.
To explain the activation of CYP2C9 metabolism by its
interaction with CYP2C19, the previous study examined a
side-to-proximal dimer (PDB: 1OG5; Figure 7) which has the
proximal face of one unit being occluded by the side of the protein
containing the C-terminal end of the I-helix and the J-helix. In
the previous study, it was postulated that the CYP2C9 dimer
would bind CPR with greater affinity than a CYP2C9 monomer
because the exposed J and K helices of the obstructed proximal
face would contribute to CPR binding by the exposed proximal
face of the self-interacting CYP2C9 unit. Although this is an
intriguing conclusion to be drawn from this crystal structure
arrangement, it must also be considered that this complex instead
represents an inhibitory, homomeric CYP2C9 complex because
FIGURE 7 | Crystal structure of side-to-proximal dimer of CYP2C9
bound to warfarin (PDB: 1OG5). The units of the dimer are oriented with the
N-terminal region (shown in blue) at the base of the dimers in a “membrane
plane” running perpendicular to the plane of the image. The heme groups are
shown as red spheres with α-helices drawn as cylindrical features. The F-G
helices region on the distal surfaces of the dimer are shown in yellow. Warfarin
molecules (pink) are bound in the active sites.
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one of the two proximal faces is sterically hindered in its ability
to bind CPR. Thus, at least one of the two CYP2C9 units in the
dimer would be catalytically limited. Furthermore, it is possible
that CPR binding to the “exposed” proximal side of the alternate
unit also would be limited because it is partially obstructed in the
crystal structure.
Because positional heterogeneity implies that any heteromeric
P450–P450 interaction stimulating a P450 catalytic activity
can also be interpreted as the homomeric interactions being
inhibitory, the side-to-proximal interaction of CYP2C9 may
instead be inhibitory and not one that is characterized by
increased CPR-binding affinity. As a result, the stimulation of
CYP2C9 through its interaction with CYP2C19 may be mediated
through a quaternary structure that fully exposes the CYP2C9
proximal face, possibly doubling the amount of catalytically
active CYP2C9 relative to what would be observed with the
homomeric CYP2C9 dimer (PDB: 1OG5). The CYP2C19 crystal
lattice (PDB:4GQS; Figure 8) shows one arrangement that would
be a credible membrane alignment in which the N-terminal ends
of a symmetrical dimer interact in a manner that would expose
the proximal faces at a rather flat angle to the membrane normal
with the distal faces buried below the membrane surface. In
conjunction with this arrangement, many hydrophobic residues
on the distal side project below what would be the membrane
surface in this orientation. Thus, the functional effects reported
for this interaction could be explained if a greater proportion
of CYP2C9 adopted the “CYP2C19-like” arrangement at the
expense of the side-to-proximal dimer associated with the
CYP2C9 crystal lattice, and more of the CYP2C19 adopted the
CYP2C9 homodimer arrangement.
FIGURE 8 | Crystal structure of side-to-side dimer of CYP2C19 bound
to (2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)
methanon (PDB: 4GQS). This arrangement typifies the interactions that can
be observed in the CYP2C9 crystal lattice. The units of the dimer are oriented
with the N-terminal region at the base of the dimers in a “membrane plane”
running perpendicular to the plane of the image. The crystal is predominated
by many side-on interactions, many of which do not orient in a manner
consistent with being incorporated in a single membrane bilayer. The heme
groups are shown as red spheres with α-helices drawn as cylindrical features.
The molecules of (2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,
5-dimethylphenyl) methanon bound to the active site are shown in pink.
The distinction between a conformational mechanism and the
one involving a change in the arrangement of a P450 complex
that exposes the proximal face of the P450 is significant. In
the second case, the amount of a specific P450 participating in
the metabolism of a substrate would increase because a higher
proportion of the P450 would have the ability to interact with
CPR. It is important to note that this effect could mistakenly be
attributed to a change in the rate of a catalytic step of the reaction
cycle. To take the effects of the CYP2C9-CYP2C19 interaction
as an example (Hazai and Kupfer, 2005), stimulation of the
CYP2C9-mediated metabolism of methoxychlor was observed
in the presence of CYP2C19 when CPR was at a saturating
concentration. This would not happen if the change was caused
by a conformation-related increase in the binding affinity of
CPR and CYP2C9 because the CPR level was saturating both
in the presence and absence of CYP2C19. However, the effect
could be explained if the interaction of CYP2C9 with CYP2C19
causes more of the proximal face of CYP2C9 to be exposed
for binding to CPR. Thus, any P450–P450 interaction that has
been attributed to a change in the rate of a catalytic step, other
than substrate binding, may in fact be caused by this mechanism
instead. In other words, any apparent change in the kcat of a
reaction associated with a P450–P450 interaction could instead
be attributable to an alteration in the amount of available active
enzyme through a re-rearrangement within a P450 multimer that
exposes or hides more of the proximal face of the affected P450
(i.e., an effective increase it total active enzyme would present as
an increase in kcat).
Another important kinetic distinction in the formation of the
proximal-to-proximal dimer is that the P450 in this arrangement
would be effectively removed from the population of P450
capable of binding CPR. Thus, if there is a net exchange of
one P450 form for another in this arrangement, the effective
CPR:P450 ratio would increase for the P450 that is activated
through this mechanism. This would be another potential
mechanism for enzymatic stimulation in the mixed system.
P450–P450 Interactions That Influence
Substrate Binding
As reviewed previously (Reed and Backes, 2016), the interactions
of CYP2C9 with CYP2D6 (Subramanian et al., 2009) (and
possibly with CYP3A4) (Subramanian et al., 2010) and CYP2B4
with CYP2E1 (Kenaan et al., 2013) have been shown to
cause inhibition of CYP2C9 and CYP2B4, respectively, by
increasing the dissociation constants for substrate binding.
Changes in substrate binding could be plausibly explained
through P450–P450 interactions that involve the distal side of
the affected P450. A distal-to-distal P450 quaternary structure is
commonly observed in P450 crystal lattices. A membrane-bound
analog of this type of dimer is typified by the crystal structure
of CYP2C8 (Hu et al., 2010). In these types of dimers, the P450s
can assume either closed or open conformations around the
active site, and the F and G helices of the interacting P450s
form the dimerization interface. Interestingly, the dimerization
of CYP2C8 probably causes the F/G loops to be pulled out of
the membrane bilayer (Schoch et al., 2004; Ozalp et al., 2006).
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This effect in turn, would likely affect substrate binding to the
enzyme and would probably inhibit metabolism of hydrophobic
substrates that partition largely to the membrane. Perhaps, in its
interaction with CYP2C9, CYP2D6 may favor a rearrangement
of the CYP2C9 that obstructs its distal face and in turn,
causes its substrate to bind less tightly to its active site and
inhibits CYP2C9-mediated metabolism in the process. Similarly,
by consideration of positional heterogeneity as the primary
determinant of P450–P450 effects, it would be presumed that
CYP3A4 binds to the distal side of CYP2C9 to disrupt binding
of S-naproxen and S-flurbiprofen, and in a similar manner,
CYP2E1 (at high enzyme concentrations) distorts the distal side
of CYP2B4 and negatively influences binding of benzphetamine
to its active site (Kenaan et al., 2013).
A more recent study (Bostick et al., 2016) has reported that
the interaction of CYP2D6 and CYP2C9 resulted in stimulation
of the CYP2C9-mediated metabolism of S-flurbiprofen [the
same substrate in the study reporting inhibition of CYP2C9
(Subramanian et al., 2009)]. There were several distinctions in
the methods used in the two studies that could explain the
discrepancy in the findings. Most importantly, the reaction went
for 16 h in the later study, and it was reported that the rates were
not linear over this time period. Thus, “stimulation” could merely
reflect longer enzymatic stability when CYP2C9 was in the mixed
complex, and the earlier study probably describes the effects of
the CYP2C9-CYP2D6 interaction more accurately.
Putative Hexameric Quaternary
Structure of Membrane-Bound CYP2C9
In examining crystal lattices of purified P450s for the putative
hexameric aggregate that has been implicated by electron
microscopy (Tsuprun et al., 1986; Myasoedova and Tsuprun,
1993) and saturation transfer electron paramagnetic resonance
(Schwarz et al., 1982), an interesting arrangement can be
observed in the crystal lattice of CYP2C9 (PDB: 1OG5;
Figures 9A,B) in which a large-scale pattern that includes a
trimer of asymmetric dimers can be observed. The dimers
referred to are the side-to-proximal dimers described above.
The arrangement is intriguing in that it is consistent with
functional membrane binding and has similar features to the
hexameric structures of CYP1A2 (Myasoedova and Tsuprun,
1993) and CYP2B4 (Tsuprun et al., 1986) observed by electron
microscopy as it is comprised of two types of contacts between
the CYP2C9 units of the hexamer. In addition to the side-to-
proximal interaction, the three sets of dimers are joined together
with threefold symmetry along the distal faces and the side
between the proximal and distal faces that contains the regions
between the B/C helices and the H/I helices in addition to the
C-terminus of the enzyme. Future research should consider this
hexamer as a possible quaternary structure when metabolism by
CYP2C9 is assessed in the context of P450–P450 interactions.
DISCUSSION
Physical studies have convincingly shown that P450s have a
propensity to form complexes in membranes. Studies measuring
FIGURE 9 | Crystal lattice of side-to-proximal dimer of CYP2C9 (PDB:
1OG5) (shown in Figure 7) showing conceivable hexameric association
within a membrane. The crystal lattice of the side-to-proximal dimer shown
in Figure 7 was examined for higher ordered quaternary structure. (A) Shows
a trimeric association of the dimers in threefold symmetry formed from a side
abutting in an angle against a neighboring distal region of an adjacent
CYP2C9 unit. The N-terminal, membrane-binding region for each unit is at the
bottom of the hexamer in the plane of the page. (B) Shows the same hexamer
with the blue N-terminal ends arranged at the bottom of the hexamer in a
common plane that runs perpendicular to the plane of the image. The heme
groups are shown as red spheres with α-helices drawn as cylindrical features.
The F-G helices region on the distal faces of the hexamer units are shown in
yellow.
FRET/LRET and surface plasmon resonance now allow for
determinations of the dynamics of P450–P450 association.
Measurements indicate dissociation constants ranging from 1 to
50 nM (0.05–0.6 pmol/m2 for calculations based on the two-
dimensional lipid bilayer). Thus, P450s bind with affinities that
are higher than those measured for some signaling complexes
within the plasma membrane where the dissociation constants of
various Gα subunits for the Gβγ subunit, coupled to the N-formyl
peptide receptor, ranged from 1 to 3 µM (Bennett et al., 2001).
Studies with cross-linkers and those designed to monitor the
rotational mobility of P450s indicate the presence of dimeric
to hexameric (and larger?) P450 multimers in membranes with
some P450–P450 interactions being governed by electrostatic
forces possibly involving amine groups in the polar linker region
and/or the proximal faces of the enzymes. In natural membranes,
P450s form complexes of varying sizes with higher ordered
aggregates containing essentially rotationally immobilized P450
units.
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These P450–P450 interactions would not be of particular
interest if they did not impart functional changes that affect drug
metabolism. However, the P450 units in these multimers display
positional heterogeneity with respect to chemical/enzymatic
reduction, spin state, and access to substrate. The heterogeneity
of P450 multimers with respect to these properties is a testament
to the quasi-irreversible nature of P450–P450 associations and
is the underlying source of the functional effects of P450–P450
interactions with regards to drug metabolism.
An integral question concerning the functional effects of
P450–P450 interactions involves the physiologic rationale for
their existence. Given their important role in the elimination
of hydrophobic xenobiotics, it may seem counter-intuitive that
their activities could be selectively inhibited by oligomerization.
Enzymatic regulation through oligomerization also provides
a means for the P450 system to respond immediately to
the presence of a given substrate through quaternary re-
arrangements that “unmask” otherwise latent P450-mediated
activities. If this were not the case, the P450 system might be
ineffective at removing the compound until delayed induction
of the relevant P450s. In addition, the P450 catalytic cycle
depends on the activation of molecular oxygen through the
transfer of electrons to the heme group. This process can result
in uncoupling and the generation of destructive reactive oxygen
species. Thus, the regulation of P450-mediated activities through
oligomerization may provide a mechanism to limit deleterious
uncoupling reactions. This topic has been addressed more fully
in other reviews (Zangar et al., 2004; Davydov, 2011). It is also
possible that P450 oligomerization has a more complex role with
the expression of specific P450s serving to silence or enhance the
activities of P450s with which they tend to interact.
Despite the fact that general mechanisms involving altered
CPR and/or substrate binding have been identified for the
functional effects of P450–P450 interactions, the specific ways
that the interactions cause these changes have been difficult
to interpret. Typically, general explanations attribute the
phenomena to protein conformation changes. Undoubtedly,
undefined conformation changes are the underlying causes given
that the effects of P450–P450 interactions are substrate-specific.
For instance, all interactions involving CYP2E1 and CYP2B4 do
not cause activation of the former and inhibition of the latter
(Kelley et al., 2006). However, p-nitrophenol and benzphetamine
trigger specific conformation changes in CYP2E1 and CYP2B4,
respectively, that lead to those effects when the two P450s interact
(Kenaan et al., 2013).
While the underlying protein conformational changes that
affect oligomerization are important to elucidate, the actual
changes in oligomerization affecting positional heterogeneity
are possibly the ultimate source of functional changes. In
fact, it can be reasoned that certain arrangements of P450s
would have very predictable consequences on drug metabolism.
Thus, for this review, we have examined the crystal lattices of
several P450 structures to identify arrangements that may be
analogous to their organization in membranes, with the ultimate
objective of identifying potential changes in oligomerization that
would explain the alterations in function observed with specific
P450–P450 interactions.
To explain the role of oligomerization in affecting the
enzymatic function of drug-metabolizing P450s, it is proposed
that the degree and the variability of P450 oligomerization
represents a P450-specific equilibrium that is influenced by
the conformational state of the protein. The conformational
variability of most P450s (except CYP1A) is proposed to
be distinguished by the open and closed states represented
by CYP2B4 crystal structures (PDB: 1PO5 and PDB: 1SUO,
respectively), with ligand-free CYP2B4 existing in the membrane
in both states. In most cases, substrate binds to or triggers
formation of the closed state. The exception to this trend
would be cases such as that with CYP3A4 when large substrates
are bound to the active site which in itself induces the open
conformation of the enzyme.
The model maintains that each P450 displays a specific
tendency to distribute to different proportions of P450–P450
associations that can be categorized as distal-to-distal, proximal-
to-proximal, side-to-side, and side to either proximal or distal
faces. Thus, interactions between different P450s cause a
redistribution of each P450 to different proportions of each
arrangement which is influenced by the tendency of the binding
partner to adopt a specific arrangement. It is proposed that
a functional effect is associated with a P450–P450 interaction
when the interaction causes changes in the relative proportions
(as compared to the proportions observed in homomeric
reconstituted systems) of side-on; distal-to-distal; and proximal-
to-proximal P450 arrangements. More specifically, an interaction
with a P450 that favors distal-to-distal (e.g., CYP2D6, PDB:
2F9Q) or proximal-to-proximal (e.g., CYP1A2) arrangements
would be expected to result in inhibition of P450s that participate
in predominantly side-on interactions [e.g., CYP2B4 (Figure 4)
and CYP2C19 (Figure 8)]. In conjunction, this has been shown
to be the case for several P450–P450 interactions involving these
P450s (Hazai and Kupfer, 2005; Reed et al., 2010; Kenaan et al.,
2013).
This is not meant to imply that CYP2B4 and CYP2C19
only arrange in side-on interactions in the membrane. Clearly,
the functional heterogeneity of CYP2B4 has been demonstrated
(Davydov et al., 1985, 1995; Backes and Eyer, 1989) and may
represent a mixture of distal-to-distal (and possibly proximal-
to-proximal of the open form) in addition to the side-
on interactions. Conformational changes caused by substrate
binding would be predicted to alter the proportions of the
P450 in each characteristic state of oligomerization. Interestingly,
distal-to-proximal interactions were not observed in any of the
mammalian structures although they have been reported for
bacterial P450s (Ravichandran et al., 1993). This leads to the
possibility that the arrangement of P450 units in multimers
is not random. Thus, distal-to-distal and proximal-to-proximal
interactions may be specific mechanisms that have evolved to
regulate the activities of membrane-bound P450s.
For most P450s except CYP1A2, the open conformation of
P450 appears to be uniquely associated with both proximal-to-
proximal and the distal-to-distal dimeric interaction in which
the F-helix of one binding partner intercalates with the active
site of the interacting P450 (for simplicity, this will be referred
to as the intercalated open-form dimer). As described above,
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both of these open arrangements are inactive. CYP1A2 presents
an unusual situation for the drug-metabolizing P450s because
it is not thought to be able to adopt the open conformation.
However, unlike most of the drug-metabolizing P450s, CYP1A2
can adopt the proximal-to-proximal arrangement when it
is in the closed, substrate-binding conformation. For other
drug metabolizing P450s, the proximal-to-proximal interaction
has only been associated with crystal lattices of open form
P450s. Thus, rearrangement of CYP1A2 from its proximal-to-
proximal orientation to one associated with optimal catalytic
activity upon its interaction with another P450 would stimulate
CYP1A2 by increasing the total amount of “enzymatically active
CYP1A2” and also by increasing the effective CPR:CYP1A2
ratio. Conversely, the P450 interacting with CYP1A2 may be
inhibited because of the increased accessibility of CYP1A2 to
the limiting concentrations of CPR. Inhibition may also occur
if the affected P450 interacts as an open form in a proximal-to-
proximal manner with CYP1A2.
Distal-to-distal interactions commonly observed in many
P450 crystal structures in which the units of the P450 multimer
interact on the periphery of the distal regions of P450s in the
closed conformation are proposed to be impaired in substrate
binding. The analogous membrane-bound CYP2C8 dimer has
been proposed to be deficient in lipophilic substrate binding from
the membrane (Hu et al., 2010). Changes in the relative amounts
of this type of dimer may explain the functional interactions of
CYP2C9-CYP2D6 (Subramanian et al., 2009); CYP2C9-CYP3A4
(Subramanian et al., 2010); and possibly CYP2E1-CYP2B4 (when
a high concentration of CYP2E1 interacts with CYP2B4) (Kenaan
et al., 2013). CYP inhibition in these instances is caused by an
increase in the proportion of the affected P450 in the closed-
form, distal-to-distal arrangement and a corresponding decrease
in the proportion of enzyme involved in side-on interactions.
Homotropic and heterotropic cooperation in metabolism by
CYP3A4 have been related to this type of distal-to-distal dimer
(Davydov et al., 2013) indicating a limitation in the ability of
it to bind substrate until a putative access channel is opened
by effector binding to a peripheral site on the adjoining distal
regions of the dimer (Williams et al., 2004; Davydov et al.,
2015).
The proposed equilibria actually can explain all of the reported
functional effects of these interactions. For instance, changes
in the proportion of a P450 in a quasi-irreversible proximal-
to-proximal arrangement which are caused by interactions
with another P450 can explain the functional effects involving
modifications in CPR-binding capability. This also includes
mechanisms implicating a change in the apparent kcat as the
positional change of the affected P450 would present more or
less of the total enzyme population for interactions with CPR.
Note, the heterocomplex would need to be stable in the presence
of excess CPR like the CYP2C9-CYP2C19 complex in order for
rigorous kinetic analysis to detect an apparent change in kcat.
The purported effects for the proximal-to-proximal interaction
are believed to explain the reported functional interactions for
homomeric CYP1A2 (Reed et al., 2012) and for those between
CYP2C9-CYP2C19 (Hazai and Kupfer, 2005); CYP1A2-CYP2B4
(Backes et al., 1998); and CYP2E1-CYP2B4 (Kenaan et al., 2013).
In Fernando et al. (2008) three functional populations
were identified in the study of the positional heterogeneity of
P450–P450 complexes. One population responded to substrate
by shifting rapidly to the high spin form and subsequently being
reduced enzymatically to form the ferrous-CO complex. This
could represent closed-form, side-on P450–P450 interactions
fully capable of substrate and reductase binding (“HS+” in the
Fernando study).
Another population did not shift to high spin upon addition
of substrate and could not be reduced (“HS−” in previous
study). This characteristic could actually be representative of
the intercalated, open-formed P450 dimer and/or the open-form
proximal-to-proximal dimer. Clearly, the proximal-to-proximal
dimer would not be reducible given the fact that the dimer
is physically unable to interact with CPR. Furthermore, if the
dimerization limited conversion to the closed conformation, the
proximal-to-proximal CYP2B4 dimer also would be expected
to be intransigent to a substrate-induced spin state transition.
The “HS−” population also could represent the open-form,
intercalated dimer of CYP2B4 given the fact that it was thought to
be incapable of functionally interacting with CPR (note, a putative
opened-form dimer of CYP3A4 must be able to interact with CPR
in order to metabolize large substrates) and substrate would not
bind to the intercalated P450 dimer since the active site is blocked
by the F-helix of the binding partner. In support of the possibility
that the HS− population is represented (at least in part) by
the intercalated dimer, the biphasicity of the pre-steady state
reduction of CYP2B4 by CPR was explained by a model involving
a slow equilibrium between two conformations that bind to CPR,
but only one of which could be reduced (Backes and Eyer, 1989).
Thus, these two groups of CYP2B4 would be consistent with
P450 in side-on interactions and the open intercalated dimer of
CYP2B4. It is important to note that both types of open-form
dimerization may be a means to regulate P450 activities and may
be related by a dynamic equilibrium. However, because of the
constraints of the lipid membrane and the limitation imposed
by the P450s being tethered by the amino terminal tail, trimeric
quaternary structures comprised of both proximal-to-proximal
and distal-to-distal arrangements do not appear to be possible.
Thus, the two types of dimers are exclusive of one another.
The final population in the previous study consisted of low
spin CYP3A4 that was slowly converted to high spin prior to
enzymatic reduction (“HS0”). Substrate binding was proposed to
slowly shift the enzyme to the high spin/reducible form. This is
fully consistent with our predicted properties of the closed-form
distal-to-distal P450 complex as substrate binding is proposed to
be limited for this population which would in turn, cause a slower
spin state transition and subsequent reduction by the reductase.
The Fernando study indicated that ANF (the allosteric activator
of CYP3A4 that is believed to facilitate substrate binding by
interaction at the peripheral effector site of the dimer) was shown
to dramatically decrease the proportion of the HS0 population.
This would be expected if the peripheral binding by ANF
facilitates substrate access to the active sites of these closed form
CYP3A4 distal-to-distal dimers.
Although there has been significant progress on the topic of
the functional effects of P450–P450 interactions, there is still
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much more that is unknown than known about how these
interactions influence catalytic activities and drug metabolism
in vivo. For instance, of the roughly 40 possible binary P450–P450
interactions in liver that involve the major P450s in drug
metabolism and of the approximately 1500 drugs that have
been approved by the FDA (Kinch et al., 2014), only about 12
specific P450–P450 interactions related to the metabolism of
approximately 30 substrates (many of which are not even drugs)
have been studied (Reed and Backes, 2016). Another topic of
relevance that needs to be explored is the study of tissue-specific
P450–P450 interactions involving the unique assemblages of
P450s expressed in each tissue and the consequent functional
effects of these interactions.
In total, these findings suggest that heteromeric P450
association serves as a means to regulate specific P450-mediated
drug metabolism in vivo. Only rigorous comparative studies
will determine whether specific P450s preferentially interact. It
is possible that all P450s have similar tendencies to interact
with one another. If this is the case, identification of the P450s
involved in the metabolism of specific drugs (information that is
routinely obtained before phase I drug studies) will allow for the
determination of specific P450–P450 interactions that influence
metabolism of the given drug by the implicated P450. This
information will be invaluable in pharmaceutical risk assessment
and in pharmacokinetic evaluations of drug metabolism and
disposition.
AUTHOR CONTRIBUTIONS
Substantial contributions to the conception or design of the work;
or the acquisition, analysis, or interpretation of data for the
work – JR and WB. Drafting the work or revising it critically
for important intellectual content – JR and WB. Final approval
of the version to be published – JR and WB. Agreement to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved – JR and WB.
FUNDING
This work was supported by the National Institutes of Health
Grants ES004344 and ES013648 from NIEHS, USPHS.
REFERENCES
Ahn, T., Guengerich, F. P., and Yun, C. H. (1998). Membrane insertion of
cytochrome P450 1A2 promoted by anionic phospholipids. Biochemistry 37,
12860–12866. doi: 10.1021/bi980804f
Anzenbacher, P., and Anzenbacherová, E. (2001). Cytochromes P450 and
metabolism of xenobiotics. Cell Mol. Life Sci. 58, 737–747. doi: 10.1007/
PL00000897
Baas, B. J., Denisov, I. G., and Sligar, S. G. (2004). Homotropic cooperativity of
monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment.
Arch. Biochem. Biophys. 430, 218–228. doi: 10.1016/j.abb.2004.07.003
Backes, W. L., Batie, C. J., and Cawley, G. F. (1998). Interactions among
P450 enzymes when combined in reconstituted systems: formation of a 2B4-
1A2 complex with a high affinity for NADPH-cytochrome P450 reductase.
Biochemistry 37, 12852–12859. doi: 10.1021/bi980674a
Backes, W. L., and Eyer, C. S. (1989). Cytochrome P-450 LM2 reduction. Substrate
effects on the rate of reductase-LM2 association. J. Biol. Chem. 264, 6252–6259.
Baylon, J. L., Lenov, I. L., Sligar, S. G., and Tajkhorshid, E. (2013). Characterizing the
membrane-bound state of cytochrome P450 3A4: structure, depth of insertion,
and orientation. J. Am. Chem. Soc. 135, 8542–8551. doi: 10.1021/ja4003525
Bennett, T. A., Key, T. A., Gurevich, V. V., Neubig, R., Prossnitz, E. R., and Sklar,
L. A. (2001). Real-time analysis of G protein-coupled receptor reconstitution
in a solubilized system. J. Biol. Chem. 276, 22453–22460. doi: 10.1074/jbc.
M009679200
Bostick, C. D., Hickey, K. M., Wollenberg, L. A., Flora, D. R., Tracy, T. S., and
Gannett, P. M. (2016). Immobilized cytochrome P450 for monitoring of P450-
P450 interactions and metabolism. Drug Metab. Dispos. 44, 741–749. doi: 10.
1124/dmd.115.067637
Bridges, A., Gruenke, L., Chang, Y. T., Vakser, I. A., Loew, G., and Waskell, L.
(1998). Identification of the binding site on cytochrome P450 2B4 for
cytochrome b5 and cytochrome P450 reductase. J. Biol. Chem. 273, 17036–
17049. doi: 10.1074/jbc.273.27.17036
Brignac-Huber, L. M., Park, J. W., Reed, J. R., and Backes, W. L. (2016).
Cytochrome P450 Organization and function are modulated by endoplasmic
reticulum phospholipid heterogeneity. Drug Metab. Dispos. 44, 1859–1866. doi:
10.1124/dmd.115.068981
Cawley, G. F., Batie, C. J., and Backes, W. L. (1995). Substrate-dependent
competition of different P450 isozymes for limiting NADPH-cytochrome P450
reductase. Biochemistry 34, 1244–1247. doi: 10.1021/bi00004a018
Cawley, G. F., Zhang, S., Kelley, R. W., and Backes, W. L. (2001).
Evidence supporting the interaction of CYP2B4 and CYP1A2 in microsomal
preparations. Drug Metab. Dispos. 29, 1529–1534.
Cojocaru, V., Balali-Mood, K., Sansom, M. S., and Wade, R. C. (2011). Structure
and dynamics of the membrane-bound cytochrome P450 2C9. PLoS Comput.
Biol. 7:e1002152. doi: 10.1371/journal.pcbi.1002152
Davydov, D. R. (2011). Microsomal monooxygenase as a multienzyme system: the
role of P450-P450 interactions. Exp. Opin. Drug Metab. Toxicol. 7, 543–558.
doi: 10.1517/17425255.2011.562194
Davydov, D. R., Davydova, N. Y., Sineva, E. V., and Halpert, J. R. (2015).
Interactions among cytochromes P450 in microsomal membranes:
oligomerization of cytochromes P450 2E1, 3A5, and 2E1 and its functional
consequences. J. Biol. Chem. 290, 3850–3864. doi: 10.1074/jbc.M114.615443
Davydov, D. R., Davydova, N. Y., Sineva, E. V., Kufareva, I., and Halpert, J. R.
(2013). Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of
alpha-naphthoflavone. Biochem. J. 453, 219–230. doi: 10.1042/BJ20130398
Davydov, D. R., Deprez, E., Hoa, G. H., Knyushko, T. V., Kuznetsova, G. P.,
Koen, Y. M., et al. (1995). High-pressure-induced transitions in microsomal
cytochrome P450 2B4 in solution: evidence for conformational inhomogeneity
in the oligomers. Arch. Biochem. Biophys. 320, 330–344. doi: 10.1016/0003-
9861(95)90017-9
Davydov, D. R., Fernando, H., Baas, B. J., Sligar, S. G., and Halpert, J. R.
(2005). Kinetics of dithionite-dependent reduction of cytochrome P450 3A4:
heterogeneity of the enzyme caused by its oligomerization. Biochemistry 44,
13902–13913. doi: 10.1021/bi0509346
Davydov, D. R., Kariakin, A. A., Petushkova, N. A., and Peterson, J. A. (2000a).
Association of cytochromes P450 with their reductases: opposite sign of the
electrostatic interactions in P450BM-3 as compared with the microsomal 2B4
system. Biochemistry 39, 6489–6497. doi: 10.1021/bi992936u
Davydov, D. R., Karyakin, A. V., Binas, B., Kurganov, B. I., and Archakov, A. I.
(1985). Kinetic studies on reduction of cytochromes P-450 and b5 by dithionite.
Eur. J. Biochem. 150, 155–159. doi: 10.1111/j.1432-1033.1985.tb09001.x
Davydov, D. R., Petushkova, N. A., Archakov, A. I., and Hoa, G. H. (2000b).
Stabilization of P450 2B4 by its association with P450 1A2 revealed by high-
pressure spectroscopy. Biochem. Biophys. Res. Commun. 276, 1005–1012. doi:
10.1006/bbrc.2000.3596
Davydov, D. R., Petushkova, N. A., Bobrovnikova, E. V., Knyushko, T. V., and
Dansette, P. (2001). Association of cytochromes P450 1A2 and 2B4: are the
interactions between different P450 species involved in the control of the
Frontiers in Pharmacology | www.frontiersin.org January 2017 | Volume 8 | Article 28 | 121
fphar-08-00028 January 25, 2017 Time: 15:36 # 18
Reed and Backes Predicting P450–P450 Complex Formation
monooxygenase activity and coupling? Adv. Exp. Med. Biol. 500, 335–338.
doi: 10.1007/978-1-4615-0667-6_53
Davydov, D. R., Rumfeldt, J. A., Sineva, E. V., Fernando, H., Davydova, N. Y., and
Halpert, J. R. (2012). Peripheral ligand-binding site in cytochrome P450 3A4
located with fluorescence resonance energy transfer (FRET). J. Biol. Chem. 287,
6797–6809. doi: 10.1074/jbc.M111.325654
Davydov, D. R., Sineva, E. V., Sistla, S., Davydova, N. Y., Frank, D. J., Sligar,
S. G., et al. (2010). Electron transfer in the complex of membrane-bound
human cytochrome P450 3A4 with the flavin domain of P450BM-3: the effect
of oligomerization of the heme protein and intermittent modulation of the spin
equilibrium. Biochim. Biophys. Acta 1797, 378–390. doi: 10.1016/j.bbabio.2009.
12.008
Davydov, D. R., Yang, Z., Davydova, N., Halpert, J. R., and Hubbell, W. L. (2016).
Conformational mobility in cytochrome P450 3A4 explored by pressure-
perturbation EPR spectroscopy. Biophys. J. 110, 1485–1498. doi: 10.1016/j.bpj.
2016.02.026
Dean, W. L., and Gray, R. D. (1982). Hydrodynamic properties of monomeric
cytochromes P-450LM2 and P-450LM4 in n-octylglucoside solution. Biochem.
Biophys. Res. Commun. 107, 265–271. doi: 10.1016/0006-291X(82)91699-0
Denisov, I. G., Grinkova, Y. V., Baylon, J. L., Tajkhorshid, E., and Sligar, S. G. (2015).
Mechanism of drug-drug interactions mediated by human cytochrome P450
CYP3A4 monomer. Biochemistry 54, 2227–2239. doi: 10.1021/acs.biochem.
5b00079
Ekroos, M., and Sjogren, T. (2006). Structural basis for ligand promiscuity in
cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 103, 13682–13687. doi:
10.1073/pnas.0603236103
Fernando, H., Davydov, D. R., Chin, C. C., and Halpert, J. R. (2007). Role of subunit
interactions in P450 oligomers in the loss of homotropic cooperativity in the
cytochrome P450 3A4 mutant L211F/D214E/F304W. Arch. Biochem. Biophys.
460, 129–140. doi: 10.1016/j.abb.2006.12.025
Fernando, H., Halpert, J. R., and Davydov, D. R. (2008). Kinetics of electron transfer
in the complex of cytochrome P450 3A4 with the flavin domain of cytochrome
P450BM-3 as evidence of functional heterogeneity of the heme protein. Arch.
Biochem. Biophys. 471, 20–31. doi: 10.1016/j.abb.2007.11.020
French, J. S., Guengerich, F. P., and Coon, M. J. (1980). Interactions of cytochrome
P-450, NADPH-cytochrome P-450 reductase, phospholipid, and substrate in
the reconstituted liver microsomal enzyme system. J. Biol. Chem. 255, 4112–
4119.
Greinert, R., Finch, S. A., and Stier, A. (1982). Cytochrome P-450 rotamers control
mixed-function oxygenation in reconstituted membranes. Rotational diffusion
studied by delayed fluorescence depolarization. Xenobiotica 12, 717–726. doi:
10.3109/00498258209038946
Grinkova, Y. V., Denisov, I. G., and Sligar, S. G. (2010). Functional reconstitution
of monomeric CYP3A4 with multiple cytochrome P450 reductase molecules in
Nanodiscs. Biochem. Biophys. Res. Commun. 398, 194–198. doi: 10.1016/j.bbrc.
2010.06.058
Guengerich, F. P. (2001). Common and uncommon cytochrome P450 reactions
related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611–650.
doi: 10.1021/tx0002583
Guengerich, F. P. (2003). Cytochromes P450, drugs, and diseases. Mol. Interv. 3,
194–204. doi: 10.1124/mi.3.4.194
Guengerich, F. P. (2006). A malleable catalyst dominates the metabolism of drugs.
Proc. Natl. Acad. Sci. U.S.A. 103, 13565–13566. doi: 10.1073/pnas.0606333103
Guengerich, F. P., and Holladay, L. A. (1979). Hydrodynamic characterization
of highly purified and functionally active liver microsomal cytochrome P-450.
Biochemistry 18, 5442–5449. doi: 10.1021/bi00591a029
Gut, J., Richter, C., Cherry, R. J., Winterhalter, K. H., and Kawato, S. (1982).
Rotation of cytochrome P-450. II. Specific interactions of cytochrome P-450
with NADPH-cytochrome P-450 reductase in phospholipid vesicles. J. Biol.
Chem. 257, 7030–7036.
Gut, J., Richter, C., Cherry, R. J., Winterhalter, K. H., and Kawato, S. (1983).
Rotation of cytochrome P-450. Complex formation of cytochrome P-450
with NADPH-cytochrome P-450 reductase in liposomes demonstrated by
combining protein rotation with antibody-induced cross-linking. J. Biol. Chem.
258, 8588–8594.
Hazai, E., Bikadi, Z., Simonyi, M., and Kupfer, D. (2005). Association of
cytochrome P450 enzymes is a determining factor in their catalytic activity.
J. Comput. Aided Mol. Des. 19, 271–285. doi: 10.1007/s10822-005-4995-4
Hazai, E., and Kupfer, D. (2005). Interactions between CYP2C9 and CYP2C19 in
reconstituted binary systems influence their catalytic activity: possible rationale
for the inability of CYP2C19 to catalyze methoxychlor demethylation in human
liver microsomes. Drug Metab. Dispos. 33, 157–164. doi: 10.1124/dmd.104.
001578
Houston, J. B., and Galetin, A. (2005). Modelling atypical CYP3A4 kinetics:
principles and pragmatism. Arch. Biochem. Biophys. 433, 351–360. doi: 10.1016/
j.abb.2004.09.010
Hu, G., Johnson, E. F., and Kemper, B. (2010). CYP2C8 exists as a dimer in natural
membranes. Drug Metab. Dispos. 38, 1976–1983. doi: 10.1124/dmd.110.034942
Ibeanu, G. C., Ghanayem, B. I., Linko, P., Li, L., Pederson, L. G., and Goldstein,
J. A. (1996). Identification of residues 99, 220, and 221 of human cytochrome
P450 2C19 as key determinants of omeprazole activity. J. Biol. Chem. 271,
12496–12501. doi: 10.1074/jbc.271.21.12496
Iwase, T., Sakaki, T., Yabusaki, Y., Ohkawa, H., Ohta, Y., and Kawato, S. (1991).
Rotation and interactions of genetically expressed cytochrome P-450IA1 and
NADPH-cytochrome P-450 reductase in yeast microsomes. Biochemistry 30,
8347–8351. doi: 10.1021/bi00098a010
Jamakhandi, A. P., Kuzmic, P., Sanders, D. E., and Miller, G. P. (2007). Global
analysis of protein-protein interactions reveals multiple CYP2E1-reductase
complexes. Biochemistry 46, 10192–10201. doi: 10.1021/bi7003476
Johnson, E. F., and Stout, C. D. (2013). Structural diversity of eukaryotic membrane
cytochrome p450s. J. Biol. Chem. 288, 17082–17090. doi: 10.1074/jbc.R113.
452805
Kandel, S. E., and Lampe, J. N. (2014). Role of protein-protein interactions in
cytochrome P450-mediated drug metabolism and toxicity. Chem. Res. Toxicol.
27, 1474–1486. doi: 10.1021/tx500203s
Kawato, S., Gut, J., Cherry, R. J., Winterhalter, K. H., and Richter, C. (1982).
Rotation of cytochrome P-450. I. Investigations of protein-protein interactions
of cytochrome P-450 in phospholipid vesicles and liver microsomes. J. Biol.
Chem. 257, 7023–7029.
Kelley, R. W., Cheng, D., and Backes, W. L. (2006). Heteromeric complex
formation between CYP2E1 and CYP1A2: evidence for the involvement
of electrostatic interactions. Biochemistry 45, 15807–15816. doi: 10.1021/
bi061803n
Kelley, R. W., Reed, J. R., and Backes, W. L. (2005). Effects of ionic strength on
the functional interactions between CYP2B4 and CYP1A2. Biochemistry 44,
2632–2641. doi: 10.1021/bi0477900
Kenaan, C., Shea, E. V., Lin, H. L., Zhang, H., Pratt-Hyatt, M. J., and Hollenberg,
P. F. (2013). Interactions between CYP2E1 and CYP2B4: effects on affinity for
NADPH-cytochrome P450 reductase and substrate metabolism. Drug Metab.
Dispos. 41, 101–110. doi: 10.1124/dmd.112.046094
Kinch, M. S., Haynesworth, A., Kinch, S. L., and Hoyer, D. (2014). An overview
of FDA-approved new molecular entities: 1827-2013. Drug Discov. Today 19,
1033–1039. doi: 10.1016/j.drudis.2014.03.018
Koley, A. P., Buters, J. T., Robinson, R. C., Markowitz, A., and Friedman,
F. K. (1995). CO binding kinetics of human cytochrome P450 3A4. Specific
interaction of substrates with kinetically distinguishable conformers. J. Biol.
Chem. 270, 5014–5018. doi: 10.1074/jbc.270.10.5014
Koley, A. P., Dai, R. K., Robinson, R. C., Markowitz, A., and Friedman, F. K.
(1997). Differential interaction of erythromycin with cytochromes P450 3A1/2
in the endoplasmic reticulum: a CO flash photolysis study. Biochemistry 36,
3237–3241. doi: 10.1021/bi962110h
Koley, A. P., Robinson, R. C., and Friedman, F. K. (1996). Cytochrome P450
conformation and substrate interactions as probed by CO binding kinetics.
Biochimie 78, 706–713. doi: 10.1016/S0300-9084(97)82528-X
Koley, A. P., Robinson, R. C., Markowitz, A., and Friedman, F. K. (1994). Kinetics
of CO binding to cytochromes P450 in the endoplasmic reticulum. Biochemistry
33, 2484–2489. doi: 10.1021/bi00175a017
Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie,
A. E., et al. (1998). Evaluation of atypical cytochrome P450 kinetics with two-
substrate models: evidence that multiple substrates can simultaneously bind
to cytochrome P450 active sites. Biochemistry 37, 4137–4147. doi: 10.1021/
bi9715627
Lynch, T., and Price, A. (2007). The effect of cytochrome P450 metabolism on drug
response, interactions, and adverse effects. Am. Fam. Physician 76, 391–396.
McDougle, D. R., Baylon, J. L., Meling, D. D., Kambalyal, A., Grinkova, Y. V.,
Hammernik, J., et al. (2015). Incorporation of charged residues in the CYP2J2
Frontiers in Pharmacology | www.frontiersin.org January 2017 | Volume 8 | Article 28 | 122
fphar-08-00028 January 25, 2017 Time: 15:36 # 19
Reed and Backes Predicting P450–P450 Complex Formation
F-G loop disrupts CYP2J2-lipid bilayer interactions. Biochim. Biophys. Acta
1848, 2460–2470. doi: 10.1016/j.bbamem.2015.07.015
McIntosh, P. R., and Freedman, R. B. (1980). Characteristics of a copper-dependent
cross-linking reaction between two forms of cytochrome P-450 in rabbit-liver
microsomal membranes. Biochem. J. 187, 227–237. doi: 10.1042/bj1870227
McIntosh, P. R., Kawato, S., Freedman, R. B., and Cherry, R. J. (1980). Evidence
from cross-linking and rotational diffusion studies that cytochrome P450 can
from molecular aggregates in rabbit-liver microsomal membranes. FEBS Lett.
122, 54–58. doi: 10.1016/0014-5793(80)80400-5
Miwa, G. T., West, S. B., Huang, M. T., and Lu, A. Y. H. (1979). Studies on the
association of cytochrome P-450 and NADPH- cytochrome c reductase during
catalysis in a reconstituted hydroxylating system. J. Biol. Chem. 254, 5695–5700.
Myasoedova, K. N., and Berndt, P. (1990). Cytochrome P-450LM2 oligomers in
proteoliposomes. FEBS Lett. 275, 235–238. doi: 10.1016/0014-5793(90)81479-8
Myasoedova, K. N., and Tsuprun, V. L. (1993). Cytochrome P-450: hexameric
structure of the purified LM4 form. FEBS Lett. 325, 251–254. doi: 10.1016/0014-
5793(93)81083-C
Nelson, D. R. (2006). Cytochrome P450 nomenclature. Methods Mol. Biol. 320,
1–10.
Ozalp, C., Szczesna-Skorupa, E., and Kemper, B. (2005). Bimolecular fluorescence
complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-
cytochrome p450 reductase molecular interactions in living cells. Drug Metab.
Dispos. 33, 1382–1390. doi: 10.1124/dmd.105.005538
Ozalp, C., Szczesna-Skorupa, E., and Kemper, B. (2006). Identification of
membrane-contacting loops of the catalytic domain of cytochrome P450 2C2
by tryptophan fluorescence scanning. Biochemistry 45, 4629–4637. doi: 10.1021/
bi051372t
Pernecky, S. J., and Coon, M. J. (1996). N-terminal modifications that alter P450
membrane targeting and function. Methods Enzymol. 272, 25–34. doi: 10.1016/
S0076-6879(96)72005-0
Pernecky, S. J., Larson, J. R., Philpot, R. M., and Coon, M. J. (1993). Expression
of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in
Escherichia coli: influence of NH2-terminal region on localization in cytosol and
membranes. Proc. Natl. Acad. Sci. U.S.A. 90, 2651–2655. doi: 10.1073/pnas.90.
7.2651
Petrek, M., Kosinova, P., Koca, J., and Otyepka, M. (2007). MOLE: a Voronoi
diagram-based explorer of molecular channels, pores, and tunnels. Structure 15,
1357–1363. doi: 10.1016/j.str.2007.10.007
Petrek, M., Otyepka, M., Banas, P., Kosinova, P., Koca, J., and Damborsky, J. (2006).
CAVER: a new tool to explore routes from protein clefts, pockets and cavities.
BMC Bioinformatics 7:316. doi: 10.1186/1471-2105-7-316
Pochapsky, T. C., Kazanis, S., and Dang, M. (2010). Conformational plasticity and
structure/function relationships in cytochromes P450. Antioxid. Redox. Signal.
13, 1273–1296. doi: 10.1089/ars.2010.3109
Ravichandran, K. G., Boddupalli, S. S., Hasermann, C. A., Peterson, J. A., and
Deisenhofer, J. (1993). Crystal structure of hemoprotein domain of P450BM-3,
a prototype for microsomal P450’s. Science 261, 731–736. doi: 10.1126/science.
8342039
Reed, J. R., and Backes, W. L. (2012). Formation of P450.P450 complexes and
their effect on P450 function. Pharmacol. Ther. 133, 299–310. doi: 10.1016/j.
pharmthera.2011.11.009
Reed, J. R., and Backes, W. L. (2016). The functional effects of physical interactions
involving cytochromes P450: putative mechanisms of action and the extent
of these effects in biological membranes. Drug Metab. Rev. 48, 453–469. doi:
10.1080/03602532.2016.1221961
Reed, J. R., Connick, J. P., Cheng, D., Cawley, G. F., and Backes, W. L. (2012).
Effect of Homomeric P450·P450 Complexes on P450 Function. Biochem. J. 446,
489–497. doi: 10.1042/BJ20120636
Reed, J. R., Eyer, M., and Backes, W. L. (2010). Functional interactions between
cytochromes P450 1A2 and 2B4 require both enzymes to reside in the same
phospholipid vesicle: evidence for physical complex formation. J. Biol. Chem.
285, 8942–8952. doi: 10.1074/jbc.M109.076885
Rietjens, I. M., Ancher, L. J., and Veeger, C. (1989). On the role of phospholipids in
the reconstituted cytochrome P-450 system. A model study using dilauroyl and
distearoyl glycerophosphocholine. Eur. J. Biochem. 181, 309–316. doi: 10.1111/
j.1432-1033.1989.tb14725.x
Roberts, A. G., Cheesman, M. J., Primak, A., Bowman, M. K., Atkins, W. M., and
Rettie, A. E. (2010). Intramolecular heme ligation of the cytochrome P450 2C9
R108H mutant demonstrates pronounced conformational flexibility of the B-C
loop region: implications for substrate binding. Biochemistry 49, 8700–8708.
doi: 10.1021/bi100911q
Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D.,
et al. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons
exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348–14355.
doi: 10.1074/jbc.M611692200
Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, D., and Johnson,
E. F. (2004). Structure of human microsomal cytochrome P450 2C8: evidence
for a peripheral fatty acid binding site. J. Biol. Chem. 279, 9497–9503. doi:
10.1074/jbc.M312516200
Schwarz, D., Pirrwitz, J., and Ruckpaul, K. (1982). Rotational diffusion of
cytochrome P-450 in the microsomal membrane-evidence for a clusterlike
organization from saturation transfer electron paramagnetic resonance
spectroscopy. Arch. Biochem. Biophys. 216, 322–328. doi: 10.1016/0003-
9861(82)90217-X
Scott, E. E., He, Y. A., Wester, M. R., White, M. A., Chin, C. C., Halpert, J. R., et al.
(2003). An open conformation of mammalian cytochrome P450 2B4 at 1.6-A
resolution. Proc. Natl. Acad. Sci. U.S.A. 100, 13196–13201. doi: 10.1073/pnas.
2133986100
Scott, E. E., Spatzenegger, M., and Halpert, J. R. (2001). A truncation of 2B
subfamily cytochromes P450 yields increased expression levels, increased
solubility, and decreased aggregation while retaining function. Arch. Biochem.
Biophys. 395, 57–68. doi: 10.1006/abbi.2001.2574
Scott, E. E., White, M. A., He, Y. A., Johnson, E. F., Stout, C. D., and Halpert,
J. R. (2004). Structure of mammalian cytochrome P450 2B4 complexed with
4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450
conformations and the coordination of redox partner binding. J. Biol. Chem.
279, 27294–27301. doi: 10.1074/jbc.M403349200
Sevrioukova, I. F., Li, H., Zhang, H., Peterson, J. A., and Poulos, T. L. (1999).
Structure of a cytochrome P450-redox partner electron-transfer complex. Proc.
Natl. Acad. Sci. U.S.A. 96, 1863–1868. doi: 10.1073/pnas.96.5.1863
Shou, M., Dai, R., Cui, D., Korzekwa, K. R., Baillie, T. A., and Rushmore, T. H.
(2001). A kinetic model for the metabolic interaction of two substrates at
the active site of cytochrome P450 3A4. J. Biol. Chem. 276, 2256–2262. doi:
10.1074/jbc.M008799200
Sineva, E. V., Rumfeldt, J. A., Halpert, J. R., and Davydov, D. R. (2013). A large-
scale allosteric transition in cytochrome P450 3A4 revealed by luminescence
resonance energy transfer (LRET). PLoS ONE 8:e83898. doi: 10.1371/journal.
pone.0083898
Subramanian, M., Low, M., Locuson, C. W., and Tracy, T. S. (2009). CYP2D6-
CYP2C9 protein-protein interactions and isoform-selective effects on substrate
binding and catalysis. Drug Metab. Dispos. 37, 1682–1689. doi: 10.1124/dmd.
109.026500
Subramanian, M., Zhang, H., and Tracy, T. S. (2010). CYP2C9-CYP3A4 protein-
protein interactions in a reconstituted expressed enzyme system. Drug Metab.
Dispos. 38, 1003–1009. doi: 10.1124/dmd.109.030155
Szczesna-Skorupa, E., Mallah, B., and Kemper, B. (2003). Fluorescence resonance
energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular
interactions in living cells. J. Biol. Chem. 278, 31269–31276. doi: 10.1074/jbc.
M301489200
Tamburini, P. P., MacFarquhar, S., and Schenkman, J. B. (1986). Evidence of binary
complex formations between cytochrome P-450, cytochrome b5, and NADPH-
cytochrome P-450 reductase of hepatic microsomes. Biochem. Biophys. Res.
Commun. 134, 519–526. doi: 10.1016/S0006-291X(86)80451-X
Tsalkova, T. N., Davydova, N. Y., Halpert, J. R., and Davydov, D. R. (2007).
Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4
explored with an engineered enzyme bearing a fluorescent probe. Biochemistry
46, 106–119. doi: 10.1021/bi061944p
Tsuprun, V. L., Myasoedova, K. N., Berndt, P., Sograf, O. N., Orlova, E. V.,
Chernyak, V. Y., et al. (1986). Quaternary structure of the liver microsomal
cytochrome P-450. FEBS Lett. 205, 35–40. doi: 10.1016/0014-5793(86)80861-4
Watanabe, J., Asaka, Y., Fujimoto, S., and Kanamura, S. (1993). Densities of
NADPH-ferrihemoprotein reductase and cytochrome P-450 molecules in the
endoplasmic reticulum membrane of rat hepatocytes. J. Histochem. Cytochem.
41, 43–49. doi: 10.1177/41.1.8417111
White, R. E., and Coon, M. J. (1980). Oxygen activation by cytochrome P-450.
Annu. Rev. Biochem. 49, 315–356. doi: 10.1146/annurev.bi.49.070180.001531
Frontiers in Pharmacology | www.frontiersin.org January 2017 | Volume 8 | Article 28 | 123
fphar-08-00028 January 25, 2017 Time: 15:36 # 20
Reed and Backes Predicting P450–P450 Complex Formation
Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., and McRee, D. E.
(2000a). Mammalian microsomal cytochrome P450 monooxygenase: structural
adaptations for membrane binding and functional diversity. Mol. Cell. 5,
121–131. doi: 10.1016/S1097-2765(00)80408-6
Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., and McRee, D. E. (2000b).
Microsomal cytochrome P450 2C5: comparison to microbial P450s and
unique features. J. Inorg. Biochem. 81, 183–190. doi: 10.1016/S0162-0134(00)
00102-1
Williams, P. A., Cosme, J., Vinkovic, D. M., Ward, A., Angove, H. C., Day,
P. J., et al. (2004). Crystal structures of human cytochrome P450 3A4 bound
to metyrapone and progesterone. Science 305, 683–686. doi: 10.1126/science.
1099736
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson,
E. F. (2004). The structure of human microsomal cytochrome P450 3A4
determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem. 279,
38091–38094. doi: 10.1074/jbc.C400293200
Zangar, R. C., Davydov, D. R., and Verma, S. (2004). Mechanisms that
regulate production of reactive oxygen species by cytochrome P450.
Toxicol. Appl. Pharmacol. 199, 316–331. doi: 10.1016/j.taap.2004.
01.018
Zanger, U. M., and Schwab, M. (2013). Cytochrome P450 enzymes in drug
metabolism: regulation of gene expression, enzyme activities, and impact of
genetic variation. Pharmacol. Ther. 138, 103–141. doi: 10.1016/j.pharmthera.
2012.12.007
Zhukov, A., and Ingelman-Sundberg, M. (1999). Relationship between cytochrome
P450 catalytic cycling and stability: fast degradation of ethanol-inducible
cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation
of its electron donor NADPH-cytochrome P450 reductase. Biochem. J. 340
(Pt 2), 453–458. doi: 10.1042/0264-6021:3400453
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Reed and Backes. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org January 2017 | Volume 8 | Article 28 | 124
fphar-08-00755 October 26, 2017 Time: 17:19 # 1
ORIGINAL RESEARCH




Dr. Margarete Fischer-Bosch Institut
















†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Pharmacogenetics
and Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology
Received: 11 May 2017
Accepted: 04 October 2017
Published: 30 October 2017
Citation:
Campelo D, Lautier T, Urban P,
Esteves F, Bozonnet S, Truan G and




Switching: The Critical Role of Ionic
Strength. Front. Pharmacol. 8:755.
doi: 10.3389/fphar.2017.00755
The Hinge Segment of Human
NADPH-Cytochrome P450
Reductase in Conformational
Switching: The Critical Role of Ionic
Strength
Diana Campelo1†, Thomas Lautier2†, Philippe Urban2, Francisco Esteves1,
Sophie Bozonnet2, Gilles Truan2* and Michel Kranendonk1*
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NADPH-cytochrome P450 reductase (CPR) is a redox partner of microsomal
cytochromes P450 and is a prototype of the diflavin reductase family. CPR contains 3
distinct functional domains: a FMN-binding domain (acceptor reduction), a linker (hinge),
and a connecting/FAD domain (NADPH oxidation). It has been demonstrated that the
mechanism of CPR exhibits an important step in which it switches from a compact,
closed conformation (locked state) to an ensemble of open conformations (unlocked
state), the latter enabling electron transfer to redox partners. The conformational
equilibrium between the locked and unlocked states has been shown to be highly
dependent on ionic strength, reinforcing the hypothesis of the presence of critical salt
interactions at the interface between the FMN and connecting FAD domains. Here
we show that specific residues of the hinge segment are important in the control of
the conformational equilibrium of CPR. We constructed six single mutants and two
double mutants of the human CPR, targeting residues G240, S243, I245 and R246
of the hinge segment, with the aim of modifying the flexibility or the potential ionic
interactions of the hinge segment. We measured the reduction of cytochrome c at
various salt concentrations of these 8 mutants, either in the soluble or membrane-
bound form of human CPR. All mutants were found capable of reducing cytochrome
c yet with different efficiency and their maximal rates of cytochrome c reduction were
shifted to lower salt concentration. In particular, residue R246 seems to play a key role
in a salt bridge network present at the interface of the hinge and the connecting domain.
Interestingly, the effects of mutations, although similar, demonstrated specific differences
when present in the soluble or membrane-bound context. Our results demonstrate that
the electrostatic and flexibility properties of the hinge segment are critical for electron
transfer from CPR to its redox partners.
Keywords: diflavin reductase, protein dynamics, multidomain proteins, conformational exchange, electron
transfer, protein–protein interaction
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INTRODUCTION
Monooxygenase enzymes occur in all kingdoms of life and
cytochromes P450 (P450s) represent the largest superfamily
of them (Lamb and Waterman, 2013; Munro et al., 2013).
In mammals, microsomal P450s catalyze the oxidation of a
wide variety of essential endogenous and xenobiotic compounds
(Coon, 2005; Rendic and Guengerich, 2015) by a two-electron
activation of molecular oxygen, whereby one atom of oxygen
is inserted into the organic substrate and the other is reduced
to water (Guengerich, 2007). The catalytic cycle of P450
enzymes depends on redox partners for electron delivery. The
NADPH-cytochrome P450 reductase (CPR) is strictly required
for the activity of microsomal P450s, while cytochrome b5 can
potentially be a donor molecule, albeit only for the second
electron transfer step (Scott et al., 2016).
Human CPR, encoded by the POR gene, is a 78-kDa
multidomain diflavin reductase that binds both FMN and FAD
and is attached to the cytoplasmic side of the endoplasmic
reticulum via a transmembrane segment at its N-terminus.
The domains that bear the two cofactors are: a flavodoxin-
like FMN-binding domain and a ferredoxin-NADP+ reductase
like FAD-binding domain. The third domain, called the hinge
segment, links the FMN and the connecting/FAD domain.
Electrons flow through CPR from NADPH to oxidized FAD as
a hydride ion transfer to the FAD N5 atom, then, one by one,
from the FAD to the FMN, then from the FMN hydroquinone
to external acceptors, with the FMN cycling mainly between the
hydroquinone and the blue semiquinone states (Murataliev et al.,
1999).
Although studies of CPR have predominantly focused on
its role in P450 catalysis, CPR also support electron transfer
to other enzymes like heme oxygenase (Schacter et al., 1972),
squalene epoxidase (Ono and Bloch, 1975), dehydrocholesterol
reductase (Nishino and Ishibashi, 2000), and though not
uniquely, cytochrome b5, involved also in fatty acid desaturation
and elongation reactions (Oshino et al., 1971). The determinants
of this promiscuity in physiological acceptors are not yet known,
however, they might indicate that the mechanisms of recognition
of this heterogenic group of redox partners by CPR are probably
not highly stringent.
The first X-ray diffraction studies on soluble rat CPR showed
a surprising compact structure in which the distance of FAD to
FMN was about 4 Å, the two isoalloxazine rings almost coplanar
and some parts of the FMN domain tightly packed against the
rest of the CPR protein (Wang et al., 1997). This conformation,
referred thereafter as part of a locked state, was easily ascribed to
the conformation allowing electron transfer from FAD to FMN.
Several other X-ray structures of CPR displaying the same spatial
organization were subsequently obtained (Lamb et al., 2006; Xia
et al., 2011b; McCammon et al., 2016). This conformational
state as obtained in crystals, also occurs in solution (Vincent
et al., 2012). Furthermore, a CPR mutant in which the FMN
Abbreviations: CPR, NADPH cytochrome P450 reductase; DCPIP, 2,6-
dichlorophenolindophenol; FMN, flavin mononucleotide; FAD, flavin adenine
dinucleotide; kobs, observed rate constant; NOS, nitric oxide synthase; P450,
cytochrome P450; WT, wild-type.
domain was linked to the FAD domain via a disulfide bridge was
competent for electron transfer to the FMN moiety, ultimately
proving that the locked state is fit for the internal flavin electron
transfer but is unable to reduce external cytochrome acceptors
unless the disulfide bridge is reduced (Xia et al., 2011a). This led
to the hypothesis that interdomain motions have to take place to
render the FMN domain accessible to electron acceptors.
The crystal structure of a mutant CPR in which the
hinge segment was shortened by deletion of four residues
(1TGEE) shows three different molecules per asymmetric
unit. In each of them, the FMN domain is in a different
position, more and more distant from the rest of the protein,
whereas their connecting and FAD-binding domains are strictly
superimposable, demonstrating a marked reorientation of the
FMN domain relative to the FAD domain (Hamdane et al.,
2009). Another evidence for domain mobility has come from
the structural study of a chimeric enzyme consisting of the
FMN-binding domain of yeast CPR and the remainder of
the molecule, including the hinge segment, from human CPR
(Aigrain et al., 2009). This chimeric enzyme, which is active
in NADPH reduction of cytochromes c and P450, displays a
single, well-defined, molecule in the asymmetric unit. In this
structure, the FMN domain is no longer making any interface
with the connecting and FAD domains. Hence, large domain
movements can happen in CPR (∼86 Å distance between the two
flavins). Furthermore, the redox potential of the flavins exhibit
changes that maybe attributed to this large conformational
change (Aigrain et al., 2011). The various conformations in
which the FMN domain is no longer making an interface with
the FAD domain represent an ensemble of structures that can
be designated as the unlocked state. SAXS studies on human
CPR have also been crucial in demonstrating that, in solution,
human CPR is in equilibrium between a closed, compact and a
series of open, extended conformations (Ellis et al., 2009; Huang
et al., 2013; Frances et al., 2015). The abovementioned mutant
CPR containing a disulfide bond, though capable of NADPH-
mediated ferricyanide reduction, is essentially incapable of
supporting P450 activity unless the disulfide bond is reduced (Xia
et al., 2011a). The ability of both flavin domains to move relatively
back and forth from each other is thus a prerequisite for the FMN
domain to interact with its physiological acceptors. However, the
structural determinants that guide this conformational transition
between open and closed forms, a process demonstrated to be
essential for gating the interflavin electron transfer in CPR and
thus to its redox partners, are still not fully identified.
It has long been known that electron transfer from CPR to
cytochromes P450 displays a strong ionic strength dependency
which demonstrated that the electron transfer complex between
the CPR and a P450 is, beside hydrophobic interactions, strongly
based on charge pair interactions (Tamburini and Schenkman,
1986; Nadler and Strobel, 1988, 1991; Davydov et al., 1996,
2000; Bridges et al., 1998). Most of these studies evidenced that
ionic interactions between CPR and its redox partners were
the major determinants of the salt effects on P450s activities
and are reviewed in (Hlavica et al., 2003). However, we also
demonstrated that the ionic strength effect on cytochrome c
reduction by the soluble form of human CPR depends on the
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conformational equilibrium between the locked and unlocked
states (Frances et al., 2015). From the comparative studies of
the open conformation seen in the chimeric yeast-human CPR,
two residues in the hinge, G240 and S243, were proposed to be
important molecular determinants for the large conformational
changes (Aigrain et al., 2009). Beside these two residues, I245
and R246 were also recently identified, in a molecular dynamics
simulation study, as two essential residues of the hinge segment,
forming a part of the conformational axis and involved in a
rotational movement of the FMN domain relative to the rest
of the protein (Sündermann and Oostenbrink, 2013). S243 and
R246 were also found to display large chemical shifts during the
change in the conformational equilibrium between the locked
and unlocked states (Frances et al., 2015). Additionally, the
hinge segment was also found to be directly controlling electron
transfer to cytochrome c from the reductase domain of nNOS
(Haque et al., 2007, 2012) as well as in CPR (Grunau et al., 2007).
In this work we have targeted four specific residues of the
hinge segment indicated above, for site-directed mutagenesis to
test their potential role in the conformational equilibrium of
human CPR. By analyzing the salt-dependent changes of the
cytochrome c reductase activity in the context of both soluble and
membrane-bound forms of CPR, we propose several hypotheses
on the role played by these residues on the transition between




Dichlorophenolindophenol (DCPIP) and potassium ferricyanide
were from Fluka (Buchs, Switzerland). L-Arginine, ampicillin,
kanamycin sulfate, chloramphenicol, cytochrome c (horse heart),
isopropyl β-D-1-thiogalactopyranoside (dioxane-free), thiamine,
glucose 6-phosphate, glucose 6-phosphate dehydrogenase,
NADP+ and NADPH were obtained from Sigma–Aldrich
(St. Louis, MO, United States). Phenylmethanesulfonyl fluoride
was purchased from Gerbu Biotechnik GmbH (Heidelberg,
Germany). Bacto agar, Bacto peptone and Bacto tryptone were
obtained from BD Biosciences (San Jose, CA, United States).
Bacto yeast extract was obtained from Formedium (Norwich,
England). A polyclonal antibody from rabbit serum raised
against recombinant human CPR obtained from Genetex
(Irvine, CA, United States) was used for immunodetection of the
membrane-bound CPR, while the respective antibody used the
in the case of the soluble form of the enzyme was obtained from
Thermofisher Scientific (Waltham, MA, United States).
Construction and Cloning of the Different
Mutants
Soluble Forms of Human CPR
Soluble CPR mutants, deleted of their first 44 N-terminal
amino acids, were cloned by the Gibson method using a
synthetic DNA fragment containing the desired mutation, with a
compatible divergent PCR amplification of the plasmid pET15b
expressing the soluble form of the human CPR, containing a
N-terminal 6xHis tag. DNA sequencing confirmed the absence
of any undesired mutations. The constructed plasmids were
transformed into competent Escherichia coli BL21 (DE3) cells for
expression.
Membrane-Bound Forms of Human CPR
Plasmid pLCM_POR (Kranendonk et al., 2008) was used
for the expression of the membrane-bound, full-length forms
of human CPR. Mutants containing alanine substitutions
of residues I245 and R246 were initially obtained through
standard site-directed mutagenesis, using the sub-cloning vector
pUC_POR, containing the initial segment (1–1269 bp) of human
POR cDNA comprising the FMN and hinge domains (based
on National Center for Biotechnology Information sequence
NM_000941, encoding the CPR consensus protein sequence
(NP_000932)). The mutated segments were obtained from the
different mutated pUC_POR plasmids, using EcoRI + AatII
restriction enzymes and cloned back into full-length CPR
expression vector pLCM_POR. CPR mutants containing proline
substitutions of residues G240, S243, I245 and R246 were
obtained by the Gibson method using a synthetic DNA fragment
containing the desired mutation and a compatible divergent PCR
amplification of the plasmid pET15b expressing the soluble form
of human CPR. The mutated gene fragments were sub-cloned
in vector pUC_POR using Megaprimer PCR of whole plasmid
(MegaWhop) (Miyazaki and Takenouchi, 2002), followed by
DpnI treatment. The mutated segments were obtained using
Eco81I + SacI restriction enzymes and cloned back into the
CPR expression vector pLCM_POR. The different constructed
pLCM_POR plasmids were transformed into DH5α E. coli
cells for plasmid propagation. POR cDNA of plasmids was
fully sequenced to confirm the introductions of the designed
mutations and the absence of any undesired mutations. CPR
mutants were expressed in E. coli BTC, using the specialized
bi-plasmid system for co-expression of CPR with human CYPs
(Duarte et al., 2005). The pLCM_POR and the CYP-void plasmid
pCW1 (Kranendonk et al., 2008) were transfected through
standard electroporation procedures.
Protein Expression and Isolation
Soluble Forms of CPR
Protein expression in BL21 (DE3) cells was carried out at 29◦C in
Terrific Broth medium complemented with 1 mg.l−1 riboflavin
and 100 µg.ml−1 ampicillin during 36 h (Frances et al., 2015).
Cultures were spun down for 10 min at 7,200 g and suspended
in 20 mM Na/K phosphate buffer pH 7.4 (buffer A). Cell lysis
was achieved by 4 cycles of sonication (30 s of burst followed by
intervals of 2 min for cooling) in buffer A containing a protease
inhibitor cocktail (aprotinin 0.3 µM, leupeptin 1 µM, pepstatin
A 1.5 µM, benzamidine 100 µM, metabisulfite 100 µM).
Cell debris were removed by centrifugation at 8,200 g for
1 h at 4◦C. His-tagged proteins were bound on a TALON
polyhistidine-TAG Purification Resin (Clontech, Mountain View,
CA, United States), equilibrated with buffer A, containing 0.25
M NaCl and 0.25 M KCl, washed with this equilibrium buffer
and eluted with a 0.25 M imidazole step gradient. Imidazole
was eliminated from the eluted fraction by sequential washes in
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buffer A using a Vivaspin-15 centrifugal concentrator (Sartorius,
Goettingen, Germany). The protein solution was stored at 4◦C in
buffer A, containing 1 µM of both FMN and FAD. Purity of the
sample was determined by SDS–PAGE and examination of the
280/450 nm ratio measured by optical spectroscopy.
Membrane-Bound Forms of CPR
Expression of the full-length membrane bound CPR mutants
was obtained in BTC bacteria and membrane fractions of the
different strains were prepared and characterized for protein
content as described previously (Marohnic et al., 2010; Palma
et al., 2013). CPR content of membrane fractions was quantified
by immunodetection against a standard curve of purified human,
full-length WT CPR, using polyclonal rabbit anti-CPR primary
antibody and biotin-goat anti-rabbit antibody in combination
with the fluorescent streptavidin conjugate (WesternDot 625
Western Blot Kit; Invitrogen). Densitometry of CPR signals
was performed using LabWorks 4.6 software (UVP, Cambridge,
United Kingdom).
DCPIP and Ferricyanide Reduction
Assay and Cytochrome c Reduction
Microplate Assay
DCPIP and Ferricyanide Reduction
With DCPIP, assays were performed in 20 mM Tris-HCl buffer
containing 1 mM EDTA, and various NaCl concentrations
(from 50 mM up to 1.4 M), pH 7.4 at 25◦C in the presence
of 70 µM DCPIP. Initial rates were monitored at 600 nm
using 1εM = 21,000 M−1.cm−1. With ferricyanide, assays were
performed in the same conditions as described above, but in the
presence of 1 mM ferricyanide. Initial rates were monitored at
420 nm using 1εM = 1,020 M−1cm−1.
Cytochrome c Reduction Activities
Initial experiments were performed with soluble CPR.
Cytochrome c reductase activity was followed at 550 nm
(1εM = 21,000 M−1.cm−1) with CPR concentrations ranging
from 2 to 20 nM. In cuvette assays, cytochrome c (100 µM final)
and NADPH (200 µM final) were mixed in 20 mM Tris-HCl
buffer containing 1 mM EDTA, and various NaCl concentrations
(from 50 mM up to 1.4 M), pH 7.4 at 25◦C. The reaction was
initiated by adding CPR. A set of preliminary rate assays were
performed in a microtiter plate format to optimize linearity of
the reaction traces for the mutants, with conditions close to the
traditional cuvette approach. In particular, the concentrations
of CPR, cytochrome c and NADPH were varied in several
control experiments to ensure linearity. In these assays, CPR and
NADPH (200 µM final) were mixed and the reaction was started
by diluting directly this mix in microplate wells containing
20 mM Tris-HCl buffer pH 7.4, supplemented with cytochrome
c (100 or 200 µM) and the ad hoc NaCl final concentration
(from 50 mM to 1.25 M) at 37◦C. The reaction was monitored
at 550 nm for 5 min in a PowerWave X select microplate reader
(Biotek Instruments, Winooski, VT, United States).
A first set of kinetic measurements was performed in triplicate
using the two cytochrome c concentrations indicated above.
A second set of triplicate experiments was repeated with
another batch of purified CPR. Reduction velocities were found
virtually equal when using cytochrome c at 100 or 200 µM
(data not shown). Cytochrome c was subsequently used in the
microplate format at 200 µM (final concentration) for all kinetic
measurements. CPR samples (soluble forms) were diluted up to
concentrations giving linear velocity traces to compensate for
lower or increased velocities, see Supplementary Table S1. Each
kobs value is the average of six measurements: one triplicate using
a first batch of enzyme and a second triplicate, using a second
batch of purified CPR.
The conditions of the microplate rate assay were then verified
for the membrane-bound CPRs, to ensure linearity of the reaction
traces. Reactions were followed for 4 min in a multi-mode
microtiter plate reader (SpectraMax R©i3x, Molecular Devices) and
each sample was assayed at least in triplicate. The optimal dilution
of the membrane bound WT CPR was determined (0.5 pmol/ml),
using 200 µM of cytochrome c, NADPH regenerating system
(NADPH 200 µM, glucose 6-phosphate 500 µM and glucose
6-phosphate dehydrogenase 0.04 U/mL, final concentrations)
and 372 mM NaCl in a 100 mM Tris buffer (pH 7.4). The
same CPR dilution was applied in the cuvette assay under
the same conditions except for cytochrome c (50 µM) and
NADPH (200 µM, without regeneration) and was measured
during 60 s, which resulted in virtually the same kobs as
with the microtiter plate format assay. Finally, the membrane
bound mutants were assayed with CPR well-concentrations,
proportionally diluted as those determined for the soluble forms
(see Supplementary Table S1). Control experiments with E. coli
(BTC) membranes without CPR expression demonstrated no
cytochrome c reduction upon dilution.
RESULTS
Ionic Strength Dependency of the
Electron Transfer of the Soluble Form of
Human CPR to Three Artificial Acceptors
In order to further understand the role of the ionic strength in
electron transfer from CPR to acceptors such as cytochrome c and
discriminate between the two major hypotheses (salt-dependent
conformational equilibrium or electrostatic interactions with
the substrates), we analyzed and compared the ionic strength
dependency of CPR toward DCPIP and ferricyanide with
that of cytochrome c. DCPIP and ferricyanide have unique
characteristics in term of charge and electron receiving
capabilities (redox potential). Figure 1 shows the activity profiles
of the soluble, WT form of human CPR in function of the ionic
strength for cytochrome c-, DCPIP- and ferricyanide-reduction.
Cytochrome c and DCPIP related graphs share the same bell-
shaped curve. For cytochrome c, the concentration of NaCl giving
the maximal kobs is around 400 mM, a value quite comparable
to the one measured in our previous study (Frances et al.,
2015). However, the maximum of kobs is different for DCPIP
(575 mM). This difference might be attributed to the fact that
DCPIP is an obligate two electrons (hydride) acceptor, which
may have a different overall electron transfer scheme compared
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FIGURE 1 | Variation of kobs in function of the ionic strength. The activity of
the soluble, WT form of human CPR was assayed with various acceptors,
namely cytochrome c (A), DCPIP (B) or ferricyanide (C).
to cytochrome c. The ionic strength dependent variation of
kobs measured for the reduction of DCPIP and cytochrome
c by soluble human CPR display both a bell-shaped profile.
However, these substrates are different in term of net charge
(cytochrome c contains + 9.5 charges at pH 7.0 while DCPIP is
neutral). This result thus strengthens the hypothesis that the ionic
strength dependency of electron flow from CPR to acceptors is
mainly determined by the conformational equilibrium between
the locked and unlocked states of CPR and only in a minor
manner by electrostatic interactions between the FMN domain
and the acceptor.
We also analyzed the reduction of ferricyanide, another non-
natural substrate. Interestingly, the salt-dependent kobs profile
is totally different from the ones seen with cytochrome c or
DCPIP, being composed of two straight lines crossing at a NaCl
concentration of around 450 mM. The constant rise of the kobs
might be attributed to a gradual increase of the redox potential of
ferricyanide due to the increase of ionic strength in Tris-based
buffers (O’Reilly, 1973). Therefore, the ferricyanide reduction,
which mainly occurs at the FAD cofactor (Vermilion et al.,
1981), may be relatively independent from the salt concentration
and hence from the conformational equilibrium, a result that
was previously observed with the 1TGEE mutant (Hamdane
et al., 2009). Interestingly, the inflection occurs around a salt
concentration quite similar to the one yielding the maximum
kobs with cytochrome c. However, we do not have any coherent
explanation for the peculiar salt profile observed with this
substrate.
Based on these latter results, we decided to use cytochrome
c reduction as an appropriate reporter to probe salt-mediated
conformational equilibrium changes in electron transfer of
specific CPR mutants.
Design of the Different Mutants
The hinge segment is defined by a stretch of 14–15 amino
acids that does not display any particularly defined secondary
structure. It is also the only part of the CPR structure where
evident structural changes can be seen when comparing the two
open conformations of CPR (crystallographic structures of the
1TGEE mutant and the yeast/human chimera) and the other
closed conformations of CPR (yeast, human, rat). Residues G240
and S243 (numbering according to the human CPR consensus
amino acid sequence NP_000932) correspond to positions with
strongly modified phi and psi angles between the closed and open
forms (Aigrain et al., 2009). These two residues were therefore
mutated into prolines in order to test if and how geometrical
constraints modify the conformational equilibrium of CPR.
Residues I245 and R246 were selected based on the observation
that the backbone atoms of both residues were rotated in the
1TGEE mutant or in the closed to open transition visualized
by molecular modeling (Hamdane et al., 2009; Sündermann and
Oostenbrink, 2013). For this last residue, we evidently switched
the cationic Arg residue into a non-charged one (either Ala or
Pro) while for the previous Ile residue, we preferred mutations
affecting either the mobility/rigidity (Ile to Ala or Pro). Two
double mutants, cumulating charge and flexibility changes were
also designed for residues 245/246. Finally, as the physiological
form of CPR is membrane-bound and the membrane anchoring
segment may have a profound influence on the equilibrium
between locked and unlocked states or the open-closed exchange
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FIGURE 2 | Positions of the studied mutations in CPR. The structure of the yeast-human open form CPR chimera (3FJO, in dark green) and the WT soluble human
closed form CPR (5FA6, chain A, in pink) were used to analyze the variations in the hinge segment between the closed and open form of CPR. Mutated residues are
displayed as sticks of either green or magenta colors according to the structures. (A) Both structures were aligned onto their FMN domains. (B) Both structures were
aligned onto their connecting/FAD domains. The figure was prepared using the PyMol software (Schrödinger, 2015).
rates, we analyzed the effects of these mutations in both the
soluble and membrane bound context.
Based on these rationales, six single mutants (G240P, S243P,
I245A, I245P, R246A and R246P) and two double mutants
(I245A/R246A and I245R/R246I) were produced both in the
soluble and membrane-bound (full-length) forms of CPR.
Figure 2 provides a representation of the positions of the four
targeted amino acids in the structure of the closed conformation
of human CPR (5FA6, chain A) and on the structure of the open
conformation of the yeast/human chimeric CPR (3FJO). The
two structures (5FA6, chain A and 3FJO) were aligned onto the
FAD domain (Figure 2A) or the FMN domain (Figure 2B). Both
views provide the rationale for the design of our mutants: G240
corresponds to the position where the hinge is tilted in the open
conformation compared to the closed conformation (Figure 2A);
S243 side chain orientation is different between the two forms
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(Figure 2A); I245 and R246 show an interesting proximity and
potential interaction with the connecting domain (Figures 2A,B).
Production of the Various Mutants of
Human CPR
Soluble Forms
Eight different plasmids encoding the soluble CPR mutants
G240P, S243P, I245A, I245P, R246A, R246P, I245A/R246A and
I245R/R246I were introduced into E. coli and the various proteins
expressed and purified as described in Section “Material and
Methods.” SDS−PAGE gel analysis shows that the different
mutant proteins present the same profile than the wild type,
with a major band just below 70 kDa which corresponds to the
soluble form of the CPR (69 kDa). Biological duplication of the
entire expression and purification stages was performed to ensure
repeatability. Some discrete bands, at lower molecular weights
compared to WT CPR were detected either with Coomassie
staining or by western blot analysis (see Supplementary
Figure S1), indicating some minor degradation of the purified
enzymes. However, these represent less than 5% of the full-
length soluble CPR and hence would have a minor impact on the
kinetic assays. All CPR mutants presented the same absorbance
spectra as the WT soluble enzyme, with a maximum of absorption
at 450 nm, indicating no or minor changes in the chemical
surrounding of both flavins. Last, all mutants were obtained in
the semiquinone form, like the WT CPR, indicating no major
changes in the absolute redox potential values of the flavins in
the mutant forms. These results emphasize that the introduced
mutations did not apparently modify the surroundings of the
flavins.
Membrane-Bound Forms
The eight different mutants were introduced in the E. coli BTC
strain, expressed and bacterial microsomes were isolated, as
described previously (Kranendonk et al., 2008). No expression
problems were encountered, except for mutant G240P for which
the level of expression was substantially lower than for the
other mutants. Immunodetection of CPR in isolated microsomes
showed only trace amounts of the G240P mutant protein,
not sufficient for subsequent analysis. Other CPR mutants
demonstrated expression levels comparable with the WT form
(see Supplementary Figure S1).
Mutations Affect Differently the Soluble
and Membrane-Bound Forms of CPR
Assay Conditions
Our study was designed to test the variation of cytochrome c
reduction in various salt concentration conditions for nine CPR
enzymes variants (WT + eight mutants) in the context of the
soluble or membrane bound forms. We therefore developed and
optimized a 96-well plate format assay to follow cytochrome c
reduction. These experiments were performed at 37◦C, contrarily
to the primary test realized at room temperature in cuvette
with the WT, soluble form of human CPR (Figure 1). Optimal
conditions of the microplate rate assay were determined to
ensure the linearity of the reaction traces. Initially, assays
FIGURE 3 | Variation of the kobs for cytochrome c reduction in function of the
ionic strength for the WT and mutants of the soluble forms of human CPR.
Cytochrome c reduction assays were performed in triplicate in 96 well
microtiter plates as described in the Material and Methods section. (A) Salt
dependent profile of the kobs with the WT and the mutants. Symbols depicting
the different mutants are included in the panel. (B) Maximal kobs values were
extracted from panel A and plotted as a function of the salt concentration.
Symbols depicting the different mutants are identical as the ones in (A). kobs
values represent the average of three replicates and the error bars depict the
standard deviation.
were performed at two cytochrome c concentrations (100 and
200 µM) in order to ensure that saturation was reached at
all salt concentrations, which virtually gave the same velocities
(data not shown). Subsequently cytochrome c was used at
200 µM. CPR concentrations in the tests were also optimized
to obtain linear traces for each mutant (both for the soluble
and membrane bound forms) in order to compensate for lower
or higher activities (see Supplementary Table S1). We verified
that salt profiles were equivalent between the tests performed in
the cuvette and in the 96-well plate format (data not shown).
Figure 3A displays the salt profile of the WT as well as mutants
in the context of their soluble form at 37◦C. Clearly the WT
profile is superimposable to the one in Figure 1, although minor
differences can be seen, notably for the concentration of salt that
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gives the maximal value of kobs (425 mM at 25◦C instead of
395 mM at 37◦C). This minor variation could be explained by
the temperature shift from 25◦C to 37◦C, probably favoring the
opening mechanism and therefore the unlocked state. Apart from
this difference, no other changes were noted and the comparison
of the salt profiles of the mutants either in their soluble or
membrane bound forms was pursued at 37◦C, with the 96 well
plate assay format.
The Hinge Partly Controls the Conformational
Equilibrium of the Soluble CPR Form
As mentioned earlier, the ionic strength dependency of
cytochrome c reduction by CPR can be partly considered as
a direct measure of the proportion of the locked vs. unlocked
states (Frances et al., 2015) and the bell shaped curve of
this ionic strength dependence has been also reported in the
electron transfer from the flavodoxin of Desulfovibrio vulgaris to
cytochrome b553 (Sadeghi et al., 2000). We therefore performed
a full analysis of the ionic strength dependency of cytochrome c
reduction for all single and double mutants (Figure 3). Figure 3A
depicts the 8 different ionic strength profiles obtained with the
various mutants compared with the WT one. All curves of the
kobs vs. ionic strength display the same typical bell shaped curve
seen with the WT CPR. With the exception of the S243P mutant,
all ionic strength profiles are shifted to the left (lower NaCl
concentrations). Moreover, nearly all of them (except S243P and
I245A) have lower maximal kobs values. This result indicates
that the various introduced mutations have pronounced effects
either on the conformational equilibrium or the electron transfer
efficiency, yet all of them are still active (lowest kobs is 30% of
the one observed with WT CPR). The redox potentials of both
flavins and cytochrome c are known to depend to some extent
on the ionic strength. While for cytochrome c these changes are
known and relatively small (Gopal et al., 1988), it is difficult to
predict the changes that would occur for the flavins. Based on
our observation that the microenvironment of flavins is probably
not significantly altered between mutants and WT CPR (equal
absorption spectra) we have based our working hypotheses on
the assumption that the redox potential of the flavins are not
functionally different between the mutants and the WT soluble
or membrane-bound forms of CPR.
From Figure 3A, maximal kobs values were extracted and
used to generate a graph comparing the salt concentration at
which the maximum kobs occur and the maximal kobs value
itself (Figure 3B). The case of S243P and I245A is interesting.
Both have approximately the same kobs (slightly higher than
the WT for S243P). However, I245A denotes a clear difference
in term of optimal ionic strength contrarily to S243P and
WT. Another example is the situation for I245A, G240P and
I245P, for which the optimal ionic strengths are identical yet
the three mutants have different maximal kobs values. Hence
these data seem to indicate a separation between the efficiency
of cytochrome c reduction and the conformational equilibrium
of CPR (represented by the salt concentration at which the
maximal kobs occurs). However, globally, when the profiles are
shifted to lower ionic strength the maximal kobs values are
lower.
The effects on the conformational equilibrium are interesting
and merit further analysis. With the exception of S243P, all
mutants either favored the unlocked state or destabilized the
locked state. The introduction of a proline residue (G240P,
I245P and R246P) probably imposes strong constraints on the
hinge and may therefore stabilize discrete conformations of
the unlocked state. The removal of the positive charge of the
arginine residue at position 246 (R246A) may loosen the potential
interactions between the hinge and the connecting domain and
also destabilize the locked state. It should also be noted that the
double mutants present the maximal displacements in term of salt
profile and that the charge suppression at position 246 cannot be
compensated by the introduction of an arginine at position 245
(see the double mutant I245R/R246I).
Lower maximal kobs values are probably associated to some
decrease in the rate constants of one or several electron transfer
steps. We already demonstrated that conformational exchange
occurs at a much faster rate than electron transfer (Frances et al.,
2015). Hence, during the course of steady state activity, CPR
opens and closes several times before electrons are transferred
from FAD to FMN. This also means that the locked state might
actually have several closed conformations, not all of them
productive for inter-flavin electron transfer, a feature that has
already been described (Hay et al., 2010). Therefore, the mutants
might disfavor the occurrence of productive conformations in
the locked state, hereby reducing the maximal kobs value. Hence,
although there would not be a direct relationship between
conformational equilibrium and maximal kobs, the effects of some
of the mutations on the destabilization of the locked state could
also change the rate limiting step.
The Hinge Controls the Conformational
Equilibrium of the Membrane Bound CPR
The same mutants, when present in the full-length, membrane-
anchored form, were subsequently studied. Figure 4 presents
the same analysis of both the variation of kobs and the
optimal ionic strength value for each of the mutants in the
context of the membrane bound form. Our first striking
result is that the ionic strength giving the maximum kobs
for the WT membrane bound form is shifted to higher salt
concentrations compared to the WT soluble form, indicating
a stronger interaction between the two domains (Figure 4A).
Various hypotheses can be formulated to account for this
fact. First, the presence of the negatively charged phospholipid
heads of the membrane probably modifies the electrostatic
potential around the FMN domain, potentially strengthening
the interactions between the two flavin domains and thus
favoring the equilibrium toward the locked state. Second, the
presence of the membrane close to the FMN domain might
impeach movements of the FAD domain compared to those
attainable with the soluble form. This restriction of movement
could favor the closing mechanism, hereby stabilizing the locked
state.
Despite the above peculiarity of membranous CPR, Figure 4A
shows that, as seen with the majority of the soluble forms,
all mutants have their salt profiles shifted to lower ionic
strengths when compared to the WT. This result confirms that
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FIGURE 4 | Variation of the kobs for cytochrome c reduction in function of the
ionic strength for the WT and mutants of the membrane bound forms of
human CPR. Cytochrome c reduction assays were performed in triplicate in
96 well microtiter plates as described in the Material and Methods section.
(A) Salt dependent profile of the kobs with the WT and the mutants. Symbols
depicting the different mutants are included in the panel. (B) Maximal kobs
values were extracted from panel A and plotted as a function of the salt
concentration. Symbols depicting the different mutants are identical as the
ones in (A). kobs values represent the average of three replicates and the error
bars depict the standard deviation.
the generated mutants have a greater tendency to favor the
unlocked state, independently of the presence or absence of
the membrane. Although differences exist between individual
mutants depending on the context (soluble or membrane bound
forms), again the maximal effects are seen with the R246
mutations and the double mutants containing mutations at the
positions 246 and 245.
Maximal kobs values were also extracted and plotted against
the corresponding salt concentration (Figure 4B). Overall, the
salt concentration at which kobs is maximal covers a larger range
with the membrane bound forms compared to the soluble forms.
This indicates that the influence of salt on the conformational
equilibrium is greater when CPR is attached to the membrane
than when the various domains have more degree of liberty, i.e.,
when in the soluble form.
Interestingly, Figure 4B shows marked differences in the
clustering of mutants compared to Figure 3B. This suggests again
that the salt concentration giving the highest possible kobs (1:1
proportion of locked/unlocked states) does not correlate with
the value of the kobs itself. This is particularly evident with the
membrane-bound forms of the S243 and I245 mutants.
Some parallels can be drawn between mutants in the
soluble and the membrane bound forms from comparison of
Figures 3B, 4B: (i) the group which had lower cytochrome c
reduction rates in the soluble form (R246A, R246P, I245R/R246I
and I245A/R246A) have almost the same kobs than the WT in
the membrane bound form and, (ii) the group that had similar
cytochrome c reduction rates than the wild type in the soluble
form (S243P, I245A and I245P), display a greater efficiency of
electron transfer to cytochrome c in the membrane bound form.
DISCUSSION
The role of the hinge segment in diflavin reductase enzymes
was studied both in NOS enzymes (Haque et al., 2007, 2012)
and in CPR (Hamdane et al., 2009), using either lengthening
or shortening of the primary sequence. Our study was designed
to address the role of specific residues of the hinge segment
of CPR (G240, S243, I245 and R246) without modifying its
length. We have analyzed the salt-induced changes in the
conformational equilibrium between the locked and unlocked
states, via cytochrome c reduction, in the context of both the
soluble and membrane-bound forms of CPR. In our first set of
experiments using the soluble form of WT CPR, we compared the
ionic strength profiles of the kobs with three artificial substrates.
Our results confirmed that the well-known salt dependency
of either cytochrome c or P450 reductions (Voznesensky and
Schenkman, 1992) can be mostly attributed to a change in the
conformational equilibrium of CPR, between the locked state,
non-competent in electron transfer to cytochrome c and the
unlocked state capable of transferring electrons from the reduced
FMN to acceptors. However, as explained in Section “The Hinge
Partly Controls the Conformational Equilibrium of the Soluble
CPR Form,” we cannot rule out that the redox potentials of
the flavins in the mutants forms of CPR are equivalent. Still,
as mentioned before, the fact that the absorption spectra of the
different WT and mutant CPRs are indistinguishable indicates
that the chemical environment of the flavins is similar in all
studied proteins. In the rest of the discussion, we therefore
assumed that these redox potentials are equal between all CPR
forms studied, bearing in mind that the various properties of the
mutants (especially the rate constants) might, to some extent, be
attributed to these putative redox potentials changes.
In the membrane bound form of WT CPR, the kobs is
lower than the one measured with the soluble form, a feature
already seen upon solubilization of CPR (Phillips and Langdon,
1962). A possible explanation is a potential restrictive access of
cytochrome c to the FMN domain caused by the membrane,
giving rise to the observed differences between the effects of
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FIGURE 5 | Hydrogen bond network around residue R246 of human CPR. (A) Position of R246, Q247, D445 and E449 in the structure of the soluble form of WT
human CPR. The color coding is as follows: FMN domain, cyan; hinge segment, green; connecting domain, orange; FAD domain, red. Flavins are depicted in yellow
sticks, the various positions as stick in the same color code of the domain to which they belong. (B) Detailed view of the hydrogen bonding network. The color
coding is the same as in (A).
mutations when present in the soluble or membrane bound
forms. Interestingly, none of the introduced mutations were
capable of completely abolishing the CPR electron transfer to
cytochrome c but rather displayed several intermediate features,
either changing the salt profile or the efficiency of electron
transfer, or both. We thus hypothesize that the targeted positions,
although important, are only a part of the structural determinants
promoting the conformational exchange between the locked and
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unlocked states. It is also worth noting that the ionic strength
profiles obtained with all mutant forms (soluble and membrane-
bound, except for the soluble form of the S243P mutant) were
shifted to lower salt concentrations compared to that of the WT
CPR. This clearly indicates that the majority of changes that
were introduced displaced the equilibrium toward the unlocked
state. This is not completely surprising for the mutations that
potentially enhance the flexibility (I245A) or removed salt
bridges between the hinge and the connecting domain (R246A).
However, for the mutations introducing proline residues in the
hinge (G240P, S243P, I245P, R246P) the shift in the ionic strength
profile might indicate that rigidifying these positions could result
either in the destabilization of the locked state or the stabilization
of the unlocked state. Still, the maintenance of a rather effective
cytochrome c reduction in all cases might indicate that the loss
of flexibility in the mutants bearing a proline residue may also be
partly compensated by the hinge flexibility involving residues at
other positions.
The second interesting feature of our mutants is that we
can separate the ionic strength profile from the efficiency of
the electron transfer to cytochrome c, i.e., there is no evident
direct relationship between the salt concentration at which kobs
is maximal and the value of kobs itself (Figures 3B, 4B). Thus,
in our conditions, the rate limiting steps remain independent of
the conformational equilibrium. The conformational exchange
frequency between the locked and unlocked states is at minimum
600 s−1 (Frances et al., 2015), a value 10 times greater than
the kobs observed with cytochrome c and coherent with the one
determined by Haque et al. (2014). This also means that the
locked state might actually have several closed conformations,
not all of them productive for inter-flavin electron transfer, a
feature that has already been described (Hay et al., 2010). Hence,
there would not be a direct relationship between conformational
equilibrium and maximal kobs and the effects of our introduced
mutations, destabilization of the locked state, could also affect the
rate limiting step giving rise to either equal, lower or higher kobs
values compared to the WT forms.
In the soluble form of human CPR, only the S243P and
possibly the I245A mutations have no effect on the rate of
cytochrome c reduction. However, in the membrane bound
form, these two mutants, along with I245P, present cytochrome
c reduction rates higher than the WT form, and higher than
the soluble counterparts. To our knowledge, this is the first
report of kobs values up to 8,000 min−1 for electron transfer to
cytochrome c with CPR. However, these features were already
observed in some mutants affecting the charge pairing between
the FMN and FAD domains of nNOS (Haque et al., 2013) and
in a C-terminal-truncated version of murine iNOS in which
cytochrome c reduction attained 31,467 min−1 (Roman et al.,
2000). In the nNOS mutants, the increase of kobs for cytochrome
c reduction was attributed to a change of the conformational
behavior. However, in our case, the maximal kobs was determined
at a salt concentration where the conformational equilibrium
corresponds to a 1:1 ratio of locked/unlocked states, as we
demonstrated before (Frances et al., 2015). Therefore, the high
maximal kobs values observed in the mutants may be attributed
to a change in the FAD to FMN electron transfer rate limiting
step, because, in the case of cytochrome c reduction by CPR,
this step is considered the slowest. Still, it should be reminded
here that natural redox partners of CPR such as microsomal
P450, may have specific structural requisites to bind CPR and
form productive electron-transfer complexes with its membrane
anchored redox partners, a situation evidently different with
soluble partners such as cytochrome c. The differences in our
results for the soluble and membrane-bound forms seem to
indicate that residues S243 and I245 of human CPR are playing
a role in this specific aspect.
Figure 5 depicts the position of the R246 amino acid in the
structure of the WT, soluble form of human CPR (McCammon
et al., 2016). The R246 is in close contact with two acidic residues
(D445 and E449) present in the connecting domain (Figure 5A).
Mutations at position 246 abolish a charge pairing with these
two acidic residues. The distances of the three nitrogen atoms
of R246 (NE, NH1 and NH2) with both terminal oxygens of
D445 and E449 and the carbonyl oxygen of D445 are compatible
with hydrogen bonds (Figure 5B). Furthermore, one terminal
oxygen atom of E449 is also in a distance compatible to form
a hydrogen bond with the amide nitrogen atom of Q247.
This relatively strong hydrogen bonding network is evidently
disrupted in the mutants changing R246 into any non-charged
residue. The addition of a charge at the previous residue (in the
double mutant I245R/R246I) does not restore the WT phenotype
because I245 side-chain is clearly not oriented favorably in order
to substitute for R246 in the complex hydrogen bonding network.
This result is reminiscent of the mutations analyzed by Shen and
coworkers demonstrating a similar shift in the salt profile when
removing potential ionic interactions between the FMN and the
connecting domains by mutating E216 into a glutamine residue
(Shen and Kasper, 1995). Our results thus demonstrate that the
hinge segment also actively participates in the construction of the
FMN/FAD interface. When the loss of critical ionic interactions
modifies the equilibrium between the locked and unlocked states,
the ionic strength at which the maximal value of kobs occurs is
evidently lower, yet the maximum kobs value may remain roughly
constant, as demonstrated by several of the mutant CPRs.
A final remark should be made concerning the salt
concentration at which the maximal kobs was observed for
the WT, membrane bound form of CPR, which is around
500 mM NaCl. It is clear that the ionic strength at this
salt concentration is much higher than the physiological one,
154 mM KCl (physiological serum). As such it seems that the
conformational equilibrium of CPR, in vivo, is probably in favor
of the locked state, thereby reinforcing the idea of an external
trigger for opening CPR (Grunau et al., 2006, 2007), such as the
presence of membrane-bound P450s which are physiologically
outnumbering CPR molecules by a factor of 5–10 in the liver.
How this competition for CPR is affected by the conformational
equilibrium is still an open and intriguing question.
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Human liver cytochrome P450 3A4 is the main enzyme involved in drug metabolism.
This makes it an attractive target for biocatalytic applications, such as the synthesis
of pharmaceuticals and drug metabolites. However, its poor solubility, stability and
low coupling have limited its application in the biotechnological context. We previously
demonstrated that the solubility of P450 3A4 can be increased by creating fusion proteins
between the reductase from Bacillus megaterium BM3 (BMR) and the N-terminally
modified P450 3A4 (3A4-BMR). In this work, we aim at increasing stability and coupling
efficiency by varying the length of the loop connecting the two domains to allow higher
inter-domain flexibility, optimizing the interaction between the domains. Starting from
the construct 3A4-BMR containing the short linker Pro-Ser-Arg, two constructs were
generated by introducing a 3 and 5 glycine hinge (3A4-3GLY-BMR and 3A4-5GLY-BMR).
The three fusion proteins show the typical absorbance at 450 nm of the reduced
heme-CO adduct as well as the correct incorporation of the FAD and FMN cofactors.
Each of the three chimeric proteins were more stable than P450 3A4 alone. Moreover,
the 3A4-BMR-3-GLY enzyme showed the highest NADPH oxidation rate in line with the
most positive reduction potential. On the other hand, the 3A4-BMR-5-GLY fusion protein
showed a Vmax increased by 2-fold as well as a higher coupling efficiency when compared
to 3A4-BMR in the hydroxylation of the marker substrate testosterone. This protein also
showed the highest rate value of cytochrome c reduction when this external electron
acceptor is used to intercept electrons from BMR to P450. The data suggest that the
flexibility and the interaction between domains in the chimeric proteins is a key parameter
to improve turnover and coupling efficiency. These findings provide important guidelines
in engineering catalytically self-sufficient human P450 for applications in biocatalysis.
Keywords: P450 biocatalysis, domain interaction, glycine linker, stability, uncoupling, electron transfer
INTRODUCTION
Cytochromes P450 are heme-thiolate monooxygenases found in all domains of life (Coon, 2005;
Bernhardt, 2006) able tometabolize several endogenousmolecules and xenobiotics, including drugs
(Nelson et al., 1996; Ortiz de Montellano, 2005; Isin and Guengerich, 2007).
They catalyze many chemical reactions such as hydroxylation of non-activated carbon atoms,
epoxidation of double bonds and dealkylation on C-, N-, and S- atoms (Isin and Guengerich, 2007).
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Electrons for these reactions are provided by NADPH and
transferred to the heme cofactor via different redox partners
classified by Hannemann et al. (2007). Thus, NADPH is used as
electron source and in the presence of molecular oxygen, reaction
product(s) can be generated in single or multistep reactions.
Although the human liver enzymes are an attractive
biotechnological target in their use as biocatalysts for their ability
to produce pharmaceuticals and drug metabolites, limitations are
given by poor stability and by the so-called “uncoupling,” the
formation of reactive oxygen species at the heme site leading
to the release of intermediates such as superoxide and peroxide
during the reaction cycle (Guengerich, 2002; Meunier et al., 2004;
Zangar et al., 2004; Denisov et al., 2005). The uncoupling process
can lead to a loss of NADPH redox equivalents as high as 99% in
human cytochrome P450 1A2 (Mayuzumi et al., 1993) or 16% for
3A4 (Perret and Pompon, 1998) and it can be seen as a wasteful
process. These high uncoupling levels, together with the need of
a reductase, are a considerable disadvantage in the use of human
enzymes as biocatalysts.
On the other hand, bacterial P450 enzymes are known to
be well coupled and as in the case of P450 BM3 from Bacillus
megaterium, have been shown to be able to produce drug
metabolites typical of the human enzymes with a high coupling
efficiency (Di Nardo et al., 2007; Di Nardo and Gilardi, 2012).
This has led to a wide range of protein engineering studies on this
enzyme to widen its catalytic abilities (Tsotsou et al., 2012, 2013;
Ryu et al., 2014; Di Nardo et al., 2015; Ren et al., 2015; Capoferri
et al., 2016).
One factor that makes P450 BM3 a well-coupled biocatalyst
resides in the productive interaction between the heme catalytic
domain (BMP) and its flavin-containing reductase domain
(BMR) that, unlike in other cytochromes P450, are all part of
the same polypetide chain. For this reason we already reported
the construction of different fusion human P450 enzymes,
engineered by connecting the reductase domain BMR with
human cytochromes P450 2E1(Fairhead et al., 2005), 3A4,
2C9, 2C19 (Dodhia et al., 2006), 2A6, CYP2C6, and CYP4F11
(Ortolani, 2012; Rua, 2012a; Castrignanò et al., 2014), monkey
2C20 (Rua et al., 2012b) and dog CYP2D15 (Sadeghi and Gilardi,
2013; Rua et al., 2015).
As human cytochrome P450 3A4 is responsible for the
metabolism of the majority of commercial drugs and it is at the
origin of many drug-drug interactions of clinical concern (Evans
and Relling, 1999), we further characterized the parameters
influencing uncoupling in the reconstituted fusion protein P450
3A4-apo-BMR, such as flavin content, substrate, and NADPH
concentration, pH and ionic strength (Degregorio et al., 2011).
Among P450 systems, P450 BM3 is considered as a model for
self-sufficiency and high coupling efficiency (Munro et al., 1996;
Noble et al., 1999). In 2005, Neeli and colleagues suggested
that BM3 fatty acid hydroxylation activity can be related to a
dimeric form of the enzyme and for this protein electron transfer
is achieved through an “inter subunits” interaction between
protomers rather than direct flow between the di-flavin and the
heme held by the same polypeptide chain (Neeli et al., 2005).
In the present work we consider another parameter that
can influence the coupling efficiency in the fusion protein
P450 3A4-BMR: the length of the loop linking the oxygenase
domain with the reductase one. In 1995, Govindaraj and Poulos
demonstrated that the length of the linker is the critical feature
that controls flavin-to-heme electron transfer in cytochrome
P450 BM3 (Govindaraj and Poulos, 1995). Moreover, the role of
the linker sequence in facilitating the ability of cyt b5 to reduce
P450 2B4 was explored by altering the length and sequence of the
flexible linker region between the heme domain and membrane
anchor of cyt b5 (Clarke et al., 2004). Clarke and co-workers
demonstrated that, although the sequence of the linker region can
be varied without significant effects on the properties of cyt b5,
the linker region has a critical minimum length of 6–8 residues.
Here we aim at elucidating first if then how the length of the
linker connecting the reductase and catalytic domain in the 3A4-
BMR fusion protein has an effect in modulating the activity and
the uncoupling process.
Flexibility between protein domains is a critical parameter in
modulating the uncoupling process via the formation of an active
complex and by tuning the electron flow to the heme. The ability
of the reductase of P450 BM3 from B. megaterium (BMR) to
transfer electrons in the redox chain fromNADPH to the heme is
evaluated by varying the length of the linker region between BMR
and the N-terminally modified 3A4 heme domain. As shown in
Figure 1, the BMR and P450 3A4 domains possess the surface
charges complementarity that is known to be more crucial for the
complex formation than when the physiological redox partner,
cytochrome P450 reductase (hCPR) was used instead. In order
for catalysis to occur, this active complex should form with high
propensity. Thus, starting from the 3A4-BMR chimera in which
the BMR domain is linked to the 3A4 via the short linker Pro-
Ser-Arg, two new constructs are engineered to include 3- or
5-Gly inserted after the Pro-Ser-Arg loop leading to 3A4-3GLY-
BMR and 3A4-5GLY-BMR chimeric proteins. This glycine rich
region close to the C-terminal of P450 3A4 has been proposed
to function as a flexible hinge that can provide the enzyme the
degrees of freedom required to achieve a functional complex. The
effect of the linker length on the electron transfer between the
reductase and the catalytic domains in the presence of NADPH
as electron supplier is studied for the three chimeras.
The electrons delivery from NADPH to the flavins of the
reductase domainis is evaluated in the three complexes by
anaerobic stopped flow spectroscopy measurement of NADPH
consumption rate in the absence of substrate. The electron
transfer capability of reducing equivalents by flavins of the
reductase domain is investigated using cyt c as an artificial
electron acceptor (Guengerich et al., 2009) and the effect
of the linker length is examined. Finally, the ability of the
BMR to sustain catalysis at the 3A4 catalytic domain is
explored in relation to the length of the linker by investigating
enzyme activity and coupling efficiency during erythromycin
N-demethylation and testosterone 6β-hydroxylation.
MATERIALS AND METHODS
Chemicals and Reagents
The pCW-3A4-BMR plasmid containing the gene of human
P450 3A4 fused to the reductase of cytochrome P450 BM3
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FIGURE 1 | (A) Surface charge distribution of P450 3A4 (left, PDB ID 1TQN) and the FMN binding domain of P450 BM3 (right, PDB ID 1BVY). Heme and FMN are
shown in black. (B) Complex between P450 3A4 and the FMN binding domain of BMR. The complex was created by super-imposition of the crystal structure of P450
3A4 with the heme domain of P450 BM3 in the complex crystal structure.
from B. megaterium (BMR) linked via a Pro-Ser-Arg linker
was available in our laboratory (Dodhia et al., 2006). GenElute
plasmid miniprep kit was obtained from Sigma (Italy). PCR
purification kit and gel extraction kit were purchased from
Macherey-Nagel (Germany).
The primers for PCR and oligonucleotides for the linker
region between P450 3A4 and BMR reductase were prepared
by MWG (Germany). DNA Ladder, restriction endonucleases
enzymes Avr II and Hind III, Vent polymerase, T4 DNA ligase
enzyme and buffers used in sub-cloning were from New England
Biolabs (UK) and Promega (Italy). Horse heart cytochrome c,
erythromycin, testosterone, 6β-hydroxytestosterone, horseradish
peroxidase type X, superoxide dismutase from bovine
erythrocytes, catalase, N,N-dimethylaniline, and 4-amino-
2,3-dimethyl-1-phenyl-3-pyrazolin-5-one were purchased from
Sigma (Italy). NADPH (tetrasodium salt) was acquired from
Calbiochem (Germany). Human CPR was purchased from Life
Technologies. All other chemicals, biochemicals used in this
study were purchased from Sigma (Italy) at the highest available
grade and used as recommended by the manufacturer.
Engineering the Linkers in the 3A4-BMR
Chimeras
The strategy used in the construction of the fusion proteins is
based upon introduction of 3 or 5 glycines in the pre-existent
Pro-Ser-Arg linker connecting P450 CYP 3A4 domain and BMR
one domain via 3 amino acids (Pro-Ser-Arg) by using as a starting
template the vector pCW-3A4-BMR available in our laboratory
(Figure 2A; Dodhia et al., 2006). Glycine was chosen to allow
the highest flexibility of the loop to support conformational
rearrangements between the two domains as much as possible.
All PCR reactions were performed in a DNA thermal
cycler (PerkinElmer Life Sciences, Italy) and employed Vent
polymerase under conditions recommended by themanufacturer
(Promega, Italy).
The 3A4-3GLY-BMR chimera was engineered to contain the
N-terminally modified human P450 CYP 3A4 (aa 13-503), the
linker Pro-Ser-Arg-Gly-Gly-Gly and the C-terminal reductase
(aa 472-1049) of P450 BM3 from B. megaterium. The 3A4-
5GLY-BMR chimera contains the N-terminally modified human
P450 3A4 (aa 13-503), the linker Pro-Ser-Arg-Gly-Gly-Gly-
Gly-Gly and the C-terminal reductase domain (aa 472-1049)
of B. megaterium. The gene coding for the BMR reductase
was amplified using the forward 5-AGTGGAGCCCCTAGG
TCAGGCGGTGGCAAAAAGGCAGAAAACGCTCATAAT-3′
and reverse 5′-GCTCATGTTTGACAGCTTATCATCGAT




TTACCC-3′ primers were used for the 5-glycine chimera. The
forward primers were synthesized with an overhanging Hind
III restriction site upstream of the BMR start codon, whereas
the reverse primers contained an Avr II site downstream of the
stop codon. The underlined letters represent the endonuclease
restriction sites. DNA was melted for 2min at 94◦C, followed
by 30 cycles of 1min at 94◦C, 1min and 45 s at 60◦C, 1min at
72◦C. The polymerase chain reaction products obtained were
digested with Hind III and Avr II endonucleases and purified by
the GeneClean II method as described by the manufacturer. The
pCW-3A4-BMR vector was digested for 1 h at 37◦C with Hind
III and Avr II and genomic DNA corresponding to pCW-3A4
was isolated by NAGEL KIT extraction and then ligated using
T4 DNA ligase with the sticky sites of the digest PCR products.
The ligation mix was transformed into E. coli DH5α cells and
plated on LB agar containing 100µg/ml ampicillin. The positive
clones were chosen and the plasmid DNA was purified using
a Mini-prep plasmid extraction kit (Sigma, Italy). The correct
insertion of the glycine codons was verified by DNA sequencing.
Expression, Purification, and
Characterization
Heterologous expression of 3A4-BMR, 3A4-3GLY-BMR, and
3A4-5GLY-BMR was performed by transforming competent
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FIGURE 2 | (A) Schematic illustration of the chimeras construction strategy. (B) SDS-PAGE of the purified chimeric proteins.
E. Coli DH5α cells with the corresponding plasmid vectors.
The proteins were purified using diethylaminoethyl and
hydroxylapatite columns as described before (Dodhia et al.,
2006). The purity of the enzymes was checked by sodium dodecyl
sulfate polyacrylamide gel electrophoresis on 7.5% gel using a
Mini-Protean apparatus (Bio-Rad, USA) with Coomassie blue
staining.
Protein concentrations were determined from the absorption
at 450 nm of the carbon monoxide-bound reduced form by using
the Omura and Sato method (Omura and Sato, 1964) using
an extinction coefficient of 91mM−1 cm−1. Protein reduction
was achieved by addition of saturating sodium dithionite,
and formation of the carbon monoxy-adduct of the heme
was obtained by bubbling the reduced enzyme with carbon
monoxide.
Determination of the Heme and Flavin
Contents
The ratio protein:heme:FMN:FAD were calculated using
different spectroscopic methods. Protein concentration was
estimated using Bradford assay (Bradford, 1976), while the
heme concentration was obtained from the CO-binding
assay described above (Omura and Sato, 1964). FAD and
FMN contents were calculated using fluorescence emission
spectroscopy in each purified enzymes (Faeder and Siegel, 1973).
Excitation at 450 nm produced fluorescence emission spectra
with an emission maximum at 535 nm as expected for flavin-
containing proteins. Quantification of FAD and FMN present in
the protein is based on the different behavior of the two cofactors
at different pH-values (Aliverti et al., 1999). The samples were
boiled for 3min to release the flavins, then rapidly cooled on ice
and centrifuged at 14,000 g for 10min. An aliquot of the clear
supernatant was diluted with standard buffer (0.1M potassium
phosphate buffer pH 7.7, containing 0.1mM EDTA) so that the
final volume was 1.5mL and the mixture was transferred to a
1 cm path-length fluorimeter cuvette.
Fluorescence emission was recorded at 535 nm; the excitation
wavelength was set at 450 nm. After the initial fluorescence
measurement at pH 7.7, the pH of the solution was adjusted to
2.6 by the addition of 0.1mL of 1 N HCl (final concentration
62.5mM) and the fluorescence was determined again. The
concentrations of FAD and FMN in the supernatant were
determined from the fluorescence intensity compared to those
obtained for standard solutions of flavins by using as extinction
coefficients 11.3 and 12.2mM−1cm−1, respectively (Aliverti et al.,
1999).
Time Dependent Loss of CO-Binding
The stability of 3A4-BMR fusion proteins was compared with
that of CYP 3A4 by following the loss of CO-binding at a
temperature of 37◦C. Recombinant CYP3A4 was expressed and
purified as described byDodhia et al. (2006). CO-binding spectral
assay was performed at 37◦C both in the presence of CYP3A4
and 3A4-BMR chimeric proteins as described in the Section
Determination of the Heme and Flavin Contents by using 1.6µM
protein solutions. The absorbance at 450 nm was followed for
60min by collecting one spectrum every 5min at 37◦C. All the
collected spectra were corrected by subtraction of the spectrum
of the reduced protein and the loss of CO-binding was measured
as a percentage loss in absorbance of the peak at 450 nm.
Anaerobic Stopped Flow
Spectrophotometric Evaluation of NADPH
Consumption
Rates of NADPH oxidation were measured using a Hi-
Tech scientific SF-61 single mixing stopped-flow system (TgK
Scientific, UK) at 25◦C in a glovebox (Belle Technology, UK) with
an oxygen concentration below 10 ppm. NADPH consumption
was monitored at 340 nm (ε = 6.22mM−1 cm−1) for 750 sunder
anaerobic conditions. Proteins and reducing agent solutions (in
the absence and presence of saturating amounts of substrate)
were prepared in syringes in an anaerobic glove box and
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transferred to the sample handling unit of the stopped-flow
instrument. The experiment was performed by mixing the
NADPH (syringe A, 200µM NADPH in 50mM potassium
phosphate buffer pH 8.0) and the enzyme or enzyme plus
substrate solutions (syringe B, 1µMenzyme in 50mMpotassium
phosphate buffer pH 8.0+150µMerythromycin or testosterone).
Analysis of the resulting kinetic data was performed with Kinetic
studio V3 software (TgK Scientific, UK). In order to calculate the
NADPH consumption rate, the plot of absorbance at 340 nm vs.
time was fitted to a single exponential decay function.
Determination of the Reduction Potentials
of the Chimeras
Potentiometric titrations were performed in an anaerobic
glovebox (Belle Technology, UK) with an oxygen concentration
below 10 ppm using a cuvette equipped with a gold laminar
working electrode and an Ag/AgCl reference electrode connected
to a potentiostat controlled by GPES3 software (Ecochemie,
The Netherlands). Ambient reduction potentials were adjusted
by addition of aliquots (2–5µL) of anaerobically freshly
prepared sodium dithionite solution. Titrations were performed
in 50mM potassium phosphate, pH 8. Electrode-solution
mediation was facilitated by adding the following mediators
at 5µM concentration: methyl viologen (Em = −440mV),
benzyl viologen (Em = −359mV), safranine O (Em =
−280mV), anthraquinone-2,6-di sulfonic acid (Em =−185mV),
phenazinemethosulfate (Em = +80mV), methylene blue (Em
= +11mV). The modified cuvette was flushed with oxygen-
free nitrogen before and during the measurements. After
equilibration at each potential, the optical spectrum was
recorded. Reduction of the heme in 3A4-BMR fusion proteins
was followed by the increase in the absorption at 550 nm
related to the merging of Q-bands, using a diode array
spectrophotometer (TgK Scientific, UK). The fraction of reduced
heme, proportional to the measured spectral transition, was
plotted against potential, and the data were fitted to the Nernst
equation:
E = Em + (RT/nF)ln([ox]/[red])
where [ox] and [red] are the concentrations of oxidized and
reduced heme, respectively, E is the solution reduction potential
at equilibrium, n is the number of electrons, Em is the midpoint
potential, F is the Faraday constant, R is the gas constant, and T
is the absolute temperature.
Determination of the Catalytic Activity and
Coupling Efficiency
The enzymatic activity of chimeras was determined
toward erythromycin N-demethylation and testosterone
6β-hydroxylation.
Erythromycin N-demethylation was investigated under
aerobic conditions by quantification of the formaldehyde
arising from the N-demethylation of erythromycin using
the Nash method (Nash, 1953), using a concentration
range of this substrate under 120µM where this molecule
still acts as a substrate. Uncoupling reactions leading to
hydrogen peroxide were determined and quantified using
the N,N-dimethylaniline/4-amino-2,3-dimethyl-1-phenyl-3-
pyrazolin-5-one/crude horseradish peroxidase colorimetric assay
as described by Sugiura et al. (1977). Reactions were carried
out at 37◦C in a 1 cm path length quartz cuvette and consisted
of the following mixture: 0.1M potassium phosphate buffer
pH 8.0, 2% glycerol, 5mM MgCl2, 100mM KCl, 1µM of the
chimeric protein and different concentrations of erythromycin
in the range 0–120µM. For each protein preparation, some
preliminary experiments were performed in order to assess
linearity of reaction rates with respect to time. After blanking
the absorbance at 412 nm with the erythromycin incubated
at 37◦C for 5min with 1µM of the enzymes, catalysis was
initiated by addition of 150µM NADPH. The reactions were
then stopped after 30min by addition of HCl. The samples
were centrifuged at 13,000 rpm for 5min and 0.5mL of the
supernatant were transferred to another tube and mixed with
0.5mL of a concentrated Nash reagent (3 g ammonium acetate,
40µL acetylacetone, 60µL acetic acid in 10mL of water) as
described before (Dodhia et al., 2006).
The reaction linearity was assessed over a 40min time. Thus,
the mixture was incubated at 50◦C for 30min and the samples
were analyzed by measuring absorbance at 412 nm to determine
the formation of formaldehyde. The amount of formaldehyde
produced during the reaction was quantified by using a
calibration curve constructed in the same reaction condition
with a range of concentration between 0 and 30µM. Zero-time
controls were performed in the absence of erythromycin.
Coupling efficiency was calculated as the ratio of
formaldehyde produced during erythromycin N-demethylation
and the total amount of NADPH consumed by the chimeras.
Testosterone 6β-hydroxylation was investigated at 37◦C by
incubating 1µM protein in the presence of testosterone in
a concentration range between 1 and 150µM for 5min.
Catalysis was initiated by addition of 200µM NADPH. The
reaction linearity was assessed over a 40min time. The reactions
were then stopped after 30min by addition of HCl. The
samples were centrifuged at 13,000 rpm for 5min. The amount
of 6β-hydroxytestosterone formed was evaluated by HPLC
coupled with a diode array UV detector (Agilent-1200, Agilent
technologies, USA) equipped with a 4.6 × 250mm, 5µm
C18 column. Testosterone and 6β-hydroxytestosterone were
separated using a gradient elution programmed as follows:
isocratic elution of 20% acetonitrile and 80% water, 0–2min;
linear gradient elution from 20 to 90% acetonitrile and from
80 to 10% water, 2–20min; linear gradient elution from 90 to
20% acetonitrile and from 10 to 80% water, 20–22min; isocratic
elution of 20% acetonitrile and 80% water 22min-end of the
run. The flow rate was set at 1mL/min and detection wavelength
was 244 nm. Retention times were 9.2min and 13.1min for 6β-
testosterone and testosterone, respectively. Coupling efficiency
was calculated as the ratio of 6β-hydroxytestosterone produced
and the total amount of NADPH consumed by the chimeras.
Measurement of Cytochrome c Reduction
by the BMR of the Chimeras
Cytochrome c reduction activity spectrophotometric assay was
performed as described by Guengerich et al. (2009) with slight
modification. In particular, 10µM of cyt c (in 0.1M potassium
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phosphate buffer pH 8.0) were pipetted into a 0.5mL quartz
cuvette (1 cm path-length). Then, 0.1µM of chimeric proteins
were added and gently mixed. The assay was started by adding
NADPH to a final concentration of 75µM. Using the kinetic
mode of the spectrophotometer, the absorbance increase at
550 nm upon cytochrome c reduction was monitored for 5min.
The rate of cytochrome c reduction was calculated using
reduced cyt c extinction coefficient at 550 nm,7.04mM−1cm−1,
as nmol of reduced cyt c per min. The experiment was
carried out both in the absence and in the presence of 20%
glycerol.
Statistical Analysis
All collected data were recorded at least in triplicate and
expressed as mean ± standard deviation. The comparison of the
results obtained was performed by one way ANOVA and two way
ANOVA followed by Student-Newman-Keuls post hoc test using
SigmaPlot software.
RESULTS
Protein Purification and UV-Visible
Properties of the P450 3A4-BMR Chimeras
After expression and purification (Figure 2B), the UV-visible
spectral properties of the purified chimeras were analyzed
between 300 and 600 nm for the oxidized, reduced and carbon
monoxide bound forms. The spectra show the typical features of
both heme and flavin cofactors (Figures 3A–D). These comprise
the characteristic Soret peak at 418 nm corresponding to the
oxidized heme iron, the β and α bands at 535 and 570 nm, the
shoulder around 455–485 nm belonging to the oxidized FAD and
FMN of the BMR domain.
Full reduction of the chimeras was achieved by addition of
excess sodium dithionite leading to the hydroquinone forms with
a concomitant decrease in the intensity in the visible region
spectra (Figures 3A–D, dashed lines). In all cases a clear shift to
450 nm upon CO bubbling indicates the presence of a properly
folded P450 domain (Figures 3A–D, dark gray lines).
The correct stoichiometry of the heme and flavin
incorporation in the chimeras was also investigated by
absorption and fluorescence spectroscopy. The heme content
was determined from the absorbance value at 450 nm of the
CO-adduct and the amount of the total protein was obtained
by Bradford method. In all chimeras the ratio heme:protein
resulted to be close to 1:1 (Table 1). This indicates that the
proteins have a full complement of bound heme cofactor.
The FAD and FMN content was determined by fluorescence
emission spectroscopy as detailed in the materials and methods
section, resulting in a FAD-to-protein and FMN-to-protein
ratio of 0.81 and 0.82 for 3A4-BMR, 0.83, and 0.87 for 3A4-
3GLY-BMR and 0.83 and 0.83 for P450 3A4-5GLY-BMR
(Table 1). The ratios in flavins:heme content suggest that
there is a minimal amount of apoenzyme with a nearly-
stoichiometric amount of each cofactor and indicating that the
domains are independently able to uptake the cofactor while
folding.
NADPH Consumption and Reduction
Potentials of the Heme
Since the inter-domain interactions modulated by the loops
are crucial in determining both the electron transfer rates and
reduction potentials, these parameters were evaluated on the
three chimeras.
Rates of NADPH oxidation by the chimeras were measured by
rapid scanning stopped flow spectrophotometry by following the
decrease in absorbance at 340 nm for 750 s in anaerobic condition
(Sevrioukova et al., 1996; Davydov et al., 2010), as this is the first
essential step in the electron transfer chain involving the FAD and
FMN cofactors of BMR to sustain the 3A4 catalysis (Guengerich,
1983). The NADPH consumption rates were estimated by
fitting the absorbance decrease with single exponential decay
equation both for 3A4-BMR chimeras and for CYP3A4 in
the presence of hCPR as reference system. Moreover, NADPH
oxidation rates were calculated also in the presence of substrate,
erythromycin and testosterone, in saturating conditions. The
results are summarized in the Figure 4. As reported, compared
to CYP3A4/hCPR system, 3A4-BMR chimeric proteins were
found significantly faster both in absence and in presence of
substrate, resulting more efficient in the transfer of reducing
equivalents from NADPH. In addition, 3A4-3GLY-BMR protein
resulted significantly faster in NADPH consumption with respect
to the other two constructs (P < 0.05), both in the presence
and in the absence of substrate. Moreover, the presence of both
erythromycin and testosterone significantly enhances NADPH
consumption rate in all the examined fusion proteins. This effect
is probably due to the fact that the substrate-bound complex has a
higher reduction potential and is capable to accept electrons from
the redox partner more easily leading to a faster reduction of the
heme-Fe3+ to heme-Fe2+ (Sligar et al., 1979; Guengerich, 1983).
Reduction potentials of the heme were determined with
anaerobic spectro-potentiometric titrations of the chimeras
using the method described by Dutton (1978). The change in
population from the oxidized (Fe3+) to the reduced (Fe2+)
state upon addition of sodium dithionite reducing agent was
monitored by observing the spectral transition related to the
merging of the Q-bands in a single band at 550 nm. Reduction
potential values were calculated by plotting the calculated 3A4-
BMR reduced fraction vs. the recorded potential using the
Nernst’s equation. Midpoint potential values were calculated to
be−367± 3mV,−327± 8mV, and−397± 8mV for 3A4-BMR,
3A4-3GLY-BMR and 3A4-5GLY-BMR, respectively.
The differences observed in NADPH oxidation and reduction
potentials indicate that the loops indeed have an impact on these
parameters and therefore also different functional performace in
catalysis are expected.
Stability of the Chimeras
In order to study if and how the length of the loop has an
impact on the stability of the P450 catalytic module, the time
dependent decrease of the absorbance at 450 nm upon reduction
and CO binding was used to compare the relative stability of
P450 proteins (Lin et al., 2005; Foti et al., 2011; Amunugama
et al., 2012). This assay is based on the assumption that the loss
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FIGURE 3 | Left: UV-vis spectra of the purified cytochrome P450 3A4 (A), 3A4-BMR (B), 3A4-3GLY-BMR (C), and 3A4-5GLY-BMR (D) in their oxidized (black
line), reduced (dashed line), and reduced/carbon monoxide-bound (dark gray line) forms. Sodium dithionite completely reduces the flavin cofactors in all enzymes,
leading to spectral bleaching. Binding of carbon monoxide results in the formation of Fe2+-CO complex with heme Soret absorption maxima shifted to 450 nm in all
cases. Right: Time-dependent decrease of the absorbance at 450 nm of the CO-bound cytochrome P450 3A4 (E), 3A4-BMR (F), 3A4-3GLY-BMR (G), and
3A4-5GLY-BMR (H). CO binding loss is significantly higher, in terms of both rate and total absorbance decrease, for CYP 3A4 compared to the three BMR linked
chimeras. Insets: difference spectra generated by subtraction of the reduced P450 spectrum to each Fe2+-CO complex spectrum.
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0.97 ± 0.03 0.98 ± 0.01 0.98 ± 0.02
FMN content (nmol
FMN/nmol protein)
0.82 ± 0.01 0.87 ± 0.03 0.83 ± 0.05
FAD content (nmol
FAD/nmol protein)
0.81 ± 0.04 0.83 ± 0.02 0.83 ± 0.02
FIGURE 4 | Anaerobic NADPH oxidation rates for cytochrome P450
3A4-BMR, 3A4-3GLY-BMRand 3A4-5GLY-BMR compared to those
obtained for CYP 3A4 + hCPR system, obtained both in absence (white
bars) and in presence of substrate erythromycin (light gray) and
testosterone (dark gray). Data are mean ± SD for 3 to 6 replicates.
*P < 0.001 compared to CYP 3A4 + hCPR system; #P < 0.05,
##P < 0.001 compared to the protein in absence of substrate; two way
ANOVA.
of the band at 450 nm is associated with a loss of activity of
P450 enzymes (Omura and Sato, 1964). Thus, the absorbance at
450 nm was followed for 60min at 37◦C after the CO-binding
assay for CYP 3A4 as well as the three 3A4-BMR fusion proteins.
The results are shown as percentage residual absorbance in the
Figures 3E–H. Figure 3E shows that 3A4 domain when alone
retains only 10 ± 1% of the initial absorbance at 450 nm with
a loss of 450 nm peak rate of 0.072 ± 0.011min−1, whereas
3A4-BMR (Figure 2F), 3A4-3GLY-BMR (Figure 2G), and 3A4-
5GLY-BMR (Figure 2H) show a higher stability with a residual
absorbance at 450 nm of 42± 7, 30± 1, and 42± 1% respectively
and a loss of 450 nm peak rate of 0.032 ± 0.003min−1, 0.046
± 0.004min−1, and 0.047 ± 0.005min−1 respectively. These
values show that, in these experimental conditions, the stability
is significantly higher for the 3A4-BMR chimeras (P < 0.001,
one way ANOVA) when compared to the 3A4 alone.
Catalytic Properties and Coupling
Efficiency of the Chimeras
Turnover of the different chimeras was studied in the presence
of the substrates erythromycin and testosterone using NADPH
as electron source, and the results are reported in Table 2.
Quantification of both the amount of product formed in
the N-demethylation of erythromycin and coupling efficiency,
determined from the ratio product formed/NADPH oxidized,
were performed for the three chimeras. Erythromycin N-
demethylation rates were calculated at increasing concentration
of the substrate in the presence of all the 3A4-BMR constructs,
and the experimental data were fitted to the Michaelis-Menten
model in order to calculate kinetic parameters (Figure 5A). The
KM-values of 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR
were 20.8 ± 3.6, 27.4 ± 4.0, and 21.3 ± 4.4µM respectively. In
this case no statistically relevant differences were found. These
results show that the glycine linker length does not influence
3A4-BMR affinity for erythromycin substrate, indicating that the
binding pockets of the heme domain of the chimeras are not
perturbed.
Further analysis in terms of turnover rate led to Vmax-values
of 0.0515 ±.0004, 0.1177 ± 0.0006, and 0.1387 ± 0.0009 nmol
min−1 for 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR
(Figure 4B), respectively. In this case, a statistically significant
increase in Vmax for 3A4-3GLY-BMR and 3A4-5GLY-BMR with
respect to the 3A4-BMR construct was observed. This shows
that the glycine linker increases the enzyme turnover rate in
the presence of erythromycin substrate. Moreover, a significant
increase in Vmax-value was found for 3A4-5GLY-BMR compared
to 3A4-3GLY-BMR.
Also the testosterone 6β-hydroxylation rates were calculated
at increasing concentrations of the substrate in the presence of
all the 3A4-BMR constructs, and the results were fitted to the
Michaelis-Menten model in order to calculate kinetic parameters
(Figure 5D). The KM-values obtained from fitting the Michaelis-
Menten curves of 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-
BMRwere 19.6± 2.6, 21.3± 2.7, and 19.8± 2.2µM respectively,
indicating again no statistically relevant differences in the binding
pocket. The Vmax-values were 0.0066± 0.0002, 0.0089 ± 0.0002,
and 0.0113 ± 0.0003 nmol min−1 respectively for 3A4-BMR,
3A4-3GLY-BMR, and 3A4-5GLY-BMR enzymes (Figure 5E). As
observed in the presence of erythromycin, when comparing
Vmax results, a statistically significant increase was found for
3A4-3GLY-BMR and 3A4-5GLY-BMR with respect to the 3A4-
BMR construct. Also in this case the glycine linker increases the
enzyme turnover rates, with a significant higher Vmax-value for
3A4-5GLY-BMR compared to 3A4-3GLY-BMR.
The coupling efficiency percentage during erythromycin N-
demethylation, calculated as ratio of HCHO formed andNADPH
consumed, were found to be 9.4 ± 0.5, 10.0 ± 0.8, and 12.5
± 0.9% for 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR,
respectively (Figure 5C). When performing statistical analysis of
these results, the 3A4-5GLY-BMR fusion protein was foundmore
coupled than the other two constructs, whereas no significant
difference was found when comparing 3A4-BMR and 3A4-3GLY-
BMR. A similar comparison was also performed for testosterone
catalysis by calculating coupling efficiency as the ratio of
the amount of 6β-hydroxytestosterone formed and NADPH
consumed. The calculated coupling efficiency percentage ratios
were found to be 3.4 ± 0.1, 4.6 ± 0.1, and 5.8 ± 0.2% for
3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR, respectively
(Figure 5F).
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TABLE 2 | Catalysis and uncoupling parameters for erythromycin N-demethylation and testosterone 6β-hydroxylation for 3A4-BMR, 3A4-3GLY-BMR, and
3A4-5GLY-BMR.
Erythromycin N-demethylation Testosterone 6β-hydroxylation
KM(µM) Vmax(nmol min
−1) Coupling efficiency%(a) KM(µM) Vmax (nmol min
−1) Coupling efficiency%(b)
3A4-BMR 20.8 ± 3.6 0.0515 ± 0.0004 9.4 ± 0.5 19.6 ± 2.6 0.0066 ± 0.0002 3.4 ± 0.1
3A4-3GLY-BMR 27.4 ± 4.0 0.1177 ± 0.0006 10.0 ± 0.8 21.3 ± 2.7 0.0089 ± 0.0002 4.6 ± 0.1
3A4-5GLY-BMR 21.3 ± 4.4 0.1387 ± 0.0009 12.5 ± 0.9 19.8 ± 2.2 0.0113 ± 0.0003 5.8 ± 0.2
Coupling parameters are determined at saturating erythromycin (120µM) and testosterone(150µM) concentrations. Values are means ± standard deviation of four experiments.
(a)The coupling efficiency is calculated as: HCHO × 100/NADPH consumed.
(b)The coupling efficiency is calculated as 6β-hydroxytestosterone × 100/NADPH consumed.
NADPH–Cytochrome c Reduction by
3A4-BMR Chimeras
The results from enzymatic activity, coupling and reduction
potentials indicate that the different loops affect the interaction
between the BMR and 3A4 domains of the chimeras, probably
due to the different degrees of length and flexibility associated
with them. Cytochrome c was therefore used as external probe to
check its ability to intercept the electrons of NADPH delivered by
the BMRwhen this is exposed and hence available to interact with
proteins other than the 3A4 domain. The ability of cytochrome c
to be reduced by NADPH via free cytochrome P450 reductase has
already been described in the literature (Guengerich et al., 2009).
The capability of 3A4-BMR chimeras to use NADPH electrons
to reduce cytochrome c is strictly related to cytochrome c ability
to interact directly with the BMR domain when this is exposed.
In order to explore the effect of viscosity on the interaction of
cytochrome c with the chimera BMR domain, we performed
the experiments both in the absence and in the presence of
20% glycerol. The reduction rates were calculated as nmoles of
reduced cytochrome c per min and the results are summarized in
the Figure 5.
The 3A4-5GLY-BMR chimera shows the highest cytochrome
c reduction rate compared to the other two proteins. Moreover,
the presence of 20% glycerol significantly impaired cytochrome c
reduction ability of all the three constructs, with the 3A4-5GLY-
BMR being the most affected one.
DISCUSSION
Cytochromes P450 have been extensively used in our laboratories
to investigate their potential for applications in biocatalysis
as electron transfer domains in chimeric constructs (Cunha
et al., 1999; Sadeghi et al., 2011; Sadeghi and Gilardi, 2013).
This work investigates how the stability and activity of self-
sufficient chimeric human enzymes can be optimized not only by
creating fusion proteins but also with the correct choice of loop
connecting the reductase and the catalytic domains.
The stability of the P450 catalytic domain is significantly
improved in the presence of the BMR domain since all the
three fusion proteins showed a 1.5–2 fold lower rate of P450
loss compared to P450 3A4. In this case, the presence of an
extra domain rather than the length of the loop is essential
for stability as no significant differences are observed among
the three proteins. However, the length of the loop has an
impact on other parameters, such as NADPH oxidation rates
and reduction potential. In particular, the chimeric proteins show
a higer NADPH consumption rate compared to the CYP3A4-
hCPR system at a 1:1 molar ratio. Moreover, the 3A4-3GLY-
BMR protein shows a 2-folds faster rate in NADPH consumption
with respect to the other two constructs. This effect suggests that
the 3GLY construct is more prone to accept electrons from the
redox partner with respect to no GLY and 5GLY leading to a
faster reduction of the heme-Fe3+ to heme-Fe2+ (Sligar et al.,
1979). These data show that there is a critical length of the
linker between the domains that can modulate the inter-domain
interactions that determine the rate of the electron transfer.
The fastest oxidation rate in the 3GLY protein is explained by
its more positive reduction potential compared to the other two
fusion proteins. It is known that in redox proteins, the interaction
with the redox partner can influence the conformation, the
reduction potential and in general, the dielectric environment of
the redox cofactor (Bendall, 1996). Here, the three fusion proteins
show a different, although negative, reduction potential that can
reflect a different dielectric heme environment triggered by a
different domain arrangement and interaction.
When investigating the catalytic domain ability to use
reducing equivalents for erythromycin N-demethylation and
testosterone 6β-hydroxylation during the catalytic event, the
5GLY construct resulted the best for both turnover rate and
coupling efficiency. Thus, the increase in turnover number and
coupling efficiency is neither directly related to an improvement
in electron transfer rate nor to a more positive heme iron
reduction potential. Differences in substrate binding can also
be excluded as the KM-values measured for both erythromycin
and testosterone substrates are similar for the three proteins
and within the range of previously published data (Riley and
Howbrook, 1998; Yuan et al., 2002). Moreover, these data are
consistent with previously published results in which it was
demonstrated that the use of artificial redox chains allows the
regulation of the electron flow to the P450 catalytic domain
through the mediation of the non-physiological reductase
domain by lowering the electron transfer rate and improving
the correct electrochemical inter-domain tuning thus enhancing
coupling efficiency and catalytic activity (Dodhia et al., 2008;
Degregorio et al., 2011; Castrignanò et al., 2014).
In order to investigate if there is a correlation between
the observed improved turnover/coupling efficiency and
an increased inter-domain flexibility in the 5GLY protein,
cytochrome c was used as external probe to check its ability to
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FIGURE 5 | Activity and coupling of the 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR chimeras toward erythromycin N-demethylation. (A) Catalytic
activity measured as HCHO production rate in the presence of 3A4-BMR (circles), 3A4-3GLY-BMR (triangles) and 3A4-5GLY-BMR (squares) as function of
erythromycin concentration fitted with MichaelisMenten curves. (B) Summary of Vmax-values calculated during erythromycin N-demethylation in the presence of
cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR. (C) Summary of coupling percentage values calculated during erythromycin N-demethylation in
the presence of cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR. (D) Catalytic activity measured as 6β-hydroxytestosterone production rate in the
presence of 3A4-BMR (circles), 3A4-3GLY-BMR (triangles) and 3A4-5GLY-BMR (squares) as function of testosterone concentration fitted with Michaelis Menten
curves. (E) Summary of Vmax-values calculated during testosterone 6β-hydroxylation in the presence of cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and
3A4-5GLY-BMR. (F) Summary of coupling percentage values calculated during testosterone6β-hydroxylation in the presence of cytochrome P450 3A4-BMR,
3A4-3GLY-BMR and 3A4-5GLY-BMR. All reactions were carried out at 37◦C for 30min. Data are mean ± SD of at least 3 replicates. R2> 0.99. *P < 0.01,
**P < 0.001 compared to 3A4-BMR, #P < 0.05, ##P < 0.001 compared to 3A4-3GLY-BMR, one way ANOVA.
intercept the electrons of NADPH delivered by the BMR when
this is exposed and hence available to interact with proteins
other than the 3A4 domain. The 5GLY resulted in the fastest in
cytochrome c reduction and this result can be explained by the
highest flexibility between the reductase and catalytic domain
of the chimera allowing a better interaction with cytochrome
c and an easier electron delivery from BMR reductase domain
(Figure 6). This interpretation is further confirmed by the fact
that the impairment of inter-domain flexibility upon glycerol
addition that increases the medium viscosity, causes a significant
decrease in the cytochrome c reduction rate in all the three
constructs, with a more marked effect on the more flexible for
5GLY loop.
Taken together, the erythromycin N-demethylation and
testosterone 6β-hydroxylation activity and the coupling results
show that the 3A4-5GLY-BMR chimera is the more catalytically
efficient and the more coupled. This result suggests that the
higher linker flexibility allows a more proficient arrangement of
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catalytic and reductase domains and improves the tuning of the
electron transfer to the active site leading to a more accurate
electrons delivery from the NADPH electron source during the
catalytic event (Figure 7).
FIGURE 6 | Summary of NADPH-cytochrome c reduction rates by
3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR chimeras. Data obtained
in the presence of 0% glycerol (black bars) and 20% glycerol (gray bars) are
shown. They are mean ± SD of at least 3 replicates. *P < 0.001 vs. 0%
glycerol; #P < 0.001 vs. 3A4 BMR and 3GLY(two way ANOVA followed by
Student-Newman-Keuls post hoc test).
CONCLUSIONS
The creation of chimeric proteins was shown before to improve
the solubility of P450 3A4 and to generate catalytically self-
sufficient enzymes (Degregorio et al., 2011). Here, the P450
3A4-BMR catalytic performance is improved in terms of
coupling efficiency and enzyme turnover by engineering the loop
connecting the P450 3A4 and the BMR modules. The glycine
linker acts as a flexible hinge that can control electron flow
rate, catalytic activity and coupling efficiency of the 3A4-BMR
chimeras. Data in this work highlight that the modulation of
the length of the linker connecting the modules of a multi-
domain protein has an impact on electron transfer, catalytic
ability and coupling efficiency of the system that can be ascribed
to the modulation of inter-domain flexibility and interactivity
rather than to a different tuning of the electron transfer
process. These parameters can be considered as the major
requirement for an optimization of the electron delivery to the
heme iron center showing that the design of the linker hinge
between the interacting domains plays a crucial role in the
optimization of reductase domain improvement of P450 catalytic
efficiency. Our results suggest that for the 3A4-BMR fusion
proteins studied here, the electron transfer may be achieved
through the direct flow between the reductase and the heme
domain rather than through “inter subunits” interaction between
FIGURE 7 | Model of BMR-P450 active complex formation and interaction in the three different chimeric proteins. The length of the inter-domains loop
favors the formation of different types of complexes that can justify different electron transfer rates, turnover and coupling efficiency. P (proline), S (serine), and R
(arginine) are the three amino acids common to the three chimeras. G is glycine.
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protomers in a dimeric system as suggested for the P450 BM3
system.
This molecular design approach can be successfully developed
for the obtainment of performing enzymatic paradigms
suitable for biotechnological applications. The next step is the
introduction of such catalysts in bacterial cells for the large-scale
production of drug metabolites using whole cells as a less
expensive system.
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